From: <Saved by Blink>
Snapshot-Content-Location: https://ir.vikingtherapeutics.com/press-releases?
Subject: Viking Therapeutics - Press Releases
Date: Sun, 13 Apr 2025 17:02:03 -0400
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----"


------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/html
Content-ID: <frame-19F2AE6B61F15174C4209C1DDE396C6C@mhtml.blink>
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/press-releases?

<!DOCTYPE html><html lang=3D"en-US" data-ember-extension=3D"1"><!--<![endif=
]--><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3DUTF-8"><link rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-90dded=
43-0c2e-4904-8c88-06532348acc1@mhtml.blink" /><link rel=3D"stylesheet" type=
=3D"text/css" href=3D"cid:css-f5bdcc36-e2f6-4e67-a23a-ce93881fcc8c@mhtml.bl=
ink" /><link rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-49ddf4b3-=
3340-4f7e-b70c-3df76045a0ae@mhtml.blink" /><link rel=3D"stylesheet" type=3D=
"text/css" href=3D"cid:css-a6862650-9da1-4702-949a-80e43b63dddf@mhtml.blink=
" /><link rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-4daecc4a-424=
4-41c0-8cbf-990f7e160d94@mhtml.blink" /><link rel=3D"stylesheet" type=3D"te=
xt/css" href=3D"cid:css-f3b80716-04d7-43c8-a8df-a6b3c39d51f1@mhtml.blink" /=
><link rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-9777b737-9473-4=
306-b5d5-50404d05a661@mhtml.blink" /><link rel=3D"stylesheet" type=3D"text/=
css" href=3D"cid:css-8884a772-68a2-472e-aac5-2d1331d759dd@mhtml.blink" /><l=
ink rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-c30bfeed-d10a-4edf=
-a078-b533e59f7e95@mhtml.blink" />
<!-- begin spin_special_output(head_start) -->







<link href=3D"https://ir.vikingtherapeutics.com/css/wd_wcag.css" type=3D"te=
xt/css" rel=3D"stylesheet" wd_script_id=3D"wd_wcag.css">



<link href=3D"https://ir.vikingtherapeutics.com/css/wd_wai_datepicker.css" =
type=3D"text/css" rel=3D"stylesheet" wd_script_id=3D"wd_wai_datepicker.css"=
>



<link href=3D"https://ir.vikingtherapeutics.com/css/wd_form.css" type=3D"te=
xt/css" rel=3D"stylesheet" wd_script_id=3D"wd_form.css">


<link href=3D"https://ir.vikingtherapeutics.com/css/jquery.qtip.css" type=
=3D"text/css" rel=3D"stylesheet" wd_script_id=3D"jquery.qtip.css">








<!-- end spin_special_output(head_start) -->

		=09
	=09
	=09
	=09
		<link href=3D"https://ir.vikingtherapeutics.com/css/HttpCombiner.ashx" ty=
pe=3D"text/css" rel=3D"stylesheet">
	=09
		<!--[if lt IE 9]>=09
		<meta http-equiv=3D"X-UA-Compatible" content=3D"IE=3Dedge,chrome=3D1">
		<![endif]-->=09
		<title>Viking Therapeutics - Press Releases</title>
	=09
 <meta name=3D"keywords" content=3D"">
 <meta name=3D"description" content=3D"">
 <meta name=3D"twitter:card" content=3D"summary">
 <meta property=3D"og:site_name" content=3D"Viking Therapeutics InvestorRoo=
m">
 <meta property=3D"og:url" content=3D"https://ir.vikingtherapeutics.com/pre=
ss-releases">
		<meta name=3D"viewport" content=3D"width=3Ddevice-width, initial-scale=3D=
1.0">
		<link rel=3D"stylesheet" id=3D"fp_webfont_Open_Sans-css" href=3D"https://=
fonts.googleapis.com/css?family=3DOpen+Sans%3A400%2C400italic&amp;ver=3D3.5=
.2" type=3D"text/css" media=3D"all">
		<link href=3D"https://fonts.googleapis.com/css2?family=3DOpen+Sans:wght@7=
00&amp;display=3Dswap" rel=3D"stylesheet">
		<link rel=3D"stylesheet" id=3D"fp_frontend_css-css" href=3D"https://ir.vi=
kingtherapeutics.com/css/frontend.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"contact-form-7-css" href=3D"https://ir.vik=
ingtherapeutics.com/css/styles.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"bootstrap-css" href=3D"https://ir.vikingth=
erapeutics.com/css/bootstrap.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"font-awesome-css" href=3D"https://ir.vikin=
gtherapeutics.com/css/font-awesome.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"font-awesome-ie7-css" href=3D"https://ir.v=
ikingtherapeutics.com/css/font-awesome-ie7.css" type=3D"text/css" media=3D"=
all">
		<link rel=3D"stylesheet" id=3D"shortcodes-css" href=3D"https://ir.vikingt=
herapeutics.com/css/shortcodes.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"audioPlayerV1-skin-css" href=3D"https://ir=
.vikingtherapeutics.com/css/style.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"prettyPhoto-css" href=3D"https://ir.viking=
therapeutics.com/css/prettyPhoto.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"flexSlider-css" href=3D"https://ir.vikingt=
herapeutics.com/css/flexslider.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"retweets-css" href=3D"https://ir.vikingthe=
rapeutics.com/css/retweets.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"flip-css" href=3D"https://ir.vikingtherape=
utics.com/css/flip.css" type=3D"text/css" media=3D"all">
		<link rel=3D"stylesheet" id=3D"main-stylesheet-css" href=3D"https://ir.vi=
kingtherapeutics.com/css/style(1).css" type=3D"text/css" media=3D"all">
	=09
	=09
		<link rel=3D"shortcut icon" href=3D"https://www.vikingtherapeutics.com/wp=
-content/uploads/logo-favico.png">
	=09
	=09
		<!--[if lt IE 9]>=09
		<script>
			document.createElement('header');
			document.createElement('nav');
			document.createElement('section');
			document.createElement('article');
			document.createElement('aside');
			document.createElement('footer');
		</script>
		<![endif]-->=09
		<link rel=3D"stylesheet" type=3D"text/css" href=3D"https://ir.vikingthera=
peutics.com/css/ir-inline.css">
		<link rel=3D"stylesheet" type=3D"text/css" href=3D"https://ir.vikingthera=
peutics.com/css/ccbnIR.css">
	=09
		</head><body class=3D"wd_pageid_ page page-id-11 page-parent page-templat=
e page-template-page-fullwidth-php layout-2cr" cz-shortcut-listen=3D"true">=
<div id=3D"mboxScriptContainer" style=3D"display:none;visibility:hidden;"><=
/div>
	=09
	=09
		<link rel=3D"stylesheet" type=3D"text/css" href=3D"https://ir.vikingthera=
peutics.com/css/wdcontent.css">
		<link rel=3D"stylesheet" type=3D"text/css" href=3D"https://ir.vikingthera=
peutics.com/css/wd_media_query.css">

		<link rel=3D"alternate" href=3D"https://ir.vikingtherapeutics.com/press-r=
eleases?pagetemplate=3Drss" type=3D"application/rss+xml" title=3D"Viking Th=
erapeutics - Press Releases">	=09
=09
<!-- begin spin_special_output(head_end) -->
<link rel=3D"canonical" href=3D"https://ir.vikingtherapeutics.com/press-rel=
eases">
<!-- end spin_special_output(head_end) -->

   =20
		<div id=3D"mboxScriptContainer" style=3D"display:none;visibility:hidden;"=
></div>
	=09
		<div id=3D"wrap" class=3D"navPositionleft">
			<div id=3D"container" class=3D"container">
				<header id=3D"header">
					<div class=3D"navbar">
						<div class=3D"navbar-inner">
							<div class=3D"container">
								<div class=3D"logo_holder"><a href=3D"http://www.vikingtherapeutics=
.com/"><img src=3D"https://www.vikingtherapeutics.com/wp-content/uploads/vi=
king-logo-top-3.png" alt=3D"Viking Therapeutics"></a></div>
								<a class=3D"btn-flat" data-toggle=3D"collapse" data-target=3D".nav-=
collapse"><span class=3D"icon-bar"></span><span class=3D"icon-bar"></span><=
span class=3D"icon-bar"></span></a>
								<div class=3D"nav-collapse collapse" style=3D"height: 0;">
									<nav id=3D"jqueryslidemenu" class=3D"jqueryslidemenu">
										<ul class=3D"nav" style=3D"margin-top: 43px;">
											<li id=3D"menu-item-21" class=3D"menu-item menu-item-type-post_t=
ype menu-item-object-page current-menu-item page_item page-item-9 current_p=
age_item menu-item-21"><a href=3D"http://www.vikingtherapeutics.com/">Home<=
/a></li>
											<li id=3D"menu-item-372" class=3D"menu-item menu-item-type-custo=
m menu-item-object-custom menu-item-has-children menu-item-372 dropdown"><a=
 href=3D"https://ir.vikingtherapeutics.com/press-releases?#" class=3D"dropd=
own-toggle" data-toggle=3D"dropdown">About<b class=3D"caret"></b></a>
												<ul class=3D"sub-menu dropdown-menu">
													<li id=3D"menu-item-374" class=3D"menu-item menu-item-type-pos=
t_type menu-item-object-page menu-item-374"><a href=3D"http://www.vikingthe=
rapeutics.com/about/">Overview</a></li>
													<li id=3D"menu-item-371" class=3D"menu-item menu-item-type-pos=
t_type menu-item-object-page menu-item-371"><a href=3D"http://www.vikingthe=
rapeutics.com/about/management/">Management</a></li>
													<li id=3D"menu-item-370" class=3D"menu-item menu-item-type-pos=
t_type menu-item-object-page menu-item-370"><a href=3D"http://www.vikingthe=
rapeutics.com/about/board-of-directors/">Board of Directors</a></li>
													<li id=3D"menu-item-369" class=3D"menu-item menu-item-type-pos=
t_type menu-item-object-page menu-item-369"><a href=3D"http://www.vikingthe=
rapeutics.com/about/careers/">Careers</a></li>
												</ul>
											</li>
											<li id=3D"menu-item-381" class=3D"menu-item menu-item-type-custo=
m menu-item-object-custom menu-item-has-children menu-item-381 dropdown"><a=
 href=3D"https://ir.vikingtherapeutics.com/press-releases?#" class=3D"dropd=
own-toggle" data-toggle=3D"dropdown">Pipeline<b class=3D"caret"></b></a>
												<ul class=3D"sub-menu dropdown-menu">
													<li id=3D"menu-item-384" class=3D"menu-item menu-item-type-pos=
t_type menu-item-object-page menu-item-384"><a href=3D"http://www.vikingthe=
rapeutics.com/pipeline/overview/">Overview</a></li>
													<li id=3D"menu-item-394" class=3D"no-link menu-item menu-item-=
type-post_type menu-item-object-page menu-item-has-children menu-item-394">=
<a href=3D"http://www.vikingtherapeutics.com/pipeline/vk0214/">Metabolic Di=
sease Programs</a>
														<ul class=3D"sub-menu">
															<li id=3D"menu-item-1141" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1141"><a href=3D"https://vikingth=
erapeutics.com/pipeline/metabolic-disease-program/vk2809/">VK2809 (NASH)</a=
></li>
															<li id=3D"menu-item-1140" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1140"><a href=3D"https://vikingth=
erapeutics.com/pipeline/metabolic-disease-program/vk2735/">VK2735 (Metaboli=
c Disorders)</a></li>
														</ul>
													</li>
													<li id=3D"menu-item-887" class=3D"no-link menu-item menu-item-=
type-post_type menu-item-object-page menu-item-has-children menu-item-887">=
<a href=3D"http://www.vikingtherapeutics.com/pipeline/rare-disease-programs=
/">Rare Disease Program</a>
														<ul class=3D"sub-menu">
															<li id=3D"menu-item-1139" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1139"><a href=3D"https://vikingth=
erapeutics.com/pipeline/rare-disease-programs/vk0214/">VK0214 (X-ALD)</a></=
li>
														</ul>
													</li>
													<li id=3D"menu-item-888" class=3D"no-link menu-item menu-item-=
type-post_type menu-item-object-page menu-item-has-children menu-item-888">=
<a href=3D"http://www.vikingtherapeutics.com/pipeline/other-pipeline-progra=
ms/">Other Pipeline Programs</a>
														<ul class=3D"sub-menu">
															<li id=3D"menu-item-1138" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1138"><a href=3D"https://vikingth=
erapeutics.com/pipeline/other-pipeline-programs/vk5211/">VK5211 (Hip Fractu=
re, Muscle Wasting)</a></li>
															<li id=3D"menu-item-1136" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1136"><a href=3D"https://vikingth=
erapeutics.com/pipeline/other-pipeline-programs/vk0612/">VK0612 (Type 2 Dia=
betes)</a></li>
															<li id=3D"menu-item-1137" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1137"><a href=3D"https://vikingth=
erapeutics.com/pipeline/other-pipeline-programs/vk1430/">VK1430 (Hypertrigl=
yceridemia, NASH)</a></li>
															<li id=3D"menu-item-1135" class=3D"menu-item menu-item-type-=
post_type menu-item-object-page menu-item-1135"><a href=3D"https://vikingth=
erapeutics.com/pipeline/other-pipeline-programs/epor-agonist-program/">EPOR=
 Agonist Program (Anemia)</a></li>
														</ul>
													</li>
												</ul>
											</li>
											<li id=3D"menu-item-555" class=3D"menu-item menu-item-type-custo=
m menu-item-object-custom menu-item-has-children menu-item-555 dropdown"><a=
 href=3D"https://ir.vikingtherapeutics.com/press-releases?#" class=3D"dropd=
own-toggle" data-toggle=3D"dropdown">Investors &amp; Media<b class=3D"caret=
"></b></a>
												<ul class=3D"sub-menu dropdown-menu">
												=09

<li>
	<a href=3D"https://ir.vikingtherapeutics.com/overview" target=3D"_self">
		Overview	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/stock-information" target=3D"=
_self">
		Stock Information	</a>
</li>




<li>
	<a class=3D"ir-active" href=3D"https://ir.vikingtherapeutics.com/press-rel=
eases" target=3D"_self">
		News &amp; Events	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/sec-filings" target=3D"_self"=
>
		SEC Filings	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/analyst-coverage" target=3D"_=
self">
		Analyst Coverage	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/governance-highlights" target=
=3D"_self">
		Corporate Governance	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/information-request" target=
=3D"_self">
		Shareholder Services	</a>
</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/corporatepresentation" target=
=3D"_self">
		Corporate Presentation 	</a>
</li>




												</ul>
											</li>
											<li id=3D"menu-item-23" class=3D"menu-item menu-item-type-post_t=
ype menu-item-object-page menu-item-23"><a href=3D"http://www.vikingtherape=
utics.com/contact/">Contact</a></li>
										</ul>
										<div class=3D"clear"></div>
									</nav>
								</div>
								<div class=3D"pull-right">
									<ul class=3D"nav_social"></ul>
								</div>
							</div>
						</div>
					</div>
				</header>
				<hr class=3D"cool_divider">
				<div class=3D"page_title">
					<div class=3D"clearfix"></div>
				</div>
				<div id=3D"main" role=3D"main" class=3D"row layout_">
					<section id=3D"content" class=3D"span12">
						<article id=3D"post-11" class=3D"post-11 page type-page status-publis=
h hentry">
							<h1>News &amp; Events</h1>
							<p><img class=3D"alignnone size-large wp-image-52" alt=3D"Investors"=
 src=3D"https://ir.vikingtherapeutics.com/images/section-stock-1024x262.jpg=
" width=3D"1024" height=3D"262"></p>
							<div class=3D"row-fluid">
																<div class=3D"span4">
									<ul class=3D"ir-nav">
									=09

<li>
	<a href=3D"https://ir.vikingtherapeutics.com/overview" target=3D"_self">
		Overview	</a>
	</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/stock-information" target=3D"=
_self">
		Stock Information	</a>
	</li>




<li>
	<a class=3D"ir-active" href=3D"https://ir.vikingtherapeutics.com/press-rel=
eases" target=3D"_self">
		News &amp; Events	</a>
		<ul class=3D"sub-nav">


	<li>
		<a href=3D"https://ir.vikingtherapeutics.com/press-releases" target=3D"_s=
elf" class=3D"ir-active">
			Press Releases		</a>
	</li>




	<li>
		<a href=3D"https://ir.vikingtherapeutics.com/webcasts" target=3D"_self">
			Webcasts		</a>
	</li>


</ul>


</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/sec-filings" target=3D"_self"=
>
		SEC Filings	</a>
	</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/analyst-coverage" target=3D"_=
self">
		Analyst Coverage	</a>
	</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/governance-highlights" target=
=3D"_self">
		Corporate Governance	</a>
	</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/information-request" target=
=3D"_self">
		Shareholder Services	</a>
	</li>




<li>
	<a href=3D"https://ir.vikingtherapeutics.com/corporatepresentation" target=
=3D"_self">
		Corporate Presentation 	</a>
	</li>




									</ul>
																		<div class=3D"wd_search_form_container"><form name=3D"bas=
ic_search" method=3D"get" action=3D"https://ir.vikingtherapeutics.com/index=
.php?s=3D82" class=3D"wd_search_form wd_search_form_basic"><input type=3D"t=
ext" name=3D"query" value=3D"" size=3D"32" placeholder=3D"Search" title=3D"=
Search"> <input type=3D"submit" name=3D"submit" value=3D"Search"></form>
</div>									<a style=3D"margin: 0 auto;display: block;text-align: center=
;" href=3D"https://ir.vikingtherapeutics.com/email-alerts"><button>Sign Up =
for Email Alerts</button></a>=20
									<br>
									<a style=3D"margin: 0 auto;display: block;text-align: center;" hre=
f=3D"https://ir.vikingtherapeutics.com/ir-contacts"><button>Investor Relati=
ons Contacts</button></a>=20
								</div>
																								<div class=3D"span8">									<div class=3D"ccbnCon=
tent">
																				<!-- BEGIN CONTENT -->=09
										<div class=3D"wd_content">
																					<div id=3D"wd_printable_content">
<div class=3D"wd_newsfeed_releases">


 <div class=3D"wd_wai_datepicker">
  <div class=3D"wd_wai_datepickerDialog" id=3D"wd_datepicker_dialog_nf_star=
t" role=3D"dialog" aria-modal=3D"true" aria-labelledby=3D"wd_wai_id_dialog_=
label_nf_start">
    <div class=3D"wd_wai_header">
      <button class=3D"wd_wai_prevYear" aria-label=3D"previous year">
        <span class=3D"fa fa-angle-double-left fa-lg"></span>
      </button>
      <button class=3D"wd_wai_prevMonth" aria-label=3D"previous month">
        <span class=3D"fa fa-angle-left fa-lg"></span>
      </button>
      <div id=3D"wd_wai_id_dialog_label_nf_start" class=3D"wd_wai_monthYear=
" aria-live=3D"polite">March 2025</div>
      <button class=3D"wd_wai_nextMonth" aria-label=3D"next month" disabled=
=3D"">
        <span class=3D"fa fa-angle-right fa-lg"></span>
      </button>
      <button class=3D"wd_wai_nextYear" aria-label=3D"next year" disabled=
=3D"">
        <span class=3D"fa fa-angle-double-right fa-lg"></span>
      </button>
    </div>
    <table id=3D"wd_wai_myDatepickerGrid_nf_start" class=3D"wd_wai_dates" r=
ole=3D"grid" aria-labelledby=3D"wd_wai_id_dialog_label_nf_start">
      <thead>
        <tr class=3D"wd_wai_week_row">
          <th scope=3D"col" abbr=3D"Sunday">Sun</th>
          <th scope=3D"col" abbr=3D"Monday">Mon</th>
          <th scope=3D"col" abbr=3D"Tuesday">Tue</th>
          <th scope=3D"col" abbr=3D"Wednesday">Wed</th>
          <th scope=3D"col" abbr=3D"Thursday">Thu</th>
          <th scope=3D"col" abbr=3D"Friday">Fri</th>
          <th scope=3D"col" abbr=3D"Saturday">Sat</th>
        </tr>
      </thead>
      <tbody><tr class=3D"wd_wai_dateRow"><td class=3D"wd_wai_dateCell"><bu=
tton class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025=
-02-23">23</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_w=
ai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-02-24">24</button=
></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disa=
bled" tabindex=3D"-1" data-date=3D"2025-02-25">25</button></td><td class=3D=
"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" tabindex=3D"=
-1" data-date=3D"2025-02-26">26</button></td><td class=3D"wd_wai_dateCell">=
<button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2=
025-02-27">27</button></td><td class=3D"wd_wai_dateCell"><button class=3D"w=
d_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-02-28">28</but=
ton></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" =
tabindex=3D"-1" data-date=3D"2025-03-01">1</button></td></tr><tr class=3D"w=
d_wai_dateRow"><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateBu=
tton" tabindex=3D"-1" data-date=3D"2025-03-02">2</button></td><td class=3D"=
wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-d=
ate=3D"2025-03-03">3</button></td><td class=3D"wd_wai_dateCell"><button cla=
ss=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-04">4</button=
></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tab=
index=3D"-1" data-date=3D"2025-03-05">5</button></td><td class=3D"wd_wai_da=
teCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"20=
25-03-06">6</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_=
wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-07">7</button></td><td=
 class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"=
-1" data-date=3D"2025-03-08">8</button></td></tr><tr class=3D"wd_wai_dateRo=
w"><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabind=
ex=3D"-1" data-date=3D"2025-03-9">9</button></td><td class=3D"wd_wai_dateCe=
ll"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-0=
3-10">10</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai=
_dateButton" tabindex=3D"-1" data-date=3D"2025-03-11">11</button></td><td c=
lass=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1=
" data-date=3D"2025-03-12">12</button></td><td class=3D"wd_wai_dateCell"><b=
utton class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-13">=
13</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateB=
utton" tabindex=3D"-1" data-date=3D"2025-03-14">14</button></td><td class=
=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" da=
ta-date=3D"2025-03-15">15</button></td></tr><tr class=3D"wd_wai_dateRow"><t=
d class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D=
"-1" data-date=3D"2025-03-16">16</button></td><td class=3D"wd_wai_dateCell"=
><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-1=
7">17</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_da=
teButton" tabindex=3D"-1" data-date=3D"2025-03-18">18</button></td><td clas=
s=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" d=
ata-date=3D"2025-03-19">19</button></td><td class=3D"wd_wai_dateCell"><butt=
on class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-20">20<=
/button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButt=
on" tabindex=3D"-1" data-date=3D"2025-03-21">21</button></td><td class=3D"w=
d_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-da=
te=3D"2025-03-22">22</button></td></tr><tr class=3D"wd_wai_dateRow"><td cla=
ss=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" =
data-date=3D"2025-03-23">23</button></td><td class=3D"wd_wai_dateCell"><but=
ton class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-24">24=
</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateBut=
ton" tabindex=3D"-1" data-date=3D"2025-03-25">25</button></td><td class=3D"=
wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"0" data-da=
te=3D"2025-03-26">26</button></td><td class=3D"wd_wai_dateCell"><button cla=
ss=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-03-27">=
27</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateB=
utton disabled" tabindex=3D"-1" data-date=3D"2025-03-28">28</button></td><t=
d class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" ta=
bindex=3D"-1" data-date=3D"2025-03-29">29</button></td></tr><tr class=3D"wd=
_wai_dateRow" style=3D"visibility: visible;"><td class=3D"wd_wai_dateCell">=
<button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2=
025-03-30">30</button></td><td class=3D"wd_wai_dateCell"><button class=3D"w=
d_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-03-31">31</but=
ton></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton d=
isabled" tabindex=3D"-1" data-date=3D"2025-04-01">1</button></td><td class=
=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" tabindex=
=3D"-1" data-date=3D"2025-04-02">2</button></td><td class=3D"wd_wai_dateCel=
l"><button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=
=3D"2025-04-03">3</button></td><td class=3D"wd_wai_dateCell"><button class=
=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-04-04">4<=
/button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButt=
on disabled" tabindex=3D"-1" data-date=3D"2025-04-05">5</button></td></tr><=
/tbody>
    </table>
    <div class=3D"wd_wai_dialogButtonGroup">
      <button class=3D"wd_wai_dialogButton wd_wai_dp_cancelbuton" value=3D"=
Cancel">Cancel      </button>
      <button class=3D"wd_wai_dialogButton wd_wai_dp_okbuton" value=3D"Go">=
Go</button>
    </div>
  </div>

 </div>


 <div class=3D"wd_wai_datepicker">
  <div class=3D"wd_wai_datepickerDialog" id=3D"wd_datepicker_dialog_nf_end"=
 role=3D"dialog" aria-modal=3D"true" aria-labelledby=3D"wd_wai_id_dialog_la=
bel_nf_end">
    <div class=3D"wd_wai_header">
      <button class=3D"wd_wai_prevYear" aria-label=3D"previous year">
        <span class=3D"fa fa-angle-double-left fa-lg"></span>
      </button>
      <button class=3D"wd_wai_prevMonth" aria-label=3D"previous month">
        <span class=3D"fa fa-angle-left fa-lg"></span>
      </button>
      <div id=3D"wd_wai_id_dialog_label_nf_end" class=3D"wd_wai_monthYear" =
aria-live=3D"polite">March 2025</div>
      <button class=3D"wd_wai_nextMonth" aria-label=3D"next month" disabled=
=3D"">
        <span class=3D"fa fa-angle-right fa-lg"></span>
      </button>
      <button class=3D"wd_wai_nextYear" aria-label=3D"next year" disabled=
=3D"">
        <span class=3D"fa fa-angle-double-right fa-lg"></span>
      </button>
    </div>
    <table id=3D"wd_wai_myDatepickerGrid_nf_end" class=3D"wd_wai_dates" rol=
e=3D"grid" aria-labelledby=3D"wd_wai_id_dialog_label_nf_end">
      <thead>
        <tr class=3D"wd_wai_week_row">
          <th scope=3D"col" abbr=3D"Sunday">Sun</th>
          <th scope=3D"col" abbr=3D"Monday">Mon</th>
          <th scope=3D"col" abbr=3D"Tuesday">Tue</th>
          <th scope=3D"col" abbr=3D"Wednesday">Wed</th>
          <th scope=3D"col" abbr=3D"Thursday">Thu</th>
          <th scope=3D"col" abbr=3D"Friday">Fri</th>
          <th scope=3D"col" abbr=3D"Saturday">Sat</th>
        </tr>
      </thead>
      <tbody><tr class=3D"wd_wai_dateRow"><td class=3D"wd_wai_dateCell"><bu=
tton class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025=
-02-23">23</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_w=
ai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-02-24">24</button=
></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disa=
bled" tabindex=3D"-1" data-date=3D"2025-02-25">25</button></td><td class=3D=
"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" tabindex=3D"=
-1" data-date=3D"2025-02-26">26</button></td><td class=3D"wd_wai_dateCell">=
<button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2=
025-02-27">27</button></td><td class=3D"wd_wai_dateCell"><button class=3D"w=
d_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-02-28">28</but=
ton></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" =
tabindex=3D"-1" data-date=3D"2025-03-01">1</button></td></tr><tr class=3D"w=
d_wai_dateRow"><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateBu=
tton" tabindex=3D"-1" data-date=3D"2025-03-02">2</button></td><td class=3D"=
wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-d=
ate=3D"2025-03-03">3</button></td><td class=3D"wd_wai_dateCell"><button cla=
ss=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-04">4</button=
></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tab=
index=3D"-1" data-date=3D"2025-03-05">5</button></td><td class=3D"wd_wai_da=
teCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"20=
25-03-06">6</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_=
wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-07">7</button></td><td=
 class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"=
-1" data-date=3D"2025-03-08">8</button></td></tr><tr class=3D"wd_wai_dateRo=
w"><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabind=
ex=3D"-1" data-date=3D"2025-03-9">9</button></td><td class=3D"wd_wai_dateCe=
ll"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-0=
3-10">10</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai=
_dateButton" tabindex=3D"-1" data-date=3D"2025-03-11">11</button></td><td c=
lass=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1=
" data-date=3D"2025-03-12">12</button></td><td class=3D"wd_wai_dateCell"><b=
utton class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-13">=
13</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateB=
utton" tabindex=3D"-1" data-date=3D"2025-03-14">14</button></td><td class=
=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" da=
ta-date=3D"2025-03-15">15</button></td></tr><tr class=3D"wd_wai_dateRow"><t=
d class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D=
"-1" data-date=3D"2025-03-16">16</button></td><td class=3D"wd_wai_dateCell"=
><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-1=
7">17</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_da=
teButton" tabindex=3D"-1" data-date=3D"2025-03-18">18</button></td><td clas=
s=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" d=
ata-date=3D"2025-03-19">19</button></td><td class=3D"wd_wai_dateCell"><butt=
on class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-20">20<=
/button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButt=
on" tabindex=3D"-1" data-date=3D"2025-03-21">21</button></td><td class=3D"w=
d_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" data-da=
te=3D"2025-03-22">22</button></td></tr><tr class=3D"wd_wai_dateRow"><td cla=
ss=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"-1" =
data-date=3D"2025-03-23">23</button></td><td class=3D"wd_wai_dateCell"><but=
ton class=3D"wd_wai_dateButton" tabindex=3D"-1" data-date=3D"2025-03-24">24=
</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateBut=
ton" tabindex=3D"-1" data-date=3D"2025-03-25">25</button></td><td class=3D"=
wd_wai_dateCell"><button class=3D"wd_wai_dateButton" tabindex=3D"0" data-da=
te=3D"2025-03-26">26</button></td><td class=3D"wd_wai_dateCell"><button cla=
ss=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-03-27">=
27</button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateB=
utton disabled" tabindex=3D"-1" data-date=3D"2025-03-28">28</button></td><t=
d class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" ta=
bindex=3D"-1" data-date=3D"2025-03-29">29</button></td></tr><tr class=3D"wd=
_wai_dateRow" style=3D"visibility: visible;"><td class=3D"wd_wai_dateCell">=
<button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2=
025-03-30">30</button></td><td class=3D"wd_wai_dateCell"><button class=3D"w=
d_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-03-31">31</but=
ton></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton d=
isabled" tabindex=3D"-1" data-date=3D"2025-04-01">1</button></td><td class=
=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButton disabled" tabindex=
=3D"-1" data-date=3D"2025-04-02">2</button></td><td class=3D"wd_wai_dateCel=
l"><button class=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=
=3D"2025-04-03">3</button></td><td class=3D"wd_wai_dateCell"><button class=
=3D"wd_wai_dateButton disabled" tabindex=3D"-1" data-date=3D"2025-04-04">4<=
/button></td><td class=3D"wd_wai_dateCell"><button class=3D"wd_wai_dateButt=
on disabled" tabindex=3D"-1" data-date=3D"2025-04-05">5</button></td></tr><=
/tbody>
    </table>
    <div class=3D"wd_wai_dialogButtonGroup">
      <button class=3D"wd_wai_dialogButton wd_wai_dp_cancelbuton" value=3D"=
Cancel">Cancel      </button>
      <button class=3D"wd_wai_dialogButton wd_wai_dp_okbuton" value=3D"Go">=
Go</button>
    </div>
  </div>

 </div>

<div class=3D"wd_subscribe_link">
	<a href=3D"https://ir.vikingtherapeutics.com/email-alerts?type=3D1">
		<span class=3D"wd_subscribe_title">E-mail Alerts</span><span class=3D"wd_=
subscribe_icon"><img src=3D"https://ir.vikingtherapeutics.com/images/webdri=
ver/email_alerts.png" title=3D"E-mail Alerts" role=3D"presentation"></span>
	</a>
</div>

<div class=3D"wd_item_search_form_container"><form name=3D"item_basic_searc=
h_43" method=3D"get" action=3D"https://ir.vikingtherapeutics.com/press-rele=
ases" class=3D"wd_search_form wd_search_form_basic"><div class=3D"wd_search=
_basic_fields"><label for=3D"item_basic_search_43_year" class=3D"wd_sr-only=
">Year</label>
<select name=3D"year" id=3D"item_basic_search_43_year">
 <option value=3D"">All Years</option>
 <option value=3D"2025">2025</option>
 <option value=3D"2024">2024</option>
 <option value=3D"2023">2023</option>
 <option value=3D"2022">2022</option>
 <option value=3D"2021">2021</option>
 <option value=3D"2020">2020</option>
 <option value=3D"2019">2019</option>
 <option value=3D"2018">2018</option>
 <option value=3D"2017">2017</option>
 <option value=3D"2016">2016</option>
 <option value=3D"2015">2015</option>
</select>
<label for=3D"item_basic_search_43_keywords" class=3D"wd_sr-only">Keywords<=
/label><input type=3D"text" name=3D"keywords" value=3D"" size=3D"32" placeh=
older=3D"Search" wd_original_value=3D"" id=3D"item_basic_search_43_keywords=
"> <button type=3D"submit" class=3D"wd_search_button" title=3D"Search">Go</=
button></div> <a class=3D"wd_search_advanced_link" href=3D"https://ir.vikin=
gtherapeutics.com/press-releases?#">Advanced Search</a></form>
 <form method=3D"get" class=3D"wd_search_form wd_search_form_advanced" styl=
e=3D"display:none;" name=3D"item_advanced_search_43" action=3D"https://ir.v=
ikingtherapeutics.com/press-releases" enctype=3D"multipart/form-data">
  =20
   <div class=3D"wd_form_field wd_form_field_pos_right">
    <div class=3D"wd_form_field_label">
<label for=3D"item_advanced_search_43_keywords">Search</label>
    </div>
    <div class=3D"wd_form_field_input">
     <input type=3D"text" name=3D"keywords" value=3D"" size=3D"40" placehol=
der=3D"Keywords" id=3D"item_advanced_search_43_keywords">&nbsp;<span class=
=3D"wd_search_titles_only"><input type=3D"checkbox" name=3D"titles_only" va=
lue=3D"1" id=3D"items_search_43_titles_only">&nbsp;<label for=3D"items_sear=
ch_43_titles_only">Search Headlines Only</label></span>
    </div>
   </div>
   <div class=3D"wd_form_field wd_form_field_pos_right">
    <div class=3D"wd_form_field_label">
<label for=3D"item_advanced_search_43_start">From</label>
    </div>
    <div class=3D"wd_form_field_input">
<input type=3D"text" name=3D"start" value=3D"" size=3D"32" placeholder=3D"D=
ate" dp_id=3D"nf_start" dp_num=3D"1" mindate=3D"2015-02-02" maxdate=3D"2025=
-03-26" id=3D"wd_wai_dp_input_nf_start"><button type=3D"button" class=3D"ic=
on wd_wai_dp_button" id=3D"wd_wai_dp_button_nf_start" title=3D"Choose Date"=
><span class=3D"wd_datepicker-icon fa fa-calendar"></span></button>
    </div>
   </div>
   <div class=3D"wd_form_field wd_form_field_pos_right">
    <div class=3D"wd_form_field_label">
<label for=3D"item_advanced_search_43_end">To</label>
    </div>
    <div class=3D"wd_form_field_input">
<input type=3D"text" name=3D"end" value=3D"" size=3D"32" placeholder=3D"Dat=
e" dp_id=3D"nf_end" dp_num=3D"2" mindate=3D"2015-02-02" maxdate=3D"2025-03-=
26" id=3D"wd_wai_dp_input_nf_end"><button type=3D"button" class=3D"icon wd_=
wai_dp_button" id=3D"wd_wai_dp_button_nf_end" title=3D"Choose Date"><span c=
lass=3D"wd_datepicker-icon fa fa-calendar"></span></button>
    </div>
   </div>
   <fieldset class=3D"wd_form_field wd_form_field_pos_right">
    <legend class=3D"wd_form_field_label">Asset Types</legend>
    <div class=3D"wd_form_field_input">
<span class=3D"wd_checkbox"><input type=3D"checkbox" name=3D"asset_types[]"=
 checked=3D"yes" value=3D"1" id=3D"item_advanced_search_43_asset_types_1">&=
nbsp;<label for=3D"item_advanced_search_43_asset_types_1">Video</label></sp=
an> <span class=3D"wd_checkbox"><input type=3D"checkbox" name=3D"asset_type=
s[]" checked=3D"yes" value=3D"2" id=3D"item_advanced_search_43_asset_types_=
2">&nbsp;<label for=3D"item_advanced_search_43_asset_types_2">Audio</label>=
</span> <span class=3D"wd_checkbox"><input type=3D"checkbox" name=3D"asset_=
types[]" checked=3D"yes" value=3D"3" id=3D"item_advanced_search_43_asset_ty=
pes_3">&nbsp;<label for=3D"item_advanced_search_43_asset_types_3">Photos</l=
abel></span> <span class=3D"wd_checkbox"><input type=3D"checkbox" name=3D"a=
sset_types[]" checked=3D"yes" value=3D"4" id=3D"item_advanced_search_43_ass=
et_types_4">&nbsp;<label for=3D"item_advanced_search_43_asset_types_4">Docu=
ments</label></span> <span class=3D"wd_checkbox"><input type=3D"checkbox" n=
ame=3D"asset_types[]" checked=3D"yes" value=3D"11" id=3D"item_advanced_sear=
ch_43_asset_types_11">&nbsp;<label for=3D"item_advanced_search_43_asset_typ=
es_11">Events</label></span> <span class=3D"wd_checkbox"><input type=3D"che=
ckbox" name=3D"asset_types[]" checked=3D"yes" value=3D"24" id=3D"item_advan=
ced_search_43_asset_types_24">&nbsp;<label for=3D"item_advanced_search_43_a=
sset_types_24">Standard</label></span>
    </div>
   </fieldset>
  =20
  <div class=3D"wd_form_footer">
   <div class=3D"wd_form_buttons">
<input type=3D"submit" value=3D"Search">&nbsp;<a href=3D"https://ir.vikingt=
herapeutics.com/press-releases?#">Basic Search</a>
   </div>
  </div>
 </form>
</div>


<ul class=3D"wd_layout-simple wd_item_list"><li class=3D"wd_item">
<div class=3D"wd_date">Mar 26, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"0" aria-describedby=3D"qtip-0"><a h=
ref=3D"https://ir.vikingtherapeutics.com/2025-03-26-Viking-Therapeutics-Ann=
ounces-Completion-of-Enrollment-in-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2=
735-Tablet-Formulation-in-Patients-with-Obesity">Viking Therapeutics Announ=
ces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735=
 Tablet Formulation in Patients with Obesity</a></div></div>
=09
=09
=09
=09
</div>
</li><li class=3D"wd_item">
<div class=3D"wd_date">Mar 11, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"1"><a href=3D"https://ir.vikingther=
apeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agree=
ment-With-CordenPharma-to-Support-Commercialization-of-VK2735">Viking Thera=
peutics Signs Broad Manufacturing Agreement With CordenPharma to Support Co=
mmercialization of VK2735</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Long-Term Agreement =
Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pha=
rmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Milli=
on Annual Autoinjector...</p></div>
=09
=09
</div>
</li><li class=3D"wd_item">
<div class=3D"wd_date">Mar 4, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"2" aria-describedby=3D"qtip-2"><a h=
ref=3D"https://ir.vikingtherapeutics.com/2025-03-04-Viking-Therapeutics-to-=
Participate-at-Upcoming-Investor-Conferences">Viking Therapeutics to Partic=
ipate at Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li><li class=3D"wd_item">
<div class=3D"wd_date">Feb 5, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"3" aria-describedby=3D"qtip-3"><a h=
ref=3D"https://ir.vikingtherapeutics.com/2025-02-05-Viking-Therapeutics-Rep=
orts-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corpor=
ate-Update">Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Fi=
nancial Results and Provides Corporate Update</a></div></div>
=09
=09
=09
=09
</div>
</li><li class=3D"wd_item">
<div class=3D"wd_date">Jan 29, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"4" aria-describedby=3D"qtip-4"><a h=
ref=3D"https://ir.vikingtherapeutics.com/2025-01-29-Viking-Therapeutics-to-=
Report-Financial-Results-for-Fourth-Quarter-and-Year-End-2024-on-February-5=
,-2025">Viking Therapeutics to Report Financial Results for Fourth Quarter =
and Year-End 2024 on February 5, 2025</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 8, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"5"><a href=3D"https://ir.vikingther=
apeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2=
-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Ob=
esity">Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dos=
ing Trial of VK2735 Tablet Formulation in Patients with Obesity</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>13-Week Study to Eva=
luate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Ja=
n. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VK=
TX), a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 6, 2025</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"6"><a href=3D"https://ir.vikingther=
apeutics.com/2025-01-06-Viking-Therapeutics-to-Present-at-43rd-Annual-J-P-M=
organ-Healthcare-Conference">Viking Therapeutics to Present at 43rd Annual =
J.P. Morgan Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 19, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"7"><a href=3D"https://ir.vikingther=
apeutics.com/2024-11-19-Viking-Therapeutics-Presents-Results-from-Phase-2b-=
VOYAGE-Study-of-VK2809-in-Biopsy-Confirmed-NASH-MASH-at-the-75th-Liver-Meet=
ing-R-2024">Viking Therapeutics Presents Results from Phase 2b VOYAGE Study=
 of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting=C2=AE 20=
24</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Oral Late Breaker Pr=
esentation Summarizes Positive Results Including Successful Achievement of =
Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class=
 Profile Highlighted by...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 12, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"8"><a href=3D"https://ir.vikingther=
apeutics.com/2024-11-12-Viking-Therapeutics-to-Present-Data-from-Phase-2b-V=
OYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-NASH-MASH-at-the-75=
th-Liver-Meeting-R-2024">Viking Therapeutics to Present Data from Phase 2b =
VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 7=
5th Liver Meeting=C2=AE 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 4, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"9"><a href=3D"https://ir.vikingther=
apeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Ob=
esity-Program-at-ObesityWeek-R-2024">Viking Therapeutics Reports New Data f=
rom VK2735 Obesity Program at ObesityWeek=C2=AE 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Up to 6.8% Placebo-A=
djusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with =
Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing =
with Oral VK2735; Mild...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 31, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"10" aria-describedby=3D"qtip-10"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-10-31-Viking-Therapeutics-t=
o-Participate-at-Upcoming-Investor-Conferences">Viking Therapeutics to Part=
icipate at Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 28, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"11"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-10-28-Viking-Therapeutics-to-Highlight-Clinical-Data-fro=
m-VK2735-Obesity-Program-in-Presentations-at-ObesityWeek-R-2024">Viking The=
rapeutics to Highlight Clinical Data from VK2735 Obesity Program in Present=
ations at ObesityWeek=C2=AE 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Results from VENTURE=
 Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial o=
f Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 =
/PRNewswire/ -- Viking...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 23, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"12"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports T=
hird Quarter 2024 Financial Results and Provides Corporate Update</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735=
 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expec=
ted to Begin 4Q24 Results...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 16, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"13"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-10-16-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Third-Quarter-2024-on-October-23,-2024">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2024 on October 23, 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 1=
6, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX)=
, a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 9, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"14"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-10-09-Viking-Therapeutics-Announces-Results-from-Phase-1=
b-Clinical-Trial-of-VK0214-in-Patients-with-X-ALD">Viking Therapeutics Anno=
unces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD=
</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Reductions in Very L=
ong-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Onc=
e Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study S=
AN DIEGO, Oct. 9, 2024...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 28, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"15" aria-describedby=3D"qtip-15"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-08-28-Viking-Therapeutics-t=
o-Participate-at-Morgan-Stanley-22nd-Annual-Global-Healthcare-Conference">V=
iking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Heal=
thcare Conference</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 24, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"16"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-07-24-Viking-Therapeutics-Reports-Second-Quarter-2024-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Second Quarter 2024 Financial Results and Provides Corporate Update</a></di=
v></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-=
of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Obesity Ex=
pected to Begin 4Q24...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 17, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"17"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-07-17-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Second-Quarter-2024-on-July-24,-2024">Viking Therapeutics to Report Finan=
cial Results for Second Quarter 2024 on July 24, 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, =
2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a=
 clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 24, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"18"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-06-24-Viking-Therapeutics-Presents-Preclinical-Data-on-N=
ovel-Dual-Amylin-and-Calcitonin-Receptor-Agonists-at-84th-Scientific-Sessio=
ns-of-the-American-Diabetes-Association">Viking Therapeutics Presents Precl=
inical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th S=
cientific Sessions of the American Diabetes Association</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Company's Receptor C=
o-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake=
 and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice=
 SAN DIEGO, June 24, 2024...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 4, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"19" aria-describedby=3D"qtip-19"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-06-04-Viking-Therapeutics-A=
nnounces-Positive-52-Week-Histologic-Data-from-Phase-2b-VOYAGE-Study-of-VK2=
809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH">V=
iking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b=
 VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Ste=
atohepatitis (NASH)</a></div></div>
=09
=09
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 30, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"20" aria-describedby=3D"qtip-20"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-05-30-Viking-Therapeutics-t=
o-Participate-at-Upcoming-Investor-Conferences">Viking Therapeutics to Part=
icipate at Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 24, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"21"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-04-24-Viking-Therapeutics-Reports-First-Quarter-2024-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports F=
irst Quarter 2024 Financial Results and Provides Corporate Update</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GI=
P Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weigh=
t Loss (14.7% From...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 17, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"22"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-04-17-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-First-Quarter-2024-on-April-24,-2024">Viking Therapeutics to Report Finan=
cial Results for First Quarter 2024 on April 24, 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO, April 17=
, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX),=
 a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 26, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"23"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1=
-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agoni=
st-VK2735">Viking Therapeutics Announces Results from Phase 1 Clinical Tria=
l of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735</a><=
/div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Up to 3.3% Placebo-A=
djusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735=
 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-R=
elated Adverse Events...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 4, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"24" aria-describedby=3D"qtip-24"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-03-04-Viking-Therapeutics-A=
nnounces-Closing-of-Public-Offering-of-Common-Stock-Including-Full-Exercise=
-of-Underwriters-Option-to-Purchase-Additional-Shares">Viking Therapeutics =
Announces Closing of Public Offering of Common Stock Including Full Exercis=
e of Underwriters' Option to Purchase Additional Shares</a></div></div>
=09
=09
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 28, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"25" aria-describedby=3D"qtip-25"><a=
 href=3D"https://ir.vikingtherapeutics.com/2024-02-28-Viking-Therapeutics-A=
nnounces-Pricing-of-550-Million-Public-Offering-of-Common-Stock">Viking The=
rapeutics Announces Pricing of $550 Million Public Offering of Common Stock=
</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 27, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"26"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Proposed-Public-Offe=
ring-of-Common-Stock">Viking Therapeutics Announces Proposed Public Offerin=
g of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 27, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"27"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Re=
sults-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-=
in-Patients-with-Obesity">Viking Therapeutics Announces Positive Top-Line R=
esults from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735=
 in Patients with Obesity</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Study Achieves Prima=
ry and all Secondary Endpoints, Demonstrating Statistically Significant Red=
uctions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Plac=
ebo-Adjusted Mean Weight...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 7, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"28"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-02-07-Viking-Therapeutics-Reports-Fourth-Quarter-and-Yea=
r-End-2023-Financial-Results-and-Provides-Corporate-Update">Viking Therapeu=
tics Reports Fourth Quarter and Year-End 2023 Financial Results and Provide=
s Corporate Update</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Results for Phase 2 VENTURE Trial of GLP-1/GIP=
 Agonist VK2735 in Obesity Expected in 1Q24 Histology Results for Phase 2b =
VOYAGE Study Evaluating...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 31, 2024</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"29"><a href=3D"https://ir.vikingthe=
rapeutics.com/2024-01-31-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Fourth-Quarter-and-Year-End-2023-on-February-7,-2024">Viking Therapeutics=
 to Report Financial Results for Fourth Quarter and Year-End 2023 on Februa=
ry 7, 2024</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, February 7 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 3=
1, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX)=
, a clinical-stage...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 13, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"30" aria-describedby=3D"qtip-30"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-11-13-Viking-Therapeutics-P=
resents-New-Data-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biop=
sy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH-at-The-Liver-Meeting-R-2023=
">Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK280=
9 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at=
 The Liver Meeting=C2=AE 2023</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 2, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"31"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-11-02-Viking-Therapeutics-to-Participate-at-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate at Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 25, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"32"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-10-25-Viking-Therapeutics-Reports-Third-Quarter-2023-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports T=
hird Quarter 2023 Financial Results and Provides Corporate Update</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2=
735 in Obesity Fully Enrolled; Results Expected 1H24 Phase 2b VOYAGE Study =
Evaluating VK2809 for the...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 23, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"33"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-10-23-Viking-Therapeutics-Announces-Completion-of-Enroll=
ment-in-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-=
Patients-with-Obesity">Viking Therapeutics Announces Completion of Enrollme=
nt in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Pa=
tients with Obesity</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>13-Week Study to Eva=
luate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased f=
rom 125 to 176 Patients Due to Elevated Demand SAN DIEGO, Oct. 23, 2023 /PR=
Newswire/ -- Viking...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 18, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"34"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-10-18-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Third-Quarter-2023-on-October-25,-2023">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2023 on October 25, 2023</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, October 25 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 1=
8, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX)=
, a clinical-stage...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 17, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"35" aria-describedby=3D"qtip-35"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-P=
resents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Ago=
nist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023">Viking Therapeutics P=
resents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Ago=
nist VK2735 in Oral Presentation at ObesityWeek 2023</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 10, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"36"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-10-10-Viking-Therapeutics-to-Highlight-Data-from-Phase-1=
-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentat=
ion-at-ObesityWeek-2023">Viking Therapeutics to Highlight Data from Phase 1=
 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentat=
ion at ObesityWeek 2023</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Presentation to High=
light VK2735's Preliminary Safety, Tolerability, and Pharmacodynamic Effect=
s in Healthy Volunteers SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Viking The=
rapeutics, Inc. ("Viking")...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 7, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"37"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-09-07-Viking-Therapeutics-to-Participate-at-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate at Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 6, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"38" aria-describedby=3D"qtip-38"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-09-06-Viking-Therapeutics-A=
nnounces-Initiation-of-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Ago=
nist-VK2735-in-Patients-with-Obesity">Viking Therapeutics Announces Initiat=
ion of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in P=
atients with Obesity</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 26, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"39"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-07-26-Viking-Therapeutics-Reports-Second-Quarter-2023-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Second Quarter 2023 Financial Results and Provides Corporate Update</a></di=
v></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Reported Positive Top-Line Results from Phase =
2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH, Showing u=
p to 55% Median Liver Fat...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 19, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"40" aria-describedby=3D"qtip-40"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-07-19-Viking-Therapeutics-t=
o-Report-Financial-Results-for-Second-Quarter-2023-on-July-26,-2023">Viking=
 Therapeutics to Report Financial Results for Second Quarter 2023 on July 2=
6, 2023</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 16, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"41"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-05-16-Viking-Therapeutics-Announces-Positive-Top-Line-Re=
sults-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirme=
d-Non-Alcoholic-Steatohepatitis-NASH">Viking Therapeutics Announces Positiv=
e Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Bi=
opsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Study Achieves Prima=
ry Endpoint, Demonstrating Statistically Significant Reductions in Liver Fa=
t from Baseline to Week 12 in Patients Receiving VK2809 as Compared to Plac=
ebo Up to 52% Mean Liver...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 26, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"42"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-04-26-Viking-Therapeutics-Reports-First-Quarter-2023-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports F=
irst Quarter 2023 Financial Results and Provides Corporate Update</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Three Additional Data Announcements Expected i=
n 2023 Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and=
 Fibrosis; Data Expected...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 20, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"43"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-04-20-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-First-Quarter-2023-on-April-26-2023">Viking Therapeutics to Report Financ=
ial Results for First Quarter 2023 on April 26, 2023</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, April 26 at 4:30 p.m. Eastern Time SAN DIEGO, April 20=
, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX),=
 a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 11, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"44"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-04-11-Viking-Therapeutics-to-Present-at-22nd-Annual-Need=
ham-Healthcare-Conference">Viking Therapeutics to Present at 22nd Annual Ne=
edham Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 3, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"45" aria-describedby=3D"qtip-45"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-04-03-Viking-Therapeutics-A=
nnounces-Closing-of-Public-Offering-of-Common-Stock-And-Full-Exercise-of-Un=
derwriters-Option-to-Purchase-Additional-Shares">Viking Therapeutics Announ=
ces Closing of Public Offering of Common Stock And Full Exercise of Underwr=
iters' Option to Purchase Additional Shares</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 30, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"46"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-03-30-Viking-Therapeutics-Announces-Pricing-of-250-Milli=
on-Public-Offering-of-Common-Stock">Viking Therapeutics Announces Pricing o=
f $250 Million Public Offering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 29, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"47"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-03-29-Viking-Therapeutics-Announces-Proposed-Public-Offe=
ring-of-Common-Stock">Viking Therapeutics Announces Proposed Public Offerin=
g of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 28, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"48"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-=
1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2=
735">Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate =
Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Expands Potential Op=
portunities for VK2735 with Highly Differentiated Dosing Option Data Antici=
pated in 2H2023 SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeuti=
cs, Inc. (Viking) (NASDAQ:...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 28, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"49"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1=
-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735">Viking Therapeut=
ics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Recepto=
r Agonist VK2735</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Up to 6.0% Placebo-A=
djusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735=
 Shown to be Safe and Well-Tolerated in 28-Day Study Phase 2 Trial in Obesi=
ty Planned for Mid-2023...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 7, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"50" aria-describedby=3D"qtip-50"><a=
 href=3D"https://ir.vikingtherapeutics.com/2023-03-07-Viking-Therapeutics-t=
o-Participate-at-Upcoming-Investor-Conferences">Viking Therapeutics to Part=
icipate at Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 8, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"51"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-02-08-Viking-Therapeutics-Reports-Fourth-Quarter-and-Yea=
r-End-2022-Financial-Results-and-Provides-Corporate-Update">Viking Therapeu=
tics Reports Fourth Quarter and Year-End 2022 Financial Results and Provide=
s Corporate Update</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Data from Three Clinical Programs Expected in =
2023 Enrollment Completed in Phase 2b VOYAGE Study of VK2809 for NASH and F=
ibrosis; Data Expected in...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 7, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"52"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-02-07-Viking-Therapeutics-to-Present-at-SVB-Securities-G=
lobal-Biopharma-Conference">Viking Therapeutics to Present at SVB Securitie=
s Global Biopharma Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 1, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"53"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-02-01-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Fourth-Quarter-and-Year-End-2022-on-February-8,-2023">Viking Therapeutics=
 to Report Financial Results for Fourth Quarter and Year-End 2022 on Februa=
ry 8, 2023</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, February 8 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 1=
, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX),=
 a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 9, 2023</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"54"><a href=3D"https://ir.vikingthe=
rapeutics.com/2023-01-09-Viking-Therapeutics-Announces-Completion-of-Enroll=
ment-in-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-N=
on-Alcoholic-Steatohepatitis-NASH">Viking Therapeutics Announces Completion=
 of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-C=
onfirmed Non-Alcoholic Steatohepatitis (NASH)</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Randomized, Double-B=
lind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Dose=
s for up to 52 Weeks; Data for Primary Endpoint Expected in First Half of 2=
023 SAN DIEGO, Jan. 9,...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 8, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"55"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-11-08-Viking-Therapeutics-to-Present-at-Stifel-2022-Heal=
thcare-Conference">Viking Therapeutics to Present at Stifel 2022 Healthcare=
 Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 26, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"56"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-10-26-Viking-Therapeutics-Reports-Third-Quarter-2022-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports T=
hird Quarter 2022 Financial Results and Provides Corporate Update</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference call sche=
duled for 4:30 p.m. ET today Company Positioned to Announce Data from Three=
 Clinical Programs in 2023 VK2809 Phase 2b VOYAGE Study On Track to Complet=
e Enrollment in Q4 2022;...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 19, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"57"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-10-19-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Third-Quarter-2022-on-October-26,-2022">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2022 on October 26, 2022</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, October 26 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 1=
8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX)=
, a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 6, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"58"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-09-06-Viking-Therapeutics-to-Participate-at-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate at Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 2, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"59"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-08-02-Viking-Therapeutics-to-Participate-in-Fireside-Cha=
t-at-BTIG-Biotechnology-Conference-2022">Viking Therapeutics to Participate=
 in Fireside Chat at BTIG Biotechnology Conference 2022</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 27, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"60" aria-describedby=3D"qtip-60"><a=
 href=3D"https://ir.vikingtherapeutics.com/2022-07-27-Viking-Therapeutics-R=
eports-Second-Quarter-2022-Financial-Results-and-Provides-Corporate-Update"=
>Viking Therapeutics Reports Second Quarter 2022 Financial Results and Prov=
ides Corporate Update</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 20, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"61"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-07-20-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Second-Quarter-2022-on-July-27,-2022">Viking Therapeutics to Report Finan=
cial Results for Second Quarter 2022 on July 27, 2022</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, July 27 at 4:30 p.m. Eastern Time SAN DIEGO, July 20, =
2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a=
 clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 19, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"62"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-07-19-Viking-Therapeutics-Announces-FDA-Has-Lifted-Clini=
cal-Hold-on-Phase-1b-Trial-of-VK0214-in-Patients-with-X-ALD">Viking Therape=
utics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in=
 Patients with X-ALD</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 6, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"63"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-07-06-Viking-Therapeutics-to-Present-at-William-Blair-Bi=
otech-Focus-Conference-2022">Viking Therapeutics to Present at William Blai=
r Biotech Focus Conference 2022</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 16, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"64"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-05-16-Viking-Therapeutics-to-Present-at-H-C-Wainwright-G=
lobal-Investment-Conference">Viking Therapeutics to Present at H.C. Wainwri=
ght Global Investment Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 27, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"65" aria-describedby=3D"qtip-65"><a=
 href=3D"https://ir.vikingtherapeutics.com/2022-04-27-Viking-Therapeutics-R=
eports-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update">=
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provid=
es Corporate Update</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 20, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"66"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-04-20-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-First-Quarter-2022-on-April-27,-2022">Viking Therapeutics to Report Finan=
cial Results for First Quarter 2022 on April 27, 2022</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Conference Call Sche=
duled for Wednesday, April 27 at 4:30 p.m. Eastern Time SAN DIEGO, April 20=
, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX),=
 a clinical-stage...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 6, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"67"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-04-06-Viking-Therapeutics-to-Present-at-the-21st-Annual-=
Needham-Virtual-Healthcare-Conference">Viking Therapeutics to Present at th=
e 21st Annual Needham Virtual Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 8, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"68"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-03-08-Viking-Therapeutics-to-Present-at-Upcoming-Investo=
r-Conferences">Viking Therapeutics to Present at Upcoming Investor Conferen=
ces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 9, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"69" aria-describedby=3D"qtip-69"><a=
 href=3D"https://ir.vikingtherapeutics.com/2022-02-09-Viking-Therapeutics-R=
eports-Fourth-Quarter-and-Year-End-2021-Financial-Results-and-Provides-Corp=
orate-Update">Viking Therapeutics Reports Fourth Quarter and Year-End 2021 =
Financial Results and Provides Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
=09
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 7, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"70" aria-describedby=3D"qtip-70"><a=
 href=3D"https://ir.vikingtherapeutics.com/2022-02-07-Viking-Therapeutics-t=
o-Present-at-SVB-Leerink-11th-Annual-Global-Healthcare-Conference">Viking T=
herapeutics to Present at SVB Leerink 11th Annual Global Healthcare Confere=
nce</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 2, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"71"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-02-02-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Fourth-Quarter-and-Year-End-2021-on-February-9,-2022">Viking Therapeutics=
 to Report Financial Results for Fourth Quarter and Year-End 2021 on Februa=
ry 9, 2022</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Februa=
ry 9 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 24, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"72"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-01-24-Viking-Therapeutics-Announces-Clinical-Hold-on-Pha=
se-1b-Trial-of-VK0214-in-Patients-with-X-ALD">Viking Therapeutics Announces=
 Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD</a></div>=
</div>
	<div class=3D"wd_subtitle">FDA Requests Completion of One Additional Precl=
inical Study</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 10, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"73"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-=
1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist">=
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK273=
5, Company's Lead Dual GLP-1/GIP Receptor Agonist</a></div></div>
	<div class=3D"wd_subtitle">First-in-Human Clinical Trial for Novel Therape=
utic with Potential to Treat Range of Metabolic Disorders</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 3, 2022</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"74"><a href=3D"https://ir.vikingthe=
rapeutics.com/2022-01-03-Viking-Therapeutics-to-Present-at-H-C-Wainwright-B=
ioConnect-2022-Conference">Viking Therapeutics to Present at H.C. Wainwrigh=
t BioConnect 2022 Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 9, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"75"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-11-09-Viking-Therapeutics-to-Present-at-Stifel-2021-Virt=
ual-Healthcare-Conference">Viking Therapeutics to Present at Stifel 2021 Vi=
rtual Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 3, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"76"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-11-03-Viking-Therapeutics-Reports-Third-Quarter-2021-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports T=
hird Quarter 2021 Financial Results and Provides Corporate Update</a></div>=
</div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 1, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"77"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-N=
ovel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021">Viking Therapeutics Pre=
sents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek=C2=
=AE 2021</a></div></div>
	<div class=3D"wd_subtitle">The Company's Dual-Receptor Agonists Demonstrat=
e Potent Weight Loss and Improve Metabolic Profile in Diet-Induced Obese Mi=
ce</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 27, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"78"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-10-27-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Third-Quarter-2021-on-November-3,-2021">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2021 on November 3, 2021</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Novemb=
er 3 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 25, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"79" aria-describedby=3D"qtip-79"><a=
 href=3D"https://ir.vikingtherapeutics.com/2021-10-25-Viking-Therapeutics-t=
o-Present-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-=
2021">Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/G=
IP Agonists at ObesityWeek 2021</a></div></div>
	<div class=3D"wd_subtitle">Poster Presentations to Highlight Data From the=
 Company's Multi-Receptor Agonists in a Rodent Model of Obesity</div>
=09
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 5, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"80" aria-describedby=3D"qtip-80"><a=
 href=3D"https://ir.vikingtherapeutics.com/2021-10-05-Viking-Therapeutics-t=
o-Present-at-H-C-Wainwrights-5th-Annual-NASH-Investor-Conference">Viking Th=
erapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Confere=
nce</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 2, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"81"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-09-02-Viking-Therapeutics-to-Participate-in-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate in Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 28, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"82"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-07-28-Viking-Therapeutics-Reports-Second-Quarter-2021-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Second Quarter 2021 Financial Results and Provides Corporate Update</a></di=
v></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 21, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"83"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-07-21-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Second-Quarter-2021-on-July-28,-2021">Viking Therapeutics to Report Finan=
cial Results for Second Quarter 2021 on July 28, 2021</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, July 2=
8 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 24, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"84"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-06-24-Viking-Therapeutics-Announces-Initiation-of-Phase-=
1b-Clinical-Trial-of-VK0214-in-Patients-with-X-ALD">Viking Therapeutics Ann=
ounces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-A=
LD</a></div></div>
	<div class=3D"wd_subtitle">Novel, Selective Thyroid Receptor Beta Agonist =
Being Evaluated in X-ALD Patients Following Successful Completion of Phase =
1 Healthy Volunteer Study</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 17, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"85"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-06-17-Viking-Therapeutics-Announces-Results-from-Phase-1=
-Clinical-Trial-of-Novel-Oral-Thyroid-Receptor-Beta-Agonist-VK0214">Viking =
Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Th=
yroid Receptor Beta Agonist VK0214</a></div></div>
	<div class=3D"wd_subtitle">First-in-Human Clinical Trial of Novel, Selecti=
ve Thyroid Receptor Beta Agonist Demonstrates Encouraging Safety and Tolera=
bility; Predictable Pharmacokinetics</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 10, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"86"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-06-10-Viking-Therapeutics-to-Participate-in-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate in Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 28, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"87"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-04-28-Viking-Therapeutics-Reports-First-Quarter-2021-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports F=
irst Quarter 2021 Financial Results and Provides Corporate Update</a></div>=
</div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 21, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"88"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-04-21-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-First-Quarter-2021-on-April-28-2021">Viking Therapeutics to Report Financ=
ial Results for First Quarter 2021 on April 28, 2021</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, April =
28 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 7, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"89"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-04-07-Viking-Therapeutics-to-Present-at-20th-Annual-Need=
ham-Virtual-Healthcare-Conference">Viking Therapeutics to Present at 20th A=
nnual Needham Virtual Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 4, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"90"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-03-04-Viking-Therapeutics-to-Participate-at-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate at Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 17, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"91"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-02-17-Viking-Therapeutics-Reports-Fourth-Quarter-and-Yea=
r-End-2020-Financial-Results-and-Provides-Corporate-Update">Viking Therapeu=
tics Reports Fourth Quarter and Year-End 2020 Financial Results and Provide=
s Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 10, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"92"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-02-10-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Fourth-Quarter-and-Year-End-2020-on-February-17-2021">Viking Therapeutics=
 to Report Financial Results for Fourth Quarter and Year-End 2020 on Februa=
ry 17, 2021</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Februa=
ry 17 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 6, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"93"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-01-06-Viking-Therapeutics-Announces-Senior-Management-Te=
am-Appointments">Viking Therapeutics Announces Senior Management Team Appoi=
ntments</a></div></div>
	<div class=3D"wd_subtitle">Greg Zante Promoted to Chief Financial Officer =
and Marianne Mancini Promoted to Chief Operating Officer</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 5, 2021</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"94"><a href=3D"https://ir.vikingthe=
rapeutics.com/2021-01-05-Viking-Therapeutics-to-Present-at-H-C-Wainwright-B=
ioConnect-2021-Conference">Viking Therapeutics to Present at H.C. Wainwrigh=
t BioConnect 2021 Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 10, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"95"><a href=3D"https://ir.vikingthe=
rapeutics.com/2020-11-10-Viking-Therapeutics-to-Present-at-Stifel-Healthcar=
e-Conference-2020">Viking Therapeutics to Present at Stifel Healthcare Conf=
erence 2020</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 28, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"96"><a href=3D"https://ir.vikingthe=
rapeutics.com/2020-10-28-Viking-Therapeutics-Reports-Third-Quarter-2020-Fin=
ancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports T=
hird Quarter 2020 Financial Results and Provides Corporate Update</a></div>=
</div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 21, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"97"><a href=3D"https://ir.vikingthe=
rapeutics.com/2020-10-21-Viking-Therapeutics-to-Report-Financial-Results-fo=
r-Third-Quarter-2020-on-October-28-2020">Viking Therapeutics to Report Fina=
ncial Results for Third Quarter 2020 on October 28, 2020</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Octobe=
r 28 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 9, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"98"><a href=3D"https://ir.vikingthe=
rapeutics.com/2020-09-09-Viking-Therapeutics-Announces-Initiation-of-Phase-=
1-Clinical-Trial-of-VK0214">Viking Therapeutics Announces Initiation of Pha=
se 1 Clinical Trial of VK0214</a></div></div>
	<div class=3D"wd_subtitle">First-in-human clinical trial of novel, selecti=
ve thyroid receptor =C3=9F agonist for X-ALD</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 2, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"99"><a href=3D"https://ir.vikingthe=
rapeutics.com/2020-09-02-Viking-Therapeutics-to-Participate-in-Upcoming-Inv=
estor-Conferences">Viking Therapeutics to Participate in Upcoming Investor =
Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 28, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"100" aria-describedby=3D"qtip-100">=
<a href=3D"https://ir.vikingtherapeutics.com/2020-08-28-Viking-Therapeutics=
-Presents-New-Data-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoho=
lic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol-at-The-Digital-I=
nternational-Liver-Congress-TM-2020">Viking Therapeutics Presents New Data =
from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Dis=
ease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Live=
r Congress=E2=84=A2 2020</a></div></div>
	<div class=3D"wd_subtitle">VK2809-Treated Patients Maintain Durable, Stati=
stically Significant Liver Fat Reductions at Week 16, Four Weeks Following =
Last Study Dose</div>
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 20, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"101"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-08-20-Viking-Therapeutics-to-Present-New-Data-from-Phas=
e-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFL=
D-and-Elevated-LDL-Cholesterol-at-The-Digital-International-Liver-Congress-=
TM-2020">Viking Therapeutics to Present New Data from Phase 2 Study of VK28=
09 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated =
LDL-Cholesterol at The Digital International Liver Congress=E2=84=A2 2020</=
a></div></div>
	<div class=3D"wd_subtitle">Oral Presentation to Highlight New Efficacy Dat=
a Measured at Week 16 and Additional Week 12 Efficacy Data Stratified by Ba=
seline Characteristics and Risk Factors</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 29, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"102"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-07-29-Viking-Therapeutics-Reports-Second-Quarter-2020-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2020 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 28, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"103"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-07-28-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 22, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"104"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-07-22-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Second-Quarter-2020-on-July-29-2020">Viking Therapeutics to Report Finan=
cial Results for Second Quarter 2020 on July 29, 2020</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, July 2=
9 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 27, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"105" aria-describedby=3D"qtip-105">=
<a href=3D"https://ir.vikingtherapeutics.com/2020-05-27-Viking-Therapeutics=
-to-Participate-in-Upcoming-Investor-Conferences">Viking Therapeutics to Pa=
rticipate in Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 12, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"106"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-05-12-Viking-Therapeutics-Announces-2020-Annual-Meeting=
-of-Stockholders-to-be-Held-as-Virtual-Meeting">Viking Therapeutics Announc=
es 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting</a></d=
iv></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced a...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 30, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"107"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-04-30-Viking-Therapeutics-Reports-First-Quarter-2020-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
First Quarter 2020 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 28, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"108"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-04-28-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 23, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"109" aria-describedby=3D"qtip-109">=
<a href=3D"https://ir.vikingtherapeutics.com/2020-04-23-Viking-Therapeutics=
-to-Report-Financial-Results-for-First-Quarter-2020-on-April-30-2020">Vikin=
g Therapeutics to Report Financial Results for First Quarter 2020 on April =
30, 2020</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Thursday, April 3=
0 at 4:30 p.m. Eastern Time</div>
=09
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 7, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"110"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-04-07-Viking-Therapeutics-to-Participate-in-19th-Annual=
-Needham-Healthcare-Conference">Viking Therapeutics to Participate in 19th =
Annual Needham Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 26, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"111"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-02-26-Viking-Therapeutics-Reports-Fourth-Quarter-and-Ye=
ar-End-2019-Financial-Results-and-Provides-Corporate-Update">Viking Therape=
utics Reports Fourth Quarter and Year-End 2019 Financial Results and Provid=
es Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 24, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"112"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-02-24-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 19, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"113"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-02-19-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Fourth-Quarter-and-Year-End-2019-on-February-26-2020">Viking Therapeutic=
s to Report Financial Results for Fourth Quarter and Year-End 2019 on Febru=
ary 26, 2020</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Februa=
ry 26 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 6, 2020</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"114"><a href=3D"https://ir.vikingth=
erapeutics.com/2020-01-06-Viking-Therapeutics-to-Present-at-Biotech-Showcas=
e-2020">Viking Therapeutics to Present at Biotech Showcase 2020</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 19, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"115"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-11-19-Viking-Therapeutics-Announces-Initiation-of-Phase=
-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-=
Steatohepatitis-NASH">Viking Therapeutics Announces Initiation of Phase 2b =
VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Stea=
tohepatitis (NASH)</a></div></div>
	<div class=3D"wd_subtitle">Randomized, Double-Blind, Placebo-Controlled, M=
ulticenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 12, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"116"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-11-12-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 5, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"117"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-11-05-Viking-Therapeutics-Reports-Third-Quarter-2019-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Third Quarter 2019 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 8:30 a.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 31, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"118"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-10-31-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Third-Quarter-2019-on-November-5-2019">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2019 on November 5, 2019</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Tuesday, November=
 5 at 8:30 a.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 25, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"119"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-09-25-Viking-Therapeutics-to-Present-at-2019-Cantor-Glo=
bal-Healthcare-Conference">Viking Therapeutics to Present at 2019 Cantor Gl=
obal Healthcare Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 28, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"120" aria-describedby=3D"qtip-120">=
<a href=3D"https://ir.vikingtherapeutics.com/2019-08-28-Viking-Therapeutics=
-to-Participate-in-Upcoming-Investor-Conferences">Viking Therapeutics to Pa=
rticipate in Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 1, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"121"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-08-01-Viking-Therapeutics-Reports-Second-Quarter-2019-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2019 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 25, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"122"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-07-25-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Second-Quarter-2019-on-August-1-2019">Viking Therapeutics to Report Fina=
ncial Results for Second Quarter 2019 on August 1, 2019</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Thursday, August =
1 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 2, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"123"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-07-02-Viking-Therapeutics-Appoints-Kathy-Rouan-Ph-D-to-=
Board-of-Directors">Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Boa=
rd of Directors</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 28, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"124"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-05-28-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 2, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"125" aria-describedby=3D"qtip-125">=
<a href=3D"https://ir.vikingtherapeutics.com/2019-05-02-Viking-Therapeutics=
-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update=
">Viking Therapeutics Reports First Quarter 2019 Financial Results and Prov=
ides Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 30, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"126"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-04-30-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 25, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"127"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-04-25-Viking-Therapeutics-to-Report-Financial-Results-f=
or-First-Quarter-2019-on-May-2-2019">Viking Therapeutics to Report Financia=
l Results for First Quarter 2019 on May 2, 2019</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Thursday, May 2 a=
t 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 11, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"128"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-04-11-Viking-Therapeutics-Presents-New-Data-from-Phase-=
2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-=
and-Elevated-LDL-Cholesterol-at-The-International-Liver-Congress-TM-2019">V=
iking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patien=
ts with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Choleste=
rol at The International Liver Congress=E2=84=A2 2019</a></div></div>
	<div class=3D"wd_subtitle">Patients Receiving 5 mg Daily Doses of VK2809 D=
emonstrated Statistically Significant Median Reduction in Liver Fat Content=
 of 53.8%</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 4, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"129"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-04-04-Viking-Therapeutics-to-Present-New-Data-from-Phas=
e-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFL=
D-and-Elevated-LDL-Cholesterol-at-The-International-Liver-Congress-TM-2019"=
>Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Pa=
tients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Chol=
esterol at The International Liver Congress=E2=84=A2 2019</a></div></div>
	<div class=3D"wd_subtitle">Late-Breaker Presentation to Highlight Efficacy=
, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New =
Data from Study's 5 mg Treatment Arm</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 28, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"130"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-03-28-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 13, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"131"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-03-13-Viking-Therapeutics-Reports-Fourth-Quarter-and-Ye=
ar-End-2018-Financial-Results-and-Provides-Corporate-Update">Viking Therape=
utics Reports Fourth Quarter and Year-End 2018 Financial Results and Provid=
es Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 6, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"132"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-03-06-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Fourth-Quarter-and-Year-End-2018-on-March-13-2019">Viking Therapeutics t=
o Report Financial Results for Fourth Quarter and Year-End 2018 on March 13=
, 2019</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, March =
13 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 26, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"133"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-02-26-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences-and-Events">Viking Therapeutics to Participate in Upcomi=
ng Investor Conferences and Events</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 2, 2019</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"134"><a href=3D"https://ir.vikingth=
erapeutics.com/2019-01-02-Viking-Therapeutics-to-Present-at-Biotech-Showcas=
e-2019">Viking Therapeutics to Present at Biotech Showcase 2019</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 12, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"135"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-11-12-Viking-Therapeutics-Presents-Results-from-Phase-2=
-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-a=
nd-Elevated-LDL-Cholesterol-in-Oral-Late-Breaker-Presentation-at-The-Liver-=
Meeting-R-2018">Viking Therapeutics Presents Results from Phase 2 Study of =
VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Eleva=
ted LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting=
=C2=AE 2018</a></div></div>
	<div class=3D"wd_subtitle">Study Achieves Primary Endpoint, Demonstrating =
Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at =
Week 12</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 7, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"136"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-11-07-Viking-Therapeutics-Reports-Third-Quarter-2018-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Third Quarter 2018 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 31, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"137"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-10-31-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Third-Quarter-2018-on-November-7-2018">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2018 on November 7, 2018</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Novemb=
er 7 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 8, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"138"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-10-08-Viking-Therapeutics-Announces-Data-from-In-Vivo-S=
tudy-of-VK2809-Presented-at-Oral-Plenary-Session-of-the-88th-Annual-Meeting=
-of-American-Thyroid-Association-ATA">Viking Therapeutics Announces Data fr=
om In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th An=
nual Meeting of American Thyroid Association (ATA)</a></div></div>
	<div class=3D"wd_subtitle">VK2809 Treatment Leads to Rapid Reduction in St=
eatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Dis=
ease Type Ia (GSD Ia)</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 4, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"139"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-10-04-Viking-Therapeutics-Announces-VK2809-Phase-2-Stud=
y-Results-Selected-for-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-=
R-2018">Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected=
 for Oral Late-Breaker Presentation at The Liver Meeting=C2=AE 2018</a></di=
v></div>
	<div class=3D"wd_subtitle">Presentation to Highlight Positive 12-Week Data=
 for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with =
Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 1, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"140" aria-describedby=3D"qtip-140">=
<a href=3D"https://ir.vikingtherapeutics.com/2018-10-01-Viking-Therapeutics=
-Presents-Results-from-Phase-2-Study-of-VK5211-in-Patients-Recovering-from-=
Hip-Fracture-in-Plenary-Oral-Presentation-at-ASBMR-2018-Annual-Meeting">Vik=
ing Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients =
Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Ann=
ual Meeting</a></div></div>
	<div class=3D"wd_subtitle">Study Achieves Primary Endpoint, Demonstrating =
Statistically Significant, Dose-Dependent Increases in Lean Body Mass Rangi=
ng from 4.8% to 9.1% Following Treatment with VK5211</div>
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 26, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"141"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-09-26-Viking-Therapeutics-to-Participate-in-Upcoming-In=
vestor-Conferences">Viking Therapeutics to Participate in Upcoming Investor=
 Conferences</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 20, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"142"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-09-20-Viking-Therapeutics-Announces-Pricing-of-175-8-Mi=
llion-Public-Offering-of-Common-Stock">Viking Therapeutics Announces Pricin=
g of $175.8 Million Public Offering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 19, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"143"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-09-19-Viking-Therapeutics-Announces-Proposed-Public-Off=
ering-of-Common-Stock">Viking Therapeutics Announces Proposed Public Offeri=
ng of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 18, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"144"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-09-18-Viking-Therapeutics-Announces-Positive-Top-Line-R=
esults-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Li=
ver-Disease-NAFLD-and-Elevated-LDL-Cholesterol">Viking Therapeutics Announc=
es Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with =
Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol</a><=
/div></div>
	<div class=3D"wd_subtitle">Study Achieves Primary Endpoint, Demonstrating =
Statistically Significant Reductions in LDL-C in Patients Receiving VK2809<=
/div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 28, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"145" aria-describedby=3D"qtip-145">=
<a href=3D"https://ir.vikingtherapeutics.com/2018-08-28-Viking-Therapeutics=
-to-Participate-in-Upcoming-Investor-Conferences">Viking Therapeutics to Pa=
rticipate in Upcoming Investor Conferences</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 9, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"146"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-08-09-Viking-Therapeutics-Reports-Second-Quarter-2018-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2018 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 2, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"147"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-08-02-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Second-Quarter-2018-on-August-9-2018">Viking Therapeutics to Report Fina=
ncial Results for Second Quarter 2018 on August 9, 2018</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Thursday, August =
9 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 17, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"148"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-07-17-Viking-Therapeutics-Announces-VK5211-Phase-2-Stud=
y-Results-Selected-for-Plenary-Oral-Presentation-at-ASBMR-2018-Annual-Meeti=
ng">Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for=
 Plenary Oral Presentation at ASBMR 2018 Annual Meeting</a></div></div>
	<div class=3D"wd_subtitle">Presentation to Highlight Data for Novel, Orall=
y Available SARM in Patients Recovering from Hip Fracture Surgery</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 12, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"149"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-06-12-Viking-Therapeutics-Announces-Closing-of-Public-O=
ffering-of-Common-Stock">Viking Therapeutics Announces Closing of Public Of=
fering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 7, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"150"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-06-07-Viking-Therapeutics-Announces-Pricing-of-67-5-Mil=
lion-Public-Offering-of-Common-Stock">Viking Therapeutics Announces Pricing=
 of $67.5 Million Public Offering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 6, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"151"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-06-06-Viking-Therapeutics-Announces-Proposed-Public-Off=
ering-of-Common-Stock">Viking Therapeutics Announces Proposed Public Offeri=
ng of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 5, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"152"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-06-05-Viking-Therapeutics-Completes-Enrollment-in-Phase=
-2-Study-of-VK2809-in-Patients-with-Hypercholesterolemia-and-Non-Alcoholic-=
Fatty-Liver-Disease">Viking Therapeutics Completes Enrollment in Phase 2 St=
udy of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty=
 Liver Disease</a></div></div>
	<div class=3D"wd_subtitle">Top-Line Results Expected in Second Half of 201=
8</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 9, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"153"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-05-09-Viking-Therapeutics-Reports-First-Quarter-2018-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
First Quarter 2018 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 2, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"154"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-05-02-Viking-Therapeutics-to-Report-Financial-Results-f=
or-First-Quarter-2018-on-May-9-2018">Viking Therapeutics to Report Financia=
l Results for First Quarter 2018 on May 9, 2018</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, May 9 =
at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 7, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"155"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-03-07-Viking-Therapeutics-Reports-Fourth-Quarter-and-Ye=
ar-End-2017-Financial-Results-and-Provides-Corporate-Update">Viking Therape=
utics Reports Fourth Quarter and Year-End 2017 Financial Results and Provid=
es Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">Conference call scheduled for 4:30 p.m. ET toda=
y</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 6, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"156"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-03-06-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 28, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"157"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-02-28-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Fourth-Quarter-and-Year-End-2017-on-March-7-2018">Viking Therapeutics to=
 Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, =
2018</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, March =
7 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 7, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"158"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-02-07-Viking-Therapeutics-to-Present-at-2018-BIO-CEO-In=
vestor-Conference">Viking Therapeutics to Present at 2018 BIO CEO &amp; Inv=
estor Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 6, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"159"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-02-06-Viking-Therapeutics-Announces-Closing-of-Public-O=
ffering-of-Common-Stock">Viking Therapeutics Announces Closing of Public Of=
fering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 2, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"160"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-02-02-Viking-Therapeutics-Announces-Pricing-of-55-0-Mil=
lion-Public-Offering-of-Common-Stock">Viking Therapeutics Announces Pricing=
 of $55.0 Million Public Offering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 1, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"161"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-02-01-Viking-Therapeutics-Announces-Proposed-Public-Off=
ering-of-Common-Stock">Viking Therapeutics Announces Proposed Public Offeri=
ng of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 2, 2018</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"162"><a href=3D"https://ir.vikingth=
erapeutics.com/2018-01-02-Viking-Therapeutics-to-Present-at-Biotech-Showcas=
e-2018">Viking Therapeutics to Present at Biotech Showcase 2018</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 11, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"163"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-12-11-Viking-Therapeutics-Announces-Closing-of-Public-O=
ffering-of-Common-Stock">Viking Therapeutics Announces Closing of Public Of=
fering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 6, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"164"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-12-06-Viking-Therapeutics-Announces-Pricing-of-12-8-Mil=
lion-Public-Offering-of-Common-Stock">Viking Therapeutics Announces Pricing=
 of $12.8 Million Public Offering of Common Stock</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 5, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"165" aria-describedby=3D"qtip-165">=
<a href=3D"https://ir.vikingtherapeutics.com/2017-12-05-Viking-Therapeutics=
-Announces-Proposed-Public-Offering-of-Common-Stock">Viking Therapeutics An=
nounces Proposed Public Offering of Common Stock</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 28, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"166"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-11-28-Viking-Therapeutics-Announces-Positive-Top-Line-R=
esults-from-Phase-2-Study-of-VK5211-in-Patients-Recovering-from-Hip-Fractur=
e">Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Stu=
dy of VK5211 in Patients Recovering from Hip Fracture</a></div></div>
	<div class=3D"wd_subtitle">Study Achieves Primary Endpoint, Demonstrating =
Statistically Significant, Dose Dependent Increases in Lean Body Mass Rangi=
ng from 4.8% to 9.1% Following Treatment with VK5211</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 8, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"167"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-11-08-Viking-Therapeutics-Reports-Third-Quarter-2017-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Third Quarter 2017 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 hip fracture study nearing com=
pletion, data expected 4Q17</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 1, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"168"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-11-01-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Third-Quarter-2017-on-November-8-2017">Viking Therapeutics to Report Fin=
ancial Results for Third Quarter 2017 on November 8, 2017</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, Novemb=
er 8 at 4:30p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 24, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"169"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-10-24-Viking-Therapeutics-Presents-Results-from-In-Vivo=
-Study-of-VK2809-in-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH-at-=
the-Annual-Meeting-of-the-American-Association-for-the-Study-of-Liver-Disea=
ses-AASLD">Viking Therapeutics Presents Results from In Vivo Study of VK280=
9 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Me=
eting of the American Association for the Study of Liver Diseases (AASLD)</=
a></div></div>
	<div class=3D"wd_subtitle">Statistically Significant Reductions Observed i=
n Fibrosis, Steatosis and NAS Score Following Eight Weeks of VK2809 Treatme=
nt vs Vehicle Controls</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 23, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"170"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-10-23-Viking-Therapeutics-Presents-Results-from-Proof-o=
f-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy=
-X-ALD-at-the-87th-Annual-Meeting-of-the-American-Thyroid-Association">Viki=
ng Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in I=
n Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Me=
eting of the American Thyroid Association</a></div></div>
	<div class=3D"wd_subtitle">Results Demonstrate Significant Reductions in P=
lasma and Tissue Very Long Chain Fatty Acids, Potential Biomarkers of Thera=
peutic Effects, Following Treatment With VK0214</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 4, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"171"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-10-04-Viking-Therapeutics-Announces-Top-Line-Results-fr=
om-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleuk=
odystrophy-X-ALD">Viking Therapeutics Announces Top-Line Results from Proof=
-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrop=
hy (X-ALD)</a></div></div>
	<div class=3D"wd_subtitle">Treatment with VK0214 led to Significant Reduct=
ions in Plasma and Tissue Levels of Very Long Chain Fatty Acids (VLCFAs)</d=
iv>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 29, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"172"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-09-29-Viking-Therapeutics-Announces-Purchase-Agreements=
-for-up-to-16-25-Million-with-Lincoln-Park-Capital">Viking Therapeutics Ann=
ounces Purchase Agreements for up to $16.25 Million with Lincoln Park Capit=
al</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 25, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"173"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-09-25-Viking-Therapeutics-to-Host-Key-Opinion-Leader-Ev=
ent-to-Discuss-Musculoskeletal-Therapeutics-in-Hip-Fracture-and-Other-Setti=
ngs">Viking Therapeutics to Host Key Opinion Leader Event to Discuss Muscul=
oskeletal Therapeutics in Hip Fracture and Other Settings</a></div></div>
	<div class=3D"wd_subtitle">Presentation and Webcast to Highlight Novel SAR=
M VK5211 and Potential Therapeutic Applications</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 11, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"174"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-09-11-Viking-Therapeutics-Announces-Results-of-Gene-Exp=
ression-Analysis-from-In-Vivo-Study-of-VK2809-in-Non-Alcoholic-Steatohepati=
tis-NASH">Viking Therapeutics Announces Results of Gene Expression Analysis=
 from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)</a></=
div></div>
	<div class=3D"wd_subtitle">Statistically Significant Changes Observed in M=
ultiple NASH-Associated Genes Following Eight Weeks of VK2809 Treatment</di=
v>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 7, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"175"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-09-07-Viking-Therapeutics-Announces-Presentation-of-Dat=
a-from-In-Vivo-Proof-of-Concept-Study-of-VK2809-in-Glycogen-Storage-Disease=
-Ia-GSD-Ia-at-the-13th-International-Congress-of-Inborn-Errors-of-Metabolis=
m-ICIEM">Viking Therapeutics Announces Presentation of Data from In Vivo Pr=
oof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at t=
he 13th International Congress of Inborn Errors of Metabolism (ICIEM)</a></=
div></div>
	<div class=3D"wd_subtitle">VK2809 Leads to Statistically Significant Reduc=
tions in Liver Triglyceride Levels and Liver Weight Compared to Controls</d=
iv>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 5, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"176"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-09-05-Viking-Therapeutics-to-Present-at-Rodman-Renshaws=
-19th-Annual-Global-Investment-Conference">Viking Therapeutics to Present a=
t Rodman &amp; Renshaw's 19th Annual Global Investment Conference</a></div>=
</div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 9, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"177"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-08-09-Viking-Therapeutics-Reports-Second-Quarter-2017-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2017 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 hip fracture study fully enrol=
led, data expected 4Q17</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 2, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"178"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-08-02-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Second-Quarter-2017-After-Market-Close-on-August-9-2017">Viking Therapeu=
tics to Report Financial Results for Second Quarter 2017 After Market Close=
 on August 9, 2017</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, August=
 9 at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 12, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"179"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-07-12-Viking-Therapeutics-Completes-Enrollment-in-Phase=
-2-Study-of-VK5211-in-Patients-Recovering-from-Hip-Fracture">Viking Therape=
utics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recoverin=
g from Hip Fracture</a></div></div>
	<div class=3D"wd_subtitle">Top-Line Results Expected in the Fourth Quarter=
</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 6, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"180" aria-describedby=3D"qtip-180">=
<a href=3D"https://ir.vikingtherapeutics.com/2017-07-06-Viking-Therapeutics=
-Appoints-Charles-A-Rowland-Jr-to-Board-of-Directors">Viking Therapeutics A=
ppoints Charles A. Rowland Jr. to Board of Directors</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 14, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"181"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-06-14-Viking-Therapeutics-Announces-4-3-Million-Registe=
red-Direct-Offering">Viking Therapeutics Announces $4.3 Million Registered =
Direct Offering</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 6, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"182"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-06-06-Viking-Therapeutics-Announces-Promising-Top-Line-=
Results-from-In-Vivo-Study-of-VK2809-in-Non-Alcoholic-Steatohepatitis-NASH"=
>Viking Therapeutics Announces Promising Top Line Results from In Vivo Stud=
y of VK2809 in Non-Alcoholic Steatohepatitis (NASH)</a></div></div>
	<div class=3D"wd_subtitle">Statistically Significant Reductions Observed i=
n Fibrosis, Liver Collagen, Liver and Plasma Lipids, and NAS Following Eigh=
t Weeks of VK2809 Treatment</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 31, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"183"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-05-31-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 10, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"184"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-05-10-Viking-Therapeutics-Reports-First-Quarter-2017-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
First Quarter 2017 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 hip fracture study enrollment =
nearing completion</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 3, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"185"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-05-03-Viking-Therapeutics-to-Report-Financial-Results-f=
or-First-Quarter-2017-After-Market-Close-on-May-10-2017">Viking Therapeutic=
s to Report Financial Results for First Quarter 2017 After Market Close on =
May 10, 2017</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Wednesday, May 10=
 at 4:30p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 28, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"186"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-03-28-Viking-Therapeutics-to-Present-at-H-C-Wainwright-=
Co-s-1st-Annual-NASH-Investor-Conference">Viking Therapeutics to Present at=
 H.C. Wainwright &amp; Co.'s 1st Annual NASH Investor Conference</a></div><=
/div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 21, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"187"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-03-21-Viking-Therapeutics-Reports-Fourth-Quarter-and-Ye=
ar-End-2016-Financial-Results-and-Provides-Corporate-Update">Viking Therape=
utics Reports Fourth Quarter and Year-End 2016 Financial Results and Provid=
es Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 study in hip fracture proceedi=
ng, with results expected mid-year</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 2, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"188"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-03-02-Viking-Therapeutics-to-Report-Financial-Results-f=
or-Fourth-Quarter-and-Year-End-2016-After-Market-Close-on-March-21-2017">Vi=
king Therapeutics to Report Financial Results for Fourth Quarter and Year-E=
nd 2016 After Market Close on March 21, 2017</a></div></div>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Tuesday, March 21=
st at 4:30p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 28, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"189"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-02-28-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 14, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"190"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-02-14-Viking-Therapeutics-and-PoC-Capital-Enter-Agreeme=
nt-to-Fund-Clinical-Development-of-VK2809-in-Glycogen-Storage-Disease-Ia-GS=
D-Ia">Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical =
Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)</a></div></di=
v>
	<div class=3D"wd_subtitle">Company to File IND and Initiate Human Proof-of=
-Concept Study in 2017</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 9, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"191"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-02-09-Viking-Therapeutics-Announces-Initial-Results-fro=
m-In-Vivo-Proof-of-Concept-Study-of-VK2809-in-Glycogen-Storage-Disease-Ia-G=
SD-Ia">Viking Therapeutics Announces Initial Results from In Vivo Proof-of-=
Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)</a></div></=
div>
	<div class=3D"wd_subtitle">Treatment with Novel Thyroid Receptor Beta Agon=
ist Led to Significant Reductions in Liver Triglyceride Levels and Liver We=
ight Compared to Controls</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 7, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"192"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-02-07-Viking-Therapeutics-to-Present-at-2017-BIO-CEO-In=
vestor-Conference">Viking Therapeutics to Present at 2017 BIO CEO &amp; Inv=
estor Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 5, 2017</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"193"><a href=3D"https://ir.vikingth=
erapeutics.com/2017-01-05-Viking-Therapeutics-Announces-Senior-Level-Appoin=
tments-to-Management-Team">Viking Therapeutics Announces Senior Level Appoi=
ntments to Management Team</a></div></div>
	<div class=3D"wd_subtitle">Company Adds New SVP of Corporate Development, =
VP of Finance and Operations, and VP of Clinical Development to Support Ong=
oing Advancement of Development Pipeline</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 21, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"194"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-12-21-Viking-Therapeutics-to-Present-at-Biotech-Showcas=
e-2017">Viking Therapeutics to Present at Biotech Showcase 2017</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 6, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"195" aria-describedby=3D"qtip-195">=
<a href=3D"https://ir.vikingtherapeutics.com/2016-12-06-Viking-Therapeutics=
-Receives-Orphan-Drug-Designation-for-VK0214-from-the-U-S-Food-and-Drug-Adm=
inistration-for-the-Treatment-of-X-Linked-Adrenoleukodystrophy">Viking Ther=
apeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and=
 Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy</a>=
</div></div>
	<div class=3D"wd_subtitle">- Orphan Drug Designation program provides deve=
lopment and regulatory benefits to medications intended for the safe and ef=
fective treatment, diagnosis or prevention of rare diseases</div>
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 29, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"196"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-11-29-Viking-Therapeutics-to-Present-at-the-LD-Micro-Ma=
in-Event">Viking Therapeutics to Present at the LD Micro Main Event</a></di=
v></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 15, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"197" aria-describedby=3D"qtip-197">=
<a href=3D"https://ir.vikingtherapeutics.com/2016-11-15-Viking-Therapeutics=
-Presents-New-Clinical-Data-on-VK2809-in-Subjects-with-Elevated-Cholesterol=
-at-American-Heart-Association-Scientific-Sessions-2016">Viking Therapeutic=
s Presents New Clinical Data on VK2809 in Subjects with Elevated Cholestero=
l at American Heart Association Scientific Sessions 2016</a></div></div>
	<div class=3D"wd_subtitle">-- Statistically Significant Reductions in Athe=
rogenic Proteins Observed Following 14 Days of Treatment --</div>
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 10, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"198"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-11-10-Viking-Therapeutics-Reports-Third-Quarter-2016-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Third Quarter 2016 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">Conference Call and Webcast Today at 4:30 p.m. =
Eastern</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 3, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"199"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-11-03-Viking-Therapeutics-to-Host-Conference-Call-to-Di=
scuss-Third-Quarter-2016-Financial-Results">Viking Therapeutics to Host Con=
ference Call to Discuss Third Quarter 2016 Financial Results</a></div></div=
>
	<div class=3D"wd_subtitle">Conference Call Scheduled for Thursday, Novembe=
r 10th at 4:30 p.m. Eastern Time</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, announced today...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 13, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"200"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-10-13-Viking-Therapeutics-to-Present-at-the-2016-BIO-In=
vestor-Forum">Viking Therapeutics to Present at the 2016 BIO Investor Forum=
</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 4, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"201"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-10-04-Viking-Therapeutics-Doses-First-Patient-in-Phase-=
2-Clinical-Trial-of-VK2809-in-Patients-with-Hypercholesterolemia-and-Non-Al=
coholic-Fatty-Liver-Disease">Viking Therapeutics Doses First Patient in Pha=
se 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non=
-Alcoholic Fatty Liver Disease</a></div></div>
	<div class=3D"wd_subtitle">Novel Oral Thyroid Receptor Agonist has Unique =
Potential to Simultaneously Improve Plasma Lipid Profile and Reduce Hepatic=
 Steatosis</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 26, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"202"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-09-26-Viking-Therapeutics-Presents-Positive-Proof-of-Co=
ncept-Data-for-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-A=
LD-at-the-86th-Annual-Meeting-of-the-American-Thyroid-Association">Viking T=
herapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo M=
odel of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of=
 the American Thyroid Association</a></div></div>
	<div class=3D"wd_subtitle">VK0214 Treatment Triggers Rapid, Progressive an=
d Statistically Significant Reductions in Multiple Very Long Chain Fatty Ac=
ids (VLCFAs) Compared to Controls</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 7, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"203"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-09-07-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 1, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"204"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-09-01-Viking-Therapeutics-Presents-Phase-1-Data-and-Hig=
hlights-Ongoing-Phase-2-Study-of-VK5211-at-5th-Fragility-Fracture-Network-G=
lobal-Congress-2016">Viking Therapeutics Presents Phase 1 Data and Highligh=
ts Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global=
 Congress 2016</a></div></div>
	<div class=3D"wd_subtitle">- Phase 1 Data Show Predictable PK, Favorable S=
afety Profile in Older Women and Men -</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 25, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"205" aria-describedby=3D"qtip-205">=
<a href=3D"https://ir.vikingtherapeutics.com/2016-08-25-Viking-Therapeutics=
-Enters-Into-12-5-Million-Common-Stock-Purchase-Agreement-with-Aspire-Capit=
al">Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agr=
eement with Aspire Capital</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 10, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"206"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-08-10-Viking-Therapeutics-Reports-Second-Quarter-2016-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2016 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 study in hip fracture proceedi=
ng in U.S., expanding in EU</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 26, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"207"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-07-26-Viking-Therapeutics-Announces-Positive-Top-Line-R=
esults-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-A=
drenoleukodystrophy-X-ALD">Viking Therapeutics Announces Positive Top-Line =
Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked =
Adrenoleukodystrophy (X-ALD)</a></div></div>
	<div class=3D"wd_subtitle">Treatment with VK0214 Significantly Reduced Lev=
els of Very Long Chain Fatty Acids (VLCFAs) Compared to Controls</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel therapies for metabolic and endocrine =
disorders, today announced...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 24, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"208"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-05-24-Viking-Therapeutics-to-Present-at-the-2016-Marcum=
-Microcap-Conference">Viking Therapeutics to Present at the 2016 Marcum Mic=
rocap Conference</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 10, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"209"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-05-10-Viking-Therapeutics-Reports-First-Quarter-2016-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
First Quarter 2016 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">- VK5211 Phase 2 study for hip fracture ongoing=
</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 2, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"210" aria-describedby=3D"qtip-210">=
<a href=3D"https://ir.vikingtherapeutics.com/2016-05-02-Viking-Therapeutics=
-Announces-Full-Exercise-of-Over-Allotment-Option">Viking Therapeutics Anno=
unces Full Exercise of Over-Allotment Option</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 13, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"211"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-04-13-Viking-Therapeutics-Announces-Closing-of-Public-O=
ffering-of-Common-Stock-and-Warrants">Viking Therapeutics Announces Closing=
 of Public Offering of Common Stock and Warrants</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on=
 the development of novel, first-in-class or best-in-class therapies for me=
tabolic and endocrine...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 11, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"212"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-04-11-Viking-Therapeutics-Presents-Positive-Phase-1b-Cl=
inical-Data-on-VK2809-in-Hypercholesterolemic-Subjects">Viking Therapeutics=
 Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic=
 Subjects</a></div></div>
	<div class=3D"wd_subtitle">Novel Oral Thyroid Receptor Agonist Triggers Su=
bstantial and Clinically Meaningful Reductions in LDL Cholesterol, Triglyce=
rides and Key Atherogenic Proteins</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 8, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"213" aria-describedby=3D"qtip-213">=
<a href=3D"https://ir.vikingtherapeutics.com/2016-04-08-Viking-Therapeutics=
-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Warrants">Viking =
Therapeutics Announces Pricing of Public Offering of Common Stock and Warra=
nts</a></div></div>
=09
=09
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Mar 8, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"214"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-03-08-Viking-Therapeutics-Reports-Fourth-Quarter-and-Ye=
ar-End-2015-Financial-Results-and-Provides-Corporate-Update">Viking Therape=
utics Reports Fourth Quarter and Year-End 2015 Financial Results and Provid=
es Corporate Update</a></div></div>
	<div class=3D"wd_subtitle">- Key Advancements in Three Lead Programs:  VK5=
211, VK2809 and VK0214</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 2, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"215"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-02-02-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jan 7, 2016</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"216"><a href=3D"https://ir.vikingth=
erapeutics.com/2016-01-07-Viking-Therapeutics-to-Present-at-Biotech-Showcas=
e-2016">Viking Therapeutics to Present at Biotech Showcase 2016</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Dec 7, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"217"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-12-07-Viking-Therapeutics-Presents-New-Data-on-VK5211-D=
emonstrating-Robust-Weight-Gain-in-Primates-Following-13-Weeks-of-Treatment=
">Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weig=
ht Gain in Primates Following 13 Weeks of Treatment</a></div></div>
	<div class=3D"wd_subtitle">Results Presented at 8th Int'l Conference on Ca=
chexia, Sarcopenia and Muscle Wasting</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 23, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"218"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-11-23-Viking-Therapeutics-and-Kennedy-Krieger-Institute=
-Sign-Collaboration-Agreement-to-Evaluate-Novel-Thyroid-Beta-Agonists-for-X=
-Linked-Adrenoleukodystrophy-X-ALD">Viking Therapeutics and Kennedy Krieger=
 Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agon=
ists for X-Linked Adrenoleukodystrophy (X-ALD)</a></div></div>
	<div class=3D"wd_subtitle">Kennedy Krieger's X-ALD Research Group to Evalu=
ate Viking's Thyroid Beta Agonists, including VK0214
</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Kennedy Krieger Inst=
itute and Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-s=
tage biopharmaceutical company focused on the development of novel therapie=
s for metabolic and...</p>
</div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 17, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"219"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-11-17-Viking-Therapeutics-Submits-Investigational-New-D=
rug-IND-Application-to-Conduct-Phase-2-Clinical-Trial-of-VK2809-in-Patients=
-with-Hypercholesterolemia-and-Fatty-Liver-Disease">Viking Therapeutics Sub=
mits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical=
 Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Dise=
ase</a></div></div>
	<div class=3D"wd_subtitle">Company Expects to Initiate Study of Novel Thyr=
oid Receptor Agonist by End of 2015</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 12, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"220"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-11-12-Viking-Therapeutics-to-Present-at-Upcoming-Life-S=
cience-Industry-Events">Viking Therapeutics to Present at Upcoming Life Sci=
ence Industry Events</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 5, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"221"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-11-05-Viking-Therapeutics-Reports-Third-Quarter-2015-Fi=
nancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports =
Third Quarter 2015 Financial Results and Provides Corporate Update</a></div=
></div>
	<div class=3D"wd_subtitle">- Commenced Dosing in Phase 2 Study of VK5211 i=
n Acute Hip Fracture</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Nov 3, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"222"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-11-03-Viking-Therapeutics-Initiates-Phase-2-Trial-of-VK=
5211-in-Patients-Recovering-From-Hip-Fracture">Viking Therapeutics Initiate=
s Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture</a></div=
></div>
	<div class=3D"wd_subtitle">Oral Small Molecule SARM Designed to Stimulate =
Muscle and Bone Formation Post-Surgery</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 20, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"223"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-10-20-Viking-Therapeutics-Completes-Safety-Tolerability=
-and-Pharmacokinetic-Study-of-VK5211-a-Selective-Androgen-Receptor-Modulato=
r-SARM-in-Healthy-Elderly-Subjects">Viking Therapeutics Completes Safety, T=
olerability and Pharmacokinetic Study of VK5211, a Selective Androgen Recep=
tor Modulator (SARM), in Healthy Elderly Subjects</a></div></div>
	<div class=3D"wd_subtitle">Positive Results Pave Way for Advancing VK5211 =
into Phase 2 Trial in Hip Fracture Patients</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Oct 5, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"224"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-10-05-Viking-Therapeutics-to-Present-at-Upcoming-Invest=
or-Conferences">Viking Therapeutics to Present at Upcoming Investor Confere=
nces</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>Viking Therapeutics,=
 Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company=
 focused on the development of novel, first-in-class or best-in-class thera=
pies for metabolic and...</p></div>
=09
=09
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">Sep 1, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"225"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-09-01-Viking-Therapeutics-Initiates-Clinical-Trial-for-=
VK5211-a-Selective-Androgen-Receptor-Modulator-SARM-for-Acute-Hip-Fracture"=
>Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Andro=
gen Receptor Modulator (SARM), for Acute Hip Fracture</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, Sept. 1, =
2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX)=
, a clinical-stage biopharmaceutical company focused on the development of =
novel, first-in-class or...</p></div>
=09
=09
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Aug 13, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"226"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-08-13-Viking-Therapeutics-Reports-Second-Quarter-2015-F=
inancial-Results-and-Provides-Corporate-Update">Viking Therapeutics Reports=
 Second Quarter 2015 Financial Results and Provides Corporate Update</a></d=
iv></div>
	<div class=3D"wd_subtitle">Phase 2 Clinical Studies to Begin in Acute Hip =
Fracture and Hypercholesterolemia/Fatty Liver Disease
</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, Aug. 13, =
2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX)=
, a clinical-stage biopharmaceutical company focused on the development of =
novel, first-in-class or...</p>
</div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-08-13-Vikin=
g-Therapeutics-Reports-Second-Quarter-2015-Financial-Results-and-Provides-C=
orporate-Update#assets_43_14-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 29, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"227"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-07-29-Viking-Therapeutics-to-Conduct-Phase-2-Trial-of-V=
K2809-in-Patients-With-Cholesterolemia-and-Fatty-Liver-Disease">Viking Ther=
apeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemi=
a and Fatty Liver Disease</a></div></div>
	<div class=3D"wd_subtitle">Company Expects to Initiate Study of Novel Thyr=
oid Receptor Agonist in Q4 2015
</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, July 29, =
2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX)=
, a clinical-stage biopharmaceutical company focused on the development of =
novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-07-29-Vikin=
g-Therapeutics-to-Conduct-Phase-2-Trial-of-VK2809-in-Patients-With-Choleste=
rolemia-and-Fatty-Liver-Disease#assets_43_15-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jul 14, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"228"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-07-14-Viking-Therapeutics-Submits-Investigational-New-D=
rug-IND-Application-for-VK5211-a-Selective-Androgen-Receptor-Modulator-SARM=
-in-Acute-Hip-Fracture">Viking Therapeutics Submits Investigational New Dru=
g (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SA=
RM), in Acute Hip Fracture</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA -- (Ma=
rketwired) -- 07/14/15 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-07-14-Vikin=
g-Therapeutics-Submits-Investigational-New-Drug-IND-Application-for-VK5211-=
a-Selective-Androgen-Receptor-Modulator-SARM-in-Acute-Hip-Fracture#assets_4=
3_16-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Jun 4, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"229"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-06-04-Viking-Therapeutics-Inc-Announces-Chairman-Appoin=
tment">Viking Therapeutics, Inc. Announces Chairman Appointment</a></div></=
div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA -- (Ma=
rketwired) -- 06/04/15 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-06-04-Vikin=
g-Therapeutics-Inc-Announces-Chairman-Appointment#assets_43_17-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>



	<li class=3D"wd_item">
<div class=3D"wd_date">May 29, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"230"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-05-29-Viking-Therapeutics-Inc-Announces-Full-Exercise-o=
f-Over-Allotment-Option">Viking Therapeutics, Inc. Announces Full Exercise =
of Over-Allotment Option</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA -- (Ma=
rketwired) -- 05/29/15 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-05-29-Vikin=
g-Therapeutics-Inc-Announces-Full-Exercise-of-Over-Allotment-Option#assets_=
43_18-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 22, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"231"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-05-22-Viking-Signs-Broad-Licensing-Deal-with-Ligand-Pha=
rmaceuticals-for-Rights-to-Five-Novel-Therapeutic-Programs">Viking Signs Br=
oad Licensing Deal with Ligand Pharmaceuticals for Rights to Five Novel The=
rapeutic Programs</a></div></div>
	<div class=3D"wd_subtitle">Ligand to invest $2.5 million to support develo=
pment of novel treatments for diabetes, cancer cachexia, dyslipidemia and a=
nemia</div>
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA, May 2=
2, 2014 =E2=80=93 Viking Therapeutics, Inc., a clinical-stage biopharmaceut=
ical company focused on the development of novel, first-in-class or best-in=
-class therapies for metabolic...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-05-22-Vikin=
g-Signs-Broad-Licensing-Deal-with-Ligand-Pharmaceuticals-for-Rights-to-Five=
-Novel-Therapeutic-Programs#assets_43_22-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">May 5, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"232"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-05-05-Viking-Therapeutics-Inc-Announces-Closing-of-Init=
ial-Public-Offering">Viking Therapeutics, Inc. Announces Closing of Initial=
 Public Offering</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA -- (Ma=
rketwired) -- 05/05/15 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-05-05-Vikin=
g-Therapeutics-Inc-Announces-Closing-of-Initial-Public-Offering#assets_43_1=
9-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Apr 29, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"233"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-04-29-Viking-Therapeutics-Inc-Announces-Pricing-of-Init=
ial-Public-Offering">Viking Therapeutics, Inc. Announces Pricing of Initial=
 Public Offering</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA -- (Ma=
rketwired) -- 04/29/15 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-04-29-Vikin=
g-Therapeutics-Inc-Announces-Pricing-of-Initial-Public-Offering#assets_43_2=
0-4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

	<li class=3D"wd_item">
<div class=3D"wd_date">Feb 2, 2015</div>
<div class=3D"wd_item_wrapper">
=09
	<div class=3D"wd_title"><div class=3D"wd_tooltip-trigger" data-trigger=3D"=
hover" data-parent=3D".wd_item" data-content=3D".wd_summary" data-classes=
=3D"qtip-shadow qtip-rounded wd_tooltip" data-position=3D"{&quot;my&quot;:&=
quot;top left&quot;,&quot;at&quot;:&quot;bottom right&quot;,&quot;target&qu=
ot;:&quot;mouse&quot;}" data-hasqtip=3D"234"><a href=3D"https://ir.vikingth=
erapeutics.com/2015-02-02-Viking-Therapeutics-Announces-Research-Collaborat=
ion-for-Novel-Thyroid-Beta-Agonists-as-Potential-Treatment-for-X-Linked-Adr=
enoleukodystrophy">Viking Therapeutics Announces Research Collaboration for=
 Novel Thyroid Beta Agonists as Potential Treatment for X-Linked Adrenoleuk=
odystrophy</a></div></div>
=09
	<div class=3D"wd_summary" style=3D"display: none;"><p>SAN DIEGO, CA =E2=80=
=93 February 2, 2015 =E2=80=93 Viking Therapeutics, Inc., a clinical-stage =
company focused on developing novel, first-in-class or best-in-class therap=
ies for metabolic and endocrine...</p></div>
=09
	<ul class=3D"wd_layout-simple wd_asset_type_link_list"><li class=3D"wd_ass=
et_type_link"><a href=3D"https://ir.vikingtherapeutics.com/2015-02-02-Vikin=
g-Therapeutics-Announces-Research-Collaboration-for-Novel-Thyroid-Beta-Agon=
ists-as-Potential-Treatment-for-X-Linked-Adrenoleukodystrophy#assets_43_21-=
4">
<span class=3D"wd_icon fa fa-file-text-o" title=3D"Documents" style=3D"font=
-size: 1.2em;"></span>
<span class=3D"wd_title">Documents</span>
<span class=3D"wd_count">1</span>
</a>
</li></ul>
</div>
</li>

</ul>
<div class=3D"wd_load_more-container" style=3D"display: none;"><div class=
=3D"wd_load_more-error" style=3D"display:none;"></div><button class=3D"wd_l=
oad_more-trigger" data-args=3D"{&quot;s&quot;:&quot;43&quot;}" data-total=
=3D"235" data-offset=3D"5" data-limit=3D"5" data-content=3D".wd_item_list" =
style=3D"display: none;">Load More</button><div class=3D"wd_load_more-loadi=
ng" style=3D"display: none;">Loading...</div></div>


</div>
</div>										</div>
										<!-- END CONTENT -->
																			</div>
								</div>
							</div>
							<p>&nbsp;</p>
							<div class=3D"clear"></div>
						</article>
					</section>
					<div class=3D"clearfix"></div>
					<div class=3D"clearfix"></div>
				</div>
				<div class=3D"clearfix"></div>
			</div>
			<div class=3D"footer_wrap">
				<footer id=3D"footer" class=3D"container">
					<div class=3D"clear"></div>
					<div class=3D"sub_footer_wrap">
						<div id=3D"sidebar" class=3D"sub_footer container">
							<div class=3D"footerTop row">
							<div class=3D"span3">
										 <div id=3D"text-2" class=3D"widget widget_text"><h4>&nbsp;</h4>	=
		<div class=3D"textwidget"><a href=3D"http://www.vikingtherapeutics.com/">=
<div style=3D"vertical-align:top;width:204px;height:88px;"><img src=3D"http=
s://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-gray-1.png" a=
lt=3D"viking therapeutics" width=3D"204" height=3D"88"></div></a></div>
		</div>									</div>
								<div class=3D"span3">
									<div id=3D"text-2" class=3D"widget widget_text">
										<h4>About</h4>
										<div class=3D"textwidget">
											Viking Therapeutics is developing novel therapeutics for patient=
s suffering from metabolic and endocrine disorders.
										</div>
									</div>
								</div>
								<div class=3D"span3">
									<!---<div id=3D"text-3" class=3D"widget widget_text">
										<h4>Focus</h4>
										<div class=3D"textwidget">
											We are focused on specialty metabolic and endocrine indications.=
								=09
										</div>
									</div>--->
								</div>
								<div class=3D"span3">
									<!---<div id=3D"text-4" class=3D"widget widget_text">
										<h4>VK5211</h4>
										<div class=3D"textwidget">VK5211 is an orally available small mol=
ecule drug candidate with a differentiated mechanism of action.
										</div>
									</div>--->
								</div>
								<div class=3D"span3">
									<div id=3D"text-5" class=3D"widget widget_text">
										<h4>Contact</h4>
										<div class=3D"textwidget"><a href=3D"mailto:info@vikingtherapeuti=
cs.com">General Information</a><br>
											<a href=3D"mailto:BD@vikingtherapeutics.com">Business Developmen=
t</a><br>
											=C2=A92025 Viking Therapeutics
											<br>
											<a href=3D"http://www.vikingtherapeutics.com/terms-of-use/">Term=
s of Use</a>
											<br>
											<a href=3D"http://www.vikingtherapeutics.com/privacy-policy/">Pr=
ivacy Policy</a>
										</div>
									</div>
								</div>
							</div>
						</div>
					</div>
				</footer>
			</div>
			<div class=3D"container">
				<div class=3D"row">
					<div class=3D"span9">
						<div class=3D"footer_left">
							<div class=3D"logo"></div>
							<p></p>
						</div>
					</div>
					<div class=3D"span3">
						<div class=3D"pull-right">
							<ul class=3D"nav_social"></ul>
						</div>
					</div>
				</div>
			</div>
		</div>
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09
	=09

		<!-- InvestorRoom Scripts -->
	=09
	=09
<!-- begin spin_special_output(body_end) -->

<!-- Piwik Tracking Code -->


<!-- End Piwik Tracking Code -->
	=09
<!-- end spin_special_output(body_end) -->

<div id=3D"qtip-3" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_t=
ooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" =
aria-atomic=3D"false" aria-describedby=3D"qtip-3-content" aria-hidden=3D"fa=
lse" data-qtip-id=3D"3" style=3D"z-index: 15001;"><div class=3D"qtip-tip" s=
tyle=3D"background-color: transparent !important; border: 0px !important; w=
idth: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display: bl=
ock;"><canvas style=3D"background-color: transparent !important; border: 0p=
x !important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-c=
ontent" id=3D"qtip-3-content" aria-atomic=3D"true"><div class=3D"wd_summary=
" style=3D"display: block;"><p>Conference call scheduled for 4:30 p.m. ET t=
oday Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Plan=
ned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity=
...</p></div></div></div><div id=3D"qtip-0" class=3D"qtip qtip-default qtip=
-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"ale=
rt" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-0-c=
ontent" aria-hidden=3D"true" data-qtip-id=3D"0" style=3D"z-index: 15002;"><=
div class=3D"qtip-tip" style=3D"background-color: transparent !important; b=
order: 0px !important; width: 6px; height: 6px; line-height: 6px; left: 5px=
; top: -6px; display: block;"><canvas style=3D"background-color: transparen=
t !important; border: 0px !important;" width=3D"6" height=3D"6"></canvas></=
div><div class=3D"qtip-content" id=3D"qtip-0-content" aria-atomic=3D"true">=
<div class=3D"wd_summary" style=3D"display: block;"><p>13-Week Study Evalua=
ting the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expect=
ed in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, I=
nc. ("Viking") (NASDAQ:...</p></div></div></div><div id=3D"qtip-2" class=3D=
"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" trackin=
g=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-=
describedby=3D"qtip-2-content" aria-hidden=3D"false" data-qtip-id=3D"2" sty=
le=3D"z-index: 15003;"><div class=3D"qtip-tip" style=3D"background-color: t=
ransparent !important; border: 0px !important; width: 6px; height: 6px; lin=
e-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"back=
ground-color: transparent !important; border: 0px !important;" width=3D"6" =
height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-2-conten=
t" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;"=
><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage b=
iopharmaceutical company focused on the development of novel therapies for =
metabolic and endocrine disorders, today announced...</p></div></div></div>=
<div id=3D"qtip-4" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_t=
ooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" =
aria-atomic=3D"false" aria-describedby=3D"qtip-4-content" aria-hidden=3D"tr=
ue" data-qtip-id=3D"4" style=3D"z-index: 15004;"><div class=3D"qtip-tip" st=
yle=3D"background-color: transparent !important; border: 0px !important; wi=
dth: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display: blo=
ck;"><canvas style=3D"background-color: transparent !important; border: 0px=
 !important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-co=
ntent" id=3D"qtip-4-content" aria-atomic=3D"true"><div class=3D"wd_summary"=
 style=3D"display: block;"><p>Conference Call Scheduled for Wednesday, Febr=
uary 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- V=
iking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage...</p>=
</div></div></div><div id=3D"qtip-10" class=3D"qtip qtip-default qtip-shado=
w qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" ar=
ia-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-10-conten=
t" aria-hidden=3D"false" data-qtip-id=3D"10" style=3D"z-index: 15005;"><div=
 class=3D"qtip-tip" style=3D"background-color: transparent !important; bord=
er: 0px !important; width: 6px; height: 6px; line-height: 6px; left: 5px; t=
op: -6px; display: block;"><canvas style=3D"background-color: transparent !=
important; border: 0px !important;" width=3D"6" height=3D"6"></canvas></div=
><div class=3D"qtip-content" id=3D"qtip-10-content" aria-atomic=3D"true"><d=
iv class=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, I=
nc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company f=
ocused on the development of novel therapies for metabolic and endocrine di=
sorders, today announced...</p></div></div></div><div id=3D"qtip-15" class=
=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" trac=
king=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" ar=
ia-describedby=3D"qtip-15-content" aria-hidden=3D"false" data-qtip-id=3D"15=
" style=3D"z-index: 15006;"><div class=3D"qtip-tip" style=3D"background-col=
or: transparent !important; border: 0px !important; width: 6px; height: 6px=
; line-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D=
"background-color: transparent !important; border: 0px !important;" width=
=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-1=
5-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display:=
 block;"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical=
-stage biopharmaceutical company focused on the development of novel therap=
ies for metabolic and endocrine disorders, today announced...</p></div></di=
v></div><div id=3D"qtip-19" class=3D"qtip qtip-default qtip-shadow qtip-rou=
nded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D=
"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-19-content" aria-hi=
dden=3D"false" data-qtip-id=3D"19" style=3D"z-index: 15007;"><div class=3D"=
qtip-tip" style=3D"background-color: transparent !important; border: 0px !i=
mportant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; =
display: block;"><canvas style=3D"background-color: transparent !important;=
 border: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div clas=
s=3D"qtip-content" id=3D"qtip-19-content" aria-atomic=3D"true"><div class=
=3D"wd_summary" style=3D"display: block;"><p>Up to 75% of Patients Treated =
with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compa=
red to 29% for Placebo (p=3D0.0001) Up to 57% of VK2809-Treated Patients Ac=
hieved =E2=89=A51-Stage...</p></div></div></div><div id=3D"qtip-20" class=
=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" trac=
king=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" ar=
ia-describedby=3D"qtip-20-content" aria-hidden=3D"false" data-qtip-id=3D"20=
" style=3D"z-index: 15008;"><div class=3D"qtip-tip" style=3D"background-col=
or: transparent !important; border: 0px !important; width: 6px; height: 6px=
; line-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D=
"background-color: transparent !important; border: 0px !important;" width=
=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-2=
0-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display:=
 block;"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical=
-stage biopharmaceutical company focused on the development of novel therap=
ies for metabolic and endocrine disorders, today announced...</p></div></di=
v></div><div id=3D"qtip-24" class=3D"qtip qtip-default qtip-shadow qtip-rou=
nded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D=
"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-24-content" aria-hi=
dden=3D"false" data-qtip-id=3D"24" style=3D"z-index: 15009;"><div class=3D"=
qtip-tip" style=3D"background-color: transparent !important; border: 0px !i=
mportant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; =
display: block;"><canvas style=3D"background-color: transparent !important;=
 border: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div clas=
s=3D"qtip-content" id=3D"qtip-24-content" aria-atomic=3D"true"><div class=
=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Vi=
king") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused o=
n the development of novel therapies for metabolic and endocrine disorders,=
 today announced...</p></div></div></div><div id=3D"qtip-25" class=3D"qtip =
qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"f=
alse" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-descri=
bedby=3D"qtip-25-content" aria-hidden=3D"false" data-qtip-id=3D"25" style=
=3D"z-index: 15010;"><div class=3D"qtip-tip" style=3D"background-color: tra=
nsparent !important; border: 0px !important; width: 6px; height: 6px; line-=
height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"backgr=
ound-color: transparent !important; border: 0px !important;" width=3D"6" he=
ight=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-25-content=
" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;">=
<p>Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage bi=
opharmaceutical company focused on the development of novel therapies for m=
etabolic and endocrine disorders, today announced...</p></div></div></div><=
div id=3D"qtip-30" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_t=
ooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" =
aria-atomic=3D"false" aria-describedby=3D"qtip-30-content" aria-hidden=3D"f=
alse" data-qtip-id=3D"30" style=3D"z-index: 15011;"><div class=3D"qtip-tip"=
 style=3D"background-color: transparent !important; border: 0px !important;=
 width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display: =
block;"><canvas style=3D"background-color: transparent !important; border: =
0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip=
-content" id=3D"qtip-30-content" aria-atomic=3D"true"><div class=3D"wd_summ=
ary" style=3D"display: block;"><p>Late Breaking Poster Presentation Reports=
 New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups=
, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fib=
rosis...</p></div></div></div><div id=3D"qtip-35" class=3D"qtip qtip-defaul=
t qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=
=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"q=
tip-35-content" aria-hidden=3D"false" data-qtip-id=3D"35" style=3D"z-index:=
 15012;"><div class=3D"qtip-tip" style=3D"background-color: transparent !im=
portant; border: 0px !important; width: 6px; height: 6px; line-height: 6px;=
 left: 5px; top: -6px; display: block;"><canvas style=3D"background-color: =
transparent !important; border: 0px !important;" width=3D"6" height=3D"6"><=
/canvas></div><div class=3D"qtip-content" id=3D"qtip-35-content" aria-atomi=
c=3D"true"><div class=3D"wd_summary" style=3D"display: block;"><p>Presentat=
ion Highlights Previously Reported Weight Loss of up to 7.8% From Baseline =
as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days=
 of Treatment with VK2735 SAN DIEGO,...</p></div></div></div><div id=3D"qti=
p-38" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-p=
os-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=
=3D"false" aria-describedby=3D"qtip-38-content" aria-hidden=3D"false" data-=
qtip-id=3D"38" style=3D"z-index: 15013;"><div class=3D"qtip-tip" style=3D"b=
ackground-color: transparent !important; border: 0px !important; width: 6px=
; height: 6px; line-height: 6px; left: 5px; top: -6px; display: block;"><ca=
nvas style=3D"background-color: transparent !important; border: 0px !import=
ant;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" i=
d=3D"qtip-38-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=
=3D"display: block;"><p>Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), =
a clinical-stage biopharmaceutical company focused on the development of no=
vel therapies for metabolic and endocrine disorders, today announced...</p>=
</div></div></div><div id=3D"qtip-40" class=3D"qtip qtip-default qtip-shado=
w qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" ar=
ia-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-40-conten=
t" aria-hidden=3D"false" data-qtip-id=3D"40" style=3D"z-index: 15014;"><div=
 class=3D"qtip-tip" style=3D"background-color: transparent !important; bord=
er: 0px !important; width: 6px; height: 6px; line-height: 6px; left: 5px; t=
op: -6px; display: block;"><canvas style=3D"background-color: transparent !=
important; border: 0px !important;" width=3D"6" height=3D"6"></canvas></div=
><div class=3D"qtip-content" id=3D"qtip-40-content" aria-atomic=3D"true"><d=
iv class=3D"wd_summary" style=3D"display: block;"><p>Conference Call Schedu=
led for Wednesday, July 26 at 4:30 p.m. Eastern Time SAN DIEGO, July 19, 20=
23 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a c=
linical-stage...</p></div></div></div><div id=3D"qtip-45" class=3D"qtip qti=
p-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"fals=
e" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-described=
by=3D"qtip-45-content" aria-hidden=3D"false" data-qtip-id=3D"45" style=3D"z=
-index: 15015;"><div class=3D"qtip-tip" style=3D"background-color: transpar=
ent !important; border: 0px !important; width: 6px; height: 6px; line-heigh=
t: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"background-=
color: transparent !important; border: 0px !important;" width=3D"6" height=
=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-45-content" ar=
ia-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;"><p>V=
iking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopha=
rmaceutical company focused on the development of novel therapies for metab=
olic and endocrine disorders, today announced...</p></div></div></div><div =
id=3D"qtip-50" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_toolt=
ip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" aria=
-atomic=3D"false" aria-describedby=3D"qtip-50-content" aria-hidden=3D"false=
" data-qtip-id=3D"50" style=3D"z-index: 15016;"><div class=3D"qtip-tip" sty=
le=3D"background-color: transparent !important; border: 0px !important; wid=
th: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display: bloc=
k;"><canvas style=3D"background-color: transparent !important; border: 0px =
!important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-con=
tent" id=3D"qtip-50-content" aria-atomic=3D"true"><div class=3D"wd_summary"=
 style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ:=
 VKTX), a clinical-stage biopharmaceutical company focused on the developme=
nt of novel therapies for metabolic and endocrine disorders, today announce=
d...</p></div></div></div><div id=3D"qtip-60" class=3D"qtip qtip-default qt=
ip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"a=
lert" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-6=
0-content" aria-hidden=3D"false" data-qtip-id=3D"60" style=3D"z-index: 1501=
7;"><div class=3D"qtip-tip" style=3D"background-color: transparent !importa=
nt; border: 0px !important; width: 6px; height: 6px; line-height: 6px; left=
: 5px; top: -6px; display: block;"><canvas style=3D"background-color: trans=
parent !important; border: 0px !important;" width=3D"6" height=3D"6"></canv=
as></div><div class=3D"qtip-content" id=3D"qtip-60-content" aria-atomic=3D"=
true"><div class=3D"wd_summary" style=3D"display: block;"><p>Conference cal=
l scheduled for 4:30 p.m. ET today Clinical Data From Three Programs Antici=
pated in Next Twelve Months VK2809 Phase 2b VOYAGE Study Advancing; Complet=
ion of Enrollment Expected in 4Q...</p></div></div></div><div id=3D"qtip-65=
" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-t=
l" tracking=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"fa=
lse" aria-describedby=3D"qtip-65-content" aria-hidden=3D"false" data-qtip-i=
d=3D"65" style=3D"z-index: 15018;"><div class=3D"qtip-tip" style=3D"backgro=
und-color: transparent !important; border: 0px !important; width: 6px; heig=
ht: 6px; line-height: 6px; left: 5px; top: -6px; display: block;"><canvas s=
tyle=3D"background-color: transparent !important; border: 0px !important;" =
width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"q=
tip-65-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"dis=
play: block;"><p>Conference call scheduled for 4:30 p.m. ET today Completio=
n of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH=
 Expected in 2H22 Phase 1 Study of Dual GLP-1/GIP Agonist...</p></div></div=
></div><div id=3D"qtip-69" class=3D"qtip qtip-default qtip-shadow qtip-roun=
ded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"=
polite" aria-atomic=3D"false" aria-describedby=3D"qtip-69-content" aria-hid=
den=3D"false" data-qtip-id=3D"69" style=3D"z-index: 15019;"><div class=3D"q=
tip-tip" style=3D"background-color: transparent !important; border: 0px !im=
portant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; d=
isplay: block;"><canvas style=3D"background-color: transparent !important; =
border: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=
=3D"qtip-content" id=3D"qtip-69-content" aria-atomic=3D"true"><div class=3D=
"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. (Viking=
) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the=
 development of novel therapies for metabolic and endocrine disorders, toda=
y announced...</p></div></div></div><div id=3D"qtip-70" class=3D"qtip qtip-=
default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false"=
 role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=
=3D"qtip-70-content" aria-hidden=3D"false" data-qtip-id=3D"70" style=3D"z-i=
ndex: 15020;"><div class=3D"qtip-tip" style=3D"background-color: transparen=
t !important; border: 0px !important; width: 6px; height: 6px; line-height:=
 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"background-co=
lor: transparent !important; border: 0px !important;" width=3D"6" height=3D=
"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-70-content" aria-=
atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;"><p>Viki=
ng Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharma=
ceutical company focused on the development of novel therapies for metaboli=
c and endocrine disorders, today announced...</p></div></div></div><div id=
=3D"qtip-79" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip=
 qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" aria-a=
tomic=3D"false" aria-describedby=3D"qtip-79-content" aria-hidden=3D"false" =
data-qtip-id=3D"79" style=3D"z-index: 15021;"><div class=3D"qtip-tip" style=
=3D"background-color: transparent !important; border: 0px !important; width=
: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display: block;=
"><canvas style=3D"background-color: transparent !important; border: 0px !i=
mportant;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-conte=
nt" id=3D"qtip-79-content" aria-atomic=3D"true"><div class=3D"wd_summary" s=
tyle=3D"display: block;"><p>Viking Therapeutics, Inc. (Viking) (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel therapies for metabolic and endocrine disorders, today announced...=
</p></div></div></div><div id=3D"qtip-80" class=3D"qtip qtip-default qtip-s=
hadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert=
" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-80-co=
ntent" aria-hidden=3D"false" data-qtip-id=3D"80" style=3D"z-index: 15022;">=
<div class=3D"qtip-tip" style=3D"background-color: transparent !important; =
border: 0px !important; width: 6px; height: 6px; line-height: 6px; left: 5p=
x; top: -6px; display: block;"><canvas style=3D"background-color: transpare=
nt !important; border: 0px !important;" width=3D"6" height=3D"6"></canvas><=
/div><div class=3D"qtip-content" id=3D"qtip-80-content" aria-atomic=3D"true=
"><div class=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutic=
s, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical compa=
ny focused on the development of novel therapies for metabolic and endocrin=
e disorders, today announced...</p></div></div></div><div id=3D"qtip-100" c=
lass=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" =
tracking=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false=
" aria-describedby=3D"qtip-100-content" aria-hidden=3D"false" data-qtip-id=
=3D"100" style=3D"z-index: 15023;"><div class=3D"qtip-tip" style=3D"backgro=
und-color: transparent !important; border: 0px !important; width: 6px; heig=
ht: 6px; line-height: 6px; left: 5px; top: -6px; display: block;"><canvas s=
tyle=3D"background-color: transparent !important; border: 0px !important;" =
width=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"q=
tip-100-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"di=
splay: block;"><p>Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clin=
ical-stage biopharmaceutical company focused on the development of novel th=
erapies for metabolic and endocrine disorders, today announced...</p></div>=
</div></div><div id=3D"qtip-105" class=3D"qtip qtip-default qtip-shadow qti=
p-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-li=
ve=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-105-content" a=
ria-hidden=3D"false" data-qtip-id=3D"105" style=3D"z-index: 15024;"><div cl=
ass=3D"qtip-tip" style=3D"background-color: transparent !important; border:=
 0px !important; width: 6px; height: 6px; line-height: 6px; left: 5px; top:=
 -6px; display: block;"><canvas style=3D"background-color: transparent !imp=
ortant; border: 0px !important;" width=3D"6" height=3D"6"></canvas></div><d=
iv class=3D"qtip-content" id=3D"qtip-105-content" aria-atomic=3D"true"><div=
 class=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc=
. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company foc=
used on the development of novel therapies for metabolic and endocrine diso=
rders, today announced...</p></div></div></div><div id=3D"qtip-109" class=
=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" trac=
king=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" ar=
ia-describedby=3D"qtip-109-content" aria-hidden=3D"false" data-qtip-id=3D"1=
09" style=3D"z-index: 15025;"><div class=3D"qtip-tip" style=3D"background-c=
olor: transparent !important; border: 0px !important; width: 6px; height: 6=
px; line-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=
=3D"background-color: transparent !important; border: 0px !important;" widt=
h=3D"6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-=
109-content" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"displa=
y: block;"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinic=
al-stage biopharmaceutical company focused on the development of novel ther=
apies for metabolic and endocrine disorders, announced today...</p></div></=
div></div><div id=3D"qtip-120" class=3D"qtip qtip-default qtip-shadow qtip-=
rounded wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=
=3D"polite" aria-atomic=3D"false" aria-describedby=3D"qtip-120-content" ari=
a-hidden=3D"false" data-qtip-id=3D"120" style=3D"z-index: 15026;"><div clas=
s=3D"qtip-tip" style=3D"background-color: transparent !important; border: 0=
px !important; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -=
6px; display: block;"><canvas style=3D"background-color: transparent !impor=
tant; border: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div=
 class=3D"qtip-content" id=3D"qtip-120-content" aria-atomic=3D"true"><div c=
lass=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. =
("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focus=
ed on the development of novel therapies for metabolic and endocrine disord=
ers, today announced...</p></div></div></div><div id=3D"qtip-125" class=3D"=
qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=
=3D"false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-d=
escribedby=3D"qtip-125-content" aria-hidden=3D"false" data-qtip-id=3D"125" =
style=3D"z-index: 15027;"><div class=3D"qtip-tip" style=3D"background-color=
: transparent !important; border: 0px !important; width: 6px; height: 6px; =
line-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"b=
ackground-color: transparent !important; border: 0px !important;" width=3D"=
6" height=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-125-c=
ontent" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: bl=
ock;"><p>Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stag=
e biopharmaceutical company focused on the development of novel therapies f=
or metabolic and endocrine disorders, today announced...</p></div></div></d=
iv><div id=3D"qtip-140" class=3D"qtip qtip-default qtip-shadow qtip-rounded=
 wd_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"pol=
ite" aria-atomic=3D"false" aria-describedby=3D"qtip-140-content" aria-hidde=
n=3D"false" data-qtip-id=3D"140" style=3D"z-index: 15028;"><div class=3D"qt=
ip-tip" style=3D"background-color: transparent !important; border: 0px !imp=
ortant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; di=
splay: block;"><canvas style=3D"background-color: transparent !important; b=
order: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=
=3D"qtip-content" id=3D"qtip-140-content" aria-atomic=3D"true"><div class=
=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Vi=
king") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused o=
n the development of novel therapies for metabolic and endocrine disorders,=
 today announced...</p></div></div></div><div id=3D"qtip-145" class=3D"qtip=
 qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"=
false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-descr=
ibedby=3D"qtip-145-content" aria-hidden=3D"false" data-qtip-id=3D"145" styl=
e=3D"z-index: 15029;"><div class=3D"qtip-tip" style=3D"background-color: tr=
ansparent !important; border: 0px !important; width: 6px; height: 6px; line=
-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"backg=
round-color: transparent !important; border: 0px !important;" width=3D"6" h=
eight=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-145-conte=
nt" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;=
"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage =
biopharmaceutical company focused on the development of novel therapies for=
 metabolic and endocrine disorders, today announced...</p></div></div></div=
><div id=3D"qtip-165" class=3D"qtip qtip-default qtip-shadow qtip-rounded w=
d_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polit=
e" aria-atomic=3D"false" aria-describedby=3D"qtip-165-content" aria-hidden=
=3D"false" data-qtip-id=3D"165" style=3D"z-index: 15030;"><div class=3D"qti=
p-tip" style=3D"background-color: transparent !important; border: 0px !impo=
rtant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; dis=
play: block;"><canvas style=3D"background-color: transparent !important; bo=
rder: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=
=3D"qtip-content" id=3D"qtip-165-content" aria-atomic=3D"true"><div class=
=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Vi=
king") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused o=
n the development of novel therapies for metabolic and endocrine disorders,=
 today announced...</p></div></div></div><div id=3D"qtip-180" class=3D"qtip=
 qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"=
false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-descr=
ibedby=3D"qtip-180-content" aria-hidden=3D"false" data-qtip-id=3D"180" styl=
e=3D"z-index: 15031;"><div class=3D"qtip-tip" style=3D"background-color: tr=
ansparent !important; border: 0px !important; width: 6px; height: 6px; line=
-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"backg=
round-color: transparent !important; border: 0px !important;" width=3D"6" h=
eight=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-180-conte=
nt" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;=
"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage =
biopharmaceutical company focused on the development of novel therapies for=
 metabolic and endocrine disorders, today announced...</p></div></div></div=
><div id=3D"qtip-195" class=3D"qtip qtip-default qtip-shadow qtip-rounded w=
d_tooltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polit=
e" aria-atomic=3D"false" aria-describedby=3D"qtip-195-content" aria-hidden=
=3D"false" data-qtip-id=3D"195" style=3D"z-index: 15032;"><div class=3D"qti=
p-tip" style=3D"background-color: transparent !important; border: 0px !impo=
rtant; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; dis=
play: block;"><canvas style=3D"background-color: transparent !important; bo=
rder: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=
=3D"qtip-content" id=3D"qtip-195-content" aria-atomic=3D"true"><div class=
=3D"wd_summary" style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Vi=
king") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused o=
n the development of novel therapies for metabolic and endocrine disorders,=
 today announced...</p></div></div></div><div id=3D"qtip-197" class=3D"qtip=
 qtip-default qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"=
false" role=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-descr=
ibedby=3D"qtip-197-content" aria-hidden=3D"false" data-qtip-id=3D"197" styl=
e=3D"z-index: 15033;"><div class=3D"qtip-tip" style=3D"background-color: tr=
ansparent !important; border: 0px !important; width: 6px; height: 6px; line=
-height: 6px; left: 5px; top: -6px; display: block;"><canvas style=3D"backg=
round-color: transparent !important; border: 0px !important;" width=3D"6" h=
eight=3D"6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-197-conte=
nt" aria-atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;=
"><p>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage =
biopharmaceutical company focused on the development of novel, first-in-cla=
ss or best-in-class therapies for metabolic and...</p></div></div></div><di=
v id=3D"qtip-205" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_to=
oltip qtip-pos-tl" tracking=3D"false" role=3D"alert" aria-live=3D"polite" a=
ria-atomic=3D"false" aria-describedby=3D"qtip-205-content" aria-hidden=3D"f=
alse" data-qtip-id=3D"205" style=3D"z-index: 15034;"><div class=3D"qtip-tip=
" style=3D"background-color: transparent !important; border: 0px !important=
; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display:=
 block;"><canvas style=3D"background-color: transparent !important; border:=
 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qti=
p-content" id=3D"qtip-205-content" aria-atomic=3D"true"><div class=3D"wd_su=
mmary" style=3D"display: block;"><p>Viking Therapeutics, Inc. ("Viking") (N=
ASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the dev=
elopment of novel therapies for metabolic and endocrine disorders, today an=
nounced...</p></div></div></div><div id=3D"qtip-210" class=3D"qtip qtip-def=
ault qtip-shadow qtip-rounded wd_tooltip qtip-pos-tl" tracking=3D"false" ro=
le=3D"alert" aria-live=3D"polite" aria-atomic=3D"false" aria-describedby=3D=
"qtip-210-content" aria-hidden=3D"false" data-qtip-id=3D"210" style=3D"z-in=
dex: 15035;"><div class=3D"qtip-tip" style=3D"background-color: transparent=
 !important; border: 0px !important; width: 6px; height: 6px; line-height: =
6px; left: 5px; top: -6px; display: block;"><canvas style=3D"background-col=
or: transparent !important; border: 0px !important;" width=3D"6" height=3D"=
6"></canvas></div><div class=3D"qtip-content" id=3D"qtip-210-content" aria-=
atomic=3D"true"><div class=3D"wd_summary" style=3D"display: block;"><p>Viki=
ng Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical co=
mpany focused on the development of novel, first-in-class or best-in-class =
therapies for metabolic and endocrine...</p></div></div></div><div id=3D"qt=
ip-213" class=3D"qtip qtip-default qtip-shadow qtip-rounded wd_tooltip qtip=
-pos-tl qtip-focus" tracking=3D"false" role=3D"alert" aria-live=3D"polite" =
aria-atomic=3D"false" aria-describedby=3D"qtip-213-content" aria-hidden=3D"=
false" data-qtip-id=3D"213" style=3D"z-index: 15036;"><div class=3D"qtip-ti=
p" style=3D"background-color: transparent !important; border: 0px !importan=
t; width: 6px; height: 6px; line-height: 6px; left: 5px; top: -6px; display=
: block;"><canvas style=3D"background-color: transparent !important; border=
: 0px !important;" width=3D"6" height=3D"6"></canvas></div><div class=3D"qt=
ip-content" id=3D"qtip-213-content" aria-atomic=3D"true"><div class=3D"wd_s=
ummary" style=3D"display: block;"><p>Viking Therapeutics, Inc. (NASDAQ: VKT=
X), a clinical-stage biopharmaceutical company focused on the development o=
f novel, first-in-class or best-in-class therapies for metabolic and endocr=
ine...</p></div></div></div></body></html>
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: image/webp
Content-Transfer-Encoding: base64
Content-Location: https://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-gray-1.png
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------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://ir.vikingtherapeutics.com/images/webdriver/email_alerts.png

iVBORw0KGgoAAAANSUhEUgAAABIAAAASCAYAAABWzo5XAAAAoklEQVR42mMYBcQBVnaOciDeTCYu
hxsEFTAGYm4SsT5IL7pBWWT4JBubQZuAOA2I2YgwgA2qdhM2g+yAeBIQTwNiJTyGKIHUQNXaYRgE
VcACxPFAvA6Iw4CYCUkNE0gMKhcPVauE1SAkvhYQzwHiTpA4FHdCxbRg6vAbhBDjBOIUIF4OwlA2
J0iOFIOQ5RhBGMYnxiBdMtKRLkgv1VL2MM/4AF6fPNo2ldjPAAAAAElFTkSuQmCC

------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: https://ir.vikingtherapeutics.com/images/section-stock-1024x262.jpg
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------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: image/webp
Content-Transfer-Encoding: base64
Content-Location: https://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-top-3.png
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------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/wd_media_query.css

@charset "utf-8";

@media only screen and (min-device-width: 320px) and (max-device-width: 480=
px) {
  ul.hi_res-links li a span { max-width: 65%; }
}

@media not all {
  ul.hi_res-links li a span { max-width: 50%; }
}

@media (max-width: 767px) {
  table.wd_sec_filings td.wd_filing_type { color: rgb(0, 102, 204); -webkit=
-tap-highlight-color: rgba(0, 0, 0, 0); }
}

@media only screen and (min-width: 321px) {
}

@media only screen and (max-width: 320px) {
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) {
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) and (orientation: landscape) {
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) and (orientation: portrait) {
}

@media only screen and (min-width: 1224px) {
}

@media only screen and (min-width: 1824px) {
}

@media only screen and (-webkit-min-device-pixel-ratio: 1.5), only screen a=
nd (min-device-pixel-ratio : 1.5) {
}
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/wdcontent.css

@charset "utf-8";

.wd_search_form_container { margin-top: 10px; display: block; }

.page_header, .category_header { }

.detail_header, .detail_subheader, .category_name { }

.category_intro { margin-bottom: 15px; }

.btn { border: 1px solid gainsboro; }

.jqueryslidemenu ul li ul { border-color: rgba(0, 0, 0, 0.2); border-style:=
 solid; border-width: 1px; }

.jqueryslidemenu ul li ul li { position: relative; }

.jqueryslidemenu ul li ul ul { display: block; margin-left: 0px; top: 0px; =
position: absolute; left: -999em; }

.jqueryslidemenu ul li ul li:hover .sub-menu { left: 100%; }

#jqueryslidemenu ul li a { font-weight: 400 !important; }

.item { margin: 0px 0px 10px; overflow: auto; line-height: 1.4em; }

.item_name { position: relative; }

.item_date { font-weight: bold; }

.item_summary { }

table.wd_imagetable { }

td.imagecaption { text-align: left; padding: 3px 5px; }

#wd_printable_content { clear: both; }

div.wd_page_toolbar { float: right; clear: both; }

div.wd_page_toolbar table { width: auto; clear: right; }

div.wd_page_toolbar tbody { }

div.wd_page_toolbar tr { }

div.wd_page_toolbar td { line-height: 16px; margin: 0px; padding: 0px; vert=
ical-align: top; }

div.wd_page_toolbar span { line-height: 16px; margin: 0px; padding: 0px; ve=
rtical-align: top; }

div.wd_page_toolbar a { line-height: 16px; margin: 0px; padding: 0px; verti=
cal-align: top; }

div.wd_page_toolbar img { width: 16px; height: 16px; }

div.wd_standard { }

div.wd_events { }

div.wd_gallery { }

div.wd_gallery span.filesize { font-weight: normal; }

ul.hi_res-links { margin: 20px 0px; list-style: none; }

ul.hi_res-links li { display: inline; }

ul.hi_res-links li a, ul.hi_res-links li a:hover, ul.hi_res-links li a:link=
, ul.hi_res-links li a:visited { color: rgb(255, 255, 255); }

ul.hi_res-links li a { text-decoration: none; cursor: pointer; text-transfo=
rm: uppercase; }

ul.hi_res-links li a span { display: block; text-align: center; margin: 0px=
; padding: 2px 10px; position: relative; background: url("../images/webdriv=
er/gradient_bg.gif") center top repeat-x rgb(102, 102, 102); border-radius:=
 2px; box-shadow: rgb(136, 136, 136) 1px 1px 5px; }

div.wd_newsfeed_releases { }

@media (min-width: 975px) {
  .wd_pageid_11 #wd_printable_content p { width: 40%; margin-right: 15px; d=
isplay: block; float: left; }
  .wd_pageid_11 #wd_printable_content p:last-child { margin-right: 0px; }
}

.wd_category_checkboxes .wd_subtype { margin: 0px; }

.wd_newsfeed_releases-detail .news_body p.prnews_p { font-family: inherit; =
font-size: 100%; color: inherit; }

.wd_newsfeed_releases-teaser .tools { text-decoration: none; margin-bottom:=
 12px; }

.item_slider { margin: 20px 0px; padding: 10px; background-color: rgb(254, =
253, 225); }

.item_more { margin: 20px 0px 0px; }

.item_tooltip { width: 500px; margin: 0px; padding: 10px; }

.item_tooltip_contents { margin: 0px; padding: 10px; background-color: rgb(=
254, 253, 225); border: 2px solid rgb(165, 165, 165); }

.item_with_slider { padding: 0px 0px 0px 20px; }

.slider_control_closed { position: absolute; left: -20px; width: 20px; heig=
ht: 20px; cursor: pointer; background: url("../images/slider_open.png") rig=
ht center no-repeat; }

.slider_control_open { position: absolute; left: -20px; width: 20px; height=
: 20px; cursor: pointer; background: url("../images/slider_close.png") righ=
t center no-repeat; }

div.wd_stories { }

div.wd_formbuilder { }

table.wd_formbuilder { }

input.wd_formbuilder_submit { }

table.wd_formbuilder p { margin: 0px; }

.wd_webinator_search { }

p.search_result { }

span.search_url { }

table.wd_calendar_header { padding: 5px 0px; margin: 0px; }

table.wd_calendar_header a, table.wd_calendar_header a:visited, table.wd_ca=
lendar_header a:active, table.wd_calendar_header a:link { color: rgb(96, 14=
9, 195); }

td.wd_calendar_header_label { text-align: center; width: 100%; }

.wd_events-teaser td.wd_calendar_header_label { font-weight: bold; }

.wd_calendar_header td.wd_calendar_header_prev a { display: block; backgrou=
nd: url("../images/webdriver/assets_left_arrow.gif") left center no-repeat =
rgb(255, 255, 255); border: 1px solid rgb(225, 225, 225); padding: 12px; te=
xt-decoration: none; text-indent: -9999px; line-height: 0; }

.wd_calendar_header td.wd_calendar_header_next a { display: block; backgrou=
nd: url("../images/webdriver/assets_right_arrow.gif") right center no-repea=
t rgb(255, 255, 255); border: 1px solid rgb(225, 225, 225); padding: 12px; =
text-decoration: none; text-align: left; text-indent: -9999px; line-height:=
 0; }

.wd_events-teaser .wd_calendar_header td.wd_calendar_header_prev a, .wd_eve=
nts-teaser .wd_calendar_header td.wd_calendar_header_next a { padding: 0px =
12px; line-height: 24px; }

table.wd_calendar { background-color: rgb(255, 255, 255); table-layout: fix=
ed; border-spacing: 0px; border-collapse: collapse; }

th.wd_calendar_dayofweek_header { padding: 4px 0px; text-align: center; bac=
kground: url("../images/webdriver/events/tab_background.gif") 0px bottom re=
peat-x scroll rgb(255, 255, 255); border-width: 1px; border-style: solid; b=
order-color: rgb(225, 225, 225) rgb(204, 204, 204) rgb(225, 225, 225) rgb(2=
25, 225, 225); border-image: initial; font-weight: bold; }

td.wd_calendar_day { margin: 0px; vertical-align: top; padding: 0px 2px 30p=
x; }

.wd_events-teaser td.wd_calendar_day { margin: 0px; vertical-align: top; pa=
dding: 0px 2px; }

td.wd_calendar_this_month { background-color: rgb(255, 255, 255); border: 1=
px solid rgb(204, 204, 204); }

td.wd_calendar_prev_month, td.wd_calendar_next_month { background-color: rg=
b(248, 248, 248); border: 1px solid rgb(204, 204, 204); }

td.wd_calendar_today { background-color: rgb(242, 249, 252); }

div.wd_calendar_day_header { text-align: left; font-weight: bold; padding: =
3px; }

td.wd_calendar_prev_month div.wd_calendar_day_header, td.wd_calendar_next_m=
onth div.wd_calendar_day_header { }

div.wd_calendar_no_event { margin: 1px 0px; padding: 2px; }

.wd_events-teaser div.wd_calendar_no_event { padding: 2px; text-align: cent=
er; }

div.wd_calendar_event { cursor: pointer; padding: 2px 5px; position: relati=
ve; left: 0px; white-space: nowrap; overflow: hidden; background: rgb(96, 1=
49, 195); border-radius: 4px; color: rgb(255, 255, 255); text-decoration: n=
one; }

.wd_events-teaser div.wd_calendar_event { padding: 2px; text-align: center;=
 }

div.wd_event_tip_header { line-height: 20px; border-bottom: 1px solid rgb(1=
87, 187, 187); margin: 0px; padding: 5px; border-top-width: 0px; border-rig=
ht-width: 0px; border-left-width: 0px; border-top-style: none; border-right=
-style: none; border-left-style: none; }

div.wd_event_tip_info { background-color: rgb(255, 255, 255); margin: 0px; =
padding: 5px; }

div.wd_event_tip_info p { margin: 2px 0px 5px; padding: 0px; }

div.wd_event_tip_title { font-size: 16px; font-weight: bold; }

div.wd_event_tip_time, div.wd_event_tip_location_name, div.wd_event_tip_mor=
e { }

div.wd_event_tip_date { }

div.calendar_subscribe_links img { margin-right: 5px; }

div.calendar_subscribe_links a { text-decoration: none; }

.wd_calendar_event_tip { background-color: rgb(255, 255, 255); border: 1px =
solid rgb(255, 255, 255); font-size: 14px; line-height: 20px; }

.wd_calendar_event_tip .qtip-titlebar { background: rgb(96, 149, 195); colo=
r: rgb(255, 255, 255); }

div#wdFadeBackground { background-color: rgb(85, 85, 85); border: 5px; marg=
in: 0px; padding: 0px; z-index: 100; }

div#wdFadePopup { background-color: rgb(51, 51, 51); padding: 2px; z-index:=
 100; }

td#wdFadeContent { background-color: rgb(255, 255, 255); }

td#wdFadeClose { text-align: right; }

.tools img { vertical-align: top; }

div.wd_featurebox_title { line-height: 1.5em; margin-top: 20px; margin-bott=
om: 10px; font-family: "Open Sans"; border-bottom: 1px solid rgb(204, 204, =
204); font-weight: 300 !important; font-size: 24px !important; color: rgb(2=
6, 65, 170) !important; }

div.wd_featurebox { line-height: 1.4em; margin-bottom: 10px; overflow: auto=
; }

div.wd_featurebox p { }

div.wd_featurebox div { }

div.wd_featureboxes_top { }

div.wd_featureboxes_top div.wd_featurebox_container { }

div.wd_featureboxes_top div.wd_featurebox_title { }

div.wd_featureboxes_top div.wd_featurebox { }

div.wd_featureboxes_left { clear: both; display: block; margin-top: 10px; }

div.wd_featureboxes_left div.wd_featurebox_container { }

div.wd_featureboxes_left div.wd_featurebox_title { }

div.wd_featureboxes_left div.wd_featurebox { }

div.wd_featureboxes_left .wd_imagetable { float: none; }

div.wd_featureboxes_middle { }

div.wd_featureboxes_middle div.wd_featurebox_container { }

div.wd_featureboxes_middle div.wd_featurebox_title { }

div.wd_featureboxes_middle div.wd_featurebox { }

div.wd_featureboxes_right { }

div.wd_featureboxes_right div.wd_featurebox_container { }

div.wd_featureboxes_right div.wd_featurebox_title { }

div.wd_featureboxes_right div.wd_featurebox { }

.wd_featureboxes_socialhub { }

.wd_featureboxes_socialhub .wd_tabs_container { }

.wd_featureboxes_socialhub .wd_tabs_wrapper { background: none 0px center; =
padding: 5px; }

.wd_featureboxes_socialhub .wd_tabs { }

.wd_featureboxes_socialhub .wd_tab { margin: 1px; padding: 4px; border: 0px=
; background-color: transparent; }

.wd_featureboxes_socialhub .wd_tab-inactive { }

.wd_featureboxes_socialhub .wd_tab-active { padding: 3px; background-color:=
 rgb(221, 221, 221); border: 1px solid rgb(204, 204, 204); border-radius: 4=
px; }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper { }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper .wd_tab_content { }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper .wd_tab_content-active =
{ }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper .wd_tab_content-inactiv=
e { }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper .wd_tab_content .wd_fea=
turebox_container { }

.wd_featureboxes_socialhub .wd_tabs_content_wrapper .wd_tab_content .wd_fea=
turebox_container .wd_featurebox { }

.wd_featureboxes_tabbed { }

.wd_featureboxes_tabbed .wd_tabs_container { }

.wd_featureboxes_tabbed .wd_tabs_wrapper { background: none 0px center; bor=
der: 0px none; width: 100%; display: block; height: 33px; }

.wd_featureboxes_tabbed .wd_tabs_wrapper .wd_tabs { overflow: visible; }

.wd_featureboxes_tabbed .wd_tabs_wrapper .wd_tab { margin: 0px 0.3em 0px 0p=
x; padding: 0.5em; border-width: 1px 1px 0px; border-style: solid; border-c=
olor: rgb(204, 204, 204); border-image: initial; border-top-left-radius: 0.=
5em; border-top-right-radius: 0.5em; }

.wd_featureboxes_tabbed .wd_tabs_wrapper .wd_tab-active { margin-bottom: -1=
px; border-bottom: 1px solid rgb(255, 255, 255); }

.wd_featureboxes_tabbed .wd_tabs_wrapper .wd_tab-inactive { background-colo=
r: rgb(238, 238, 238); }

.wd_featureboxes_tabbed .wd_tabs_wrapper .wd_tab-inactive:hover { backgroun=
d-color: rgb(221, 221, 221); border-color: rgb(170, 170, 170); }

.wd_featureboxes_tabbed .wd_tabs_container { }

.wd_featureboxes_tabbed .wd_tabs_container .wd_tabs_content_wrapper { width=
: 100%; padding-top: 0px; border-top: 1px solid rgb(222, 222, 222); }

.wd_featureboxes_tabbed .wd_tabs_container .wd_tabs_content_wrapper .wd_tab=
_content.wd_tab_content-active .wd_featurebox_container .wd_featurebox { }

.wd_featureboxes_tabbed .wd_tabs_wrapper { background: none 0px center; bor=
der: 0px none; }

div.wd_rssfeeds_item { margin-bottom: 10px; }

div.wd_sponsors { padding: 0px 15px 10px; }

div.wd_sponsors p { background: rgb(204, 204, 204); margin: 0px 0px 5px; pa=
dding: 5px; }

div.wd_sponsors img { padding: 10px; }

.shadowTR { margin: 0px; border: 0px; padding: 8px 0px 0px; background: url=
("../images/shadowTR.png") right top no-repeat transparent; }

.shadowBL { margin: 0px; border: 0px; padding: 0px 0px 0px 8px; background:=
 url("../images/shadowBL.png") left bottom no-repeat transparent; }

.shadowBR { margin: 0px; border: 0px; padding: 0px 8px 0px 0px; background:=
 url("../images/shadowBR.png") right bottom no-repeat transparent; }

.shadowB { margin: 0px; border: 0px; padding: 0px 1px 8px 0px; background: =
url("../images/shadowB.png") center bottom repeat-x transparent; }

.shadowR { margin: 0px -9px 0px 0px; border: 0px; padding: 1px 8px 1px 1px;=
 background: url("../images/shadowR.png") right center repeat-y transparent=
; }

.shadow-content { margin: -9px 0px -1px -9px; border: 0px; padding: 0px; ba=
ckground: transparent; }

.subscribe_links a { padding-right: 20px; background: url("../images/webdri=
ver/email_alerts.png") right center no-repeat; }

.wd_member_col .wd_title { padding-left: 5px; }

.wd_member_col { border-bottom: 1px solid rgb(243, 243, 243); }

.wd_newsfeed_releases .wd_item { margin: 0px 0px 15px; border-bottom: 1px s=
olid rgb(204, 204, 204); padding-bottom: 15px; display: block; }

.wd_newsfeed_releases .wd_item :last-child { border-bottom: 0px solid rgb(2=
04, 204, 204); }

.wd_newsfeed_releases .wd_item .wd_date { font-size: 10pt; line-height: 12p=
t; color: rgb(153, 153, 153); }

.wd_newsfeed_releases .wd_item .wd_title { font-size: 12pt; line-height: 14=
pt; font-weight: normal; }

.wd_newsfeed_releases .wd_item .wd_asset_type_link .wd_title { font-size: 1=
0pt; line-height: 12pt; }

.wd_newsfeed_releases .wd_item .wd_subtitle { font-size: 10pt; line-height:=
 12pt; font-weight: normal; }

.wd_slider-button { display: inline-block; width: 14px; }

.wd_search_basic_fields { background: rgb(238, 238, 238); padding: 5px; bor=
der: 1px solid rgb(204, 204, 204); }

.wd_search_basic_fields select { margin-right: 5px; margin-bottom: 0px; pad=
ding: 4px; }

.wd_search_basic_fields input { margin-right: 5px; margin-bottom: 0px; padd=
ing: 4px; }

ul.wd_asset_type_link_list { margin: 10px 0px 0px; padding: 0px; overflow: =
auto; list-style: none; color: rgb(204, 204, 204); font-size: 0.8333em; bor=
der: 0px; }

.wd_selector select { margin-left: 5px; }

.ui-datepicker select { color: rgb(0, 0, 0); }

div.wd_snapshot h2 { margin: 0px; padding: 3px 0px; border-top: 2px solid r=
gb(153, 153, 153); border-bottom: 1px solid rgb(153, 153, 153); text-transf=
orm: uppercase; font-weight: bold; text-align: left; font-size: 1.2em; }

table.wd_snapshot_values th, table.wd_snapshot_values td { vertical-align: =
top; font-size: 1em; line-height: 1.3em; padding: 5px; border-bottom: 1px s=
olid rgb(153, 153, 153); }

.wd_newsfeed_releases .wd_thumbnail { display: none; }

.wd_newsfeed_releases .wd_date { float: left; }

.wd_newsfeed_releases .wd_item_wrapper { margin-left: 0px; float: left; }

.qtip .qtip-tip { display: none; }

.qtip.qtip-default { transition: 0.3s; border: 0px !important; background: =
rgb(255, 255, 255) !important; box-shadow: rgba(0, 0, 0, 0.2) 0px 0px 10px =
!important; }

.qtip .qtip-content { border: 0px !important; background: rgb(255, 255, 255=
) !important; box-shadow: rgba(0, 0, 0, 0.2) 0px 0px 10px !important; }

.wd_historical div.wd_historical_results { min-width: 35ex; }

#content .wd_calculator h4 { font-size: 19px !important; }

.wd_search_advanced_link, #content .wd_calculator .wd_calculator_input_colu=
mn > label { font-size: 13px !important; }

.wd_events select { width: auto !important; }

.wd_events button { margin-bottom: 10px; }

table.wd_sec_filings thead { background: rgb(0, 111, 192) !important; color=
: rgb(255, 255, 255) !important; }

table.wd_sec_filings thead th { border: 0px !important; }

.wd_board_members .wd_item_wrapper { padding-left: 110px; }

div.wd_form_field_pos_right div.wd_form_field_input { line-height: 1.4em; }

.wd_form_field_input label { padding-left: 3px; color: rgb(0, 0, 0); }

.wd_form_field_label label { color: rgb(0, 0, 0); }

.wd_newsfeed_releases-detail table { font-size: 12px; }

.wd_newsfeed_releases-detail table td { font-size: 12px; }

.recaptcha_terms { float: right; }

.wd_load_more-trigger, .span4 button { display: inline-block; padding: 10px=
; font-size: 0.8125em; line-height: 1.25em; color: rgb(85, 85, 85); border:=
 1px solid rgb(204, 204, 204); border-radius: 3px; box-shadow: rgba(0, 0, 0=
, 0.075) 0px 1px 1px inset; transition: border 0.2s linear, box-shadow 0.2s=
 linear; }

#content .wd_historical h4 { font-size: 18px !important; }

#content .wd_historical div { font-size: 1em; }

.wd_newsfeed_releases-detail .wd_title { line-height: 1.5em; margin-top: 20=
px; margin-bottom: 10px; font-family: "Open Sans"; font-weight: 300 !import=
ant; font-size: 24px !important; color: rgb(102, 102, 102) !important; }

.wd_newsfeed_releases-detail .wd_subtitle { font-size: 1.2em; line-height: =
1.5em; margin-top: 0px; margin-bottom: 5px; font-weight: 400 !important; co=
lor: rgb(68, 68, 68) !important; }

.wd_back { float: right; }

.wd_board_committees th, .wd_board_committees td { padding: 5px; }

.qtip .wd_label { color: rgb(0, 0, 0) !important; }

#wd_printable_content b, #wd_printable_content strong { font-weight: 700 !i=
mportant; }

.wd_board_committees th, .wd_member_col { font-weight: normal !important; }

.wd_member_col .wd_title { padding-left: 5px; }

.wd_member_col { border-bottom: 1px solid rgb(243, 243, 243); }

.wd_newsfeed_releases .wd_item { margin: 0px 0px 15px; border-bottom: 1px s=
olid rgb(204, 204, 204); padding-bottom: 15px; display: block; }

.wd_newsfeed_releases .wd_item :last-child { border-bottom: 0px solid rgb(2=
04, 204, 204); }

.wd_stories .wd_item .wd_date, .wd_newsfeed_releases .wd_item .wd_date { fo=
nt-size: 10pt; line-height: 12pt; color: rgb(153, 153, 153); }

.wd_stories .wd_item .wd_title, .wd_newsfeed_releases .wd_item .wd_title { =
font-size: 16pt; line-height: 18pt; }

.wd_stories .wd_item .wd_asset_type_link .wd_title, .wd_newsfeed_releases .=
wd_item .wd_asset_type_link .wd_title { font-size: 10pt; line-height: 12pt;=
 }

.wd_stories .wd_item .wd_subtitle, .wd_newsfeed_releases .wd_item .wd_subti=
tle { font-size: 11pt; line-height: 12pt; }

.wd_documents-detail .detail_date { display: none; }

.wd_slider-button { display: inline-block; width: 14px; }

.wd_search_basic_fields { background: rgb(238, 238, 238); padding: 5px; bor=
der: 1px solid rgb(204, 204, 204); }

.wd_search_basic_fields select { margin-right: 5px; margin-bottom: 0px; pad=
ding: 4px; }

.wd_search_basic_fields input { margin-right: 5px; margin-bottom: 0px; padd=
ing: 4px; }

ul.wd_asset_type_link_list { margin: 10px 0px 0px; padding: 0px; overflow: =
auto; list-style: none; color: rgb(204, 204, 204); font-size: 0.8333em; bor=
der: 0px; }

.wd_selector select { margin-left: 5px; }

.ui-datepicker select { color: rgb(0, 0, 0); }

div.wd_snapshot h2 { margin: 0px; padding: 3px 0px; border-top: 2px solid r=
gb(153, 153, 153); border-bottom: 1px solid rgb(153, 153, 153); text-transf=
orm: uppercase; font-weight: bold; text-align: left; font-size: 1.2em; }

table.wd_snapshot_values th, table.wd_snapshot_values td { vertical-align: =
top; font-size: 1em; line-height: 1.3em; padding: 5px; border-bottom: 1px s=
olid rgb(153, 153, 153); }

.recaptcha_terms { float: right; }

.wd_pageid_119 .wd_page_toolbar table td { border: none; }

.wd_pageid_119 #wd_printable_content p:nth-of-type(2) { margin-bottom: 0px;=
 }

.wd_pageid_119 #wd_printable_content p:nth-of-type(3) { display: none; }

.wd_pageid_119 #wd_printable_content hr { margin: 0px 0px 1em; }

@media (max-width: 767px) {
  table.wd_sec_filings thead { display: none; }
  table.wd_sec_filings tbody tr { display: flex; flex-direction: column; ma=
rgin-top: 15px; border-top: 1px solid black; padding-top: 10px; }
  table.wd_sec_filings tbody td { border: none; padding-top: 5px; }
  div.wd_ir_secfilings table.wd_sec_filings tbody tr td.wd_filing_date { or=
der: 3; }
  div.wd_ir_secfilings table.wd_sec_filings tbody tr td.wd_filing_type { or=
der: 1; text-align: left; color: black; }
  table.wd_sec_filings td.wd_filing_type::before { content: "Filing type: "=
; font-weight: bold; }
  table.wd_sec_filings td.wd_description { order: 2; display: block; }
  table.wd_sec_filings td.wd_document_format { order: 4; text-align: left; =
padding-top: 15px; }
  table.wd_sec_filings td.wd_document_format::before { content: "File forma=
t for download:"; display: block; font-weight: bold; padding-bottom: 8px; }
}
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/ccbnIR.css

@charset "utf-8";

@font-face { font-family: FontAwesome; src: url("/media_files/IROL/25/25363=
8/fontawesome-webfont.woff") format("woff"); font-weight: normal; font-styl=
e: normal; }

@media print {
  a[href^=3D"javascript:"]::after, a[href^=3D"#"]::after { content: none !i=
mportant; }
}

.span4 .toolkit { background: rgb(0, 111, 192); padding: 5px; border-radius=
: 5px; }

#content .span4 .toolkit a { color: rgb(255, 255, 255) !important; font-siz=
e: 14px; }

.ir-active { font-weight: bold; }

i.icon-chevron-up { color: rgb(26, 65, 170) !important; }

i.icon-chevron-down { color: rgb(26, 65, 170) !important; }

ul.ir-nav li { border-bottom: 1px solid rgb(230, 230, 230); }

ul.ir-nav li li { border: none; }

@media screen and (max-width: 767px) {
  body.ccbnPrint { padding-left: 0px; padding-right: 0px; }
}

label { display: inline-block; }

#content .ccbnBgTblTtl a.ccbnTblTtl { color: rgb(255, 255, 255) !important;=
 }

.ccbnOutline td td td { border: none; }

.ccbn-event-summary-heading h2 span.evttitle { font-family: "Open Sans"; fo=
nt-weight: 300 !important; font-size: 24px !important; color: rgb(102, 102,=
 102) !important; }

.ccbn-event-option-addToCal h3 { font-size: 16px !important; }

.ccbnCalendarHelpDiv table td { background: rgb(255, 255, 255) !important; =
color: rgb(0, 0, 0) !important; }

.ccbnContent input { width: auto; }

.ccbnEvent { color: rgb(255, 255, 255); background: rgb(0, 111, 192) !impor=
tant; }

.ccbnContent input { width: auto; }

.gnw_table { width: auto !important; height: auto !important; }

.gnw_table td { font-size: 12px !important; }

.ccbn-stock-chart-image img { max-width: 100%; }

.ccbnSelect select { width: auto; }

.ccbnBgTblLabelLeft { text-align: left !important; }

.ccbnPopover { padding: 5px; font-family: "Open Sans"; font-size: 12px; bor=
der: 1px solid rgb(230, 230, 230) !important; }

.ccbnContent img, .toolkit img { vertical-align: baseline; }

.toolkit { margin: 20px 0px; }

.ccbnContent img, .toolkit img { max-width: none; }

.ccbnContent, .toolkit { font-family: "Open Sans"; }

.ir-nav { margin: 0px; list-style: none; }

.ir-nav li { padding: 5px 0px; }

.sub-nav { margin: 0px 0px 0px 20px; list-style: none; }

.sub-nav a { font-size: 15px; }

.ccbnPrint .page-title { margin: 15px 0px 5px 20px; font-size: 37px; color:=
 rgb(85, 85, 85) !important; }

.ccbnPrint .ccbnContent { border: 0px; float: none; width: auto; padding: 2=
0px; margin: 0px; }

.ccbnPrintHeader { margin: 0px 20px; padding: 10px 0px; border-bottom: 1px =
solid rgb(226, 226, 222); }

.ccbnPrintLink { position: absolute; right: 20px; color: rgb(204, 204, 204)=
; font-size: 11px; }

.ccbnPrintLink a { text-decoration: none; }

.ccbnPrintLink a:hover { text-decoration: underline; color: rgb(51, 51, 51)=
; }

.ccbnTblTtl { font-weight: bold; }

.ccbnBgTblTtl td { background: rgb(0, 111, 192); color: rgb(255, 255, 255);=
 padding: 5px; }

.ccbnTblSubTtl { font-weight: bold; }

.ccbnBgTblSubTtl { background-color: rgb(221, 221, 221); }

.ccbnTblOdd { }

.ccbnBgTblOdd td { background-color: rgb(255, 255, 255); border-bottom: 1px=
 solid rgb(230, 230, 230); padding: 5px; }

.ccbnTblEven { }

.ccbnBgTblEven td { background-color: rgb(255, 255, 255); border-bottom: 1p=
x solid rgb(230, 230, 230); padding: 5px; }

.ccbnTblTxt { }

.ccbnBgTblTxt { background-color: rgb(255, 255, 255); }

.ccbnTblTxtBold { font-weight: bold; }

.ccbnBgTblTxtBold { background-color: rgb(255, 255, 255); }

.ccbnTblHighlight { }

.ccbnBgTblHighlight { background-color: rgb(255, 255, 255); }

.ccbnTblSubTxt { font-size: 0.9em; }

.ccbnBgTblSubTxt { background-color: rgb(255, 255, 255); }

.ccbnTblLnk { }

.ccbnBgTblLnk { background-color: rgb(255, 255, 255); }

.ccbnTblHighlightLnk { font-weight: bold; }

.ccbnBgTblHighlightLnk { background-color: rgb(255, 255, 255); }

.ccbnTblLabelLnk { font-weight: bold; }

.ccbnBgTblLabelLnk { background-color: rgb(255, 255, 255); }

.ccbnTtl { line-height: 1.5em; margin-top: 20px; margin-bottom: 10px; font-=
family: "Open Sans"; font-weight: 300 !important; font-size: 24px !importan=
t; color: rgb(102, 102, 102) !important; }

.ccbnBgTtl { }

.ccbnSubTtl { }

.ccbnBgSubTtl { }

.ccbnTxt { }

.ccbnBgTxt { }

.ccbnTxtBold { font-weight: bold; }

.ccbnBgTxtBold { }

.ccbnTxtBoldSub { }

.ccbnBgTxtBoldSub { }

.ccbnSubTxt { font-size: 0.9em; }

.ccbnBgSubTxt { }

.ccbnRequired { color: rgb(255, 0, 0); }

.ccbnBgRequired { }

.ccbnError { color: rgb(255, 0, 0); }

.ccbnBgError { }

.ccbnConfirmBold { font-weight: bold; }

.ccbnBgConfirmBold { }

.ccbnNeg { color: rgb(255, 0, 0); }

.ccbnBgNeg { background-color: rgb(255, 0, 0); }

.ccbnPos { color: rgb(0, 176, 0); }

.ccbnBgPos { background-color: rgb(0, 176, 0); }

.ccbnPrice { font-weight: bold; }

.ccbnBgPrice { background-color: rgb(255, 255, 255); }

.ccbnLnk { }

.ccbnBgLnk { }

.ccbnSubLnk { }

.ccbnBgSubLnk { }

.ccbnTblSubLnk { }

.ccbnBgTblSubLnk { }

.modDisclaimer { color: rgb(153, 153, 153); font-style: italic; font-size: =
13px; }

.ccbnDisclaimer { color: rgb(153, 153, 153); font-style: italic; font-size:=
 13px; }

.ccbnBgDisclaimer { background-color: rgb(255, 255, 255); }

.ccbnLabel { font-weight: bold; }

.ccbnBgLabel { background-color: rgb(255, 255, 255); }

.ccbnTblLabelLeft { font-weight: bold; }

.ccbnBgTblLabelLeft { background-color: rgb(255, 255, 255); }

.ccbnTblLabelTop { font-weight: bold; }

.ccbnBgTblLabelTop { background-color: rgb(255, 255, 255); }

.ccbnNav { }

.ccbnSelect { }

.ccbnBgSelect { }

.ccbnInput { }

.ccbnBgInput { }

.ccbnButton { }

.ccbnBgButton { }

.ccbnOutline { background-color: rgb(255, 255, 255); }

.ccbnOutlineChart { background-color: rgb(255, 255, 255); }

.ccbnOutlineQuote { background-color: rgb(255, 255, 255); }

.ccbnBgChart { background-color: rgb(255, 255, 255); }

.ccbnBgLine { background-color: rgb(0, 0, 0); }

.ccbnBgSpacer { background-color: rgb(255, 255, 255); }

#CCBNSECRes { }

.ccbnEnumBodyBg { }

.ccbnEnumBg { background-color: rgb(204, 204, 204); }

.ccbnEnumBgLogo { background-color: rgb(255, 255, 255); }

.ccbnEnumHighlightLt { background-color: rgb(255, 255, 255); }

.ccbnEnumHighlight { background-color: rgb(239, 239, 239); }

.ccbnEnumShadow { background-color: rgb(153, 153, 153); }

.ccbnEnumShadowDk { background-color: rgb(102, 102, 102); }

.ccbnEnumTabLnk { font-family: arial, helvetica, sans-serif; font-size: 10p=
x; color: rgb(0, 0, 0); text-transform: uppercase; }

a.ccbnEnumTabLnk:link { font-family: arial, helvetica, sans-serif; font-siz=
e: 10px; color: rgb(0, 0, 0); text-transform: uppercase; text-decoration: u=
nderline; }

a.ccbnEnumTabLnk:hover { text-decoration: none; }

a.ccbnEnumTabLnk:active { text-decoration: none; }

a.ccbnEnumTabLnk:visited { font-family: arial, helvetica, sans-serif; font-=
size: 10px; color: rgb(0, 0, 0); text-transform: uppercase; text-decoration=
: underline; }

.ccbnEnumPeerListLnk { font-size: 11px; }

.ccbnEnumTxtEven { font-family: arial, verdana, helvetica, sans-serif; font=
-size: 11px; }

.ccbnEnumTxtOdd { font-family: arial, verdana, helvetica, sans-serif; font-=
size: 11px; }

.ccbnBgEnumTblEven { background-color: rgb(239, 239, 239); }

.ccbnBgEnumTblOdd { background-color: rgb(255, 255, 255); }

.ccbnPopover { position: absolute; visibility: hidden; overflow: auto; widt=
h: 200px; height: auto; background: rgb(255, 255, 255); text-align: left; b=
order: 1px solid rgb(0, 0, 0); top: 0px; left: 0px; }

.ccbnDefinitionHover { width: 300px; }

.ccbnEventHeaderHover { width: 300px; }

.ccbnBioHover { width: 400px; }

.ccbnNewsHover { width: 300px; }

.ccbnRowHoverTbl tr:hover td, .ccbnRowHoverTbl tr.ccbnIE6Over td { }

.ccbnRowHoverTbl tr.ccbnBgTblTtl:hover td { }

.ccbnScroll { position: relative; overflow: hidden; height: 160px; }

.ccbnCalendarTable tbody td.ccbnEvent:hover, .ccbnCalendarTable tbody td.cc=
bnIE6Over { cursor: pointer; }

.ccbnCalendarTable thead td.ccbnCalButton:hover, .ccbnCalendarTable thead t=
d.ccbnCalButton.ccbnIE6Over { cursor: pointer; }

.ccbnCalendarDiv { height: auto; max-height: 100px; }

.ccbnCalendarHelpDiv { height: 300px; }

.ccbnCalendarDivClick { overflow: auto; height: 230px; }

.ccbnWeekend { }

.ccbnToday { border: 1px solid rgb(0, 0, 0); }

.ccbnEvent { background: rgb(187, 187, 187); }

.ccbnCalButton { }

.ccbnDay { }

.ccbnName { }

.ccbnCalendar { cursor: default; }

.ccbnCalendarTable { }

.ccbnCalCenterTitle { padding-left: 2.5em; }

.ccbnCalIconAnalyst { background: url("http://media.corporate-ir.net/media_=
files/irol/global_images/icon_am.gif") no-repeat; }

.ccbnCalIconConference { background: url("http://media.corporate-ir.net/med=
ia_files/irol/global_images/icon_cf.gif") no-repeat; }

.ccbnCalIconConferencePres { background: url("http://media.corporate-ir.net=
/media_files/irol/global_images/icon_cp.gif") no-repeat; }

.ccbnCalIconConferenceCall { background: url("http://media.corporate-ir.net=
/media_files/irol/global_images/icon_cc-ne.gif") no-repeat; }

.ccbnCalIconCustom { background: url("http://media.corporate-ir.net/media_f=
iles/irol/global_images/icon_custom.gif") no-repeat; }

.ccbnCalIconEarningsConfCall { background: url("http://media.corporate-ir.n=
et/media_files/irol/global_images/icon_cc-er.gif") no-repeat; }

.ccbnCalIconEarnings { background: url("http://media.corporate-ir.net/media=
_files/irol/global_images/icon_er.gif") no-repeat; }

.ccbnCalIconReports { background: url("http://media.corporate-ir.net/media_=
files/irol/global_images/icon_fin_rpt.gif") no-repeat; }

.ccbnCalIconMA { background: url("http://media.corporate-ir.net/media_files=
/irol/global_images/icon_ma.gif") no-repeat; }

.ccbnCalIconGuidance { background: url("http://media.corporate-ir.net/media=
_files/irol/global_images/icon_ga.gif") no-repeat; }

.ccbnCalIconOther { background: url("http://media.corporate-ir.net/media_fi=
les/irol/global_images/icon_oc.gif") no-repeat; }

.ccbnCalIconSalesCall { background: url("http://media.corporate-ir.net/medi=
a_files/irol/global_images/icon_sc.gif") no-repeat; }

.ccbnCalIconSalesRelease { background: url("http://media.corporate-ir.net/m=
edia_files/irol/global_images/icon_sar.gif") no-repeat; }

.ccbnCalIconShareholders { background: url("http://media.corporate-ir.net/m=
edia_files/irol/global_images/icon_sm.gif") no-repeat; }

.ccbnCalIconNewsRelease { background: url("http://media.corporate-ir.net/me=
dia_files/irol/global_images/icon_news.gif") no-repeat; }

.ccbnCalIconSEC { background: url("http://media.corporate-ir.net/media_file=
s/irol/global_images/icon_sec.gif") no-repeat; }

.ccbnCalIconPresentations { background: url("http://media.corporate-ir.net/=
media_files/irol/global_images/icon_pres.gif") no-repeat; }

.ccbnCalIcon52WeekHigh { background: url("http://media.corporate-ir.net/med=
ia_files/irol/global_images/icon_52wkh.gif") no-repeat; }

.ccbnCalIconAnalyst, .ccbnCalIconConference, .ccbnCalIconConferencePres, .c=
cbnCalIconConferenceCall, .ccbnCalIconCustom, .ccbnCalIconEarningsConfCall,=
 .ccbnCalIconEarnings, .ccbnCalIconReports, .ccbnCalIconMA, .ccbnCalIconGui=
dance, .ccbnCalIconOther, .ccbnCalIconSalesCall, .ccbnCalIconSalesRelease, =
.ccbnCalIconShareholders, .ccbnCalIconNewsRelease, .ccbnCalIconSEC, .ccbnCa=
lIconPresentations, .ccbnCalIcon52WeekHigh { padding-left: 20px; }

.ccbnEmpty span { visibility: hidden; }

td.ccbnCalButton:hover div.ccbnCalendarHelpDiv, .ccbnCalendarTable thead td=
.ccbnIE6Over div.ccbnCalendarHelpDiv { visibility: visible; z-index: 100; }

td.ccbnEvent:hover div.ccbnCalendarDiv, .ccbnCalendarTable tbody td.ccbnIE6=
Over div.ccbnCalendarDiv { visibility: visible; z-index: 100; }

.bwcellpaddingbottom1 { padding-bottom: 2px; font: 100% arial; }

.bwcellpaddingbottom3 { padding-bottom: 4px; font: 100% arial; }

.bwcellpaddingleft0 { padding-left: 0px; font: 100% arial; }

.bwcellpaddingleft1 { padding-left: 5px; font: 100% arial; }

.bwcellpaddingleft2 { padding-left: 10px; font: 100% arial; }

.bwcellpaddingleft4 { padding-left: 20px; font: 100% arial; }

.bwcellpaddingleft5 { padding-left: 25px; font: 100% arial; }

.bwcellpaddingleft6 { padding-left: 30px; font: 100% arial; }

.bwcellpaddingleft7 { padding-left: 35px; font: 100% arial; }

.bwcellpaddingleft8 { padding-left: 40px; font: 100% arial; }

.bwcellpaddingright0 { padding-right: 0px; font: 100% arial; }

.bwcellparagraphmargin { margin-bottom: 0px; margin-top: 0px; font: 100% ar=
ial; }

.bwdoublebottomborder { border-bottom: 2.25pt double black; font: 100% aria=
l; }

.bwlistitemmarginbottom { margin-bottom: 10px; font: 100% arial; }

.bwsinglebottomborder { border-bottom: 1pt solid black; font: 100% arial; }

.bwtablebottommargin { margin-bottom: 10px; font: 100% arial; }

.bwtextaligncenter { text-align: center; font: 100% arial; }

.bwtextalignleft { text-align: left; font: 100% arial; }

.bwtextalignright { text-align: right; font: 100% arial; }

.bwunderlinestyle { text-decoration: underline; font: 100% arial; }

.bwverticalalignbottom { vertical-align: bottom; font: 100% arial; }

.bwverticalaligntop { vertical-align: top; font: 100% arial; }

.bwwhitespacenowrap { white-space: nowrap; font: 100% arial; }

.bwbodyimg { float: left; padding-left: 0px; padding-right: 20px; padding-t=
op: 0px; padding-bottom: 0px !important; }

.bwbodyimgcaption { font-size: 85% !important; }

.bwtextaligncenter, .bwalignc { text-align: center !important; }

.bwtextalignleft, .bwalignl { text-align: left !important; }

.bwtextalignright, .bwalignr { text-align: right !important; }

.bwverticalaligntop, .bwvertalignt { vertical-align: top !important; }

.bwverticalalignmiddle, .bwvertalignm { vertical-align: middle !important; =
}

.bwverticalalignbottom, .bwvertalignb { vertical-align: bottom !important; =
}

.bwtablefigurealign, .bwfigurealign { text-align: right; vertical-align: bo=
ttom !important; }

.bwtabletextalign, .bwtxtalign { text-align: left; vertical-align: bottom !=
important; }

.bwwhitespacenowrap, .bwnowrap { white-space: normal !important; }

.bwsinglebottomborder, .bwsinglebottom { border-bottom: 1pt solid black !im=
portant; }

.bwdoublebottomborder, .bwdoublebottom { border-bottom: 2.25pt double black=
 !important; }

.bwsingletopborder, .bwsingletop { border-top: 1pt solid black !important; =
}

.bwdoubletopborder, .bwdoubletop { border-top: 2.25pt double black !importa=
nt; }

.bwcellpaddingleft0, .bwpadl0 { padding-left: 0px !important; }

.bwcellpaddingleft1, .bwpadl1 { padding-left: 5px !important; }

.bwcellpaddingleft2, .bwpadl2 { padding-left: 10px !important; }

.bwcellpaddingleft3, .bwpadl3 { padding-left: 15px !important; }

.bwcellpaddingleft4, .bwpadl4 { padding-left: 20px !important; }

.bwcellpaddingleft5, .bwpadl5 { padding-left: 25px !important; }

.bwcellpaddingleft6, .bwpadl6 { padding-left: 30px !important; }

.bwcellpaddingleft7, .bwpadl7 { padding-left: 35px !important; }

.bwcellpaddingleft8, .bwpadl8 { padding-left: 40px !important; }

.bwcellpaddingleft9, .bwpadl9 { padding-left: 45px !important; }

.bwcellpaddingleft10, .bwpadl10 { padding-left: 50px !important; }

.bwcellpaddingleft11, .bwpadl11 { padding-left: 55px !important; }

.bwcellpaddingleft12, .bwpadl12 { padding-left: 60px !important; }

.bwcellpaddingleft13, .bwpadl13 { padding-left: 65px !important; }

.bwcellpaddingleft14, .bwpadl14 { padding-left: 70px !important; }

.bwcellpaddingleft15, .bwpadl15 { padding-left: 75px !important; }

.bwcellpaddingleft16, .bwpadl16 { padding-left: 80px !important; }

.bwcellpaddingleft17, .bwpadl17 { padding-left: 85px !important; }

.bwcellpaddingleft18, .bwpadl18 { padding-left: 90px !important; }

.bwcellpaddingleft19, .bwpadl19 { padding-left: 95px !important; }

.bwcellpaddingleft20, .bwpadl20 { padding-left: 100px !important; }

.bwcellpaddingright0, .bwpadr0 { padding-right: 0px !important; }

.bwcellpaddingright1, .bwpadr1 { padding-right: 5px !important; }

.bwcellpaddingright2, .bwpadr2 { padding-right: 10px !important; }

.bwcellpaddingright3, .bwpadr3 { padding-right: 15px !important; }

.bwcellpaddingright4, .bwpadr4 { padding-right: 20px !important; }

.bwcellpaddingright5, .bwpadr5 { padding-right: 25px !important; }

.bwcellpaddingright6, .bwpadr6 { padding-right: 30px !important; }

.bwcellpaddingright7, .bwpadr7 { padding-right: 35px !important; }

.bwcellpaddingright8, .bwpadr8 { padding-right: 40px !important; }

.bwcellpaddingright9, .bwpadr9 { padding-right: 45px !important; }

.bwcellpaddingright10, .bwpadr10 { padding-right: 50px !important; }

.bwcellpaddingtop1, .bwpadt1 { padding-top: 10px !important; }

.bwcellpaddingtop2, .bwpadt2 { padding-top: 20px !important; }

.bwcellpaddingtop3, .bwpadt3 { padding-top: 30px !important; }

.bwcellpaddingtop4, .bwpadt4 { padding-top: 40px !important; }

.bwcellpaddingtop5, .bwpadt5 { padding-top: 50px !important; }

.bwcellpaddingtop6, .bwpadt6 { padding-top: 60px !important; }

.bwcellpaddingtop7, .bwpadt7 { padding-top: 70px !important; }

.bwcellpaddingtop8, .bwpadt8 { padding-top: 80px !important; }

.bwcellpaddingtop9, .bwpadt9 { padding-top: 90px !important; }

.bwcellpaddingtop10, .bwpadt10 { padding-top: 100px !important; }

.bwcellpaddingtop11, .bwpadt11 { padding-top: 110px !important; }

.bwcellpaddingtop12, .bwpadt12 { padding-top: 120px !important; }

.bwcellpaddingtop13, .bwpadt13 { padding-top: 130px !important; }

.bwcellpaddingtop14, .bwpadt14 { padding-top: 140px !important; }

.bwcellpaddingtop15, .bwpadt15 { padding-top: 150px !important; }

.bwcellpaddingtop16, .bwpadt16 { padding-top: 160px !important; }

.bwcellpaddingtop17, .bwpadt17 { padding-top: 170px !important; }

.bwcellpaddingtop18, .bwpadt18 { padding-top: 180px !important; }

.bwcellpaddingtop19, .bwpadt19 { padding-top: 190px !important; }

.bwcellpaddingtop20, .bwpadt20 { padding-top: 200px !important; }

.bwcellpaddingbottom1, .bwpadb1 { padding-bottom: 2px !important; }

.bwcellpaddingbottom2, .bwpadb2 { padding-bottom: 3px !important; }

.bwcellpaddingbottom3, .bwpadb3 { padding-bottom: 4px !important; }

.bwunderlinestyle, .bwuline { text-decoration: underline !important; }

.bwdoubleunderlinestyle, .bwdbluline { text-decoration: underline; border-b=
ottom: 1px solid black !important; }

.bwcolorred, .bwred { color: red !important; }

.bwcolorblack, .bwblack { color: black !important; }

.bwmarginleft1, .bwmarginl1 { margin-left: 30px !important; }

.bwmarginleft2, .bwmarginl2 { margin-left: 60px !important; }

.bwmarginleft3, .bwmarginl3 { margin-left: 90px !important; }

.bwmarginleft4, .bwmarginl4 { margin-left: 120px !important; }

.bwmarginleft5, .bwmarginl5 { margin-left: 150px !important; }

.bwmarginleft6, .bwmarginl6 { margin-left: 180px !important; }

.bwmarginleft7, .bwmarginl7 { margin-left: 210px !important; }

.bwmarginleft8, .bwmarginl8 { margin-left: 240px !important; }

.bwmarginleft9, .bwmarginl9 { margin-left: 270px !important; }

.bwmarginleft10, .bwmarginl10 { margin-left: 300px !important; }

.bwhangingindent, .bwhangindent { text-indent: -30px !important; }

.bwparagraphindent, .bwpindent { text-indent: 30px !important; }

.bwliststylenone, .bwlistnone { list-style-image: none; list-style-type: no=
ne !important; }

.bwliststyledisc, .bwlistdisc { list-style-type: disc !important; }

.bwliststylesquare, .bwlistsquare { list-style-type: square !important; }

.bwliststylecircle, .bwlistcircle { list-style-type: circle !important; }

.bwliststyledecimal, .bwlistdecimal { list-style-type: decimal !important; =
}

.bwliststyleloweralpha, .bwlistlowalpha { list-style-type: lower-alpha !imp=
ortant; }

.bwliststyleupperalpha, .bwlistupalpha { list-style-type: upper-alpha !impo=
rtant; }

.bwliststylelowerroman, .bwlistlowroman { list-style-type: lower-roman !imp=
ortant; }

.bwliststyleupperroman, .bwlistuproman { list-style-type: upper-roman !impo=
rtant; }

.bwlistitemmarginbottom, .bwlistitemmargb { margin-bottom: 10px !important;=
 }

.bwcellparagraphmargin, .bwcellpmargin { margin-bottom: 0px; margin-top: 0p=
x !important; }

.bwtablebottommargin, .bwtablemarginb { margin-bottom: 10px !important; }

.bwblockaligncenter, .bwblockalignc { margin-left: auto; margin-right: auto=
 !important; }

.bwblockalignleft, .bwblockalignl { margin-left: 0px; margin-right: auto !i=
mportant; }

.bwblockalignright, .bwblockalignr { margin-left: auto; margin-right: 0px !=
important; }

.bwwidthpercent1, .bwwidth1 { width: 1% !important; }

.bwwidthpercent2, .bwwidth2 { width: 2% !important; }

.bwwidthpercent3, .bwwidth3 { width: 3% !important; }

.bwwidthpercent4, .bwwidth4 { width: 4% !important; }

.bwwidthpercent5, .bwwidth5 { width: 5% !important; }

.bwwidthpercent6, .bwwidth6 { width: 6% !important; }

.bwwidthpercent7, .bwwidth7 { width: 7% !important; }

.bwwidthpercent8, .bwwidth8 { width: 8% !important; }

.bwwidthpercent9, .bwwidth9 { width: 9% !important; }

.bwwidthpercent10, .bwwidth10 { width: 10% !important; }

.bwwidthpercent11, .bwwidth11 { width: 11% !important; }

.bwwidthpercent12, .bwwidth12 { width: 12% !important; }

.bwwidthpercent13, .bwwidth13 { width: 13% !important; }

.bwwidthpercent14, .bwwidth14 { width: 14% !important; }

.bwwidthpercent15, .bwwidth15 { width: 15% !important; }

.bwwidthpercent16, .bwwidth16 { width: 16% !important; }

.bwwidthpercent17, .bwwidth17 { width: 17% !important; }

.bwwidthpercent18, .bwwidth18 { width: 18% !important; }

.bwwidthpercent19, .bwwidth19 { width: 19% !important; }

.bwwidthpercent20, .bwwidth20 { width: 20% !important; }

.bwwidthpercent21, .bwwidth21 { width: 21% !important; }

.bwwidthpercent22, .bwwidth22 { width: 22% !important; }

.bwwidthpercent23, .bwwidth23 { width: 23% !important; }

.bwwidthpercent24, .bwwidth24 { width: 24% !important; }

.bwwidthpercent25, .bwwidth25 { width: 25% !important; }

.bwwidthpercent26, .bwwidth26 { width: 26% !important; }

.bwwidthpercent27, .bwwidth27 { width: 27% !important; }

.bwwidthpercent28, .bwwidth28 { width: 28% !important; }

.bwwidthpercent29, .bwwidth29 { width: 29% !important; }

.bwwidthpercent30, .bwwidth30 { width: 30% !important; }

.bwwidthpercent31, .bwwidth31 { width: 31% !important; }

.bwwidthpercent32, .bwwidth32 { width: 32% !important; }

.bwwidthpercent33, .bwwidth33 { width: 33% !important; }

.bwwidthpercent34, .bwwidth34 { width: 34% !important; }

.bwwidthpercent35, .bwwidth35 { width: 35% !important; }

.bwwidthpercent36, .bwwidth36 { width: 36% !important; }

.bwwidthpercent37, .bwwidth37 { width: 37% !important; }

.bwwidthpercent38, .bwwidth38 { width: 38% !important; }

.bwwidthpercent39, .bwwidth39 { width: 39% !important; }

.bwwidthpercent40, .bwwidth40 { width: 40% !important; }

.bwwidthpercent41, .bwwidth41 { width: 41% !important; }

.bwwidthpercent42, .bwwidth42 { width: 42% !important; }

.bwwidthpercent43, .bwwidth43 { width: 43% !important; }

.bwwidthpercent44, .bwwidth44 { width: 44% !important; }

.bwwidthpercent45, .bwwidth45 { width: 45% !important; }

.bwwidthpercent46, .bwwidth46 { width: 46% !important; }

.bwwidthpercent47, .bwwidth47 { width: 47% !important; }

.bwwidthpercent48, .bwwidth48 { width: 48% !important; }

.bwwidthpercent49, .bwwidth49 { width: 49% !important; }

.bwwidthpercent50, .bwwidth50 { width: 50% !important; }

.bwwidthpercent51, .bwwidth51 { width: 51% !important; }

.bwwidthpercent52, .bwwidth52 { width: 52% !important; }

.bwwidthpercent53, .bwwidth53 { width: 53% !important; }

.bwwidthpercent54, .bwwidth54 { width: 54% !important; }

.bwwidthpercent55, .bwwidth55 { width: 55% !important; }

.bwwidthpercent56, .bwwidth56 { width: 56% !important; }

.bwwidthpercent57, .bwwidth57 { width: 57% !important; }

.bwwidthpercent58, .bwwidth58 { width: 58% !important; }

.bwwidthpercent59, .bwwidth59 { width: 59% !important; }

.bwwidthpercent60, .bwwidth60 { width: 60% !important; }

.bwwidthpercent61, .bwwidth61 { width: 61% !important; }

.bwwidthpercent62, .bwwidth62 { width: 62% !important; }

.bwwidthpercent63, .bwwidth63 { width: 63% !important; }

.bwwidthpercent64, .bwwidth64 { width: 64% !important; }

.bwwidthpercent65, .bwwidth65 { width: 65% !important; }

.bwwidthpercent66, .bwwidth66 { width: 66% !important; }

.bwwidthpercent67, .bwwidth67 { width: 67% !important; }

.bwwidthpercent68, .bwwidth68 { width: 68% !important; }

.bwwidthpercent69, .bwwidth69 { width: 69% !important; }

.bwwidthpercent70, .bwwidth70 { width: 70% !important; }

.bwwidthpercent71, .bwwidth71 { width: 71% !important; }

.bwwidthpercent72, .bwwidth72 { width: 72% !important; }

.bwwidthpercent73, .bwwidth73 { width: 73% !important; }

.bwwidthpercent74, .bwwidth74 { width: 74% !important; }

.bwwidthpercent75, .bwwidth75 { width: 75% !important; }

.bwwidthpercent76, .bwwidth76 { width: 76% !important; }

.bwwidthpercent77, .bwwidth77 { width: 77% !important; }

.bwwidthpercent78, .bwwidth78 { width: 78% !important; }

.bwwidthpercent79, .bwwidth79 { width: 79% !important; }

.bwwidthpercent80, .bwwidth80 { width: 80% !important; }

.bwwidthpercent81, .bwwidth81 { width: 81% !important; }

.bwwidthpercent82, .bwwidth82 { width: 82% !important; }

.bwwidthpercent83, .bwwidth83 { width: 83% !important; }

.bwwidthpercent84, .bwwidth84 { width: 84% !important; }

.bwwidthpercent85, .bwwidth85 { width: 85% !important; }

.bwwidthpercent86, .bwwidth86 { width: 86% !important; }

.bwwidthpercent87, .bwwidth87 { width: 87% !important; }

.bwwidthpercent88, .bwwidth88 { width: 88% !important; }

.bwwidthpercent89, .bwwidth89 { width: 89% !important; }

.bwwidthpercent90, .bwwidth90 { width: 90% !important; }

.bwwidthpercent91, .bwwidth91 { width: 91% !important; }

.bwwidthpercent92, .bwwidth92 { width: 92% !important; }

.bwwidthpercent93, .bwwidth93 { width: 93% !important; }

.bwwidthpercent94, .bwwidth94 { width: 94% !important; }

.bwwidthpercent95, .bwwidth95 { width: 95% !important; }

.bwwidthpercent96, .bwwidth96 { width: 96% !important; }

.bwwidthpercent97, .bwwidth97 { width: 97% !important; }

.bwwidthpercent98, .bwwidth98 { width: 98% !important; }

.bwwidthpercent99, .bwwidth99 { width: 99% !important; }

.bwwidthpercent100, .bwwidth100 { width: 100% !important; }

.ccbn-stock-quote p { clear: both; margin: 0px; }

.ccbn-dl-quote { margin: 0px; padding: 0px; }

.ccbn-dl-quote dt { clear: left; float: left; margin: 0px; padding: 0px; wi=
dth: 40%; }

.ccbn-dl-quote dd { float: left; margin: 0px; padding: 0px; width: 50%; }

.ccbn-sec-recent-filters { list-style: none; padding: 0px; margin: 0px; dis=
play: none; }

.ccbn-sec-recent-filters li { display: inline; float: left; margin: 0px 4px=
 0px 0px !important; }

.ccbn-sec-recent-filters li a { float: left; padding: 3px; text-decoration:=
 none; }

.ccbn-sec-recent-filters .ccbn-current-filter a { background: rgb(51, 51, 5=
1); color: rgb(255, 255, 255); }

.ccbn-sec-recent-groups { clear: both; }

.ccbn-sec-recent-group { display: none; }

.ccbn-sec-recent-group-active { display: block; }

.ccbn-sec-recent-group ul { list-style: none; padding: 0px; margin: 0px; }

.ccbn-sec-recent-group ul li { margin: 0px 0px 10px; padding: 0px; }

.ccbn-news ul { list-style: outside none none; margin: 0px; padding: 0px; }

.ccbn-news ul li { margin: 0px 0px 10px; padding: 0px; }

.ccbn-embedded-player-container { margin-bottom: 10px; width: 100%; display=
: none; }

.ccbn-embedded-player-480 { width: 480px; height: 295px; margin: 0px auto; =
clear: both; }

.ccbn-embedded-player-560 { width: 560px; height: 340px; margin: 0px auto; =
clear: both; }

.ccbn-embedded-player-640 { width: 640px; height: 385px; margin: 0px auto; =
clear: both; }

.ccbn-embedded-player-853 { width: 853px; height: 505px; margin: 0px auto; =
clear: both; }

.ccbn-embedded-player-popup { float: right; }

.ccbn-event-heading h1 { font-size: 24px; }

.ccbn-event-heading h1 a { background: url("http://media.corporate-ir.net/m=
edia_files/IROL/global_images/earnings-release/icon-earnings-release-32.gif=
") 0px 0px no-repeat scroll transparent; padding-left: 38px; }

.ccbn-event-heading p { }

.ccbn-tools-content #ccbn-share-page, .ccbn-tools-content #ccbn-rss-subscri=
ptions, .ccbn-tools-content #ccbn-email-subscriptions { display: none; padd=
ing: 20px; }

#ccbn-share-page .ccbn-tools-content-header { background: url("http://media=
.corporate-ir.net/media_files/IROL/global_images/earnings-release/icon-shar=
e-32.gif") 0px 0px no-repeat scroll transparent; }

#ccbn-rss-subscriptions .ccbn-tools-content-header { background: url("http:=
//media.corporate-ir.net/media_files/IROL/global_images/earnings-release/ic=
on-rss-32.gif") 0px 0px no-repeat scroll transparent; }

#ccbn-email-subscriptions .ccbn-tools-content-header { background: url("htt=
p://media.corporate-ir.net/media_files/IROL/global_images/earnings-release/=
icon-alerts-44.gif") 0px 0px no-repeat scroll transparent; }

#ccbn-share-page .ccbn-tools-content-main ul li { float: left; margin: 0px =
0px 8px; padding-right: 4%; width: 45%; list-style: none; }

#ccbn-share-page .ccbn-tools-content-main ul li a { display: block; padding=
-left: 20px; }

#ccbn-rss-subscriptions .ccbn-rss-group { float: left; padding-right: 3%; w=
idth: 45%; }

#ccbn-rss-subscriptions .ccbn-rss-group ul { margin: 0px 0px 10px; padding:=
 0px; }

#ccbn-rss-subscriptions .ccbn-rss-group li { font-size: 11px; margin-bottom=
: 5px; list-style: none; }

#ccbn-email-subscriptions .ccbn-tools-content-main label { display: block; =
font-size: 11px; }

#ccbn-email-subscriptions .ccbn-tools-content-main .ccbnInput input { displ=
ay: block; margin-bottom: 8px; width: 80%; }

.ccbn-event-downloads { margin: 0px; padding: 0px; }

.ccbn-event-downloads li { list-style: none; padding: 3px 0px; border-botto=
m: 1px solid rgb(230, 230, 230); margin: 0px !important; }

.ccbn-event-downloads li.ccbn-last { border-bottom: none; }

.ccbn-event-downloads-encodings { margin-left: 24px; padding: 0px; }

.ccbn-event-downloads-encodings a { text-transform: uppercase; }

.ccbn-related-links { margin: 0px; padding: 0px; }

.ccbn-related-links li { list-style: none; padding: 3px 0px; border-bottom:=
 1px solid rgb(230, 230, 230); margin: 0px !important; }

.ccbn-related-links li a { background: url("http://media.corporate-ir.net/m=
edia_files/IROL/global_images/icon-open-window.gif") right 0px no-repeat sc=
roll transparent; display: inline-block; min-height: 16px; padding-right: 2=
4px; }

.ccbn-related-links li.ccbn-last { border-bottom: none; }

#ccbn-share-page::after, #ccbn-rss-subscriptions::after, #ccbn-email-subscr=
iptions::after { clear: both; content: "."; display: block; height: 0px; vi=
sibility: hidden; }

#ccbn-share-page, #ccbn-rss-subscriptions, #ccbn-email-subscriptions { zoom=
: 1; }

.prntblns tr td:first-child, .prntblns tr td:first-child p { white-space: n=
ormal !important; }

p.prnews_p { margin: 0px !important; }

.prngen14 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen21 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: left !important; padding-=
left: 0px !important; padding-right: 0px !important; vertical-align: bottom=
 !important; }

.prngen4 { white-space: normal; border-width: 0.08em !important; border-sty=
le: initial !important; border-color: initial !important; text-align: left =
!important; padding-left: 0px !important; padding-right: 0px !important; ve=
rtical-align: bottom !important; }

.prngen19 { border-bottom: 0.17em double black; text-align: right !importan=
t; border-left: 0.08em !important; padding-left: 0px !important; padding-ri=
ght: 0px !important; vertical-align: bottom !important; border-top: 0.08em =
!important; border-right: 0.08em !important; }

.prngen16 { border-bottom: 0.17em double black; text-align: right !importan=
t; border-left: 0.08em !important; padding-left: 0px !important; padding-ri=
ght: 0px !important; vertical-align: bottom !important; border-top: black !=
important; border-right: 0.08em !important; }

.prngen6 { border-width: 0.08em !important; border-bottom-style: initial !i=
mportant; border-bottom-color: initial !important; text-align: right !impor=
tant; border-left-style: solid !important; border-left-color: black !import=
ant; padding-left: 0px !important; padding-right: 0px !important; vertical-=
align: bottom !important; border-top-style: initial !important; border-top-=
color: initial !important; border-right-style: initial !important; border-r=
ight-color: initial !important; }

.prngen9 { text-align: center; border-width: 0.08em !important; border-bott=
om-style: solid !important; border-bottom-color: black !important; border-l=
eft-style: initial !important; border-left-color: initial !important; paddi=
ng-left: 0px !important; padding-right: 0px !important; vertical-align: bot=
tom !important; border-top-style: initial !important; border-top-color: ini=
tial !important; border-right-style: initial !important; border-right-color=
: initial !important; }

.prngen13 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: right !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: botto=
m !important; }

.prngen2 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; padding-left: 0px !important; padding-=
right: 0px !important; vertical-align: bottom !important; }

.prngen12 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen3 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; text-align: right !important; padding-=
left: 0px !important; padding-right: 0px !important; vertical-align: bottom=
 !important; }

.prngen8 { text-align: center; border-width: 0.08em !important; border-bott=
om-style: initial !important; border-bottom-color: initial !important; bord=
er-left-style: initial !important; border-left-color: initial !important; p=
adding-left: 0px !important; padding-right: 0px !important; vertical-align:=
 bottom !important; border-top-style: solid !important; border-top-color: b=
lack !important; border-right-style: initial !important; border-right-color=
: initial !important; }

.prngen10 { text-align: center; border-width: 0.08em !important; border-sty=
le: initial !important; border-color: initial !important; padding-left: 0px=
 !important; padding-right: 0px !important; vertical-align: bottom !importa=
nt; }

.prngen23 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: solid !important; border-top-c=
olor: black !important; border-right-style: initial !important; border-righ=
t-color: initial !important; }

.prngen24 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: solid !important; border-top-c=
olor: black !important; border-right-style: initial !important; border-righ=
t-color: initial !important; }

.prngen18 { border-width: 0.08em !important; border-style: solid !important=
; border-color: black !important; text-align: center !important; padding-le=
ft: 0px !important; padding-right: 0px !important; vertical-align: bottom !=
important; }

.prngen20 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: right !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: top !=
important; }

.prngen22 { border-bottom: 0.08em solid black !important; text-align: right=
 !important; border-left: 0.08em !important; padding-left: 0px !important; =
padding-right: 0px !important; vertical-align: bottom !important; border-to=
p: black !important; border-right: 0.08em !important; }

.prngen17 { border-bottom: 0.17em double black !important; text-align: righ=
t !important; border-left: 0.08em !important; padding-left: 0px !important;=
 padding-right: 0px !important; vertical-align: bottom !important; border-t=
op: black !important; border-right: 0.08em !important; }

.prngen15 { border-width: 0.08em 0.08em 0.17em !important; border-bottom-st=
yle: double !important; border-bottom-color: black !important; text-align: =
right !important; border-left-style: initial !important; border-left-color:=
 initial !important; padding-left: 0px !important; padding-right: 0px !impo=
rtant; vertical-align: bottom !important; border-top-style: initial !import=
ant; border-top-color: initial !important; border-right-style: initial !imp=
ortant; border-right-color: initial !important; }

.prngen5 { border-width: 0.08em !important; border-bottom-style: solid !imp=
ortant; border-bottom-color: black !important; text-align: center !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen7 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; text-align: center !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: botto=
m !important; }

.prnpr8 { padding-right: 0.67em !important; }

.prntblns { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; }

.prnvab { vertical-align: bottom !important; }

.prnpl6 { padding-left: 0.5em !important; }

.prnbls { border-left: 0.08em solid black !important; }

.prnbb1 { border-bottom: 0.08em !important; }

.prnbr1 { border-right: 0.08em !important; }

.prnbt1 { border-top: 0.08em !important; }

.prntac { text-align: center !important; }

.gnw_heading { text-align: center; }

.gnw_subhead { text-align: center; }

.gnw_colhead { text-align: center; }

.gnw_colhead_uline { text-align: center; border-bottom: 1pt solid black; }

.gnw_colhead_dline { text-align: center; border-bottom: 2.5pt double black;=
 }

.gnw_label { vertical-align: bottom; text-align: left; }

.gnw_label_uline { vertical-align: bottom; text-align: left; border-bottom:=
 1pt solid black; }

.gnw_label_uline_i10 { vertical-align: bottom; text-align: right; border-bo=
ttom: 1pt solid black; }

.gnw_label_uline_i15 { vertical-align: bottom; text-align: right; border-bo=
ttom: 1pt solid black; }

.gnw_label_uline_i20 { vertical-align: bottom; text-align: right; border-bo=
ttom: 1pt solid black; }

.gnw_label_uline_i25 { vertical-align: bottom; text-align: right; border-bo=
ttom: 1pt solid black; }

.gnw_label_uline_i30 { vertical-align: bottom; text-align: right; border-bo=
ttom: 1pt solid black; }

.gnw_label_ulinetop { vertical-align: bottom; text-align: left; border-top:=
 1pt solid black; }

.gnw_label_dline { vertical-align: bottom; text-align: left; border-bottom:=
 2.5pt double black; }

.gnw_label_i10 { vertical-align: bottom; text-align: left; padding-left: 10=
px; }

.gnw_label_i15 { vertical-align: bottom; text-align: left; padding-left: 15=
px; }

.gnw_label_i20 { vertical-align: bottom; text-align: left; padding-left: 20=
px; }

.gnw_label_i25 { vertical-align: bottom; text-align: left; padding-left: 25=
px; }

.gnw_label_i30 { vertical-align: bottom; text-align: left; padding-left: 30=
px; }

.gnw_num { vertical-align: bottom; text-align: right; }

.gnw_num_uline { vertical-align: bottom; text-align: right; border-bottom: =
1pt solid black; }

.gnw_num_ulinetop { vertical-align: bottom; text-align: right; border-top: =
1pt solid black; }

.gnw_num_dline { vertical-align: bottom; text-align: right; border-bottom: =
2.5pt double black; }

.gnw_num_dlinetop { vertical-align: bottom; text-align: right; border-top: =
2.5pt double black; }

.gnw_data { vertical-align: bottom; text-align: left; }

.gnw_data_uline { vertical-align: bottom; text-align: left; border-bottom: =
1pt solid black; }

.gnw_data_dline { vertical-align: bottom; text-align: left; border-bottom: =
2.5pt double black; }

.gnw_news_media_box { margin: 15px 6px 6px; border-width: 1px; border-color=
: rgb(169, 169, 169); border-style: solid; }

.gnw_media_caption { font-size: 8pt; font-family: Verdana, Arial, Helvetica=
, Geneva, Swiss, SunSans-Regular; }

.gnw_media_bgcolor { background-color: transparent; }

.gnw_table { border-collapse: separate; border-spacing: 6px; }

.gnw_videotitle { font-weight: bold; color: rgb(29, 82, 150); }

@media screen and (max-width: 1024px) {
  td.ccbnOutline .ccbnBgTblTtl > td.ccbnCalButton { cursor: default; }
  .ccbnPopover, td.ccbnOutline .ccbnBgTblTtl > td.ccbnCalButton span { disp=
lay: none; }
  .ovrflw { overflow-x: auto; padding: 5px 5px 10px; width: 99%; }
  .ccbn-stock-chart-image img { max-width: 100% !important; }
}

@media screen and (max-width: 768px) {
  .break { display: block; text-align: left; width: auto; }
}

@media screen and (max-width: 480px) {
  ccbncontent { font-size: 12px !important; }
  .ccbnBgTblOdd td { padding: 3px; }
  .ccbnBgTblEven td { padding: 3px; }
  .ccbnBgTblTtl td { padding: 3px; }
  .ccbnTtl { font-size: 20px !important; }
  .sub-nav a { font-size: 12px; }
  .toolkit a { font-size: 12px !important; }
  .ccbnDisclaimer { font-size: 11px; }
  .ccbnContent p { font-size: 12px !important; }
}

@media screen and (max-width: 320px) {
}
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/ir-inline.css

@charset "utf-8";

body { background-color: rgb(255, 255, 255); color: rgb(51, 51, 51); }

a { color: rgb(116, 124, 120); }

.footer_wrap { background-color: rgb(250, 250, 250); }

.post_icon i { color: rgb(255, 255, 255); }

a:hover { color: rgb(255, 255, 255); }

#content a, #contact_info a { }

#content .post_title a { border-bottom: 0px; }

.stat { background-color: rgb(116, 124, 120); }

h1, h2, h3, h1 a, h2 a, h3 a, .blogpost h2 a, .widget h4 { color: rgb(85, 8=
5, 85); }

h3, .ag_projects_widget h3, h4, h3 a, h4 a, .aj_projects_widget h3 a, .foot=
er .note h4, .footer h4.subheadline { }

p, ul, ol, .button, .ui-tabs-vertical .ui-tabs-nav li a span.text, .footer =
p, .footer ul, .footer ol, .footer.button, .credits p, .credits ul, .credit=
s ol, .credits.button, .footer textarea, .footer input, .testimonial p, .co=
ntactsubmit label, .contactsubmit input[type=3D"text"], .contactsubmit text=
area { }

.except_link a:hover { color: rgb(255, 255, 255); }

.except_link a { color: rgb(255, 255, 255); }

a.portfolio_link:hover { color: rgb(255, 255, 255); }

.portfolio_link a { color: rgb(255, 255, 255); }

hr { border-top: 0px solid rgba(51, 51, 51, 0.2); border-bottom: 1px solid =
rgba(51, 51, 51, 0.2); }

.stats { border-top: 1px dotted rgba(51, 51, 51, 0.2); }

.blog article { border-bottom: 1px dotted rgba(51, 51, 51, 0.2); }

#sidebar .widget ul li { list-style: none; border-bottom: 1px dotted rgba(5=
1, 51, 51, 0.2); }

.panel .back { background: rgb(116, 124, 120); }

.panel_2col .back { background: rgb(116, 124, 120); }

.post_title h3 { margin-bottom: 0.2em; padding-bottom: 10px; border-bottom:=
 1px solid rgb(255, 255, 255); }

.post_icon { background-color: rgb(255, 255, 255); }

.author_link { color: rgb(116, 124, 120); }

.stats li em { color: rgb(116, 124, 120); }

.nav_social li a { background-color: rgb(116, 124, 120); }

.folio_desc { background-color: rgb(116, 124, 120); }

ul.fancy_tags li a { background-color: rgb(255, 255, 255); }

ul.fancy_tags li a:hover { background-color: rgb(116, 124, 120); }

.btn-flat { background-color: rgb(116, 124, 120); }

.btn-flat a:hover { background-color: rgb(255, 255, 255); }

.pagination a { background-color: rgb(116, 124, 120); border: 1px solid rgb=
(116, 124, 120); }

.pagination a:hover { background-color: rgb(255, 255, 255); border: 1px sol=
id rgb(255, 255, 255); color: rgb(255, 255, 255); }

.pagination span.current { color: rgb(255, 255, 255); border: 1px solid rgb=
(255, 255, 255); }

.quote_cite { border-bottom: 1px solid rgb(255, 255, 255); color: rgb(116, =
124, 120); }

.widget_tn_holder { background-color: rgb(255, 255, 255); }

.icon_holder_feat { background-color: rgb(116, 124, 120); }

.icon_holder_acc { background-color: rgb(255, 255, 255); }

.flexslider { background-color: rgb(116, 124, 120); }

.flex-caption-title span { background-color: rgba(116, 124, 120, 0.8); box-=
shadow: rgba(116, 124, 120, 0.8) 10px 0px 0px, rgba(116, 124, 120, 0.8) -10=
px 0px 0px; }

.flex-caption-text span { background-color: rgba(116, 124, 120, 0.5); box-s=
hadow: rgba(116, 124, 120, 0.5) 5px 0px 0px, rgba(116, 124, 120, 0.5) -7px =
0px 0px; }

.flex-control-nav li a { background: rgb(255, 255, 255); }

.flex-control-nav li.flex-active a { background: rgb(170, 170, 170); }

.img_post a span { background-color: rgba(116, 124, 120, 0.8); }

.img_post { background-color: rgb(250, 250, 250); }

.flex-direction-nav { display: none; }

.flex-direction-nav li a { background-color: rgb(255, 255, 255); color: rgb=
(255, 255, 255); }

.flex-direction-nav li a:hover { }

.nav > li > a:hover { text-decoration: none; background-color: rgb(116, 124=
, 120); }

.jqueryslidemenu ul li a { border-bottom: 1px dotted rgba(51, 51, 51, 0); }

.jqueryslidemenu > ul > li:hover > a { border-bottom: 1px solid rgb(255, 15=
3, 0); background-color: transparent; }

.in .jqueryslidemenu > ul li:hover > a { border-bottom: 1px solid rgb(255, =
255, 255); }

.dropcap2 { background: rgb(116, 124, 120); }

#content blockquote p.qp { color: rgb(116, 124, 120); }

.btn-flipit { background-color: rgb(116, 124, 120); background-image: none;=
 text-shadow: none; }

.btn-flipit:hover { background-color: rgb(255, 255, 255); background-image:=
 none; }

.more-link:hover { background-color: rgb(255, 255, 255); }

.nav_social li a { color: rgb(255, 255, 255); }

.jqueryslidemenu > ul > .current_page_item > a, .jqueryslidemenu > ul > .cu=
rrent-menu-parent > a, .jqueryslidemenu > ul > .current_page_parent > a, .j=
queryslidemenu > ul > li:hover > a, .latest_work .work_post a.work_link, fo=
oter h4, #sidebar .widget h4, .masonry_item .masonry_desc, .title_underline=
 { border-bottom-color: rgb(116, 124, 120) !important; }

.jqueryslidemenu ul li ul { border-top-color: rgb(116, 124, 120) !important=
; }

.circle_service:hover .circle_icon, .latest_work .work_post a.work_link:hov=
er, .more-link, a.post-edit-link, .pagination a:hover, #respond #submit, #r=
espond .add-on, ul.source li.active a, .simple_btn { background-color: rgb(=
116, 124, 120) !important; }

.circle_service:hover h3, .post_title h3 a:hover, .metadata ul li:hover i, =
.metadata ul li a:hover, a.post-edit-link:hover, ul.source li a:hover, ul.s=
ource li.active a:hover, .simple_btn:hover, .heroColor { color: rgb(116, 12=
4, 120) !important; }

#sidebar .widget ul li.active > a:hover { color: rgb(116, 124, 120) !import=
ant; }

#sidebar .widget ul li > a:hover { }

#respond #submit:hover { background-color: rgb(255, 255, 255) !important; c=
olor: rgb(255, 255, 255); }

.more-link:hover, .post-edit-link:hover, ul.source li.active a:hover { back=
ground-color: rgb(255, 255, 255) !important; }

#respond .add-on { border-color: rgb(116, 124, 120) !important; }

.wpcf7 input.wpcf7-submit { background-color: rgb(116, 124, 120); }

.wpcf7 input.wpcf7-submit:hover { background-color: rgb(255, 255, 255); }

.nav-tabs > li > a:hover { color: rgb(255, 255, 255); }

.nav-tabs > li > a { }

#sidebar .widget ul li > a:hover { color: rgb(255, 255, 255); }

.accordion-heading a { color: rgb(51, 51, 51); }

.accordion-heading a:hover { color: rgb(116, 124, 120); }

.flipIcon { background-color: rgb(116, 124, 120); }

.hoverBG { background-color: rgb(116, 124, 120); }

div.pp_default .pp_nav .pp_play, div.pp_default .pp_nav .pp_pause { backgro=
und-color: rgb(116, 124, 120); }

div.pp_default a.pp_arrow_previous, div.pp_default a.pp_arrow_next { backgr=
ound-color: rgb(116, 124, 120); }

div.pp_default a.pp_arrow_next { background-color: rgb(116, 124, 120); }

#sidebar .widget h4 i { color: rgb(116, 124, 120); }

#sidebar .widget .flip_stats ul li > a { color: rgb(255, 255, 255); }

.flip_stats li a { color: rgb(255, 255, 255); }

.flex-control-nav li.flex-active a { background: none 0px 0px repeat scroll=
 rgb(58, 58, 58) !important; }

#footer h4 { margin-top: 10px; }

input, textarea, .uneditable-input { width: 70%; }

.flex-caption-title span { background-color: rgba(242, 62, 15, 0); box-shad=
ow: rgba(242, 62, 15, 0) 10px 0px 0px, rgba(242, 62, 15, 0) -10px 0px 0px !=
important; }

.flex-caption-text span { background-color: rgba(242, 62, 15, 0); box-shado=
w: rgba(242, 62, 15, 0) 5px 0px 0px, rgba(242, 62, 15, 0) -7px 0px 0px !imp=
ortant; }

table.pr { border: 0px solid black; font-family: "Open Sans", Helvetica, Ar=
ial, sans-serif; font-weight: 300 !important; font-size: 16px !important; l=
ine-height: 26px !important; }

th.pr { text-align: left; padding: 10px; background-color: rgb(233, 238, 25=
1); color: rgb(85, 85, 85); font-weight: 600 !important; }

td.pr { border-bottom: 1px solid rgb(230, 230, 230); vertical-align: top; p=
adding: 15px; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/style(1).css

@charset "utf-8";

.clearfix { }

.clearfix::before, .clearfix::after { display: table; content: ""; }

.clearfix::after { clear: both; }

.hide-text { overflow: hidden; text-indent: 100%; white-space: nowrap; }

.input-block-level { display: block; width: 100%; min-height: 28px; box-siz=
ing: border-box; }

@media (max-width: 979px) {
  .btn-flat { margin-top: 4px; cursor: pointer; background-color: rgb(255, =
221, 48); float: right; padding: 10px; }
}

@media (min-width: 980px) {
  .btn-flat { display: none; }
}

.btn-flat .icon-bar { display: block; width: 18px; height: 3px; background-=
color: rgb(255, 255, 255); border-radius: 1px; }

.btn-flat .icon-bar + .icon-bar { margin-top: 3px; }

.nav-collapse.collapse { height: auto; }

@media (min-width: 980px) {
  body { font-size: 100%; }
}

@media (max-width: 979px) {
  body { font-size: 80%; }
  h1 { margin-left: 0px; }
  h3 { margin-left: 0px; }
  address { margin-left: 0px; }
}

h1 { line-height: 1em; margin-bottom: 0.2em; margin-left: 0px; }

h3 { font-size: 1.9em; margin-bottom: 0.2em; padding-bottom: 10px; }

.post_title h3 a { border-bottom: 10px; }

address { margin-bottom: 0px; }

p { font-size: 1em; }

hr { margin: 2em 0px; }

#header h1 { margin: 0px auto; text-align: center; color: rgb(67, 67, 67); =
font-size: 2.8125em; }

#header h1 a { color: inherit; }

#header h1 a:hover { text-decoration: none; }

.logo_holder { float: left; margin-right: 30px; width: 204px; height: 88px;=
 }

@media (max-width: 979px) {
  .logo_holder { margin-right: 0px; }
}

#header { position: relative; }

.navbar { margin: 0px; padding: 0px; }

.jqueryslidemenu ul { margin-bottom: -1px !important; }

.jqueryslidemenu > ul > .current_page_item > a { border-bottom: 1px dotted =
rgb(255, 202, 0); }

.jqueryslidemenu > ul > .current-menu-parent > a, .jqueryslidemenu > ul > .=
current_page_parent > a { border-bottom: 1px solid rgb(255, 202, 0); }

.jqueryslidemenu ul li a { text-decoration: none; font-size: 12px; }

.jqueryslidemenu > ul > li:hover > a { border-bottom: 1px solid rgb(255, 20=
2, 0); background-color: transparent; }

.in .jqueryslidemenu > ul li:hover > a { border-bottom: 1px solid rgb(255, =
202, 0); }

.jqueryslidemenu ul li ul { background: rgb(255, 255, 255); border-top: 1px=
 solid rgb(255, 202, 0); list-style: none; display: none; margin-top: -1px =
!important; padding: 0px !important; }

.jqueryslidemenu ul li ul li { border-bottom: 1px solid rgb(255, 255, 255);=
 }

.in .jqueryslidemenu ul li ul li { border-bottom: none; }

.jqueryslidemenu ul li ul li a { font-size: 12px; height: 30px; line-height=
: 30px; color: rgb(115, 115, 115); padding: 0px 15px !important; }

.jqueryslidemenu ul li ul li a:hover { color: rgb(115, 115, 115); backgroun=
d: rgb(248, 248, 248); }

.navPosition .navbar .nav, .navPositionleft .navbar .nav { float: left; }

.navPositionright .navbar .nav { float: right; }

@media (min-width: 980px) {
  .nav-collapse { height: auto !important; }
}

@media (max-width: 979px) {
  .navbar .nav { margin-top: 0px !important; }
  .navPositionright .navbar .nav, .navPosition .navbar .nav, .navPositionle=
ft .navbar .nav { float: none; }
}

.nav_social { margin: 10px 0px 0px; padding: 0px; bottom: 20px; right: 0px;=
 height: 40px; list-style: outside none none; }

#header .nav_social { position: absolute; }

@media (max-width: 979px) {
  #header .nav_social { display: none; }
}

.navPositionright .nav_social { top: 5px; }

.nav_social li { list-style-type: none; margin: 0px 2px -10px; float: left;=
 }

.nav_social li a { display: block; color: white; padding: 5px 5px 3px; font=
-size: 18px; }

.nav_social li a span { display: block; margin: -4px 6px; }

.nav_social li a { background-color: rgb(133, 133, 133); }

.nav_social li.n_facebook { background-color: rgb(59, 89, 152); }

.nav_social li.n_facebook a span { background-position: -440px 0px; }

.nav_social li.n_facebook:hover a { }

.nav_social li.n_twitter { background-color: rgb(51, 204, 255); }

.nav_social li.n_twitter a span { background-position: -362px 0px; }

.nav_social li.n_twitter:hover a { background-position: -362px -40px; }

.nav_social li.n_dribbble { background-color: rgb(197, 55, 109); }

.nav_social li.n_dribbble a span { background-position: -320px 0px; }

.nav_social li.n_dribbble:hover a { background-position: -320px -40px; }

.nav_social li.n_flickr { background-color: rgb(255, 0, 132); }

.nav_social li.n_flickr a span { background-position: -400px 0px; }

.nav_social li.n_flickr:hover a { background-position: -400px -40px; }

.nav_social li.n_youtube { background-color: rgb(193, 48, 42); }

.nav_social li.n_youtube a span { background-position: -240px 0px; }

.nav_social li.n_youtube:hover a { background-position: -240px -40px; }

.nav_social li.n_vimeo { background-color: rgb(26, 183, 234); }

.nav_social li.n_vimeo a span { background-position: -200px 0px; }

.nav_social li.n_vimeo:hover a { background-position: -200px -40px; }

.nav_social li.n_forrst { background-color: rgb(91, 154, 104); }

.nav_social li.n_forrst a span { background-position: 0px 0px; }

.nav_social li.n_forrst:hover a { background-position: 0px -40px; }

.nav_social li.n_skype { background-color: rgb(0, 175, 240); }

.nav_social li.n_skype a span { background-position: -280px 0px; }

.nav_social li.n_skype:hover a { background-position: -280px -40px; }

.nav_social li.n_google { background-color: rgb(221, 75, 57); }

.nav_social li.n_google a span { background-position: -80px 0px; }

.nav_social li.n_google:hover a { background-position: -80px -40px; }

.nav_social li.n_pinterest { background-color: rgb(221, 75, 57); }

.nav_social li.n_pinterest a span { background-position: -120px 0px; }

.nav_social li.n_tumblr:hover a { background-position: -120px -40px; }

.nav_social li.n_linkedin { background-color: rgb(0, 115, 178); }

.nav_social li.n_linkedin a span { background-position: -160px 0px; }

.nav_social li.n_linkedin:hover a { background-position: -160px -40px; }

.nav_social li.n_rss { background-color: rgb(255, 102, 0); }

.nav_social li.n_rss a span { background-position: -40px 0px; }

.nav_social li.n_rss:hover a { background-position: -40px -40px; }

.nav_social li a:hover { background-color: transparent !important; }

.intro_holder h1 { margin-left: 225px; }

.intro_holder p { margin-left: 225px; }

@media (max-width: 979px) {
  .intro_holder h1 { margin-left: 0px; }
  .intro_holder p { margin-left: 0px; }
}

.circle_service h3 { text-align: center; font-size: 1.375em; margin-bottom:=
 0.5em; transition: 300ms linear; }

.circle_service .circle_icon { width: 12.5em; height: 12.5em; border-radius=
: 7em; background-color: rgb(224, 222, 222); text-align: center; margin: 0p=
x auto 0.625em; transition: 300ms linear; }

.circle_service .circle_icon i { line-height: 1.8em; font-size: 7em; color:=
 rgb(255, 255, 255); transition: 300ms linear; }

.circle_service:hover h3 { color: rgb(255, 202, 0); }

.circle_service:hover .circle_icon { background-color: rgb(255, 202, 0); tr=
ansform: scale(1.1); }

.circle_service:hover .circle_icon i { font-size: 10em; line-height: 1.3em;=
 text-shadow: rgba(0, 0, 0, 0.3) 0px 1px 1px; }

.read-more i { font-size: 0.846154em; margin-left: 0.181818em; }

.read-more:hover i::before { text-decoration: none; }

.latest_work { }

.latest_work .work_post { text-align: center; margin-bottom: 30px; width: 1=
00%; }

.latest_work .work_post a.work_img { display: block; margin: 0px; position:=
 relative; transition: 300ms linear; }

.latest_work .work_post a.work_img img { width: 100%; margin: 0px auto -5px=
 0px; }

.latest_work .work_post a.work_img img.work_img_b { position: absolute; top=
: 0px; left: 0px; width: 100%; opacity: 0; transition: 200ms linear; }

.latest_work .work_post a.work_img i { position: absolute; top: 25%; left: =
42%; font-size: 2em; line-height: 1.25em; color: rgb(255, 255, 255); font-w=
eight: normal; text-shadow: rgba(0, 0, 0, 0.3) 0px 1px 0px; box-shadow: rgb=
a(255, 255, 255, 0.2) 0px 1px 0px, rgba(0, 0, 0, 0.2) 0px 1px 0px inset; ba=
ckground-color: rgba(0, 0, 0, 0.2); width: 1.25em; height: 1.25em; border-r=
adius: 50%; opacity: 0; transition: 200ms linear; transform: scale(1); }

.latest_work .work_post a.work_img:hover i { text-decoration: none; opacity=
: 1; display: block; transform: scale(1); top: 40%; }

.latest_work .work_post a.work_img:hover img.work_img_b { opacity: 1; }

.latest_work .work_post a.work_link { color: rgb(255, 255, 255); padding: 1=
.25em 1.8em; display: block; margin: 0px; border-bottom: 1px solid rgb(255,=
 255, 255); font-weight: bold; font-size: 24px; transition: 200ms linear; p=
osition: relative; overflow: hidden; text-align: left; }

.latest_work .work_post a.work_link i { position: absolute; right: 15px; to=
p: 110%; transition: 200ms linear; }

.latest_work .work_post a.work_link:hover { text-decoration: none; color: r=
gb(255, 255, 255); opacity: 0.5; }

.latest_work .work_post a.work_link:hover i { top: 32%; }

.except_link a { color: rgb(255, 255, 255); }

a.portfolio_link { font-size: 2em; color: rgb(255, 255, 255); text-align: l=
eft; display: block; margin: 0px 0px 20px; line-height: 1.55em; transition:=
 200ms linear; position: relative; overflow: hidden; }

a.portfolio_link:hover { text-decoration: none; color: rgb(255, 255, 255); =
}

.portfolio_link a i { border: 3px solid black; position: absolute; width: 1=
00%; font-size: 3em; line-height: 1.25em; color: rgb(255, 255, 255); font-w=
eight: normal; text-align: center; }

.footer_wrap { }

.widget_recent_posts ul li, .widget_popular_posts ul li { margin-bottom: 0.=
6em; min-height: 55px; }

.widget_recent_posts ul li .recent-post-img, .widget_popular_posts ul li .r=
ecent-post-img { position: relative; float: left; margin-right: 10px; }

.widget_recent_posts ul li .recent-post-img a, .widget_popular_posts ul li =
.recent-post-img a { display: block; }

.widget_recent_posts ul li .recent-post-img span, .widget_popular_posts ul =
li .recent-post-img span { box-shadow: rgba(255, 255, 255, 0.7) 0px 0px 1px=
 inset; position: absolute; width: 50px; height: 50px; display: block; top:=
 1px; left: 1px; }

.widget_recent_posts ul li .recent-post-img img, .widget_popular_posts ul l=
i .recent-post-img img { }

.widget_recent_posts ul li h6, .widget_popular_posts ul li h6 { font-weight=
: bold; font-size: 0.869565em; }

.widget_recent_posts ul li h6 a, .widget_popular_posts ul li h6 a { color: =
rgb(255, 255, 255); }

.widget_recent_posts ul li h6 a:hover, .widget_popular_posts ul li h6 a:hov=
er { text-decoration: none; color: rgb(215, 215, 215); }

.widget_recent_posts ul li time, .widget_popular_posts ul li time { font-si=
ze: 0.956522em; color: rgb(224, 224, 224); }

.widget_tn_holder { background-color: rgb(255, 203, 0); width: 50px; height=
: 50px; color: rgb(255, 255, 255); line-height: 1.25em; font-size: 3.5em; t=
ext-align: center; }

footer .widget_testimonials ul li { display: block; }

footer .widget_testimonials ul li cite { color: rgb(145, 144, 144); padding=
-left: 25px; margin-top: 0.6em; display: block; }

footer .widget_testimonials ul li cite a { color: rgb(145, 144, 144); }

footer .widget_testimonials .testimonials_nav { float: right; position: rel=
ative; }

footer .widget_testimonials .testimonials_nav a { width: 21px; height: 21px=
; display: block; text-indent: -9999px; float: left; margin-left: 10px; }

footer .widget_testimonials .testimonials_nav a.prev { background-position:=
 0px -33px; }

footer .widget_testimonials .testimonials_nav a.next { background-position:=
 0px -64px; }

footer .twitter_widget .twitter li { background-position: 0px center; paddi=
ng-left: 27px; padding-bottom: 5px; padding-top: 5px; }

footer .twitter_widget .twitter li a:hover { margin-left: 0px; }

.contact_info { }

.contact_info .contact_info li { padding-left: 25px; list-style: none; }

.contact_info .title { color: rgb(126, 126, 126); font-size: 15px; }

.contact_info .address { font-size: 15px; }

.contact_info .phone { font-size: 21px; margin-bottom: 20px; }

.contact_info .email { font-size: 21px; line-height: 40px; }

#footer { position: relative; }

footer .quick_contact .form { position: relative; }

footer .quick_contact .form input { width: 100%; height: 2.5em; border: non=
e; outline: none; line-height: 2.5em; padding: 0px 10px; color: rgb(165, 16=
4, 164); margin: 5px 0px; font-size: 0.75em; border-radius: 3px; box-shadow=
: rgba(0, 0, 0, 0.4) 0px 1px 2px inset, rgba(255, 255, 255, 0.1) 0px 1px 0p=
x; background: rgba(0, 0, 0, 0.25); box-sizing: border-box; }

footer .quick_contact .form input#quick_name { margin-top: 0px; }

footer .quick_contact .form .error { border-bottom: 2px solid rgb(255, 0, 0=
); }

footer .quick_contact .form span { top: 6px; position: absolute; left: 15px=
; color: rgb(137, 136, 136); font-size: 0.7em; margin: 0px; }

footer .quick_contact .form span.email-span { top: 46px; }

footer .quick_contact .form textarea { height: 9.16667em; width: 100%; font=
-size: 0.75em; border: none; outline: none; padding: 10px; margin: 5px 0px;=
 color: rgb(165, 164, 164); overflow: auto; border-radius: 3px; box-shadow:=
 rgba(0, 0, 0, 0.4) 0px 1px 2px inset, rgba(255, 255, 255, 0.1) 0px 1px 0px=
; background: rgba(0, 0, 0, 0.25); box-sizing: border-box; }

footer .quick_contact .form .send { font-size: 0.7em; float: right; margin-=
top: 0.8em; }

footer .name-error, footer .email-error, footer .comments-error { display: =
none; position: absolute; left: 175px; }

footer .name-error { top: 13px; }

footer .email-error { top: 47px; }

footer .comments-error { top: 89px; }

footer .mesage { color: rgb(255, 255, 255); text-shadow: rgb(0, 0, 0) 0px 1=
px 0px; }

.sub_footer { margin-bottom: 30px; }

.sub_footer_wrap p { margin: 0px; font-size: 0.7em; }

.sub_footer_wrap a:hover { color: rgb(255, 255, 255); text-decoration: none=
; }

.sub_footer_menu { list-style: none; float: left; margin: 0px; font-size: 1=
1px; }

.sub_footer_menu li { float: left; margin-left: 1em; }

.sub_footer_menu li a { color: inherit; }

.footer_left { float: left; margin-top: 5px; font-size: 11px; }

article { }

.blog article { margin-bottom: 3em; padding-bottom: 1.8em; border-bottom: 1=
px dotted rgb(223, 223, 223); }

.single article { }

.page_title { }

.page_title section { display: inline; }

@media (max-width: 979px) {
  .page_title { margin-left: 0px; }
}

.page_title h1 { color: rgb(67, 67, 67); font-weight: 800; font-size: 48px;=
 }

.page_title h2 { color: rgb(67, 67, 67); font-size: 31px; }

.flip_more { color: rgb(255, 255, 255); }

.home #breadcrumbs { display: none; }

#breadcrumbs { float: right; font-size: 0.6875em; }

#breadcrumbs a { font-size: inherit; color: rgb(188, 187, 187); }

#breadcrumbs a:hover { text-decoration: none; color: rgb(35, 35, 35); }

#breadcrumbs span { font-size: inherit; color: rgb(188, 187, 187); }

.post_title h3 { color: rgb(78, 78, 78); }

.post_title h3 a { color: inherit; }

.post_title h3 a:hover { color: rgb(255, 202, 0); }

.offset1 { margin-left: 53px; margin-top: 40px; }

@media (max-width: 979px) {
  .offset1 { margin-left: 45px; margin-top: -28px; }
}

.post_icon { width: 2.5em; height: 2.5em; text-align: center; margin: -6px =
auto 0.625em 0px; transition: 200ms linear; }

.post_icon i { line-height: 2em; font-size: 1.375em; color: rgb(255, 255, 2=
55); }

.post_icon i.quote-icon { line-height: 1.2em; font-size: 3.3em; }

.format-quote .post_title p { font-style: italic; }

.img_post { display: block; margin-top: 4px; text-align: center; }

.img_post img { max-width: 100%; }

.img_post a { display: block; position: relative; text-align: center; }

.img_post a img { max-width: 100%; margin-bottom: -4px; }

.img_post a i { position: absolute; width: 100%; font-size: 1.75em; line-he=
ight: 1.25em; color: rgb(255, 255, 255); font-weight: normal; top: 41%; opa=
city: 0; transition: 200ms linear; text-align: center; left: -10%; }

.img_post a:hover i { text-decoration: none; opacity: 1; display: block; tr=
ansform: scale(1); top: 41%; left: 0%; }

.img_post a i.hovericon { top: 30%; }

.img_post a:hover i div i.hovericon { top: 30%; }

@media only screen and (max-width: 768px) {
  .img_post a i.hovericon { top: 25%; }
  .img_post a:hover i div i.hovericon { top: 25%; }
}

@media only screen and (max-width: 480px) {
  .img_post a i.hovericon { top: 20%; font-size: 2em; }
  .img_post a:hover i div i.hovericon { top: 20%; font-size: 2em; }
}

.img_post a span { display: block; width: 100%; height: 100%; position: abs=
olute; top: 0px; left: 0px; transition: 200ms linear; opacity: 0; }

.img_post a:hover span { opacity: 1; }

.metadata { margin: 0.3125em 0px 1.25em; overflow: hidden; border-bottom: 1=
px dotted rgb(223, 223, 223); }

.metadata ul { margin: 0px; }

.metadata ul li { list-style: none; float: left; font-size: 0.6875em; margi=
n: 0.727273em 1.18182em 0.727273em 0px; color: rgb(189, 189, 189); }

.metadata ul li i { margin-right: 0.454545em; font-size: 1.18182em; }

.metadata ul li:hover i { color: rgb(255, 202, 0); }

.metadata ul li a { color: rgb(189, 189, 189); }

.metadata ul li a:hover { color: rgb(255, 202, 0); text-decoration: none; }

.metadata ul li.meta_comments { float: right; }

.metadata hr { margin: 0px; }

ul.fancy_tags { margin-top: 15px; clear: both; margin-left: 0px; }

ul.fancy_tags li { display: inline-block; margin: 0px 0.909091em 0.909091em=
 0px; float: left; border: none; font-size: 0.6875em; }

ul.fancy_tags li a { color: rgb(74, 74, 74); text-decoration: none; display=
: inline-block; padding: 3px 6px; font-weight: bold; outline: none; }

ul.fancy_tags li a:hover { color: rgb(255, 255, 255); text-decoration: none=
; }

ul.fancy_tags li a:active { color: rgb(74, 74, 74); text-decoration: none; =
background-color: rgb(207, 207, 207); box-shadow: rgba(0, 0, 0, 0.4) 0px 1p=
x 2px inset; }

.social_btns_e { height: 24px; margin: 10px 0px; }

.twitter_btn_single, .fbk_btn_single, .google_btn_single { height: 24px; fl=
oat: left; width: 150px; position: relative; text-align: left; }

.google_btn_single div { width: 70px !important; }

.single-portfolio .fbk_btn_single { clear: left; margin-bottom: 10px; }

.single-portfolio .twitter_btn_single { clear: left; margin-bottom: 10px; }

.single-portfolio .google_btn_single { clear: left; margin-bottom: 10px; }

.folio_desc { background-color: rgb(5, 139, 230); margin-left: 0px; padding=
: 0px 0px 20px 20px; }

.folio_desc h3 { border: 0px; color: rgb(255, 255, 255); padding: 30px 0px =
10px; margin-right: 20px; }

.folio_desc p { color: rgb(255, 255, 255); font-size: 12px; margin-top: -5p=
x; padding: 0px 30px 10px 0px; }

.folio_list { margin-left: 0px; list-style-type: none; list-style-image: no=
ne; }

.folio_post { width: 100%; margin-bottom: 3%; }

.more-link { background-color: rgb(255, 202, 0); border-radius: 3px; color:=
 rgb(255, 255, 255); font-size: 0.846154em; font-weight: bold; padding: 0.2=
72727em 0.545455em; }

.more-link:hover { color: rgb(255, 202, 0); background-color: rgb(255, 255,=
 255); text-decoration: none; }

.more-link i { margin-left: 0.454545em; font-weight: normal; }

a.post-edit-link { background-color: rgb(255, 202, 0); border-radius: 3px; =
color: rgb(255, 255, 255); font-size: 0.846154em; font-weight: bold; paddin=
g: 0.272727em 0.545455em; margin: 10px 0px; }

a.post-edit-link:hover { color: rgb(255, 202, 0); background-color: rgb(255=
, 255, 255); text-decoration: none; }

.pagination span.current { display: block; padding: 2px 9px; font-size: 0.6=
875em; font-weight: bold; color: rgb(255, 255, 255); float: left; text-alig=
n: center; margin-right: 15px; }

.pagination a { display: block; padding: 2px 9px; font-size: 0.6875em; colo=
r: rgb(255, 255, 255); line-height: inherit; border: none; float: left; tex=
t-align: center; margin-right: 15px; font-weight: bold; background-color: r=
gb(255, 202, 0); }

.pagination a:hover { color: rgb(255, 255, 255); }

#respond #submit, .s_btn { background-color: rgb(255, 202, 0); border-radiu=
s: 3px; color: rgb(255, 255, 255); font-size: 0.846154em; font-weight: bold=
; padding: 0.8em 1em; border: none; box-shadow: none !important; }

#respond #submit:hover, .s_btn:hover { color: rgb(255, 202, 0); background-=
color: rgb(255, 255, 255); text-decoration: none; }

.s_btn i { margin-left: 0.454545em; font-weight: normal; }

.post-quote .post_title blockquote { font-size: 1.125em; }

.post-quote .post_title p { font-family: Georgia, "Times New Roman", Times,=
 serif; font-style: italic; }

.post-image .flex-container { margin-bottom: 0px; }

#sidebar { position: relative; font-family: "Open Sans", "Helvetica Neue", =
Helvetica, Arial, sans-serif; }

.left #sidebar { float: left; }

#sidebar .widget { margin-bottom: 3.125em; position: relative; margin-left:=
 1.25em; }

#sidebar #sidebar_mid div.bt { height: 1px; }

#sidebar .widget h4 { position: relative; padding-bottom: 0.357143em; margi=
n-bottom: 0.8em; }

#sidebar .widget h4 i { bottom: 4px; height: 3px; left: 4px; position: abso=
lute; width: 5px; font-family: FontAwesome; font-weight: normal; font-style=
: normal; text-decoration: inherit; display: none; }

#sidebar .widget h4 i::before { content: "=EF=83=9D"; }

#sidebar .widget ul, #sidebar .widget ol { margin-left: 0px; margin-bottom:=
 0px; font-size: 11px; }

#sidebar .widget ol.flex-control-nav { font-size: 12px; }

#sidebar .widget .pagenav, #sidebar .widget .linkcat { list-style: none; }

#sidebar .widget ul li { list-style: none; border-bottom: 1px dotted rgb(22=
3, 223, 223); }

#sidebar .widget ul li:first-child { border-top: none; }

#sidebar .widget ul li > a { color: inherit; padding: 0.636364em 0px; displ=
ay: block; }

#sidebar .widget ul li > a:hover { color: rgb(255, 202, 0); }

#sidebar .widget ul.slides li > a { padding: 0px; }

#sidebar .widget ul li ul { margin-left: 30px; margin-bottom: 0px; margin-t=
op: 0px !important; }

#sidebar .widget ul li ul { font-size: inherit; }

#sidebar .widget ul li ul li:last-child { border-bottom: none; }

#sidebar .widget ul li ul, #sidebar .widget ul li ul li ul { display: none;=
 }

#sidebar .hasChildren span { float: right; margin-top: 5px; background: url=
("images/sidebar_menu_arrow.png") no-repeat !important; width: 7px !importa=
nt; height: 7px !important; }

#sidebar .twitter_widget ul li { margin-bottom: 20px; min-height: 20px; pad=
ding: 5px 0px 5px 5px; border: none; }

#sidebar .twitter_widget ul li i.icon-twitter { font-size: 21px; color: rgb=
(204, 204, 204); }

#sidebar .twitter_widget ul li:last-child { margin-bottom: 0px; }

#sidebar .twitter_widget ul li a { display: inline; background: none !impor=
tant; padding: 0px !important; }

#sidebar .ad_125 h4 { margin-bottom: 17px; }

#sidebar .ad_125 a { margin: 4px; display: inline-block; }

#sidebar .ad_125 a:hover img { opacity: 0.8; }

#sidebar .widget_recent_comments ul#recentcomments { margin-top: 17px; }

#sidebar .widget_recent_comments ul li { margin-bottom: 10px; padding-botto=
m: 5px; border-top: none; border-right: none; border-left: none; border-ima=
ge: initial; color: rgb(115, 115, 115); border-bottom: 1px dotted rgb(223, =
223, 223); }

#sidebar .widget_recent_comments ul li a { display: inline; background: non=
e; padding: 0px; color: rgb(67, 67, 67); }

#sidebar .widget_tag ul.wp-tag-cloud { margin-top: 20px; }

#sidebar .widget_tag ul li { display: inline-block; margin: 0px 0.909091em =
0.909091em 0px; float: left; border: none; }

#sidebar .widget_tag ul li a { background-color: rgb(220, 220, 220); displa=
y: inline-block; padding: 3px 6px; color: rgb(127, 127, 127); text-shadow: =
rgba(255, 255, 255, 0.7) 0px 1px 0px; font-weight: bold; border-radius: 3px=
; box-shadow: rgba(0, 0, 0, 0.3) 0px 1px 0px; outline: none; font-size: 11p=
x !important; }

#sidebar .widget_tag ul li a:hover { color: rgb(74, 74, 74); text-decoratio=
n: none; background-color: rgb(207, 207, 207); box-shadow: rgba(0, 0, 0, 0.=
2) 0px 1px 0px inset; }

#sidebar .widget_tag ul li a:active { color: rgb(74, 74, 74); text-decorati=
on: none; background-color: rgb(207, 207, 207); box-shadow: rgba(0, 0, 0, 0=
.4) 0px 1px 2px inset; }

#sidebar .rss_tw_btn a.suscribe_btn { background: url("images/suscribe_btn.=
png") no-repeat; display: block; width: 122px; height: 32px; float: left; m=
argin-right: 8px; }

#sidebar .rss_tw_btn a.twitter_btn { background: url("images/twitter_btn.pn=
g") no-repeat; display: block; width: 122px; height: 32px; float: left; tex=
t-indent: -999em; }

#sidebar .rss_tw_btn a:hover { opacity: 0.9; }

.rss_tw_btn a.suscribe_btn { background: url("images/suscribe_btn.png") no-=
repeat; display: block; width: 122px; height: 32px; float: left; margin-rig=
ht: 10%; text-indent: -999em; }

.rss_tw_btn a.twitter_btn { background: url("images/twitter_btn.png") no-re=
peat; display: block; width: 122px; height: 32px; float: left; }

.rss_tw_btn a:hover { opacity: 0.9; }

.widget_search { position: relative; }

.widget_search #s { background: rgb(250, 250, 250); border: 1px solid rgb(2=
23, 223, 223); width: 100%; height: 30px; display: block; padding: 0px 40px=
 0px 10px; line-height: 32px; color: rgb(133, 133, 133); box-shadow: rgba(0=
, 0, 0, 0.1) 0px 1px 2px inset, rgba(255, 255, 255, 0.1) 0px 1px 0px; box-s=
izing: border-box; }

.widget_search #s:focus { background: rgb(242, 242, 242); }

.widget_search #searchsubmit { background: url("images/search_btn.png") no-=
repeat; border: none; width: 17px; height: 17px; display: block; text-inden=
t: -9999px; position: absolute; right: 15px; top: 7px; cursor: pointer; lin=
e-height: 0; box-shadow: none; }

#wp-calendar { color: rgb(102, 102, 102); font-size: 12px; box-shadow: rgba=
(0, 0, 0, 0.3) 0px 1px 5px; }

#wp-calendar a { color: rgb(70, 123, 137); }

#wp-calendar caption { background: rgb(56, 56, 56); color: rgb(224, 224, 22=
4); font-size: 14px; padding: 10px 0px; text-align: center; text-shadow: rg=
b(0, 0, 0) 0px -1px 0px; box-shadow: rgb(72, 72, 72) 0px 1px 0px inset, rgb=
a(0, 0, 0, 0.3) 0px -1px 5px; border: 1px solid rgb(55, 55, 55); z-index: -=
99; }

#wp-calendar thead th { font-size: 8px; padding: 5px 0px; color: rgb(102, 1=
02, 102); text-transform: uppercase; text-shadow: rgba(255, 255, 255, 0.5) =
0px 1px 0px; border-bottom: 1px solid rgb(187, 187, 187); background: -webk=
it-gradient(linear, 0% 0%, 0% 100%, from(rgb(247, 247, 247)), to(rgb(241, 2=
41, 241))); }

#wp-calendar tbody td { color: rgb(102, 102, 102); text-shadow: rgba(255, 2=
55, 255, 0.5) 0px 1px 0px; padding: 8px; text-align: center; font-weight: b=
old; border-width: 1px; border-style: solid; border-image: initial; border-=
color: rgb(255, 255, 255) rgb(187, 187, 187) rgb(187, 187, 187) rgb(255, 25=
5, 255); background: -webkit-gradient(linear, 0% 0%, 0% 100%, from(rgb(237,=
 237, 237)), to(rgb(222, 222, 222))); }

#wp-calendar tbody td.pad { background: -webkit-gradient(linear, 0% 0%, 0% =
100%, from(rgb(245, 245, 245)), to(rgb(236, 236, 236))); }

#wp-calendar tfoot { color: rgb(224, 224, 224); font-size: 12px; text-align=
: center; }

#wp-calendar tfoot tr { background: -webkit-gradient(linear, 0% 0%, 0% 100%=
, from(rgb(245, 245, 245)), to(rgb(236, 236, 236))); }

#wp-calendar tfoot td { padding: 10px; }

#wp-calendar tfoot a { color: rgb(102, 102, 102); text-shadow: rgba(255, 25=
5, 255, 0.5) 0px 1px 0px; }

#wp-calendar tfoot td#prev { text-align: left; }

#wp-calendar tfoot td#next { text-align: right; }

#wp-calendar #today { color: rgb(255, 255, 255); border: 1px solid rgb(70, =
123, 137); text-shadow: rgba(0, 0, 0, 0.3) 0px 1px 0px; background: -webkit=
-gradient(radial, 50% 50%, 0, 50% 50%, 20, from(rgb(110, 175, 191)), to(rgb=
(86, 158, 177))); }

.nav-tabs > li > a { padding-top: 8px; padding-bottom: 8px; line-height: 1.=
25em; background-color: rgb(249, 249, 249); border-width: 1px; border-style=
: solid; border-color: transparent transparent rgb(235, 235, 235); border-i=
mage: initial; border-radius: 0px; }

.widget_post_tabs ul li { outline: none; border-bottom: none !important; }

.widget_post_tabs ul li > a { outline: none; padding: 8px 12px !important; =
}

.widget_post_tabs .nav-tabs { border-bottom: 1px solid rgb(235, 235, 235); =
}

.widget_post_tabs .nav-tabs > .active > a { font-weight: bold; background-c=
olor: rgb(255, 255, 255); border-color: rgb(235, 235, 235) rgb(235, 235, 23=
5) transparent; }

.widget_post_tabs .nav-tabs > a { transition: none; }

.widget_post_tabs .tab-content { padding: 1em 0.625em 0px; background-color=
: rgb(255, 255, 255); border-width: 0px 1px 1px; border-right-style: solid;=
 border-bottom-style: solid; border-left-style: solid; border-right-color: =
rgb(235, 235, 235); border-bottom-color: rgb(235, 235, 235); border-left-co=
lor: rgb(235, 235, 235); border-image: initial; border-top-style: initial; =
border-top-color: initial; box-sizing: border-box; }

.widget_post_tabs .tab-content ul li, .widget_popular_posts ul li { margin-=
bottom: 0.6em; min-height: 5.45455em; }

.widget_post_tabs .tab-content ul li .recent-post-img, .widget_popular_post=
s ul li .recent-post-img { position: relative; float: left; margin-right: 1=
0px; }

.widget_post_tabs .tab-content ul li .recent-post-img a, .widget_popular_po=
sts ul li .recent-post-img a { display: block; padding: 0px !important; }

.widget_post_tabs .tab-content ul li h6, .widget_popular_posts ul li h6 { f=
ont-size: 0.869565em; }

.widget_post_tabs .tab-content ul li h6 a, .widget_popular_posts ul li h6 a=
 { color: rgb(87, 87, 87); padding: 0px; }

.widget_post_tabs .tab-content ul li h6 a:hover, .widget_popular_posts ul l=
i h6 a:hover { text-decoration: none; color: rgb(0, 0, 0); }

.widget_post_tabs .tab-content ul li time, .widget_popular_posts ul li time=
 { font-size: 0.956522em; color: rgb(144, 144, 144); }

.author_link { text-transform: capitalize; }

#comments h4 { font-size: 1.2em; }

.commentlist { margin-left: 0px; }

#comments ol.commentlist li { list-style: none; margin-bottom: 50px; }

#comments .comment { margin-bottom: 40px; }

#comments .comment-author { }

#comments .comment-author div.inner-gravatar { position: relative; width: 5=
0px; height: 50px; margin: 0px; overflow: hidden; }

.avatar { position: relative; width: 50px; height: 50px; margin: 0px auto; =
overflow: hidden; }

#comments .comment-author div.inner-gravatar div { width: 80px; height: 80p=
x; z-index: 10; position: absolute; border-radius: 40px; }

#comments .comment-author img { z-index: 5; }

#comments .comment-author cite { font-weight: bold; margin-top: 4px; font-s=
ize: 0.75em; display: block; }

#comments .comment-author cite, #comments .comment-author cite a { color: r=
gb(117, 117, 117); font-weight: normal; }

#comments .comment-author .comment-meta a { color: rgb(174, 174, 174); font=
-size: 10px; }

ol.commentlist li .comment-entry { border-radius: 5px; margin: 0px; text-sh=
adow: rgb(255, 255, 255) 0px 1px 0px; background: rgb(241, 240, 240); posit=
ion: relative; }

ol.commentlist li .comment-entry div.inner-comment { padding: 29px; border-=
radius: 3px; }

.ie8 ol.commentlist li .comment-entry, .ie7 ol.commentlist li .comment-entr=
y { float: right; border: 1px solid rgb(202, 202, 202); margin: 0px; backgr=
ound-color: rgb(243, 243, 243); position: relative; }

ol.commentlist .comment-entry span.arrow_comment { display: block; position=
: absolute; width: 31px; height: 28px; top: 17px; left: -22px; }

.ie7 ol.commentlist .comment-entry span.arrow_comment, .ie8 ol.commentlist =
.comment-entry span.arrow_comment { background: none; }

.comment-meta { float: left; margin-left: 10px; margin-top: 5px; font-size:=
 11px; color: rgb(195, 195, 195); }

.comment-meta a { font-size: 11px; color: rgb(195, 195, 195); }

.comment-meta a:hover { text-decoration: underline; }

.reply { float: right; clear: right; }

.comment-reply-link { width: 54px; height: 23px; display: block; color: rgb=
(126, 126, 126); font-size: 11px; text-align: center; text-shadow: rgb(255,=
 255, 255) 0px 1px 0px; margin: 10px 0px; line-height: 20px; }

#comments ul.children { margin-left: 25px; margin-top: 20px; margin-bottom:=
 10px; }

#respond h4 { font-size: 1.2em; }

#respond .input { margin: 10px 15px 10px 0px; }

#respond .l_input { margin-right: 0px; }

#respond input { font-size: inherit; }

#respond .input-prepend { display: inline-block; margin-left: 23px; margin-=
bottom: 10px; }

#respond .input-xlarge { margin-bottom: 0px; }

@media (max-width: 767px) {
  #respond .input-xlarge { width: 250px; }
}

#respond input:focus { outline: none; box-shadow: rgba(0, 0, 0, 0.3) 0px 0p=
x 2px inset; background: rgb(250, 250, 250); }

#respond label { color: rgb(140, 139, 139); font-size: 13px; margin-bottom:=
 5px; display: inline-block; }

#respond textarea { min-width: 296px; height: 150px; }

#respond textarea:focus { outline: none; box-shadow: rgba(0, 0, 0, 0.3) 0px=
 0px 2px inset; background: rgb(250, 250, 250); }

#respond .add-on { color: rgb(255, 255, 255); background-color: rgb(255, 20=
2, 0); border-color: rgb(255, 202, 0); text-shadow: none; }

#respond .form-actions { background-color: transparent; border: none; }

#respond #submit { font-size: 0.75em; }

.page-template-portfolio-3columns-php header, .page-template-portfolio-2col=
umns-php header, .page-template-portfolio-4columns-php header, .page-templa=
te-portfolio-1column-php header { margin-bottom: 0px; }

.portfolio_page h2 { margin-bottom: 25px; }

ul.source { margin-bottom: 1.25em; margin-left: 0px; overflow: hidden; }

ul.source li { display: inline; margin-right: 15px; position: relative; flo=
at: left; }

ul.source li a { display: block; color: rgb(146, 146, 146); font-size: 0.68=
75em; font-weight: bold; padding: 0.272727em 0.545455em; outline: none; }

ul.source li a:hover { color: rgb(255, 202, 0); }

ul.source li.active a { background-color: rgb(255, 202, 0); color: rgb(255,=
 255, 255); }

ul.source li.active a:hover { color: rgb(255, 202, 0); background-color: rg=
b(255, 255, 255); text-decoration: none; }

ul.portfolio_items { display: block; letter-spacing: -4px; list-style-type:=
 none; margin: 0px; padding: 0px; word-spacing: -4px; }

ul.portfolio_items li { list-style: none; display: inline-block; letter-spa=
cing: normal; padding: 0px; position: relative; vertical-align: top; word-s=
pacing: normal; float: none !important; }

ul.portfolio_items li .portfolio_img_wrap { position: relative; }

ul.portfolio_items li a.portfolio_img { position: relative; clear: both; z-=
index: 1; display: block; }

ul.portfolio_items li .portfolio_img span { position: absolute; display: no=
ne; z-index: 10; top: 0px; left: 0px; }

ul.portfolio_items li a.portfolio_img img { position: relative; width: 100%=
; margin-bottom: -3px; }

#content .portfolio_items .portfolio_info p { color: rgb(170, 170, 170); }

ul.portfolio1 li { margin-bottom: 30px; }

ul.portfolio2 li { margin-bottom: 30px; width: 542px; margin-right: 3%; }

ul.portfolio3 li { margin-bottom: 30px; width: 370px; }

ul.portfolio4 li { margin-bottom: 20px; width: 257px; margin-right: 3%; }

.single-portfolio .img_post a { display: block; }

.single-portfolio .img_post a img { width: 100%; }

#masonry_container { margin: 0px auto; }

.masonry_item { width: 290px; margin-right: 20px; margin-bottom: 20px; floa=
t: left; background-color: rgb(241, 241, 241); }

.masonry_item .masonry_desc { padding: 15px; border-bottom: 2px solid rgb(2=
55, 202, 0); }

.masonry_item .masonry_desc h4 { color: rgb(87, 87, 87); margin-bottom: 0.3=
em; }

.about_us .person_item img { max-width: 100%; }

.sticky, .bypostauthor, .gallery-caption { }

.alignnone { margin: 1em 1em 1em 0px; }

.aligncenter, div.aligncenter { display: block; margin: 0.5em auto; }

.alignright { float: right; margin: 0px 0px 1em 1em; }

.alignleft { float: left; margin: 0px 1em 1em 0px; }

.aligncenter { display: block; margin: 1em auto; }

img, img[class*=3D"align"], img[class*=3D"wp-image-"] { max-width: 100%; he=
ight: auto; }

img.wp-smiley { border: none; margin-bottom: 0px; margin-top: 0px; padding:=
 0px; }

img.alignright { }

img.alignleft { margin: 1em 1em 1em 0px; }

img.aligncenter { display: block; margin: 1em auto; }

img#wpstats { display: block; margin: 0px auto; }

img[class*=3D"align"], img[class*=3D"wp-image-"], .gallery .gallery-icon im=
g { border: none; }

.wp-caption { margin-bottom: 1em; margin-left: 0px; max-width: 96%; text-al=
ign: center; }

.wp-caption img { display: block; margin: 0px auto; }

.wp-caption-text { position: relative; font-size: 0.8em; }

.gallery { margin: 0px auto; }

.gallery .gallery-item { margin: 0px 7px; float: left; text-align: center; =
width: 29% !important; }

.gallery a img { border: none; }

.gallery-columns-4 .gallery-item { margin-left: 7px; margin-right: 7px; wid=
th: 21% !important; }

.gallery-columns-4 .gallery-item img { height: auto; }

@media only screen and (max-width: 480px) {
  .gallery-columns-2 .gallery-item { width: 50%; }
  .gallery-columns-2 .gallery-item img { width: 100%; height: auto; }
}

.cool_divider { margin: 2em 0px; }

.i_medium { font-size: 150%; }

.i_large { font-size: 250%; }

.table { font-size: 0.8125em; }

.list_icons { list-style: outside none none; margin-left: 0px; font-size: 1=
3px; }

.title_underline { position: relative; border-bottom: 1px solid rgb(255, 20=
2, 0); margin-bottom: 0.8em; padding-bottom: 0.357143em; }

.title_underline i { bottom: -4px; height: 3px; left: 48%; position: absolu=
te; width: 5px; }

.simple_btn { background-color: rgb(255, 202, 0); border-radius: 3px; color=
: rgb(255, 255, 255); font-size: 0.6875em; font-weight: bold; padding: 0.27=
2727em 0.545455em; }

.simple_btn:hover { color: rgb(255, 202, 0); background-color: rgb(255, 255=
, 255); text-decoration: none; }

.simple_btn i { margin-left: 0.454545em; font-weight: normal; }

.ql_tabs a { outline: none; }

@media (min-width: 1200px) {
  .jqueryslidemenu ul li ul.children { display: none; }
  .flexslider .slides li img { width: 100%; }
  .AudioPlayerV1 { width: 670px !important; }
  .APV1_container { width: 473px !important; }
  .format-video #post_video { height: 376px; }
}

@media (min-width: 979px) and (max-width: 1199px) {
  .AudioPlayerV1 { width: 540px !important; }
  .APV1_container { width: 343px !important; }
  .format-video #post_video { height: 303px; }
  ul.portfolio2 li { width: 434px; margin-right: 3%; }
  ul.portfolio3 li { width: 283px; }
  ul.portfolio4 li { width: 206px; }
}

@media (min-width: 768px) and (max-width: 978px) {
  .format-video #post_video { height: 232px; }
  ul.portfolio2 li { width: 332px; margin-right: 3%; }
  ul.portfolio3 li { width: 216px; }
  ul.portfolio4 li { width: 159px; }
}

@media (min-width: 481px) and (max-width: 767px) {
  .sub_footer .span3 { }
  .folio_desc { padding-left: 30px; margin-left: 20px; }
  .circle_service .circle_icon { height: 9em; width: 9em; border-radius: 4.=
5em; }
  .circle_service .circle_icon i { font-size: 5em; line-height: 1.9em; }
  .circle_service:hover .circle_icon i { font-size: 7em; line-height: 1.3em=
; }
  #sidebar .widget { margin-left: 0em; }
  .format-video #post_video { height: 370px; }
  ul.portfolio2 li, ul.portfolio3 li, ul.portfolio4 li { width: 100%; margi=
n-right: 0px; }
}

@media (max-width: 480px) {
  .circle_service .circle_icon { height: 9em; width: 9em; border-radius: 4.=
5em; }
  .circle_service .circle_icon i { font-size: 5em; line-height: 1.9em; }
  .circle_service:hover .circle_icon i { font-size: 7em; line-height: 1.3em=
; }
  #sidebar .widget { margin-left: 0em; }
  .AudioPlayerV1 { width: 359px !important; }
  .APV1_container { width: 162px !important; }
  .format-video #post_video { height: 201px; }
  ul.portfolio2 li, ul.portfolio3 li, ul.portfolio4 li { width: 100%; margi=
n-right: 0px; }
}

@media print {
  * { background: transparent !important; color: black !important; text-sha=
dow: none !important; filter: none !important; }
  a, a:visited { text-decoration: underline; color: rgb(68, 68, 68) !import=
ant; }
  a[href]::after { content: " (" attr(href) ")"; }
  abbr[title]::after { content: " (" attr(title) ")"; }
  .ir a::after, a[href^=3D"javascript:"]::after, a[href^=3D"#"]::after { co=
ntent: ""; }
  pre, blockquote { border: 1px solid rgb(153, 153, 153); break-inside: avo=
id; }
  thead { display: table-header-group; }
  tr, img { break-inside: avoid; }
  @page { margin: 0.5cm; }
  p, h2, h3 { orphans: 3; widows: 3; }
  h2, h3 { break-after: avoid; }
}

.quote_cite { margin-top: -0.5em; margin-bottom: 0.4em; padding-bottom: 25p=
x; border-bottom: 1px solid; }

.flip_stats { display: block; float: none; clear: both; padding: 20px 0px 0=
px; }

.flip_stats ol, .flip_stats ul { list-style: none; margin-left: 0px; }

.flip_stats li { display: inline-block; font-size: 15px; line-height: 18px;=
 text-transform: uppercase; position: relative; }

.flip_stats li a { color: rgb(255, 255, 255); font-size: 14px; vertical-ali=
gn: baseline; }

.flip_stats li a { transition: color 0.2s; }

.flip_stats li a { margin-right: 10px; }

.flip_stats li em { font-weight: 300; font-size: 18px; display: inline-bloc=
k; margin-right: 3px; text-align: right; opacity: 0.75; }

.flip_stats li.like-count .facebook-like { display: none; width: 71px; heig=
ht: 47px; position: absolute; background: url("images/like-box-top.png") no=
-repeat transparent; z-index: 100; border-top: none; top: -21px; right: -88=
px; padding: 22px 10px 10px 20px; }

.flip_tweets strong { font-style: normal; font-size: 20px; display: inline-=
block; margin-right: 3px; text-align: right; }

.stats { border-top: 1px dotted rgb(223, 223, 223); display: block; float: =
none; clear: both; margin: 15px 0px 32px; padding: 20px 0px 0px; }

.stats ol, .stats ul { list-style: none; margin-left: 0px; }

.stats li { display: inline-block; font-size: 15px; line-height: 18px; marg=
in-right: 13px; color: rgb(153, 153, 153); text-transform: uppercase; posit=
ion: relative; border-bottom: 1px dotted rgb(223, 223, 223); }

.stats li a { color: rgb(78, 78, 78); font-size: 10px; vertical-align: base=
line; }

.stats li a { transition: color 0.2s; }

.stats li a { margin-right: 14px; }

.stats li em { font-style: normal; font-size: 20px; display: inline-block; =
margin-right: 3px; text-align: right; }

.stats li.like-count .facebook-like { display: none; width: 71px; height: 4=
7px; position: absolute; background: url("images/like-box-top.png") no-repe=
at transparent; z-index: 100; border-top: none; top: -21px; right: -88px; p=
adding: 22px 10px 10px 20px; }

.tweets strong { font-style: normal; font-size: 20px; display: inline-block=
; margin-right: 3px; text-align: right; }

.team_members { margin: 15px 0px -30px; }

.stat { padding: 1em 1em 1.5em; background-color: rgb(255, 221, 48); text-a=
lign: center; }

@media (max-width: 767px) {
  .stat { margin-bottom: 10px; }
}

.stat .fact { font-size: 4em; line-height: 1.25em; color: rgb(255, 255, 255=
); display: block; }

.stat i { text-transform: uppercase; font-size: 1em; line-height: 0.25em; c=
olor: rgb(255, 255, 255); }

.icon_holder_feat { background-color: rgb(255, 203, 0); width: 50px; height=
: 50px; color: rgb(255, 255, 255); line-height: 1.75em; font-size: 30px; te=
xt-align: center; margin-bottom: 10px; }

.icon_holder_acc { background-color: rgb(255, 203, 0); width: 50px; height:=
 50px; color: rgb(255, 255, 255); line-height: 1.75em; font-size: 30px; tex=
t-align: center; margin-bottom: 10px; }

input, textarea, .uneditable-input { padding: 10px; width: 100%; height: au=
to; box-sizing: border-box; }

#searchform { position: relative; }

#respond #submit, .s_btn { border: none; position: relative; color: rgb(255=
, 255, 255); text-transform: uppercase; font-size: 0.75em; padding: 11px 35=
px 10px; }

#respond #submit:hover, .s_btn:hover { cursor: pointer; text-decoration: no=
ne; }

.s_btn:active { }

.wpcf7 input, .wpcf7 textarea { padding: 10px; color: rgb(142, 142, 142); l=
ine-height: 20px; border: 1px solid rgb(159, 159, 159); transition: 0.2s; }

.wpcf7 .wpcf7-list-item { padding-left: 0px; margin-left: 0px; margin-right=
: 25px; }

.wpcf7 .wpcf7-list-item input { border: none; padding-left: 0px; margin-lef=
t: 0px; }

.wpcf7 select { outline: none; font-size: 16px; font-family: Arial, Helveti=
ca, sans-serif; }

.wpcf7 input:hover, .wpcf7 input:focus, .wpcf7 input:active, .wpcf7 textare=
a:hover, .wpcf7 textarea:focus, .wpcf7 textarea:active { background: rgb(23=
5, 247, 245); outline: none; }

.wpcf7 input.wpcf7-submit { border: none; position: relative; color: rgb(25=
5, 255, 255); text-transform: uppercase; font-size: 14px; padding: 11px 35p=
x 10px; }

.wpcf7 input.wpcf7-submit:hover { cursor: pointer; text-decoration: none; }

.wpcf7 input.wpcf7-submit:active { }

div.wpcf7-validation-errors { border: none; background-color: rgb(244, 174,=
 70); margin: 0px; padding: 20px; }

.wpcf7 .wpcf7-mail-sent-ok { border: none; background-color: rgb(122, 211, =
63); margin: 0px; padding: 20px; border-radius: 10px; }

.wpcf7 .wpcf7-mail-sent-ng { border: none; background-color: rgb(207, 45, 5=
6); margin: 0px; padding: 20px; border-radius: 10px; color: white; }

.wpcf7 span.wpcf7-not-valid-tip { border: none; background-color: rgb(207, =
45, 56); padding: 10px 15px; color: white; }

.wpcf7-form .fleft { float: left; }

.wpcf7-form .mright20 { margin-right: 20px; }

.wpcf7-form .mright40 { margin-right: 40px; }

.wpcf7-form .clear { clear: both; }

.stat_desc { color: rgb(255, 255, 255); font-style: normal; text-transform:=
 capitalize; }

ul.icons li [class^=3D"icon-"], ul.icons li [class*=3D" icon-"] { width: 0.=
8em; }

li [class^=3D"icon-"], li [class*=3D" icon-"] { display: inline-block; widt=
h: 1.25em; text-align: center; }

ul.icons { list-style-type: none; text-indent: -0.8em; }

li { line-height: 21px; }

@media (max-width: 767px) {
  .row-fluid > [class*=3D"span"] { margin-left: 0px; }
  a.portfolio_link { font-size: 20px; }
  .latest_work .span4 { width: 30%; float: left; }
}

@media (max-width: 630px) {
  .latest_work .span4 { width: auto; float: none; }
}

.iframeVideoWrapper { position: relative; padding-bottom: 56.25%; padding-t=
op: 10px; height: 0px; }

.iframeVideoWrapper iframe { position: absolute; top: 0px; left: 0px; width=
: 100%; height: 100%; }

.share-widget ul { list-style: none; }

.share-widget ul li { float: left; font-size: 24px; }

.sub_footer { margin-top: 30px; }

#footer .widget { margin-bottom: 0px; }

.jp-jplayer { }

.jp-video-play, div.jp-jplayer.jp-jplayer-video { width: 560px; }

.jp-video-play, div.jp-jplayer.jp-jplayer-video { width: 900px; }

div.jp-interface { position: relative; width: 100%; z-index: 100; backgroun=
d: linear-gradient(rgb(73, 75, 77) 0%, rgb(44, 46, 46) 100%); }

div.jp-type-single div.jp-interface { height: 30px; }

div.jp-interface ul.jp-controls { list-style-type: none; padding: 0px; marg=
in: 0px; }

div.jp-interface ul.jp-controls li { display: inline; }

div.jp-interface ul.jp-controls a { position: absolute; overflow: hidden; t=
ext-indent: -9999px; }

a.jp-play, a.jp-pause { width: 33px; height: 30px; z-index: 1; outline: non=
e; }

div.jp-type-single a.jp-play, div.jp-type-single a.jp-pause { top: 0px; lef=
t: 0px; }

a.jp-play { background: url("images/jplayer-black-and-yellow.png") 0px 0px =
no-repeat; }

a.jp-play:hover { background: url("images/jplayer-black-and-yellow.png") -3=
3px 0px no-repeat; }

a.jp-pause { background: url("images/jplayer-black-and-yellow.png") 0px -30=
px no-repeat; display: none; }

a.jp-pause:hover { background: url("images/jplayer-black-and-yellow.png") -=
33px -30px no-repeat; }

div.jp-progress-container { width: 60%; height: 6px; padding: 12px 0px; mar=
gin-left: 45px; display: inline-block; position: relative; }

div.jp-progress { position: absolute; overflow: hidden; }

div.jp-type-single div.jp-progress { width: 758px; }

div.jp-type-single div.jp-progress { width: 100%; height: 7px; padding: 1px=
 0px; }

div.jp-seek-bar { width: 0px; height: 5px; cursor: pointer; background: url=
("images/jplayer-black-and-yellow.png") 0px -163px repeat-x; border-radius:=
 1px; }

div.jp-play-bar { width: 0px; height: 5px; background: url("images/jplayer-=
black-and-yellow.png") 0px -133px repeat-x; border-radius: 1px; }

div.jp-volume-bar-container { width: 40px; height: 6px; padding: 12px 10px =
12px 0px; display: inline-block; float: right; }

div.jp-volume-bar { position: relative; overflow: hidden; background: url("=
images/jplayer-black-and-yellow.png") 0px -192px repeat-x; width: 40px; hei=
ght: 9px; cursor: pointer; }

div.jp-volume-bar { left: 360px; }

div.jp-type-single div.jp-volume-bar { top: 0px; left: auto; }

div.jp-volume-bar-value { width: 0px; height: 5px; margin: 1px; background:=
 url("images/jplayer-black-and-yellow.png") 0px -133px repeat-x; border-rad=
ius: 1px; }

a.jp-mute, a.jp-unmute { width: 17px; height: 13px; z-index: 1; outline: no=
ne; }

div.jp-type-single a.jp-mute, div.jp-type-single a.jp-unmute { left: 825px;=
 }

div.jp-type-single a.jp-mute, div.jp-type-single a.jp-unmute { top: 9px; le=
ft: 485px; }

.social-stats_flip { text-align: left; }

#map_container img { max-width: none; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/flip.css

@charset "utf-8";

.swipe { }

.panel { z-index: 2; min-height: 250px; position: relative; font-size: 0.8e=
m; margin-bottom: 30px; perspective: 600px; user-select: none; }

.folio_fix .panel { width: 100%; }

.panel .front { float: none; position: absolute; top: 0px; left: 0px; z-ind=
ex: 900; width: inherit; min-height: inherit; background: rgb(255, 255, 240=
); text-align: center; }

.animationflip .panel .front, .animation .panel .front { transform-style: p=
reserve-3d; backface-visibility: hidden; transition: 0.4s ease-in-out; }

.panel.fadepanel .front { z-index: 900; border-color: rgb(238, 238, 238); o=
pacity: 0; transition: opacity 1s ease-in-out; }

.panel .back { float: none; position: absolute; top: 0px; left: 0px; z-inde=
x: 800; width: inherit; min-height: inherit; background: rgb(5, 139, 230); =
opacity: 0; }

.animationflip .panel .back, .animation .panel .back { opacity: 0; transfor=
m: rotateY(180deg); transform-style: preserve-3d; backface-visibility: hidd=
en; transition: 0.4s ease-in-out; }

.panel.flip .back { z-index: 1000; opacity: 1; }

.panel.fadepanel .back { z-index: 1000; opacity: 1; transition: opacity 0.5=
s ease-in-out; }

.panel .pad { padding: 7% 10% 5%; }

.panel .pad p { font-family: Georgia, cursive; font-style: italic; text-ali=
gn: left; color: rgb(255, 255, 255); font-size: 1em; padding: 0px; line-hei=
ght: 1.55em; }

@media (min-width: 768px) and (max-width: 979px) {
  .panel .pad p { font-size: 1.1em; }
}

@media (max-width: 767px) {
  .panel .pad p { font-size: 12px; }
}

.panel.flip .action { display: none; }

.block ol li { text-align: left; margin: 0px 0px 0px 28px; }

.block .action { display: block; padding: 3px; background: rgb(51, 51, 51);=
 text-align: right; font-size: 0.8em; opacity: 0; position: absolute; curso=
r: pointer; transition: opacity 0.2s linear; }

.block:hover .action { opacity: 0.7; }

.circle div { border-radius: 100px; }

.circle div h2 { padding-top: 3em; text-align: center; }

#test { width: 500px; height: 300px; background: rgb(255, 204, 255); }

#info { width: 500px; }

.panel_2col { z-index: 2; min-height: 285px; position: relative; font-size:=
 0.8em; margin: 0px; perspective: 600px; user-select: none; width: 100%; }

.panel_2col .front { float: none; position: absolute; top: 0px; left: 0px; =
z-index: 900; width: inherit; min-height: inherit; background: rgb(255, 255=
, 240); text-align: center; }

.animationflip .panel_2col .front, .animation .panel_2col .front { transfor=
m-style: preserve-3d; backface-visibility: hidden; transition: 0.4s ease-in=
-out; }

.panel_2col.flip .front { z-index: 900; border-color: rgb(238, 238, 238); }

.panel_2col.fadepanel .front { z-index: 900; border-color: rgb(238, 238, 23=
8); opacity: 0; transition: opacity 1s ease-in-out; }

.panel_2col .back { float: none; position: absolute; top: 0px; left: 0px; z=
-index: 800; width: inherit; min-height: inherit; background: rgb(5, 139, 2=
30); opacity: 0; }

.animationflip .panel_2col .back, .animation .panel_2col .back { transform:=
 rotateY(180deg); transform-style: preserve-3d; backface-visibility: hidden=
; transition: 0.4s ease-in-out; }

.panel_2col.flip .back { z-index: 1000; opacity: 1; }

.panel_2col.fadepanel .back { z-index: 1000; opacity: 1; transition: opacit=
y 0.5s ease-in-out; }

.panel_2col .pad { padding: 10% 10% 5%; }

.panel_2col .pad p { font-family: Georgia, cursive; font-style: italic; tex=
t-align: left; color: rgb(255, 255, 255); font-size: 12px; line-height: 1.5=
5em; }

.panel_2col.flip .action { display: none; }

.block ol li { text-align: left; margin: 0px 0px 0px 28px; }

.block .action { display: block; padding: 3px; background: rgb(51, 51, 51);=
 text-align: right; font-size: 0.8em; opacity: 0; position: absolute; curso=
r: pointer; transition: opacity 0.2s linear; }

.block:hover .action { opacity: 0.7; }

.circle div { border-radius: 100px; }

.circle div h2 { padding-top: 3em; text-align: center; }

#sidebar .work_post { width: 100%; }

#info { width: 500px; }

.span6.animationflip { padding-bottom: 10px; }

.span4.animationflip { padding-bottom: 10px; }

@media (min-width: 1200px) {
  .span6.animationflip { padding-bottom: 15px; }
  .span4.animationflip { padding-bottom: 20px; }
}

@media (max-width: 768px) {
  .span6.animationflip { width: 337px; }
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) and (orientation: portrait) {
  .span6.animationflip { width: 352px; }
}

@media (max-width: 480px) {
  .span6.animationflip { width: 280px; }
}

.flipIcon { font-size: 12px; width: 45px; height: 20px; position: absolute;=
 right: 0px; top: 30px; color: rgb(255, 255, 255); text-transform: uppercas=
e; display: none; padding: 3px; user-select: none; }

.flipHover .flipIcon { }

.hoverBG { width: inherit; min-height: inherit; opacity: 0.2; display: none=
; }

.filterDisabled { opacity: 0.1; transition: opacity 0.5s ease-in-out; }

.filterEnabled { opacity: 1; transition: opacity 1s ease-in-out; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/retweets.css

@charset "utf-8";
=0A
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/flexslider.css

@charset "utf-8";

.flex-container a:active, .flexslider a:active { outline: none; }

.slides, .flex-control-nav, .flex-direction-nav { margin: 0px; padding: 0px=
; list-style: none; }

.flexslider { width: 100%; margin: 0px; padding: 0px; }

.flexslider .slides > li { display: none; }

.flexslider .slides img { max-width: 100%; display: block; }

.flex-pauseplay span { text-transform: capitalize; }

.slides::after { content: "."; display: block; clear: both; visibility: hid=
den; line-height: 0; height: 0px; }

html[xmlns] .slides { display: block; }

* html .slides { height: 1%; }

.no-js .slides > li:first-child { display: block; }

.flexslider { background: rgb(255, 255, 255); zoom: 1; margin-bottom: 15px;=
 }

.flex-viewport { max-height: 2000px; transition: 1s; }

.loading .flex-viewport { max-height: 300px; }

.flexslider .slides { zoom: 1; }

.flexslider .slides > li { position: relative; }

.flex-container { zoom: 1; position: relative; overflow: visible; margin-bo=
ttom: 50px; }

.flex-caption { background: none; zoom: 1; }

.flex-caption { display: none; padding: 2%; position: absolute; left: 5%; b=
ottom: 10%; color: rgb(255, 255, 255); }

.hover .flex-caption { display: block; }

.hover img { opacity: 0.1; }

.flex-caption-container { display: block; }

.flex-caption-container h6 { display: block; padding: 4px; margin-bottom: 5=
px; color: rgb(255, 255, 255); text-transform: uppercase; font-weight: 400;=
 font-size: 10px; }

.flex-caption-title { display: block; padding: 4px; margin-bottom: 5px; col=
or: rgb(255, 255, 255); }

.flex-slider-theme-L .flex-caption-title { color: rgb(0, 0, 0); }

.flex-caption-title span { font-size: 3em; padding: 2px 0px; line-height: 1=
.7em; }

.flex-slider-theme-L .flex-caption-title span { background: rgba(255, 255, =
255, 0.4); box-shadow: rgba(255, 255, 255, 0.4) 10px 0px 0px, rgba(255, 255=
, 255, 0.4) -10px 0px 0px; }

.flex-caption-text { font-size: 16px; display: inline-block; font-weight: n=
ormal; padding: 1px; margin-bottom: 5px; color: rgb(255, 255, 255); width: =
50%; }

@media (max-width: 480px) {
  .flex-caption-text { width: auto; }
}

.flex-slider-theme-L .flex-caption-text { color: rgb(0, 0, 0); }

.flex-caption-text span { font-family: Georgia; font-style: italic; font-si=
ze: 16px; padding: 1px 0px; line-height: 20px; }

.flex-slider-theme-L .flex-caption-text span { background: rgba(255, 255, 2=
55, 0.4); box-shadow: rgba(255, 255, 255, 0.4) 5px 0px 0px, rgba(255, 255, =
255, 0.4) -5px 0px 0px; }

.flex-direction-nav li a, #sidebar .widget ul.flex-direction-nav li > a { d=
isplay: none; }

.no-hover .flex-direction-nav li a, .hover .flex-direction-nav li a, #sideb=
ar .widget .no-hover ul.flex-direction-nav li a, #sidebar .widget .hover ul=
.flex-direction-nav li a { opacity: 1; margin: -17px 0px 0px; display: bloc=
k; position: absolute; top: 50%; cursor: pointer; font-size: 1.5em; width: =
26px; height: 26px; padding: 22px 7px 7px 20px; }

.flex-direction-nav li .flex-next { opacity: 1; right: 0px; font-family: Fo=
ntAwesome; content: "=EF=81=94"; padding-left: 23px; padding-right: 4px; }

.flex-direction-nav li .flex-prev { opacity: 1; left: 0px; font-family: Fon=
tAwesome; content: "=EF=81=94"; }

.flex-direction-nav li .disabled { opacity: 0.3; cursor: default; }

.flex-direction-nav li .flex-next::before { content: "=EF=81=94"; }

.flex-direction-nav li .flex-prev::before { content: "=EF=81=93"; }

.flex-control-nav { width: 100%; position: absolute; text-align: center; }

.flex-control-nav li { margin: 0px 0px 0px 10px; display: inline-block; zoo=
m: 1; }

.flex-control-nav li:first-child { margin: 0px; }

.flex-control-nav li a { width: 0.6em; height: 0.6em; display: block; backg=
round: rgb(255, 255, 255); cursor: pointer; text-indent: -999em; border-rad=
ius: 0.25em; }

.flex-control-nav li a:hover { background-position: 0px -13px; }

.flex-control-nav li a.active { background-position: 0px -26px; cursor: def=
ault; opacity: 0.5; }

@media (max-width: 480px) {
  .flexslider { height: 400px; }
  .flexslider .slides { height: 400px; }
  .flexslider .slides > li { height: 400px; }
  .flexslider .slides img { max-width: none; }
  .flex-caption { font-size: 0.8em; }
  .no-hover .flex-direction-nav li .flex-next { display: none; }
  .no-hover .flex-direction-nav li .flex-prev { display: none; }
  .hover .flex-direction-nav li .flex-next { display: none; }
  .hover .flex-direction-nav li .flex-prev { display: none; }
}
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/prettyPhoto.css

@charset "utf-8";

div.pp_default .pp_top, div.pp_default .pp_top .pp_middle, div.pp_default .=
pp_top .pp_left, div.pp_default .pp_top .pp_right, div.pp_default .pp_botto=
m, div.pp_default .pp_bottom .pp_left, div.pp_default .pp_bottom .pp_middle=
, div.pp_default .pp_bottom .pp_right { height: 13px; }

div.pp_default .pp_top .pp_left { }

div.pp_default .pp_top .pp_middle { }

div.pp_default .pp_top .pp_right { }

div.pp_default .pp_content .ppt { color: rgb(248, 248, 248); }

div.pp_default .pp_content_container .pp_left { padding-left: 13px; }

div.pp_default .pp_content_container .pp_right { padding-right: 13px; }

div.pp_default .pp_next:hover { cursor: pointer; }

div.pp_default .pp_previous:hover { cursor: pointer; }

div.pp_default .pp_expand { cursor: pointer; height: 28px; width: 12px; ove=
rflow: hidden; top: -21px; right: 48px; }

div.pp_default .pp_expand:hover { cursor: pointer; }

a.pp_expand::before { font-family: FontAwesome; content: "=EF=81=A5"; color=
: rgb(255, 255, 255); }

div.pp_default .pp_contract { cursor: pointer; height: 28px; width: 12px; o=
verflow: hidden; top: -21px; right: 48px; }

div.pp_default .pp_contract:hover { }

a.pp_contract::before { font-family: FontAwesome; content: "=EF=81=A6"; col=
or: rgb(255, 255, 255); }

div.pp_default .pp_close { cursor: pointer; height: 19px; width: 13px; text=
-indent: 0px; top: -27px; right: 5px; overflow: hidden; }

a.pp_close::before { font-family: FontAwesome; content: "=EF=80=8D"; color:=
 rgb(255, 255, 255); }

div.pp_default .pp_gallery ul li a { }

div.pp_default .pp_social { margin-top: 7px; }

div.pp_default .pp_gallery a.pp_arrow_previous, div.pp_default .pp_gallery =
a.pp_arrow_next { left: auto; position: static; }

div.pp_default .pp_nav .pp_play, div.pp_default .pp_nav .pp_pause { height:=
 30px; width: 30px; display: none; }

div.pp_default .pp_nav .pp_pause { background-position: -51px -29px; }

div.pp_default a.pp_arrow_previous, div.pp_default a.pp_arrow_next { margin=
: 0px 1px; text-indent: 0px; }

a.pp_arrow_previous { padding: 12px 15px 16px 18px; }

a.pp_arrow_next { padding: 12px 12px 16px 20px; }

a.pp_arrow_previous::before { font-family: FontAwesome; content: "=EF=81=93=
"; color: rgb(255, 255, 255); }

a.pp_arrow_next { left: 52px; }

a.pp_arrow_next::before { font-family: FontAwesome; content: "=EF=81=94"; c=
olor: rgb(255, 255, 255); }

div.pp_default .pp_content_container .pp_details { margin-top: 5px; positio=
n: absolute; top: 0px; z-index: 2000; }

div.pp_default .pp_nav { clear: none; height: 30px; width: 110px; position:=
 absolute; right: 30px; top: -8px; }

div.pp_default .pp_nav .currentTextHolder { color: rgb(153, 153, 153); font=
-family: Georgia; font-size: 11px; font-style: italic; left: 75px; line-hei=
ght: 25px; margin: 0px; padding: 0px 0px 0px 10px; position: absolute; top:=
 2px; display: none; }

div.pp_default .pp_close:hover, div.pp_default .pp_nav .pp_play:hover, div.=
pp_default .pp_nav .pp_pause:hover, div.pp_default .pp_arrow_next:hover, di=
v.pp_default .pp_arrow_previous:hover { opacity: 0.7; }

div.pp_default .pp_description { font-size: 11px; font-weight: 700; line-he=
ight: 14px; margin: 5px 50px 5px 0px; }

div.pp_default .pp_bottom .pp_left { }

div.pp_default .pp_bottom .pp_middle { }

div.pp_default .pp_bottom .pp_right { }

div.pp_default .pp_loaderIcon { background: url("../images/prettyPhoto/defa=
ult/loader.gif") center center / 16px 16px no-repeat; }

div.light_rounded .pp_top .pp_left { background: url("../images/prettyPhoto=
/light_rounded/sprite.png") -88px -53px no-repeat; }

div.light_rounded .pp_top .pp_right { background: url("../images/prettyPhot=
o/light_rounded/sprite.png") -110px -53px no-repeat; }

div.light_rounded .pp_next:hover { background: url("../images/prettyPhoto/l=
ight_rounded/btnNext.png") right center no-repeat; cursor: pointer; }

div.light_rounded .pp_previous:hover { background: url("../images/prettyPho=
to/light_rounded/btnPrevious.png") left center no-repeat; cursor: pointer; =
}

div.light_rounded .pp_expand { background: url("../images/prettyPhoto/light=
_rounded/sprite.png") -31px -26px no-repeat; cursor: pointer; }

div.light_rounded .pp_expand:hover { background: url("../images/prettyPhoto=
/light_rounded/sprite.png") -31px -47px no-repeat; cursor: pointer; }

div.light_rounded .pp_contract { background: url("../images/prettyPhoto/lig=
ht_rounded/sprite.png") 0px -26px no-repeat; cursor: pointer; }

div.light_rounded .pp_contract:hover { background: url("../images/prettyPho=
to/light_rounded/sprite.png") 0px -47px no-repeat; cursor: pointer; }

div.light_rounded .pp_close { background: url("../images/prettyPhoto/light_=
rounded/sprite.png") -1px -1px no-repeat; cursor: pointer; height: 22px; wi=
dth: 75px; }

div.light_rounded .pp_nav .pp_play { background: url("../images/prettyPhoto=
/light_rounded/sprite.png") -1px -100px no-repeat; height: 15px; width: 14p=
x; }

div.light_rounded .pp_nav .pp_pause { background: url("../images/prettyPhot=
o/light_rounded/sprite.png") -24px -100px no-repeat; height: 15px; width: 1=
4px; }

div.light_rounded .pp_arrow_previous { background: url("../images/prettyPho=
to/light_rounded/sprite.png") 0px -71px no-repeat; }

div.light_rounded .pp_arrow_next { background: url("../images/prettyPhoto/l=
ight_rounded/sprite.png") -22px -71px no-repeat; }

div.light_rounded .pp_bottom .pp_left { background: url("../images/prettyPh=
oto/light_rounded/sprite.png") -88px -80px no-repeat; }

div.light_rounded .pp_bottom .pp_right { background: url("../images/prettyP=
hoto/light_rounded/sprite.png") -110px -80px no-repeat; }

div.dark_rounded .pp_top .pp_left { background: url("../images/prettyPhoto/=
dark_rounded/sprite.png") -88px -53px no-repeat; }

div.dark_rounded .pp_top .pp_right { background: url("../images/prettyPhoto=
/dark_rounded/sprite.png") -110px -53px no-repeat; }

div.dark_rounded .pp_content_container .pp_left { background: url("../image=
s/prettyPhoto/dark_rounded/contentPattern.png") left top repeat-y; }

div.dark_rounded .pp_content_container .pp_right { background: url("../imag=
es/prettyPhoto/dark_rounded/contentPattern.png") right top repeat-y; }

div.dark_rounded .pp_next:hover { background: url("../images/prettyPhoto/da=
rk_rounded/btnNext.png") right center no-repeat; cursor: pointer; }

div.dark_rounded .pp_previous:hover { background: url("../images/prettyPhot=
o/dark_rounded/btnPrevious.png") left center no-repeat; cursor: pointer; }

div.dark_rounded .pp_expand { background: url("../images/prettyPhoto/dark_r=
ounded/sprite.png") -31px -26px no-repeat; cursor: pointer; }

div.dark_rounded .pp_expand:hover { background: url("../images/prettyPhoto/=
dark_rounded/sprite.png") -31px -47px no-repeat; cursor: pointer; }

div.dark_rounded .pp_contract { background: url("../images/prettyPhoto/dark=
_rounded/sprite.png") 0px -26px no-repeat; cursor: pointer; }

div.dark_rounded .pp_contract:hover { background: url("../images/prettyPhot=
o/dark_rounded/sprite.png") 0px -47px no-repeat; cursor: pointer; }

div.dark_rounded .pp_close { background: url("../images/prettyPhoto/dark_ro=
unded/sprite.png") -1px -1px no-repeat; cursor: pointer; height: 22px; widt=
h: 75px; }

div.dark_rounded .pp_description { color: rgb(255, 255, 255); margin-right:=
 85px; }

div.dark_rounded .pp_nav .pp_play { background: url("../images/prettyPhoto/=
dark_rounded/sprite.png") -1px -100px no-repeat; height: 15px; width: 14px;=
 }

div.dark_rounded .pp_nav .pp_pause { background: url("../images/prettyPhoto=
/dark_rounded/sprite.png") -24px -100px no-repeat; height: 15px; width: 14p=
x; }

div.dark_rounded .pp_arrow_previous { background: url("../images/prettyPhot=
o/dark_rounded/sprite.png") 0px -71px no-repeat; }

div.dark_rounded .pp_arrow_next { background: url("../images/prettyPhoto/da=
rk_rounded/sprite.png") -22px -71px no-repeat; }

div.dark_rounded .pp_bottom .pp_left { background: url("../images/prettyPho=
to/dark_rounded/sprite.png") -88px -80px no-repeat; }

div.dark_rounded .pp_bottom .pp_right { background: url("../images/prettyPh=
oto/dark_rounded/sprite.png") -110px -80px no-repeat; }

div.dark_rounded .pp_loaderIcon { background: url("../images/prettyPhoto/da=
rk_rounded/loader.gif") center center no-repeat; }

div.dark_square .pp_left, div.dark_square .pp_middle, div.dark_square .pp_r=
ight, div.dark_square .pp_content { background: rgb(0, 0, 0); }

div.dark_square .pp_description { color: rgb(255, 255, 255); margin: 0px 85=
px 0px 0px; }

div.dark_square .pp_loaderIcon { background: url("../images/prettyPhoto/dar=
k_square/loader.gif") center center no-repeat; }

div.dark_square .pp_expand { background: url("../images/prettyPhoto/dark_sq=
uare/sprite.png") -31px -26px no-repeat; cursor: pointer; }

div.dark_square .pp_expand:hover { background: url("../images/prettyPhoto/d=
ark_square/sprite.png") -31px -47px no-repeat; cursor: pointer; }

div.dark_square .pp_contract { background: url("../images/prettyPhoto/dark_=
square/sprite.png") 0px -26px no-repeat; cursor: pointer; }

div.dark_square .pp_contract:hover { background: url("../images/prettyPhoto=
/dark_square/sprite.png") 0px -47px no-repeat; cursor: pointer; }

div.dark_square .pp_close { background: url("../images/prettyPhoto/dark_squ=
are/sprite.png") -1px -1px no-repeat; cursor: pointer; height: 22px; width:=
 75px; }

div.dark_square .pp_nav { clear: none; }

div.dark_square .pp_nav .pp_play { background: url("../images/prettyPhoto/d=
ark_square/sprite.png") -1px -100px no-repeat; height: 15px; width: 14px; }

div.dark_square .pp_nav .pp_pause { background: url("../images/prettyPhoto/=
dark_square/sprite.png") -24px -100px no-repeat; height: 15px; width: 14px;=
 }

div.dark_square .pp_arrow_previous { background: url("../images/prettyPhoto=
/dark_square/sprite.png") 0px -71px no-repeat; }

div.dark_square .pp_arrow_next { background: url("../images/prettyPhoto/dar=
k_square/sprite.png") -22px -71px no-repeat; }

div.dark_square .pp_next:hover { background: url("../images/prettyPhoto/dar=
k_square/btnNext.png") right center no-repeat; cursor: pointer; }

div.dark_square .pp_previous:hover { background: url("../images/prettyPhoto=
/dark_square/btnPrevious.png") left center no-repeat; cursor: pointer; }

div.light_square .pp_expand { background: url("../images/prettyPhoto/light_=
square/sprite.png") -31px -26px no-repeat; cursor: pointer; }

div.light_square .pp_expand:hover { background: url("../images/prettyPhoto/=
light_square/sprite.png") -31px -47px no-repeat; cursor: pointer; }

div.light_square .pp_contract { background: url("../images/prettyPhoto/ligh=
t_square/sprite.png") 0px -26px no-repeat; cursor: pointer; }

div.light_square .pp_contract:hover { background: url("../images/prettyPhot=
o/light_square/sprite.png") 0px -47px no-repeat; cursor: pointer; }

div.light_square .pp_close { background: url("../images/prettyPhoto/light_s=
quare/sprite.png") -1px -1px no-repeat; cursor: pointer; height: 22px; widt=
h: 75px; }

div.light_square .pp_nav .pp_play { background: url("../images/prettyPhoto/=
light_square/sprite.png") -1px -100px no-repeat; height: 15px; width: 14px;=
 }

div.light_square .pp_nav .pp_pause { background: url("../images/prettyPhoto=
/light_square/sprite.png") -24px -100px no-repeat; height: 15px; width: 14p=
x; }

div.light_square .pp_arrow_previous { background: url("../images/prettyPhot=
o/light_square/sprite.png") 0px -71px no-repeat; }

div.light_square .pp_arrow_next { background: url("../images/prettyPhoto/li=
ght_square/sprite.png") -22px -71px no-repeat; }

div.light_square .pp_next:hover { background: url("../images/prettyPhoto/li=
ght_square/btnNext.png") right center no-repeat; cursor: pointer; }

div.light_square .pp_previous:hover { background: url("../images/prettyPhot=
o/light_square/btnPrevious.png") left center no-repeat; cursor: pointer; }

div.facebook .pp_top .pp_left { background: url("../images/prettyPhoto/face=
book/sprite.png") -88px -53px no-repeat; }

div.facebook .pp_top .pp_middle { background: url("../images/prettyPhoto/fa=
cebook/contentPatternTop.png") left top repeat-x; }

div.facebook .pp_top .pp_right { background: url("../images/prettyPhoto/fac=
ebook/sprite.png") -110px -53px no-repeat; }

div.facebook .pp_content_container .pp_left { background: url("../images/pr=
ettyPhoto/facebook/contentPatternLeft.png") left top repeat-y; }

div.facebook .pp_content_container .pp_right { background: url("../images/p=
rettyPhoto/facebook/contentPatternRight.png") right top repeat-y; }

div.facebook .pp_expand { background: url("../images/prettyPhoto/facebook/s=
prite.png") -31px -26px no-repeat; cursor: pointer; }

div.facebook .pp_expand:hover { background: url("../images/prettyPhoto/face=
book/sprite.png") -31px -47px no-repeat; cursor: pointer; }

div.facebook .pp_contract { background: url("../images/prettyPhoto/facebook=
/sprite.png") 0px -26px no-repeat; cursor: pointer; }

div.facebook .pp_contract:hover { background: url("../images/prettyPhoto/fa=
cebook/sprite.png") 0px -47px no-repeat; cursor: pointer; }

div.facebook .pp_close { background: url("../images/prettyPhoto/facebook/sp=
rite.png") -1px -1px no-repeat; cursor: pointer; height: 22px; width: 22px;=
 }

div.facebook .pp_description { margin: 0px 37px 0px 0px; }

div.facebook .pp_loaderIcon { background: url("../images/prettyPhoto/facebo=
ok/loader.gif") center center no-repeat; }

div.facebook .pp_arrow_previous { background: url("../images/prettyPhoto/fa=
cebook/sprite.png") 0px -71px no-repeat; height: 22px; margin-top: 0px; wid=
th: 22px; }

div.facebook .pp_arrow_previous.disabled { background-position: 0px -96px; =
cursor: default; }

div.facebook .pp_arrow_next { background: url("../images/prettyPhoto/facebo=
ok/sprite.png") -32px -71px no-repeat; height: 22px; margin-top: 0px; width=
: 22px; }

div.facebook .pp_arrow_next.disabled { background-position: -32px -96px; cu=
rsor: default; }

div.facebook .pp_nav { margin-top: 0px; }

div.facebook .pp_nav p { font-size: 15px; padding: 0px 3px 0px 4px; }

div.facebook .pp_nav .pp_play { background: url("../images/prettyPhoto/face=
book/sprite.png") -1px -123px no-repeat; height: 22px; width: 22px; }

div.facebook .pp_nav .pp_pause { background: url("../images/prettyPhoto/fac=
ebook/sprite.png") -32px -123px no-repeat; height: 22px; width: 22px; }

div.facebook .pp_next:hover { background: url("../images/prettyPhoto/facebo=
ok/btnNext.png") right center no-repeat; cursor: pointer; }

div.facebook .pp_previous:hover { background: url("../images/prettyPhoto/fa=
cebook/btnPrevious.png") left center no-repeat; cursor: pointer; }

div.facebook .pp_bottom .pp_left { background: url("../images/prettyPhoto/f=
acebook/sprite.png") -88px -80px no-repeat; }

div.facebook .pp_bottom .pp_middle { background: url("../images/prettyPhoto=
/facebook/contentPatternBottom.png") left top repeat-x; }

div.facebook .pp_bottom .pp_right { background: url("../images/prettyPhoto/=
facebook/sprite.png") -110px -80px no-repeat; }

div.pp_pic_holder a:focus { outline: none; }

div.pp_overlay { background: rgb(0, 0, 0); display: none; left: 0px; positi=
on: absolute; top: 0px; width: 100%; z-index: 9500; }

div.pp_pic_holder { display: none; position: absolute; width: 100px; z-inde=
x: 10000; }

.pp_content { height: 40px; min-width: 40px; }

* html .pp_content { width: 40px; }

.pp_content_container { position: relative; text-align: left; width: 100%; =
}

.pp_content_container .pp_left { padding-left: 20px; }

.pp_content_container .pp_right { padding-right: 20px; }

.pp_content_container .pp_details { float: left; margin: 10px 0px 2px; }

.pp_description { display: none; margin: 0px; }

.pp_social { float: left; margin: 0px; }

.pp_social .facebook { float: left; margin-left: 5px; overflow: hidden; wid=
th: 55px; }

.pp_social .twitter { float: left; }

.pp_nav { clear: right; float: left; margin: 3px 10px 0px 0px; }

.pp_nav p { float: left; margin: 2px 4px; white-space: nowrap; }

.pp_nav .pp_play, .pp_nav .pp_pause { float: left; margin-right: 4px; text-=
indent: -10000px; }

a.pp_arrow_previous, a.pp_arrow_next { display: block; float: left; height:=
 15px; margin-top: 3px; overflow: hidden; text-indent: -10000px; width: 14p=
x; }

.pp_hoverContainer { position: absolute; top: 0px; width: 100%; z-index: 20=
00; }

.pp_gallery { display: none; left: 50%; margin-top: -50px; position: absolu=
te; z-index: 10000; }

.pp_gallery div { float: left; overflow: hidden; position: relative; }

.pp_gallery ul { float: left; height: 35px; margin: 0px 0px 0px 5px; paddin=
g: 0px; position: relative; white-space: nowrap; }

.pp_gallery ul a { display: block; float: left; height: 33px; overflow: hid=
den; }

.pp_gallery ul a img { border: 0px; }

.pp_gallery li { display: block; float: left; margin: 0px 5px 0px 0px; padd=
ing: 0px; }

.pp_gallery li.default a { background: url("../images/prettyPhoto/facebook/=
default_thumbnail.gif") 0px 0px no-repeat; display: block; height: 33px; wi=
dth: 50px; }

.pp_gallery .pp_arrow_previous, .pp_gallery .pp_arrow_next { margin-top: 7p=
x !important; }

a.pp_next { background: url("../images/prettyPhoto/light_rounded/btnNext.pn=
g") 10000px 10000px no-repeat; display: block; float: right; height: 100%; =
text-indent: -10000px; width: 49%; }

a.pp_previous { background: url("../images/prettyPhoto/light_rounded/btnNex=
t.png") 10000px 10000px no-repeat; display: block; float: left; height: 100=
%; text-indent: -10000px; width: 49%; }

a.pp_expand, a.pp_contract { cursor: pointer; display: none; height: 20px; =
position: absolute; right: 30px; top: 10px; width: 20px; z-index: 20000; }

a.pp_close { display: block; line-height: 22px; position: absolute; right: =
0px; text-indent: -10000px; top: 0px; }

.pp_loaderIcon { display: block; height: 24px; left: 50%; margin: -12px 0px=
 0px -12px; position: absolute; top: 50%; width: 24px; }

#pp_full_res { line-height: 1 !important; }

#pp_full_res .pp_inline { text-align: left; }

#pp_full_res .pp_inline p { margin: 0px 0px 15px; }

div.ppt { color: rgb(255, 255, 255); display: none; font-size: 17px; margin=
: 0px 0px 5px 15px; z-index: 9999; }

div.pp_default .pp_content, div.light_rounded .pp_content { }

div.pp_default #pp_full_res .pp_inline, div.light_rounded .pp_content .ppt,=
 div.light_rounded #pp_full_res .pp_inline, div.light_square .pp_content .p=
pt, div.light_square #pp_full_res .pp_inline, div.facebook .pp_content .ppt=
, div.facebook #pp_full_res .pp_inline { color: rgb(0, 0, 0); }

div.pp_default .pp_gallery ul li a:hover, div.pp_default .pp_gallery ul li.=
selected a, .pp_gallery ul a:hover, .pp_gallery li.selected a { }

div.pp_default .pp_details, div.light_rounded .pp_details, div.dark_rounded=
 .pp_details, div.dark_square .pp_details, div.light_square .pp_details, di=
v.facebook .pp_details { position: relative; }

div.light_rounded .pp_top .pp_middle, div.light_rounded .pp_content_contain=
er .pp_left, div.light_rounded .pp_content_container .pp_right, div.light_r=
ounded .pp_bottom .pp_middle, div.light_square .pp_left, div.light_square .=
pp_middle, div.light_square .pp_right, div.light_square .pp_content, div.fa=
cebook .pp_content { background: rgb(255, 255, 255); }

div.light_rounded .pp_description, div.light_square .pp_description { margi=
n-right: 85px; }

div.light_rounded .pp_gallery a.pp_arrow_previous, div.light_rounded .pp_ga=
llery a.pp_arrow_next, div.dark_rounded .pp_gallery a.pp_arrow_previous, di=
v.dark_rounded .pp_gallery a.pp_arrow_next, div.dark_square .pp_gallery a.p=
p_arrow_previous, div.dark_square .pp_gallery a.pp_arrow_next, div.light_sq=
uare .pp_gallery a.pp_arrow_previous, div.light_square .pp_gallery a.pp_arr=
ow_next { margin-top: 12px !important; }

div.light_rounded .pp_arrow_previous.disabled, div.dark_rounded .pp_arrow_p=
revious.disabled, div.dark_square .pp_arrow_previous.disabled, div.light_sq=
uare .pp_arrow_previous.disabled { background-position: 0px -87px; cursor: =
default; }

div.light_rounded .pp_arrow_next.disabled, div.dark_rounded .pp_arrow_next.=
disabled, div.dark_square .pp_arrow_next.disabled, div.light_square .pp_arr=
ow_next.disabled { background-position: -22px -87px; cursor: default; }

div.light_rounded .pp_loaderIcon, div.light_square .pp_loaderIcon { backgro=
und: url("../images/prettyPhoto/light_rounded/loader.gif") center center no=
-repeat; }

div.dark_rounded .pp_top .pp_middle, div.dark_rounded .pp_content, div.dark=
_rounded .pp_bottom .pp_middle { background: url("../images/prettyPhoto/dar=
k_rounded/contentPattern.png") left top repeat; }

div.dark_rounded .currentTextHolder, div.dark_square .currentTextHolder { c=
olor: rgb(196, 196, 196); }

div.dark_rounded #pp_full_res .pp_inline, div.dark_square #pp_full_res .pp_=
inline { color: rgb(255, 255, 255); }

.pp_top, .pp_bottom { height: 20px; position: relative; }

* html .pp_top, * html .pp_bottom { padding: 0px 20px; }

.pp_top .pp_left, .pp_bottom .pp_left { height: 20px; left: 0px; position: =
absolute; width: 20px; }

.pp_top .pp_middle, .pp_bottom .pp_middle { height: 20px; left: 20px; posit=
ion: absolute; right: 20px; }

* html .pp_top .pp_middle, * html .pp_bottom .pp_middle { left: 0px; positi=
on: static; }

.pp_top .pp_right, .pp_bottom .pp_right { height: 20px; left: auto; positio=
n: absolute; right: 0px; top: 0px; width: 20px; }

.pp_fade, .pp_gallery li.default a img { display: none; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/style.css

@charset "utf-8";

.APV1_wrapper, .APV1_wrapper * { user-select: none; display: block !importa=
nt; cursor: default !important; border: none !important; overflow: visible =
!important; position: static !important; background: none !important; float=
: none !important; z-index: auto !important; list-style: none !important; l=
ine-height: 0 !important; direction: ltr !important; text-align: center !im=
portant; opacity: 1 !important; margin: 0px !important; padding: 0px !impor=
tant; }

.APV1_play_button, .APV1_volume_button, .APV1_volume_bar_container, .APV1_v=
olume_bar, .APV1_seek_bar, .APV1_play_bar, .APV1_progress_bar_wrapper { cur=
sor: pointer !important; }

.APV1_wrapper { width: 300px; height: 29px; overflow: hidden !important; ba=
ckground: url("sprite.png") 0px -240px repeat-x rgb(17, 17, 17) !important;=
 border-radius: 3px !important; }

.APV1_wrapper li { float: left !important; height: 100% !important; }

.APV1_seperator { width: 0px !important; height: 100% !important; border-le=
ft: 1px solid rgb(0, 0, 0) !important; border-right: 1px solid rgb(102, 102=
, 102) !important; opacity: 0.15 !important; }

.APV1_play_button, .APV1_volume_button { height: 100% !important; width: 30=
px !important; background: url("sprite.png") -1px 0px no-repeat !important;=
 }

.APV1_play_button:hover { background-position: -34px 0px !important; }

.APV1_playing .APV1_play_button { background-position: -1px -30px !importan=
t; }

.APV1_playing .APV1_play_button:hover { background-position: -34px -30px !i=
mportant; }

.APV1_volume_button { background-position: -1px -60px !important; }

.APV1_volume_button:hover { background-position: -34px -60px !important; }

.APV1_mute .APV1_volume_button { background-position: -1px -90px !important=
; }

.APV1_mute .APV1_volume_button:hover { background-position: -34px -90px !im=
portant; }

.APV1_progress_bar_container, .APV1_volume_bar_container { background: url(=
"sprite.png") 0px -222px repeat-x !important; height: 5px !important; borde=
r-bottom: 1px solid rgb(68, 68, 68) !important; margin: 11px !important; pa=
dding: 1px !important; }

.APV1_volume_bar_container { width: 30px !important; margin-left: 0px !impo=
rtant; }

.APV1_progress_bar_wrapper { position: relative !important; width: 100% !im=
portant; height: 100% !important; }

.APV1_seek_bar { width: 0px; transition: width 1s; transform: translateZ(0p=
x); background: url("sprite.png") 0px -193px repeat-x !important; height: 1=
00% !important; }

.APV1_play_bar, .APV1_seek_bar { position: absolute !important; top: 0px !i=
mportant; left: 0px !important; }

.APV1_volume_bar, .APV1_play_bar { width: 0px; transform: translateZ(0px); =
border-radius: 1px; background: url("sprite.png") 0px -163px repeat-x !impo=
rtant; height: 100% !important; }

.APV1_play_bar.APV1_transition { transition: width 500ms; }

.APV1_duration_text, .APV1_time_text { -webkit-font-smoothing: subpixel-ant=
ialiased; font-family: "Lucida Grande", Helvetica, Arial, sans-serif !impor=
tant; color: rgb(238, 238, 238) !important; font-size: 10px !important; fon=
t-weight: 700 !important; line-height: 29px !important; padding: 0px 7px !i=
mportant; }

.APV1_error .APV1_duration_text, .APV1_error .APV1_seperator, .APV1_error .=
APV1_volume_button, .APV1_error .APV1_progress_bar_container, .APV1_error .=
APV1_volume_bar_container { display: none !important; }

.APV1_error .APV1_for_play { display: block !important; }

.APV1_error .APV1_play_button { cursor: default !important; background-posi=
tion: -1px -120px !important; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/shortcodes.css

@charset "utf-8";

.preloader { background: url("../images/loading.gif") center center no-repe=
at rgb(255, 255, 255); }

.btn-large { padding: 9px 14px; font-size: 15px; line-height: normal; borde=
r-radius: 5px; }

.btn-small { padding: 5px 9px; font-size: 13px; line-height: 16px; border-r=
adius: 5px; }

.hr-1 { background: url("../images/hr_bck.jpg") repeat-x; height: 33px; dis=
play: block; border: none !important; outline: none !important; }

.one_half, .one_third, .two_third, .three_fourth, .one_fourth, .two_fourth,=
 .one_fifth, .two_fifth, .three_fifth, .four_fifth, .one_sixth, .five_sixth=
 { position: relative; margin-right: 4%; float: left; }

p.one_half, .one_third, .two_third, .three_fourth, .one_fourth, .two_fourth=
, .one_fifth, .two_fifth, .three_fifth, .four_fifth, .one_sixth, .five_sixt=
h { font-size: 0.9em; }

.one_half { width: 48%; }

.one_third { width: 30.6666%; }

.two_third { width: 65.3332%; }

.one_fourth { width: 22%; }

.two_fourth { width: 48%; }

.three_fourth { width: 74%; }

.one_fifth { width: 16.8%; }

.two_fifth { width: 37.6%; }

.three_fifth { width: 58.4%; }

.four_fifth { width: 79.2%; }

.one_sixth { width: 13.3333%; }

.two_sixth { width: 30.6666%; }

.three_sixth { width: 47.9998%; }

.four_sixth { width: 65.3332%; }

.five_sixth { width: 82.6665%; }

.last { margin-right: 0px !important; clear: right; }

.one_half .one_half { margin-right: 8.3333%; width: 45.8333%; }

.one_half .one_third { margin-right: 8.3333%; width: 27.7778%; }

.one_half .two_third { margin-right: 8.3333%; width: 63.8889%; }

.two_third .one_third { margin-right: 6.1224%; width: 29.2517%; }

.two_third .two_third { margin-right: 6.1224%; width: 64.6258%; }

.two_third .one_fourth { margin-right: 6.1224%; width: 20.4082%; }

.clearboth { clear: both; }

.space_divider { display: block; clear: both; padding: 25px; }

.video_frame { position: relative; padding-bottom: 56.25%; height: 0px; }

.video_frame iframe, .video_frame object, .video_frame embed { position: ab=
solute; top: 0px; left: 0px; width: 100%; height: 100%; }

.dropcap1, .dropcap2, .dropcap3, .dropcap4 { float: left; overflow: hidden;=
 text-align: center; }

.dropcap1 { font-size: 28px; height: 35px; line-height: 35px; margin: 0px 0=
px -4px; width: 35px; }

.dropcap2 { font-size: 3em; height: 50px; line-height: 50px; margin: 0px 5p=
x -4px 0px; width: 50px; color: rgb(255, 255, 255); }

#content blockquote.alignleft { margin: 10px 20px 0px 0px; width: 250px; }

#content blockquote.alignright { margin: 10px 0px 0px 20px; width: 250px; }

.alignleft { float: left; }

#content blockquote { color: rgb(68, 68, 68); font-family: Georgia, "Times =
New Roman", Times, serif; line-height: 19px; padding: 10px 20px 10px 45px; =
}

#content blockquote p { font-size: 15px; margin-right: 10px; }

#content blockquote p.qp { height: 35px; width: 30px; display: inline; floa=
t: left; margin-bottom: 0px; position: relative; }

#content blockquote p.qp i { font-family: FontAwesome; font-size: 112px; po=
sition: absolute; left: -34px; top: 40px; font-style: normal; }

#content blockquote p cite { font-size: 11px; color: rgb(183, 183, 183); }

.alignright { float: right; }

.alignleft { float: left; }

.code { background: url("../images/code.png") repeat rgb(244, 245, 245); pa=
dding: 20px 10px; }

.code, .pre { border: 1px solid rgb(224, 224, 224); overflow: auto; white-s=
pace: pre-wrap; line-height: 20px; font-size: 12px; display: block; }

ul.list-s li span { height: 14px; width: 16px; display: inline-block; float=
: left; margin-right: 3px; margin-top: 2px; }

ul.list-s li { list-style: none; margin-left: 0px; margin-bottom: 3px; }

ul.list1 li span { background-position: 0px 0px; }

ul.list2 li span { background-position: 0px -17px; }

ul.list3 li span { background-position: 0px -34px; }

ul.list4 li span { background-position: 0px -55px; }

ul.list5 li span { background-position: 0px -72px; }

ul.list6 li span { background-position: 0px -89px; }

ul.list7 li span { background-position: 0px -105px; }

ul.list8 li span { background-position: 0px -122px; }

ul.list9 li span { background-position: 0px -139px; }

ul.list10 li span { background-position: 0px -157px; }

ul.list11 li span { background-position: 0px -174px; }

.highlight { background-color: rgb(255, 255, 153); }

.highlight.dark { background-color: rgb(51, 51, 51); color: rgb(255, 255, 2=
55); }

.image-frame { border-radius: 2px; box-shadow: rgba(0, 0, 0, 0.35) 0px 1px =
2px; margin-bottom: 0.6em; border: 4px solid rgb(255, 255, 255) !important;=
 }

img.alignleft { float: left; margin: 2px 16px 2px 2px !important; }

img.alignright { float: right; margin: 2px 16px 2px 2px !important; }

.map-frame { background: -webkit-gradient(linear, 0% 100%, 0% 0%, from(rgb(=
232, 233, 233)), to(rgb(242, 242, 242))); margin-bottom: 1.6em; }

.alert-box i { padding: 0px 15px 0px 0px; font-size: 20px; }

.info-box { background-color: rgb(212, 230, 253); border: 1px solid rgb(137=
, 170, 205); border-radius: 3px; color: rgb(88, 135, 185); padding: 8px; ma=
rgin: 15px 0px; }

.error-box { background-color: rgb(252, 215, 216); border: 1px solid rgb(20=
5, 137, 137); border-radius: 3px; color: rgb(221, 45, 45); padding: 8px; ma=
rgin: 15px 0px; }

.check-box { background-color: rgb(215, 252, 217); border: 1px solid rgb(13=
7, 205, 137); border-radius: 5px; color: rgb(65, 154, 98); padding: 8px; ma=
rgin: 15px 0px; }

#contact-form .input { margin: 10px 0px; position: relative; }

#contact-form input { font-size: inherit; }

#contact-form .input label { width: 10px; }

#contact-form textarea { width: 100%; }

#contact-form #submit-form { font-size: 12px; }

#commentform p a { font-weight: bold; color: rgb(89, 88, 88); }

#contact-form .name-error, #contact-form .email-error, #contact-form .comme=
nts-error { display: none; position: relative; top: 5px; }

#contact-form .comments-error { position: absolute; right: 5px; top: 5px; }

#contact-form .form-actions { background-color: transparent; border: none; =
}

h3.trigger { padding: 0px 0px 0px 20px; margin: 0px 0px 5px; background: ur=
l("../images/toggles_h2.jpg") repeat-x; height: 38px; line-height: 38px; bo=
rder: 1px solid rgb(175, 175, 175); border-radius: 5px; box-shadow: rgb(219=
, 218, 218) 0px 1px 2px; }

h3.trigger a { color: rgb(112, 112, 112); text-decoration: none; display: b=
lock; text-shadow: rgb(255, 255, 255) 0px 1px 0px; font-size: 18px; backgro=
und: url("../images/toggle_arrow.png") 0px 10px no-repeat; padding: 0px 0px=
 0px 30px; line-height: 38px; }

h3.trigger a:hover { color: rgb(204, 204, 204); }

h3.trigger a.active { background-position: 0px -20px; }

.toggle_container { margin: 0px 0px 5px; padding: 0px; background: rgb(240,=
 240, 240); overflow: hidden; clear: both; border: 1px solid rgb(214, 214, =
214); border-radius: 5px; box-shadow: rgb(219, 218, 218) 0px 1px 2px; }

.toggle_container .block { padding: 20px; }

.line_full { background: url("../images/line_separ.png") center center no-r=
epeat; height: 8px; width: 880px; display: block; margin: 20px 0px; }

.hr { margin: 2em 0px; }

.tabs { list-style: none; padding: 0px; height: 30px; margin: 0px !importan=
t; }

.tabs li { float: left; text-indent: 0px; padding: 0px; margin: 0px !import=
ant; list-style-image: none !important; }

.tabs a { background: rgb(61, 60, 60); font-size: 11px; display: block; hei=
ght: 30px; line-height: 30px; width: 111px; text-align: center; text-decora=
tion: none; padding: 0px; margin: 0px; position: relative; top: 1px; color:=
 rgb(150, 149, 149) !important; }

.tabs a:active { outline: none; }

.tabs a:hover { background: rgb(75, 75, 75); color: rgb(255, 255, 255); }

.tabs .current, .tabs .current:hover, .tabs li.current a { background: rgb(=
95, 95, 95); cursor: default !important; color: rgb(184, 184, 184) !importa=
nt; }

.tabs .w1 { background-position: -519px 0px; width: 134px; }

.tabs .w1:hover { background-position: -519px -31px; }

.tabs .w1.current { background-position: -519px -62px; }

.tabs .w2 { background-position: -366px 0px; width: 154px; }

.tabs .w2:hover { background-position: -366px -31px; }

.tabs .w2.current { background-position: -366px -62px; }

.tabs .w3 { background-position: -193px 0px; width: 174px; }

.tabs .w3:hover { background-position: -193px -31px; }

.tabs .w3.current { background-position: -193px -62px; }

.tabs .w4 { background-position: 0px 0px; width: 194px; }

.tabs .w4:hover { background-position: 0px -31px; }

.tabs .w4.current { background-position: 0px -62px; }

.panes .pane { display: none; }

.panes .panes-div { background: rgb(95, 95, 95); padding: 15px; }

.accordion-heading a { font-size: 0.875em; outline: none; }

.accordion-body { font-size: 0.8125em; }

.accordion-group { margin-bottom: 4px; }

.icon_holder_accLarge { display: inline-block; width: 80px; height: 80px; c=
olor: rgb(255, 255, 255); line-height: 1.65em; font-size: 50px; text-align:=
 center; margin-bottom: 10px; }

.icon_holder_accMedium { display: inline-block; width: 50px; height: 50px; =
color: rgb(255, 255, 255); line-height: 1.75em; font-size: 30px; text-align=
: center; margin-bottom: 10px; }

.icon_holder_accSmall { display: inline-block; width: 30px; height: 30px; c=
olor: rgb(255, 255, 255); line-height: 1.75em; font-size: 18px; text-align:=
 center; margin-bottom: 10px; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/font-awesome-ie7.css

@charset "utf-8";

[class^=3D"icon-"], [class*=3D" icon-"] { font-family: FontAwesome; font-st=
yle: normal; font-weight: normal; }

.btn.dropdown-toggle [class^=3D"icon-"], .btn.dropdown-toggle [class*=3D" i=
con-"] { line-height: 1.4em; }

.icon-large { font-size: 1.3333em; }

.icon-glass { }

.icon-music { }

.icon-search { }

.icon-envelope { }

.icon-heart { }

.icon-star { }

.icon-star-empty { }

.icon-user { }

.icon-film { }

.icon-th-large { }

.icon-th { }

.icon-th-list { }

.icon-ok { }

.icon-remove { }

.icon-zoom-in { }

.icon-zoom-out { }

.icon-off { }

.icon-signal { }

.icon-cog { }

.icon-trash { }

.icon-home { }

.icon-file { }

.icon-time { }

.icon-road { }

.icon-download-alt { }

.icon-download { }

.icon-upload { }

.icon-inbox { }

.icon-play-circle { }

.icon-repeat { }

.icon-refresh { }

.icon-list-alt { }

.icon-lock { }

.icon-flag { }

.icon-headphones { }

.icon-volume-off { }

.icon-volume-down { }

.icon-volume-up { }

.icon-qrcode { }

.icon-barcode { }

.icon-tag { }

.icon-tags { }

.icon-book { }

.icon-bookmark { }

.icon-print { }

.icon-camera { }

.icon-font { }

.icon-bold { }

.icon-italic { }

.icon-text-height { }

.icon-text-width { }

.icon-align-left { }

.icon-align-center { }

.icon-align-right { }

.icon-align-justify { }

.icon-list { }

.icon-indent-left { }

.icon-indent-right { }

.icon-facetime-video { }

.icon-picture { }

.icon-pencil { }

.icon-map-marker { }

.icon-adjust { }

.icon-tint { }

.icon-edit { }

.icon-share { }

.icon-check { }

.icon-move { }

.icon-step-backward { }

.icon-fast-backward { }

.icon-backward { }

.icon-play { }

.icon-pause { }

.icon-stop { }

.icon-forward { }

.icon-fast-forward { }

.icon-step-forward { }

.icon-eject { }

.icon-chevron-left { }

.icon-chevron-right { }

.icon-plus-sign { }

.icon-minus-sign { }

.icon-remove-sign { }

.icon-ok-sign { }

.icon-question-sign { }

.icon-info-sign { }

.icon-screenshot { }

.icon-remove-circle { }

.icon-ok-circle { }

.icon-ban-circle { }

.icon-arrow-left { }

.icon-arrow-right { }

.icon-arrow-up { }

.icon-arrow-down { }

.icon-share-alt { }

.icon-resize-full { }

.icon-resize-small { }

.icon-plus { }

.icon-minus { }

.icon-asterisk { }

.icon-exclamation-sign { }

.icon-gift { }

.icon-leaf { }

.icon-fire { }

.icon-eye-open { }

.icon-eye-close { }

.icon-warning-sign { }

.icon-plane { }

.icon-calendar { }

.icon-random { }

.icon-comment { }

.icon-magnet { }

.icon-chevron-up { }

.icon-chevron-down { }

.icon-retweet { }

.icon-shopping-cart { }

.icon-folder-close { }

.icon-folder-open { }

.icon-resize-vertical { }

.icon-resize-horizontal { }

.icon-bar-chart { }

.icon-twitter-sign { }

.icon-facebook-sign { }

.icon-camera-retro { }

.icon-key { }

.icon-cogs { }

.icon-comments { }

.icon-thumbs-up { }

.icon-thumbs-down { }

.icon-star-half { }

.icon-heart-empty { }

.icon-signout { }

.icon-linkedin-sign { }

.icon-pushpin { }

.icon-external-link { }

.icon-signin { }

.icon-trophy { }

.icon-github-sign { }

.icon-upload-alt { }

.icon-lemon { }

.icon-phone { }

.icon-check-empty { }

.icon-bookmark-empty { }

.icon-phone-sign { }

.icon-twitter { }

.icon-facebook { }

.icon-github { }

.icon-unlock { }

.icon-credit-card { }

.icon-rss { }

.icon-hdd { }

.icon-bullhorn { }

.icon-bell { }

.icon-certificate { }

.icon-hand-right { }

.icon-hand-left { }

.icon-hand-up { }

.icon-hand-down { }

.icon-circle-arrow-left { }

.icon-circle-arrow-right { }

.icon-circle-arrow-up { }

.icon-circle-arrow-down { }

.icon-globe { }

.icon-wrench { }

.icon-tasks { }

.icon-filter { }

.icon-briefcase { }

.icon-fullscreen { }

.icon-group { }

.icon-link { }

.icon-cloud { }

.icon-beaker { }

.icon-cut { }

.icon-copy { }

.icon-paper-clip { }

.icon-save { }

.icon-sign-blank { }

.icon-reorder { }

.icon-list-ul { }

.icon-list-ol { }

.icon-strikethrough { }

.icon-underline { }

.icon-table { }

.icon-magic { }

.icon-truck { }

.icon-pinterest { }

.icon-pinterest-sign { }

.icon-google-plus-sign { }

.icon-google-plus { }

.icon-money { }

.icon-caret-down { }

.icon-caret-up { }

.icon-caret-left { }

.icon-caret-right { }

.icon-columns { }

.icon-sort { }

.icon-sort-down { }

.icon-sort-up { }

.icon-envelope-alt { }

.icon-linkedin { }

.icon-undo { }

.icon-legal { }

.icon-dashboard { }

.icon-comment-alt { }

.icon-comments-alt { }

.icon-bolt { }

.icon-sitemap { }

.icon-umbrella { }

.icon-paste { }

.icon-user-md { }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/font-awesome.css

@charset "utf-8";

@font-face { font-family: FontAwesome; src: url("../images/font/fontawesome=
-webfont.woff") format("woff"), url("../images/font/fontawesome-webfont.ttf=
") format("truetype"); font-weight: normal; font-style: normal; }

[class^=3D"icon-"]::before, [class*=3D" icon-"]::before { font-family: Font=
Awesome; font-weight: normal; font-style: normal; display: inline-block; te=
xt-decoration: inherit; }

a [class^=3D"icon-"], a [class*=3D" icon-"] { display: inline-block; text-d=
ecoration: inherit; }

.icon-large::before { vertical-align: top; font-size: 1.33333em; }

.btn [class^=3D"icon-"], .btn [class*=3D" icon-"] { line-height: 0.9em; }

li [class^=3D"icon-"], li [class*=3D" icon-"] { display: inline-block; widt=
h: 1.25em; text-align: center; }

li .icon-large[class^=3D"icon-"], li .icon-large[class*=3D" icon-"] { width=
: 1.875em; }

li[class^=3D"icon-"], li[class*=3D" icon-"] { margin-left: 0px; list-style-=
type: none; }

li[class^=3D"icon-"]::before, li[class*=3D" icon-"]::before { text-indent: =
-2em; text-align: center; }

li[class^=3D"icon-"].icon-large::before, li[class*=3D" icon-"].icon-large::=
before { text-indent: -1.33333em; }

.icon-glass::before { content: "=EF=80=80"; }

.icon-music::before { content: "=EF=80=81"; }

.icon-search::before { content: "=EF=80=82"; }

.icon-envelope::before { content: "=EF=80=83"; }

.icon-heart::before { content: "=EF=80=84"; }

.icon-star::before { content: "=EF=80=85"; }

.icon-star-empty::before { content: "=EF=80=86"; }

.icon-user::before { content: "=EF=80=87"; }

.icon-film::before { content: "=EF=80=88"; }

.icon-th-large::before { content: "=EF=80=89"; }

.icon-th::before { content: "=EF=80=8A"; }

.icon-th-list::before { content: "=EF=80=8B"; }

.icon-ok::before { content: "=EF=80=8C"; }

.icon-remove::before { content: "=EF=80=8D"; }

.icon-zoom-in::before { content: "=EF=80=8E"; }

.icon-zoom-out::before { content: "=EF=80=90"; }

.icon-off::before { content: "=EF=80=91"; }

.icon-signal::before { content: "=EF=80=92"; }

.icon-cog::before { content: "=EF=80=93"; }

.icon-trash::before { content: "=EF=80=94"; }

.icon-home::before { content: "=EF=80=95"; }

.icon-file::before { content: "=EF=80=96"; }

.icon-time::before { content: "=EF=80=97"; }

.icon-road::before { content: "=EF=80=98"; }

.icon-download-alt::before { content: "=EF=80=99"; }

.icon-download::before { content: "=EF=80=9A"; }

.icon-upload::before { content: "=EF=80=9B"; }

.icon-inbox::before { content: "=EF=80=9C"; }

.icon-play-circle::before { content: "=EF=80=9D"; }

.icon-repeat::before { content: "=EF=80=9E"; }

.icon-refresh::before { content: "=EF=80=A1"; }

.icon-list-alt::before { content: "=EF=80=A2"; }

.icon-lock::before { content: "=EF=80=A3"; }

.icon-flag::before { content: "=EF=80=A4"; }

.icon-headphones::before { content: "=EF=80=A5"; }

.icon-volume-off::before { content: "=EF=80=A6"; }

.icon-volume-down::before { content: "=EF=80=A7"; }

.icon-volume-up::before { content: "=EF=80=A8"; }

.icon-qrcode::before { content: "=EF=80=A9"; }

.icon-barcode::before { content: "=EF=80=AA"; }

.icon-tag::before { content: "=EF=80=AB"; }

.icon-tags::before { content: "=EF=80=AC"; }

.icon-book::before { content: "=EF=80=AD"; }

.icon-bookmark::before { content: "=EF=80=AE"; }

.icon-print::before { content: "=EF=80=AF"; }

.icon-camera::before { content: "=EF=80=B0"; }

.icon-font::before { content: "=EF=80=B1"; }

.icon-bold::before { content: "=EF=80=B2"; }

.icon-italic::before { content: "=EF=80=B3"; }

.icon-text-height::before { content: "=EF=80=B4"; }

.icon-text-width::before { content: "=EF=80=B5"; }

.icon-align-left::before { content: "=EF=80=B6"; }

.icon-align-center::before { content: "=EF=80=B7"; }

.icon-align-right::before { content: "=EF=80=B8"; }

.icon-align-justify::before { content: "=EF=80=B9"; }

.icon-list::before { content: "=EF=80=BA"; }

.icon-indent-left::before { content: "=EF=80=BB"; }

.icon-indent-right::before { content: "=EF=80=BC"; }

.icon-facetime-video::before { content: "=EF=80=BD"; }

.icon-picture::before { content: "=EF=80=BE"; }

.icon-pencil::before { content: "=EF=81=80"; }

.icon-map-marker::before { content: "=EF=81=81"; }

.icon-adjust::before { content: "=EF=81=82"; }

.icon-tint::before { content: "=EF=81=83"; }

.icon-edit::before { content: "=EF=81=84"; }

.icon-share::before { content: "=EF=81=85"; }

.icon-check::before { content: "=EF=81=86"; }

.icon-move::before { content: "=EF=81=87"; }

.icon-step-backward::before { content: "=EF=81=88"; }

.icon-fast-backward::before { content: "=EF=81=89"; }

.icon-backward::before { content: "=EF=81=8A"; }

.icon-play::before { content: "=EF=81=8B"; }

.icon-pause::before { content: "=EF=81=8C"; }

.icon-stop::before { content: "=EF=81=8D"; }

.icon-forward::before { content: "=EF=81=8E"; }

.icon-fast-forward::before { content: "=EF=81=90"; }

.icon-step-forward::before { content: "=EF=81=91"; }

.icon-eject::before { content: "=EF=81=92"; }

.icon-chevron-left::before { content: "=EF=81=93"; }

.icon-chevron-right::before { content: "=EF=81=94"; }

.icon-plus-sign::before { content: "=EF=81=95"; }

.icon-minus-sign::before { content: "=EF=81=96"; }

.icon-remove-sign::before { content: "=EF=81=97"; }

.icon-ok-sign::before { content: "=EF=81=98"; }

.icon-question-sign::before { content: "=EF=81=99"; }

.icon-info-sign::before { content: "=EF=81=9A"; }

.icon-screenshot::before { content: "=EF=81=9B"; }

.icon-remove-circle::before { content: "=EF=81=9C"; }

.icon-ok-circle::before { content: "=EF=81=9D"; }

.icon-ban-circle::before { content: "=EF=81=9E"; }

.icon-arrow-left::before { content: "=EF=81=A0"; }

.icon-arrow-right::before { content: "=EF=81=A1"; }

.icon-arrow-up::before { content: "=EF=81=A2"; }

.icon-arrow-down::before { content: "=EF=81=A3"; }

.icon-share-alt::before { content: "=EF=81=A4"; }

.icon-resize-full::before { content: "=EF=81=A5"; }

.icon-resize-small::before { content: "=EF=81=A6"; }

.icon-plus::before { content: "=EF=81=A7"; }

.icon-minus::before { content: "=EF=81=A8"; }

.icon-asterisk::before { content: "=EF=81=A9"; }

.icon-exclamation-sign::before { content: "=EF=81=AA"; }

.icon-gift::before { content: "=EF=81=AB"; }

.icon-leaf::before { content: "=EF=81=AC"; }

.icon-fire::before { content: "=EF=81=AD"; }

.icon-eye-open::before { content: "=EF=81=AE"; }

.icon-eye-close::before { content: "=EF=81=B0"; }

.icon-warning-sign::before { content: "=EF=81=B1"; }

.icon-plane::before { content: "=EF=81=B2"; }

.icon-calendar::before { content: "=EF=81=B3"; }

.icon-random::before { content: "=EF=81=B4"; }

.icon-comment::before { content: "=EF=81=B5"; }

.icon-magnet::before { content: "=EF=81=B6"; }

.icon-chevron-up::before { content: "=EF=81=B7"; }

.icon-chevron-down::before { content: "=EF=81=B8"; }

.icon-retweet::before { content: "=EF=81=B9"; }

.icon-shopping-cart::before { content: "=EF=81=BA"; }

.icon-folder-close::before { content: "=EF=81=BB"; }

.icon-folder-open::before { content: "=EF=81=BC"; }

.icon-resize-vertical::before { content: "=EF=81=BD"; }

.icon-resize-horizontal::before { content: "=EF=81=BE"; }

.icon-bar-chart::before { content: "=EF=82=80"; }

.icon-twitter-sign::before { content: "=EF=82=81"; }

.icon-facebook-sign::before { content: "=EF=82=82"; }

.icon-camera-retro::before { content: "=EF=82=83"; }

.icon-key::before { content: "=EF=82=84"; }

.icon-cogs::before { content: "=EF=82=85"; }

.icon-comments::before { content: "=EF=82=86"; }

.icon-thumbs-up::before { content: "=EF=82=87"; }

.icon-thumbs-down::before { content: "=EF=82=88"; }

.icon-star-half::before { content: "=EF=82=89"; }

.icon-heart-empty::before { content: "=EF=82=8A"; }

.icon-signout::before { content: "=EF=82=8B"; }

.icon-linkedin-sign::before { content: "=EF=82=8C"; }

.icon-pushpin::before { content: "=EF=82=8D"; }

.icon-external-link::before { content: "=EF=82=8E"; }

.icon-signin::before { content: "=EF=82=90"; }

.icon-trophy::before { content: "=EF=82=91"; }

.icon-github-sign::before { content: "=EF=82=92"; }

.icon-upload-alt::before { content: "=EF=82=93"; }

.icon-lemon::before { content: "=EF=82=94"; }

.icon-phone::before { content: "=EF=82=95"; }

.icon-check-empty::before { content: "=EF=82=96"; }

.icon-bookmark-empty::before { content: "=EF=82=97"; }

.icon-phone-sign::before { content: "=EF=82=98"; }

.icon-twitter::before { content: "=EF=82=99"; }

.icon-facebook::before { content: "=EF=82=9A"; }

.icon-github::before { content: "=EF=82=9B"; }

.icon-unlock::before { content: "=EF=82=9C"; }

.icon-credit-card::before { content: "=EF=82=9D"; }

.icon-rss::before { content: "=EF=82=9E"; }

.icon-hdd::before { content: "=EF=82=A0"; }

.icon-bullhorn::before { content: "=EF=82=A1"; }

.icon-bell::before { content: "=EF=82=A2"; }

.icon-certificate::before { content: "=EF=82=A3"; }

.icon-hand-right::before { content: "=EF=82=A4"; }

.icon-hand-left::before { content: "=EF=82=A5"; }

.icon-hand-up::before { content: "=EF=82=A6"; }

.icon-hand-down::before { content: "=EF=82=A7"; }

.icon-circle-arrow-left::before { content: "=EF=82=A8"; }

.icon-circle-arrow-right::before { content: "=EF=82=A9"; }

.icon-circle-arrow-up::before { content: "=EF=82=AA"; }

.icon-circle-arrow-down::before { content: "=EF=82=AB"; }

.icon-globe::before { content: "=EF=82=AC"; }

.icon-wrench::before { content: "=EF=82=AD"; }

.icon-tasks::before { content: "=EF=82=AE"; }

.icon-filter::before { content: "=EF=82=B0"; }

.icon-briefcase::before { content: "=EF=82=B1"; }

.icon-fullscreen::before { content: "=EF=82=B2"; }

.icon-group::before { content: "=EF=83=80"; }

.icon-link::before { content: "=EF=83=81"; }

.icon-cloud::before { content: "=EF=83=82"; }

.icon-beaker::before { content: "=EF=83=83"; }

.icon-cut::before { content: "=EF=83=84"; }

.icon-copy::before { content: "=EF=83=85"; }

.icon-paper-clip::before { content: "=EF=83=86"; }

.icon-save::before { content: "=EF=83=87"; }

.icon-sign-blank::before { content: "=EF=83=88"; }

.icon-reorder::before { content: "=EF=83=89"; }

.icon-list-ul::before { content: "=EF=83=8A"; }

.icon-list-ol::before { content: "=EF=83=8B"; }

.icon-strikethrough::before { content: "=EF=83=8C"; }

.icon-underline::before { content: "=EF=83=8D"; }

.icon-table::before { content: "=EF=83=8E"; }

.icon-magic::before { content: "=EF=83=90"; }

.icon-truck::before { content: "=EF=83=91"; }

.icon-pinterest::before { content: "=EF=83=92"; }

.icon-pinterest-sign::before { content: "=EF=83=93"; }

.icon-google-plus-sign::before { content: "=EF=83=94"; }

.icon-google-plus::before { content: "=EF=83=95"; }

.icon-money::before { content: "=EF=83=96"; }

.icon-caret-down::before { content: "=EF=83=97"; }

.icon-caret-up::before { content: "=EF=83=98"; }

.icon-caret-left::before { content: "=EF=83=99"; }

.icon-caret-right::before { content: "=EF=83=9A"; }

.icon-columns::before { content: "=EF=83=9B"; }

.icon-sort::before { content: "=EF=83=9C"; }

.icon-sort-down::before { content: "=EF=83=9D"; }

.icon-sort-up::before { content: "=EF=83=9E"; }

.icon-envelope-alt::before { content: "=EF=83=A0"; }

.icon-linkedin::before { content: "=EF=83=A1"; }

.icon-undo::before { content: "=EF=83=A2"; }

.icon-legal::before { content: "=EF=83=A3"; }

.icon-dashboard::before { content: "=EF=83=A4"; }

.icon-comment-alt::before { content: "=EF=83=A5"; }

.icon-comments-alt::before { content: "=EF=83=A6"; }

.icon-bolt::before { content: "=EF=83=A7"; }

.icon-sitemap::before { content: "=EF=83=A8"; }

.icon-umbrella::before { content: "=EF=83=A9"; }

.icon-paste::before { content: "=EF=83=AA"; }

.icon-user-md::before { content: "=EF=88=80"; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/bootstrap.css

@charset "utf-8";

article, aside, details, figcaption, figure, footer, header, hgroup, nav, s=
ection { display: block; }

audio, canvas, video { display: inline-block; }

audio:not([controls]) { display: none; }

html { font-size: 100%; text-size-adjust: 100%; }

a:focus { outline: -webkit-focus-ring-color auto 5px; outline-offset: -2px;=
 }

a:hover, a:active { outline: 0px; }

sub, sup { position: relative; font-size: 75%; line-height: 0; vertical-ali=
gn: baseline; }

sup { top: -0.5em; }

sub { bottom: -0.25em; }

img { height: auto; border: 0px; vertical-align: middle; }

button, input, select, textarea { margin: 0px; font-size: 100%; vertical-al=
ign: middle; }

button, input { line-height: normal; }

button, input[type=3D"button"], input[type=3D"reset"], input[type=3D"submit=
"] { cursor: pointer; appearance: button; }

input[type=3D"search"] { appearance: textfield; box-sizing: content-box; }

input[type=3D"search"]::-webkit-search-decoration, input[type=3D"search"]::=
-webkit-search-cancel-button { appearance: none; }

textarea { overflow: auto; vertical-align: top; }

html, body, div, span, object, iframe, h1, h2, h3, h4, h5, h6, p, blockquot=
e, pre, abbr, address, cite, code, del, dfn, em, img, ins, kbd, q, samp, sm=
all, strong, sub, sup, var, b, i, dl, dt, dd, ol, ul, li, fieldset, form, l=
abel, legend, table, caption, tbody, tfoot, thead, tr, th, td, article, asi=
de, canvas, details, figcaption, figure, footer, header, hgroup, menu, nav,=
 section, summary, time, mark, audio, video { margin: 0px; border: 0px; fon=
t-size: 100%; vertical-align: baseline; }

article, aside, details, figcaption, figure, footer, header, hgroup, menu, =
nav, section { display: block; }

::selection { background: rgb(255, 255, 255); color: rgb(0, 0, 0); text-sha=
dow: none; }

a:link { }

.clearfix { }

.clearfix::before, .clearfix::after { display: table; content: ""; }

.clearfix::after { clear: both; }

.hide-text { overflow: hidden; text-indent: 100%; white-space: nowrap; }

.input-block-level { display: block; width: 100%; min-height: 28px; box-siz=
ing: border-box; }

body { margin: 0px; font-family: "Helvetica Neue", Helvetica, Arial, sans-s=
erif; font-size: 100%; font-weight: 400; line-height: 1.25em; color: rgb(11=
5, 115, 115); background-color: rgb(255, 255, 255); }

a { text-decoration: none; font-size: inherit; outline: none; }

a:hover { text-decoration: none; }

.row { margin-left: -20px; }

.row::before, .row::after { display: table; content: ""; }

.row::after { clear: both; }

.row::before, .row::after { display: table; content: ""; }

.row::after { clear: both; }

[class*=3D"span"] { float: left; margin-left: 20px; }

.container, .navbar-fixed-top .container, .navbar-fixed-bottom .container {=
 width: 940px; }

.span12 { width: 940px; }

.span11 { width: 860px; }

.span10 { width: 780px; }

.span9 { width: 700px; }

.span8 { width: 620px; }

.span7 { width: 540px; }

.span6 { width: 460px; }

.span5 { width: 380px; }

.span4 { width: 300px; }

.span3 { width: 220px; }

.span2 { width: 140px; }

.span1 { width: 60px; }

.offset12 { margin-left: 980px; }

.offset11 { margin-left: 900px; }

.offset10 { margin-left: 820px; }

.offset9 { margin-left: 740px; }

.offset8 { margin-left: 660px; }

.offset7 { margin-left: 580px; }

.offset6 { margin-left: 500px; }

.offset5 { margin-left: 420px; }

.offset4 { margin-left: 340px; }

.offset3 { margin-left: 260px; }

.offset2 { margin-left: 180px; }

.offset1 { margin-left: 100px; }

.row { margin-left: -20px; }

.row::before, .row::after { display: table; content: ""; }

.row::after { clear: both; }

.row::before, .row::after { display: table; content: ""; }

.row::after { clear: both; }

[class*=3D"span"] { float: left; margin-left: 20px; }

.container, .navbar-fixed-top .container, .navbar-fixed-bottom .container {=
 width: 940px; }

.span12 { width: 940px; }

.span11 { width: 860px; }

.span10 { width: 780px; }

.span9 { width: 700px; }

.span8 { width: 620px; }

.span7 { width: 540px; }

.span6 { width: 460px; }

.span5 { width: 380px; }

.span4 { width: 300px; }

.span3 { width: 300px; }

.span2 { width: 140px; }

.span1 { width: 60px; }

.offset12 { margin-left: 980px; }

.offset11 { margin-left: 900px; }

.offset10 { margin-left: 820px; }

.offset9 { margin-left: 740px; }

.offset8 { margin-left: 660px; }

.offset7 { margin-left: 580px; }

.offset6 { margin-left: 500px; }

.offset5 { margin-left: 420px; }

.offset4 { margin-left: 340px; }

.offset3 { margin-left: 260px; }

.offset2 { margin-left: 180px; }

.offset1 { margin-left: 100px; }

.row-fluid { width: 100%; }

.row-fluid::before, .row-fluid::after { display: table; content: ""; }

.row-fluid::after { clear: both; }

.row-fluid::before, .row-fluid::after { display: table; content: ""; }

.row-fluid::after { clear: both; }

.row-fluid > [class*=3D"span"] { float: left; margin-left: 2.12766%; }

.row-fluid > [class*=3D"span"]:first-child { margin-left: 0px; }

.row-fluid > .span12 { width: 100%; }

.row-fluid > .span11 { width: 91.4894%; }

.row-fluid > .span10 { width: 82.9787%; }

.row-fluid > .span9 { width: 74.4681%; }

.row-fluid > .span8 { width: 65.9574%; }

.row-fluid > .span7 { width: 57.4468%; }

.row-fluid > .span6 { width: 48.9362%; }

.row-fluid > .span5 { width: 40.4255%; }

.row-fluid > .span4 { width: 31.9149%; }

.row-fluid > .span3 { width: 23.4043%; }

.row-fluid > .span2 { width: 14.8936%; }

.row-fluid > .span1 { width: 6.38298%; }

.row-fluid { width: 100%; }

.row-fluid::before, .row-fluid::after { display: table; content: ""; }

.row-fluid::after { clear: both; }

.row-fluid::before, .row-fluid::after { display: table; content: ""; }

.row-fluid::after { clear: both; }

.row-fluid > [class*=3D"span"] { float: left; margin-left: 2.12766%; }

.row-fluid > [class*=3D"span"]:first-child { margin-left: 0px; }

.row-fluid > .span12 { width: 100%; }

.row-fluid > .span11 { width: 91.4894%; }

.row-fluid > .span10 { width: 82.9787%; }

.row-fluid > .span9 { width: 74.4681%; }

.row-fluid > .span8 { width: 65.9574%; }

.row-fluid > .span7 { width: 57.4468%; }

.row-fluid > .span6 { width: 48.9362%; }

.row-fluid > .span5 { width: 40.4255%; }

.row-fluid > .span4 { width: 31.9149%; }

.row-fluid > .span3 { width: 23.4043%; }

.row-fluid > .span2 { width: 14.8936%; }

.row-fluid > .span1 { width: 6.38298%; }

.container { margin-left: auto; margin-right: auto; }

.container::before, .container::after { display: table; content: ""; }

.container::after { clear: both; }

.container::before, .container::after { display: table; content: ""; }

.container::after { clear: both; }

.container::before, .container::after { display: table; content: ""; }

.container::after { clear: both; }

.container::before, .container::after { display: table; content: ""; }

.container::after { clear: both; }

.container-fluid { padding-left: 20px; padding-right: 20px; }

.container-fluid::before, .container-fluid::after { display: table; content=
: ""; }

.container-fluid::after { clear: both; }

.container-fluid::before, .container-fluid::after { display: table; content=
: ""; }

.container-fluid::after { clear: both; }

p { margin: 0px 0px 0.625em; font-family: "Helvetica Neue", Helvetica, Aria=
l, sans-serif; font-size: 0.8125em; line-height: 1.75em; }

p small { color: rgb(153, 153, 153); }

.alert { font-size: 0.8125em; }

.lead { margin-bottom: 1.25em; font-size: 20px; font-weight: 200; line-heig=
ht: 1.875em; }

h1, h2, h3, h4, h5, h6 { margin: 0px 0px 0.6em; font-weight: normal; text-r=
endering: optimizelegibility; }

h1 small, h2 small, h3 small, h4 small, h5 small, h6 small { font-weight: n=
ormal; color: rgb(153, 153, 153); }

h1 { font-size: 3em; line-height: 1.25em; }

h1 small { font-size: 0.6em; }

h2 { font-size: 1.75em; line-height: 1.25em; }

h2 small { font-size: 0.75em; }

h3 { line-height: 1.25em; font-size: 1.475em; }

h3 small { font-size: 0.777778em; }

h4, h5, h6 { line-height: 1.25em; }

h4 { font-size: 0.9375em; }

h4 small { font-size: 0.8em; }

h5 { font-size: 12px; }

h6 { font-size: 11px; color: rgb(153, 153, 153); text-transform: uppercase;=
 }

.page-header { padding-bottom: 0.25em; margin: 1.25em 0px; border-bottom: 1=
px solid rgb(238, 238, 238); }

.page-header h1 { line-height: 1; }

ul, ol { padding: 0px; margin: 0px 0px 0.625em 25px; }

ul ul, ul ol, ol ol, ol ul { margin-bottom: 0px; }

ul { list-style: disc; }

ol { list-style: decimal; }

li { line-height: 1.25em; }

ul.unstyled, ol.unstyled { margin-left: 0px; list-style: none; }

dl { margin-bottom: 1.25em; }

dt, dd { line-height: 1.25em; }

dt { font-weight: bold; line-height: 0.25em; }

dd { margin-left: 0.625em; }

.dl-horizontal dt { float: left; clear: left; width: 120px; text-align: rig=
ht; }

.dl-horizontal dd { margin-left: 130px; }

hr { margin: 3em 0px; border-width: 1px 0px; border-right-style: initial; b=
order-left-style: initial; border-right-color: initial; border-left-color: =
initial; border-image: initial; border-top-style: solid; border-top-color: =
rgb(238, 238, 238); border-bottom-style: solid; border-bottom-color: rgb(25=
5, 255, 255); }

strong { font-weight: bold; }

em { font-style: normal; }

.muted { color: rgb(153, 153, 153); }

abbr[title] { border-bottom: 1px dotted rgb(221, 221, 221); cursor: help; }

abbr.initialism { font-size: 90%; text-transform: uppercase; }

blockquote { padding: 0px 0px 0px 15px; margin: 0px 0px 1.25em; border-left=
: 5px solid rgb(238, 238, 238); }

blockquote p { margin-bottom: 0px; font-size: 16px; font-weight: 300; line-=
height: 1.5625em; }

blockquote small { display: block; line-height: 1.25em; color: rgb(153, 153=
, 153); }

blockquote small::before { content: "=E2=80=94=C2=A0"; }

blockquote.pull-right { float: right; padding-left: 0px; padding-right: 15p=
x; border-left: 0px; border-right: 5px solid rgb(238, 238, 238); }

blockquote.pull-right p, blockquote.pull-right small { text-align: right; }

q::before, q::after, blockquote::before, blockquote::after { content: ""; }

address { display: block; margin-left: 240px; margin-bottom: 1.25em; line-h=
eight: 1.25em; font-style: normal; }

small { font-size: 100%; }

cite { font-style: normal; }

code, pre { padding: 0px 3px 2px; font-family: Menlo, Monaco, "Courier New"=
, monospace; color: rgb(115, 115, 115); border-radius: 3px; }

code { padding: 2px 4px; color: rgb(221, 17, 68); background-color: rgb(247=
, 247, 249); border: 1px solid rgb(225, 225, 232); }

pre { display: block; padding: 0.125em; margin: 0px 0px 0.625em; font-size:=
 0.751563em; line-height: 1.25em; background-color: rgb(245, 245, 245); bor=
der: 1px solid rgba(0, 0, 0, 0.15); border-radius: 4px; white-space: pre-wr=
ap; word-break: break-all; overflow-wrap: break-word; }

pre.prettyprint { margin-bottom: 1.25em; }

pre code { padding: 0px; color: inherit; background-color: transparent; bor=
der: 0px; }

.pre-scrollable { max-height: 340px; overflow-y: scroll; }

form { margin: 0px 0px 1.25em; }

fieldset { padding: 0px; margin: 0px; border: 0px; }

legend { display: block; width: 100%; padding: 0px; margin-bottom: 1.875em;=
 font-size: 1.21875em; line-height: 2.5em; color: rgb(115, 115, 115); borde=
r-width: 0px 0px 1px; border-top-style: initial; border-right-style: initia=
l; border-left-style: initial; border-top-color: initial; border-right-colo=
r: initial; border-left-color: initial; border-image: initial; border-botto=
m-style: solid; border-bottom-color: rgb(238, 238, 238); }

legend small { font-size: 0.9375em; color: rgb(153, 153, 153); }

label, input, button, select, textarea { line-height: 1.25em; }

input, button, select, textarea { font-family: "Helvetica Neue", Helvetica,=
 Arial, sans-serif; }

label { display: block; margin-bottom: 5px; color: rgb(115, 115, 115); }

input, textarea, select, .uneditable-input { display: inline-block; width: =
210px; height: 1.25em; padding: 4px; margin-bottom: 9px; font-size: 0.8125e=
m; line-height: 1.25em; color: rgb(85, 85, 85); border: 1px solid rgb(204, =
204, 204); border-radius: 3px; }

.uneditable-textarea { width: auto; height: auto; }

label input, label textarea, label select { display: block; }

input[type=3D"image"], input[type=3D"checkbox"], input[type=3D"radio"] { wi=
dth: auto; height: auto; padding: 0px; margin: 3px 0px; line-height: normal=
; cursor: pointer; border-radius: 0px; }

input[type=3D"image"] { border: 0px; }

input[type=3D"file"] { width: auto; padding: initial; line-height: initial;=
 border: initial; background-color: initial; box-shadow: none; }

input[type=3D"button"], input[type=3D"reset"], input[type=3D"submit"] { wid=
th: auto; height: auto; }

select, input[type=3D"file"] { height: 28px; line-height: 28px; }

input[type=3D"file"] { }

select { width: 220px; background-color: rgb(255, 255, 255); }

select[multiple], select[size] { height: auto; }

input[type=3D"image"] { box-shadow: none; }

textarea { height: auto; }

input[type=3D"hidden"] { display: none; }

.radio, .checkbox { padding-left: 18px; }

.radio input[type=3D"radio"], .checkbox input[type=3D"checkbox"] { float: l=
eft; margin-left: -18px; }

.controls > .radio:first-child, .controls > .checkbox:first-child { padding=
-top: 5px; }

.radio.inline, .checkbox.inline { display: inline-block; padding-top: 5px; =
margin-bottom: 0px; vertical-align: middle; }

.radio.inline + .radio.inline, .checkbox.inline + .checkbox.inline { margin=
-left: 10px; }

input, textarea { box-shadow: rgba(0, 0, 0, 0.075) 0px 1px 1px inset; trans=
ition: border 0.2s linear, box-shadow 0.2s linear; }

input:focus, textarea:focus { border-color: rgba(82, 168, 236, 0.8); box-sh=
adow: rgba(0, 0, 0, 0.075) 0px 1px 1px inset, rgba(82, 168, 236, 0.6) 0px 0=
px 8px; outline: 0px; }

input[type=3D"file"]:focus, input[type=3D"radio"]:focus, input[type=3D"chec=
kbox"]:focus, select:focus { box-shadow: none; outline: -webkit-focus-ring-=
color auto 5px; outline-offset: -2px; }

.input-mini { width: 60px; }

.input-small { width: 90px; }

.input-medium { width: 150px; }

.input-large { width: 210px; }

.input-xlarge { width: 270px; }

.input-xxlarge { width: 530px; }

input[class*=3D"span"], select[class*=3D"span"], textarea[class*=3D"span"],=
 .uneditable-input { float: none; margin-left: 0px; }

input, textarea, .uneditable-input { margin-left: 0px; }

input.span12, textarea.span12, .uneditable-input.span12 { width: 930px; }

input.span11, textarea.span11, .uneditable-input.span11 { width: 850px; }

input.span10, textarea.span10, .uneditable-input.span10 { width: 770px; }

input.span9, textarea.span9, .uneditable-input.span9 { width: 690px; }

input.span8, textarea.span8, .uneditable-input.span8 { width: 610px; }

input.span7, textarea.span7, .uneditable-input.span7 { width: 530px; }

input.span6, textarea.span6, .uneditable-input.span6 { width: 450px; }

input.span5, textarea.span5, .uneditable-input.span5 { width: 370px; }

input.span4, textarea.span4, .uneditable-input.span4 { width: 290px; }

input.span3, textarea.span3, .uneditable-input.span3 { width: 210px; }

input.span2, textarea.span2, .uneditable-input.span2 { width: 130px; }

input.span1, textarea.span1, .uneditable-input.span1 { width: 50px; }

input, textarea, .uneditable-input { margin-left: 0px; }

input.span12, textarea.span12, .uneditable-input.span12 { width: 930px; }

input.span11, textarea.span11, .uneditable-input.span11 { width: 850px; }

input.span10, textarea.span10, .uneditable-input.span10 { width: 770px; }

input.span9, textarea.span9, .uneditable-input.span9 { width: 690px; }

input.span8, textarea.span8, .uneditable-input.span8 { width: 610px; }

input.span7, textarea.span7, .uneditable-input.span7 { width: 530px; }

input.span6, textarea.span6, .uneditable-input.span6 { width: 450px; }

input.span5, textarea.span5, .uneditable-input.span5 { width: 370px; }

input.span4, textarea.span4, .uneditable-input.span4 { width: 290px; }

input.span3, textarea.span3, .uneditable-input.span3 { width: 210px; }

input.span2, textarea.span2, .uneditable-input.span2 { width: 130px; }

input.span1, textarea.span1, .uneditable-input.span1 { width: 50px; }

input[disabled], select[disabled], textarea[disabled], input[readonly], sel=
ect[readonly], textarea[readonly] { background-color: rgb(238, 238, 238); b=
order-color: rgb(221, 221, 221); cursor: not-allowed; }

.control-group.warning > label, .control-group.warning .help-block, .contro=
l-group.warning .help-inline { color: rgb(192, 152, 83); }

.control-group.warning input, .control-group.warning select, .control-group=
.warning textarea { color: rgb(192, 152, 83); border-color: rgb(192, 152, 8=
3); }

.control-group.warning input:focus, .control-group.warning select:focus, .c=
ontrol-group.warning textarea:focus { border-color: rgb(164, 126, 60); box-=
shadow: rgb(219, 197, 158) 0px 0px 6px; }

.control-group.warning .input-prepend .add-on, .control-group.warning .inpu=
t-append .add-on { color: rgb(192, 152, 83); background-color: rgb(252, 248=
, 227); border-color: rgb(192, 152, 83); }

.control-group.warning > label, .control-group.warning .help-block, .contro=
l-group.warning .help-inline { color: rgb(192, 152, 83); }

.control-group.warning input, .control-group.warning select, .control-group=
.warning textarea { color: rgb(192, 152, 83); border-color: rgb(192, 152, 8=
3); }

.control-group.warning input:focus, .control-group.warning select:focus, .c=
ontrol-group.warning textarea:focus { border-color: rgb(164, 126, 60); box-=
shadow: rgb(219, 197, 158) 0px 0px 6px; }

.control-group.warning .input-prepend .add-on, .control-group.warning .inpu=
t-append .add-on { color: rgb(192, 152, 83); background-color: rgb(252, 248=
, 227); border-color: rgb(192, 152, 83); }

.control-group.error > label, .control-group.error .help-block, .control-gr=
oup.error .help-inline { color: rgb(185, 74, 72); }

.control-group.error input, .control-group.error select, .control-group.err=
or textarea { color: rgb(185, 74, 72); border-color: rgb(185, 74, 72); }

.control-group.error input:focus, .control-group.error select:focus, .contr=
ol-group.error textarea:focus { border-color: rgb(149, 59, 57); box-shadow:=
 rgb(213, 147, 146) 0px 0px 6px; }

.control-group.error .input-prepend .add-on, .control-group.error .input-ap=
pend .add-on { color: rgb(185, 74, 72); background-color: rgb(242, 222, 222=
); border-color: rgb(185, 74, 72); }

.control-group.error > label, .control-group.error .help-block, .control-gr=
oup.error .help-inline { color: rgb(185, 74, 72); }

.control-group.error input, .control-group.error select, .control-group.err=
or textarea { color: rgb(185, 74, 72); border-color: rgb(185, 74, 72); }

.control-group.error input:focus, .control-group.error select:focus, .contr=
ol-group.error textarea:focus { border-color: rgb(149, 59, 57); box-shadow:=
 rgb(213, 147, 146) 0px 0px 6px; }

.control-group.error .input-prepend .add-on, .control-group.error .input-ap=
pend .add-on { color: rgb(185, 74, 72); background-color: rgb(242, 222, 222=
); border-color: rgb(185, 74, 72); }

.control-group.success > label, .control-group.success .help-block, .contro=
l-group.success .help-inline { color: rgb(70, 136, 71); }

.control-group.success input, .control-group.success select, .control-group=
.success textarea { color: rgb(70, 136, 71); border-color: rgb(70, 136, 71)=
; }

.control-group.success input:focus, .control-group.success select:focus, .c=
ontrol-group.success textarea:focus { border-color: rgb(53, 102, 53); box-s=
hadow: rgb(122, 186, 123) 0px 0px 6px; }

.control-group.success .input-prepend .add-on, .control-group.success .inpu=
t-append .add-on { color: rgb(70, 136, 71); background-color: rgb(223, 240,=
 216); border-color: rgb(70, 136, 71); }

.control-group.success > label, .control-group.success .help-block, .contro=
l-group.success .help-inline { color: rgb(70, 136, 71); }

.control-group.success input, .control-group.success select, .control-group=
.success textarea { color: rgb(70, 136, 71); border-color: rgb(70, 136, 71)=
; }

.control-group.success input:focus, .control-group.success select:focus, .c=
ontrol-group.success textarea:focus { border-color: rgb(53, 102, 53); box-s=
hadow: rgb(122, 186, 123) 0px 0px 6px; }

.control-group.success .input-prepend .add-on, .control-group.success .inpu=
t-append .add-on { color: rgb(70, 136, 71); background-color: rgb(223, 240,=
 216); border-color: rgb(70, 136, 71); }

input:focus:required:invalid, textarea:focus:required:invalid, select:focus=
:required:invalid { color: rgb(185, 74, 72); border-color: rgb(238, 95, 91)=
; }

input:focus:required:invalid:focus, textarea:focus:required:invalid:focus, =
select:focus:required:invalid:focus { border-color: rgb(233, 50, 45); box-s=
hadow: rgb(248, 185, 183) 0px 0px 6px; }

.form-actions { padding: 0.25em 20px 1.25em; margin-top: 1.25em; margin-bot=
tom: 1.25em; background-color: rgb(238, 238, 238); border-top: 1px solid rg=
b(221, 221, 221); }

.form-actions::before, .form-actions::after { display: table; content: ""; =
}

.form-actions::after { clear: both; }

.form-actions::before, .form-actions::after { display: table; content: ""; =
}

.form-actions::after { clear: both; }

.uneditable-input { display: block; background-color: rgb(255, 255, 255); b=
order-color: rgb(238, 238, 238); box-shadow: rgba(0, 0, 0, 0.024) 0px 1px 2=
px inset; cursor: not-allowed; }

::-webkit-input-placeholder { color: rgb(153, 153, 153); }

::-webkit-input-placeholder { color: rgb(153, 153, 153); }

.help-block, .help-inline { color: rgb(85, 85, 85); }

.help-block { display: block; margin-bottom: 0.625em; }

.help-inline { display: inline-block; vertical-align: middle; padding-left:=
 5px; }

.input-prepend, .input-append { margin-bottom: 5px; }

.input-prepend input, .input-append input, .input-prepend select, .input-ap=
pend select, .input-prepend .uneditable-input, .input-append .uneditable-in=
put { border-radius: 0px 3px 3px 0px; }

.input-prepend input:focus, .input-append input:focus, .input-prepend selec=
t:focus, .input-append select:focus, .input-prepend .uneditable-input:focus=
, .input-append .uneditable-input:focus { position: relative; z-index: 2; }

.input-prepend .uneditable-input, .input-append .uneditable-input { border-=
left-color: rgb(204, 204, 204); }

.input-prepend .add-on, .input-append .add-on { display: inline-block; widt=
h: auto; min-width: 16px; height: 1.25em; padding: 10px; font-weight: norma=
l; line-height: 1.25em; text-align: center; text-shadow: rgb(255, 255, 255)=
 0px 1px 0px; vertical-align: middle; background-color: rgb(238, 238, 238);=
 border: 1px solid rgb(204, 204, 204); }

.input-prepend .add-on, .input-append .add-on, .input-prepend .btn, .input-=
append .btn { border-radius: 3px 0px 0px 3px; }

.input-prepend .active, .input-append .active { background-color: rgb(169, =
219, 169); border-color: rgb(70, 165, 70); }

.input-prepend .add-on, .input-prepend .btn { margin-right: -1px; }

.input-append input, .input-append select .uneditable-input { border-radius=
: 3px 0px 0px 3px; }

.input-append .uneditable-input { border-left-color: rgb(238, 238, 238); bo=
rder-right-color: rgb(204, 204, 204); }

.input-append .add-on, .input-append .btn { margin-left: -1px; border-radiu=
s: 0px 3px 3px 0px; }

.input-prepend.input-append input, .input-prepend.input-append select, .inp=
ut-prepend.input-append .uneditable-input { border-radius: 0px; }

.input-prepend.input-append .add-on:first-child, .input-prepend.input-appen=
d .btn:first-child { margin-right: -1px; border-radius: 3px 0px 0px 3px; }

.input-prepend.input-append .add-on:last-child, .input-prepend.input-append=
 .btn:last-child { margin-left: -1px; border-radius: 0px 3px 3px 0px; }

.search-query { padding-left: 14px; padding-right: 14px; margin-bottom: 0px=
; border-radius: 14px; }

.form-search input, .form-inline input, .form-horizontal input, .form-searc=
h textarea, .form-inline textarea, .form-horizontal textarea, .form-search =
select, .form-inline select, .form-horizontal select, .form-search .help-in=
line, .form-inline .help-inline, .form-horizontal .help-inline, .form-searc=
h .uneditable-input, .form-inline .uneditable-input, .form-horizontal .uned=
itable-input, .form-search .input-prepend, .form-inline .input-prepend, .fo=
rm-horizontal .input-prepend, .form-search .input-append, .form-inline .inp=
ut-append, .form-horizontal .input-append { display: inline-block; margin-b=
ottom: 0px; }

.form-search .hide, .form-inline .hide, .form-horizontal .hide { display: n=
one; }

.form-search label, .form-inline label { display: inline-block; }

.form-search .input-append, .form-inline .input-append, .form-search .input=
-prepend, .form-inline .input-prepend { margin-bottom: 0px; }

.form-search .radio, .form-search .checkbox, .form-inline .radio, .form-inl=
ine .checkbox { padding-left: 0px; margin-bottom: 0px; vertical-align: midd=
le; }

.form-search .radio input[type=3D"radio"], .form-search .checkbox input[typ=
e=3D"checkbox"], .form-inline .radio input[type=3D"radio"], .form-inline .c=
heckbox input[type=3D"checkbox"] { float: left; margin-left: 0px; margin-ri=
ght: 3px; }

.control-group { margin-bottom: 0.625em; }

legend + .control-group { margin-top: 1.25em; }

.form-horizontal .control-group { margin-bottom: 1.25em; }

.form-horizontal .control-group::before, .form-horizontal .control-group::a=
fter { display: table; content: ""; }

.form-horizontal .control-group::after { clear: both; }

.form-horizontal .control-group::before, .form-horizontal .control-group::a=
fter { display: table; content: ""; }

.form-horizontal .control-group::after { clear: both; }

.form-horizontal .control-label { float: left; width: 140px; padding-top: 5=
px; text-align: right; }

.form-horizontal .controls { margin-left: 160px; }

.form-horizontal .help-block { margin-top: 0.625em; margin-bottom: 0px; }

.form-horizontal .form-actions { padding-left: 160px; }

table { max-width: 100%; border-collapse: collapse; border-spacing: 0px; ba=
ckground-color: transparent; }

.table { width: 100%; margin-bottom: 1.25em; }

.table th, .table td { padding: 8px; line-height: 1.25em; text-align: left;=
 vertical-align: top; border-top: 1px solid rgb(221, 221, 221); }

.table th { font-weight: bold; }

.table thead th { vertical-align: bottom; }

.table colgroup + thead tr:first-child th, .table colgroup + thead tr:first=
-child td, .table thead:first-child tr:first-child th, .table thead:first-c=
hild tr:first-child td { border-top: 0px; }

.table tbody + tbody { border-top: 2px solid rgb(221, 221, 221); }

.table-condensed th, .table-condensed td { padding: 4px 5px; }

.table-bordered { border-width: 1px 1px 1px 0px; border-top-style: solid; b=
order-right-style: solid; border-bottom-style: solid; border-top-color: rgb=
(221, 221, 221); border-right-color: rgb(221, 221, 221); border-bottom-colo=
r: rgb(221, 221, 221); border-image: initial; border-left-style: initial; b=
order-left-color: initial; border-collapse: separate; border-radius: 4px; }

.table-bordered th, .table-bordered td { border-left: 1px solid rgb(221, 22=
1, 221); }

.table-bordered thead:first-child tr:first-child th, .table-bordered tbody:=
first-child tr:first-child th, .table-bordered tbody:first-child tr:first-c=
hild td { border-top: 0px; }

.table-bordered thead:first-child tr:first-child th:first-child, .table-bor=
dered tbody:first-child tr:first-child td:first-child { border-radius: 4px =
0px 0px; }

.table-bordered thead:first-child tr:first-child th:last-child, .table-bord=
ered tbody:first-child tr:first-child td:last-child { border-radius: 0px 4p=
x 0px 0px; }

.table-bordered thead:last-child tr:last-child th:first-child, .table-borde=
red tbody:last-child tr:last-child td:first-child { border-radius: 0px 0px =
0px 4px; }

.table-bordered thead:last-child tr:last-child th:last-child, .table-border=
ed tbody:last-child tr:last-child td:last-child { border-radius: 0px 0px 4p=
x; }

.table-striped tbody tr:nth-child(2n+1) td, .table-striped tbody tr:nth-chi=
ld(2n+1) th { background-color: rgb(249, 249, 249); }

.table tbody tr:hover td, .table tbody tr:hover th { background-color: rgb(=
245, 245, 245); }

table .span1 { float: none; width: 44px; margin-left: 0px; }

table .span2 { float: none; width: 124px; margin-left: 0px; }

table .span3 { float: none; width: 204px; margin-left: 0px; }

table .span4 { float: none; width: 284px; margin-left: 0px; }

table .span5 { float: none; width: 364px; margin-left: 0px; }

table .span6 { float: none; width: 444px; margin-left: 0px; }

table .span7 { float: none; width: 524px; margin-left: 0px; }

table .span8 { float: none; width: 604px; margin-left: 0px; }

table .span9 { float: none; width: 684px; margin-left: 0px; }

table .span10 { float: none; width: 764px; margin-left: 0px; }

table .span11 { float: none; width: 844px; margin-left: 0px; }

table .span12 { float: none; width: 924px; margin-left: 0px; }

table .span13 { float: none; width: 1004px; margin-left: 0px; }

table .span14 { float: none; width: 1084px; margin-left: 0px; }

table .span15 { float: none; width: 1164px; margin-left: 0px; }

table .span16 { float: none; width: 1244px; margin-left: 0px; }

table .span17 { float: none; width: 1324px; margin-left: 0px; }

table .span18 { float: none; width: 1404px; margin-left: 0px; }

table .span19 { float: none; width: 1484px; margin-left: 0px; }

table .span20 { float: none; width: 1564px; margin-left: 0px; }

table .span21 { float: none; width: 1644px; margin-left: 0px; }

table .span22 { float: none; width: 1724px; margin-left: 0px; }

table .span23 { float: none; width: 1804px; margin-left: 0px; }

table .span24 { float: none; width: 1884px; margin-left: 0px; }

.dropdown { position: relative; }

.dropdown-toggle { }

.dropdown-toggle:active, .open .dropdown-toggle { outline: 0px; }

.caret { display: inline-block; width: 0px; height: 0px; vertical-align: to=
p; border-left: 4px solid transparent; border-right: 4px solid transparent;=
 border-top: 4px solid rgb(0, 0, 0); opacity: 0.3; content: ""; }

.dropdown .caret { margin-top: 8px; margin-left: 2px; }

.dropdown:hover .caret, .open.dropdown .caret { opacity: 1; }

.dropdown-menu { position: absolute; top: 100%; left: 0px; z-index: 1000; f=
loat: left; display: none; min-width: 160px; padding: 4px 0px; margin: 0px;=
 list-style: none; background-color: rgb(255, 255, 255); border-color: rgba=
(0, 0, 0, 0.2); border-style: solid; border-width: 1px; }

.dropdown-menu.pull-right { right: 0px; left: auto; }

.dropdown-menu .divider { height: 1px; margin: -0.375em 1px; overflow: hidd=
en; background-color: rgb(229, 229, 229); border-bottom: 1px solid rgb(255,=
 255, 255); }

.dropdown-menu a { display: block; padding: 3px 15px; clear: both; font-wei=
ght: normal; line-height: 1.25em; color: rgb(115, 115, 115); white-space: n=
owrap; }

.dropdown-menu li > a:hover, .dropdown-menu .active > a, .dropdown-menu .ac=
tive > a:hover { color: rgb(255, 255, 255); text-decoration: none; backgrou=
nd-color: rgb(255, 153, 0); }

.dropdown.open { }

.dropdown.open .dropdown-toggle { color: rgb(255, 255, 255); background: rg=
ba(0, 0, 0, 0.3); }

.dropdown.open .dropdown-menu { display: block; }

.pull-right .dropdown-menu { left: auto; right: 0px; }

.dropup .caret, .navbar-fixed-bottom .dropdown .caret { border-top: 0px; bo=
rder-bottom: 4px solid rgb(0, 0, 0); content: "=E2=86=91"; }

.dropup .dropdown-menu, .navbar-fixed-bottom .dropdown .dropdown-menu { top=
: auto; bottom: 100%; margin-bottom: 1px; }

.typeahead { margin-top: 2px; border-radius: 4px; }

.well { min-height: 20px; padding: 19px; margin-bottom: 20px; background-co=
lor: rgb(245, 245, 245); border: 1px solid rgba(0, 0, 0, 0.05); border-radi=
us: 4px; box-shadow: rgba(0, 0, 0, 0.05) 0px 1px 1px inset; }

.well blockquote { border-color: rgba(0, 0, 0, 0.15); }

.well-large { padding: 24px; border-radius: 6px; }

.well-small { padding: 9px; border-radius: 3px; }

.fade { transition: opacity 0.15s linear; opacity: 0; }

.fade.in { opacity: 1; }

.collapse { transition: height 0.35s; position: relative; overflow: hidden;=
 height: 0px; }

.collapse.in { height: auto; }

.close { float: right; font-size: 20px; font-weight: bold; line-height: 1.2=
5em; color: rgb(0, 0, 0); text-shadow: rgb(255, 255, 255) 0px 1px 0px; opac=
ity: 0.2; }

.close:hover { color: rgb(0, 0, 0); text-decoration: none; opacity: 0.4; cu=
rsor: pointer; }

.btn { display: inline-block; padding: 4px 10px; margin-bottom: 0px; line-h=
eight: 1.25em; color: rgb(115, 115, 115); text-align: center; text-shadow: =
rgba(255, 255, 255, 0.75) 0px 1px 1px; vertical-align: middle; background-c=
olor: rgb(245, 245, 245); background-image: -webkit-linear-gradient(top, rg=
b(255, 255, 255), rgb(230, 230, 230)); background-repeat: repeat-x; border-=
color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgb(179, 179, 179); border-rad=
ius: 4px; box-shadow: rgba(255, 255, 255, 0.2) 0px 1px 0px inset, rgba(0, 0=
, 0, 0.05) 0px 1px 2px; cursor: pointer; }

.btn:hover, .btn:active, .btn.active, .btn.disabled, .btn[disabled] { backg=
round-color: rgb(230, 230, 230); }

.btn:active, .btn.active { }

.btn:hover, .btn:active, .btn.active, .btn.disabled, .btn[disabled] { backg=
round-color: rgb(230, 230, 230); }

.btn:active, .btn.active { }

.btn:first-child { }

.btn:first-child { }

.btn:hover { color: rgb(115, 115, 115); text-decoration: none; background-c=
olor: rgb(230, 230, 230); background-position: 0px -15px; transition: backg=
round-position 0.1s linear; }

.btn:focus { outline: -webkit-focus-ring-color auto 5px; outline-offset: -2=
px; }

.btn.active, .btn:active { background-image: none; box-shadow: rgba(0, 0, 0=
, 0.15) 0px 2px 4px inset, rgba(0, 0, 0, 0.05) 0px 1px 2px; background-colo=
r: rgb(230, 230, 230); outline: 0px; }

.btn.disabled, .btn[disabled] { cursor: default; background-image: none; ba=
ckground-color: rgb(230, 230, 230); opacity: 0.65; box-shadow: none; }

.btn-large { padding: 9px 14px; font-size: 2.8125em; line-height: normal; b=
order-radius: 5px; }

.btn-large [class^=3D"icon-"] { margin-top: 1px; }

.btn-small { padding: 5px 9px; }

.btn-small [class^=3D"icon-"] { margin-top: -1px; }

.btn-mini { padding: 2px 6px; }

.btn-primary, .btn-primary:hover, .btn-warning, .btn-warning:hover, .btn-da=
nger, .btn-danger:hover, .btn-success, .btn-success:hover, .btn-info, .btn-=
info:hover, .btn-inverse, .btn-inverse:hover { text-shadow: rgba(0, 0, 0, 0=
.25) 0px -1px 0px; color: rgb(255, 255, 255); }

.btn-primary.active, .btn-warning.active, .btn-danger.active, .btn-success.=
active, .btn-info.active, .btn-inverse.active { color: rgba(255, 255, 255, =
0.75); }

.btn-primary { background-color: rgb(0, 116, 204); background-image: -webki=
t-linear-gradient(top, rgb(0, 136, 204), rgb(0, 85, 204)); background-repea=
t: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0, 0,=
 0, 0.25); }

.btn-primary:hover, .btn-primary:active, .btn-primary.active, .btn-primary.=
disabled, .btn-primary[disabled] { background-color: rgb(255, 217, 0); }

.btn-primary:active, .btn-primary.active { }

.btn-primary:hover, .btn-primary:active, .btn-primary.active, .btn-primary.=
disabled, .btn-primary[disabled] { background-color: rgb(0, 85, 204); }

.btn-primary:active, .btn-primary.active { }

.btn-warning { background-color: rgb(250, 167, 50); background-image: -webk=
it-linear-gradient(top, rgb(251, 180, 80), rgb(248, 148, 6)); background-re=
peat: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0,=
 0, 0, 0.25); }

.btn-warning:hover, .btn-warning:active, .btn-warning.active, .btn-warning.=
disabled, .btn-warning[disabled] { background-color: rgb(248, 148, 6); }

.btn-warning:active, .btn-warning.active { }

.btn-warning:hover, .btn-warning:active, .btn-warning.active, .btn-warning.=
disabled, .btn-warning[disabled] { background-color: rgb(248, 148, 6); }

.btn-warning:active, .btn-warning.active { }

.btn-danger { background-color: rgb(218, 79, 73); background-image: -webkit=
-linear-gradient(top, rgb(238, 95, 91), rgb(189, 54, 47)); background-repea=
t: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0, 0,=
 0, 0.25); }

.btn-danger:hover, .btn-danger:active, .btn-danger.active, .btn-danger.disa=
bled, .btn-danger[disabled] { background-color: rgb(189, 54, 47); }

.btn-danger:active, .btn-danger.active { }

.btn-danger:hover, .btn-danger:active, .btn-danger.active, .btn-danger.disa=
bled, .btn-danger[disabled] { background-color: rgb(189, 54, 47); }

.btn-danger:active, .btn-danger.active { }

.btn-success { background-color: rgb(91, 183, 91); background-image: -webki=
t-linear-gradient(top, rgb(98, 196, 98), rgb(81, 163, 81)); background-repe=
at: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0, 0=
, 0, 0.25); }

.btn-success:hover, .btn-success:active, .btn-success.active, .btn-success.=
disabled, .btn-success[disabled] { background-color: rgb(81, 163, 81); }

.btn-success:active, .btn-success.active { }

.btn-success:hover, .btn-success:active, .btn-success.active, .btn-success.=
disabled, .btn-success[disabled] { background-color: rgb(81, 163, 81); }

.btn-success:active, .btn-success.active { }

.btn-info { background-color: rgb(73, 175, 205); background-image: -webkit-=
linear-gradient(top, rgb(91, 192, 222), rgb(47, 150, 180)); background-repe=
at: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0, 0=
, 0, 0.25); }

.btn-info:hover, .btn-info:active, .btn-info.active, .btn-info.disabled, .b=
tn-info[disabled] { background-color: rgb(47, 150, 180); }

.btn-info:active, .btn-info.active { }

.btn-info:hover, .btn-info:active, .btn-info.active, .btn-info.disabled, .b=
tn-info[disabled] { background-color: rgb(47, 150, 180); }

.btn-info:active, .btn-info.active { }

.btn-inverse { background-color: rgb(65, 65, 65); background-image: -webkit=
-linear-gradient(top, rgb(85, 85, 85), rgb(34, 34, 34)); background-repeat:=
 repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0, 0.1) rgba(0, 0, 0=
, 0.25); }

.btn-inverse:hover, .btn-inverse:active, .btn-inverse.active, .btn-inverse.=
disabled, .btn-inverse[disabled] { background-color: rgb(34, 34, 34); }

.btn-inverse:active, .btn-inverse.active { }

.btn-inverse:hover, .btn-inverse:active, .btn-inverse.active, .btn-inverse.=
disabled, .btn-inverse[disabled] { background-color: rgb(34, 34, 34); }

.btn-inverse:active, .btn-inverse.active { }

button.btn, input[type=3D"submit"].btn { }

button.btn.btn-large, input[type=3D"submit"].btn.btn-large { }

button.btn.btn-small, input[type=3D"submit"].btn.btn-small { }

button.btn.btn-mini, input[type=3D"submit"].btn.btn-mini { }

.btn-group { position: relative; }

.btn-group::before, .btn-group::after { display: table; content: ""; }

.btn-group::after { clear: both; }

.btn-group::before, .btn-group::after { display: table; content: ""; }

.btn-group::after { clear: both; }

.btn-group:first-child { }

.btn-group:first-child { }

.btn-group + .btn-group { margin-left: 5px; }

.btn-toolbar { margin-top: 0.625em; margin-bottom: 0.625em; }

.btn-toolbar .btn-group { display: inline-block; }

.btn-group .btn { position: relative; float: left; margin-left: -1px; borde=
r-radius: 0px; }

.btn-group .btn:first-child { margin-left: 0px; border-top-left-radius: 4px=
; border-bottom-left-radius: 4px; }

.btn-group .btn:last-child, .btn-group .dropdown-toggle { border-top-right-=
radius: 4px; border-bottom-right-radius: 4px; }

.btn-group .btn.large:first-child { margin-left: 0px; border-top-left-radiu=
s: 6px; border-bottom-left-radius: 6px; }

.btn-group .btn.large:last-child, .btn-group .large.dropdown-toggle { borde=
r-top-right-radius: 6px; border-bottom-right-radius: 6px; }

.btn-group .btn:hover, .btn-group .btn:focus, .btn-group .btn:active, .btn-=
group .btn.active { z-index: 2; }

.btn-group .dropdown-toggle:active, .btn-group.open .dropdown-toggle { outl=
ine: 0px; }

.btn-group .dropdown-toggle { padding-left: 8px; padding-right: 8px; box-sh=
adow: rgba(255, 255, 255, 0.125) 1px 0px 0px inset, rgba(255, 255, 255, 0.2=
) 0px 1px 0px inset, rgba(0, 0, 0, 0.05) 0px 1px 2px; }

.btn-group .btn-mini.dropdown-toggle { padding-left: 5px; padding-right: 5p=
x; }

.btn-group .btn-small.dropdown-toggle { }

.btn-group .btn-large.dropdown-toggle { padding-left: 12px; padding-right: =
12px; }

.btn-group.open { }

.btn-group.open .dropdown-menu { display: block; margin-top: 1px; border-ra=
dius: 5px; }

.btn-group.open .dropdown-toggle { background-image: none; box-shadow: rgba=
(0, 0, 0, 0.15) 0px 1px 6px inset, rgba(0, 0, 0, 0.05) 0px 1px 2px; }

.btn .caret { margin-top: 7px; margin-left: 0px; }

.btn:hover .caret, .open.btn-group .caret { opacity: 1; }

.btn-mini .caret { margin-top: 5px; }

.btn-small .caret { margin-top: 6px; }

.btn-large .caret { margin-top: 6px; border-left: 5px solid transparent; bo=
rder-right: 5px solid transparent; border-top: 5px solid rgb(0, 0, 0); }

.btn-primary .caret, .btn-warning .caret, .btn-danger .caret, .btn-info .ca=
ret, .btn-success .caret, .btn-inverse .caret { border-top-color: rgb(255, =
255, 255); border-bottom-color: rgb(255, 255, 255); opacity: 0.75; }

.alert { padding: 8px 35px 8px 14px; margin-bottom: 1.25em; text-shadow: rg=
ba(255, 255, 255, 0.5) 0px 1px 0px; background-color: rgb(252, 248, 227); b=
order: 1px solid rgb(251, 238, 213); border-radius: 4px; color: rgb(192, 15=
2, 83); }

.alert-heading { color: inherit; }

.alert .close { position: relative; top: -2px; right: -21px; line-height: 1=
8px; }

.alert-success { background-color: rgb(223, 240, 216); border-color: rgb(21=
4, 233, 198); color: rgb(70, 136, 71); }

.alert-danger, .alert-error { background-color: rgb(242, 222, 222); border-=
color: rgb(238, 211, 215); color: rgb(185, 74, 72); }

.alert-info { background-color: rgb(217, 237, 247); border-color: rgb(188, =
232, 241); color: rgb(58, 135, 173); }

.alert-block { padding-top: 14px; padding-bottom: 14px; }

.alert-block > p, .alert-block > ul { margin-bottom: 0px; }

.alert-block p + p { margin-top: 5px; }

.nav { margin-left: 0px; margin-bottom: 1.25em; list-style: none; }

.nav > li > a { display: block; }

.nav > li > a:hover { text-decoration: none; background-color: rgb(238, 238=
, 238); }

.nav .nav-header { display: block; padding: 3px 15px; font-size: 11px; font=
-weight: bold; line-height: 1.25em; color: rgb(153, 153, 153); text-shadow:=
 rgba(255, 255, 255, 0.5) 0px 1px 0px; text-transform: uppercase; }

.nav li + .nav-header { margin-top: 9px; }

.nav-list { padding-left: 15px; padding-right: 15px; margin-bottom: 0px; }

.nav-list > li > a, .nav-list .nav-header { margin-left: -15px; margin-righ=
t: -15px; text-shadow: rgba(255, 255, 255, 0.5) 0px 1px 0px; }

.nav-list > li > a { padding: 3px 15px; }

.nav-list > .active > a, .nav-list > .active > a:hover { color: rgb(255, 25=
5, 255); text-shadow: rgba(0, 0, 0, 0.2) 0px -1px 0px; background-color: rg=
b(255, 153, 0); }

.nav-list [class^=3D"icon-"] { margin-right: 2px; }

.nav-list .divider { height: 1px; margin: -0.375em 1px; overflow: hidden; b=
ackground-color: rgb(229, 229, 229); border-bottom: 1px solid rgb(255, 255,=
 255); }

.nav-tabs, .nav-pills { }

.nav-tabs::before, .nav-pills::before, .nav-tabs::after, .nav-pills::after =
{ display: table; content: ""; }

.nav-tabs::after, .nav-pills::after { clear: both; }

.nav-tabs::before, .nav-pills::before, .nav-tabs::after, .nav-pills::after =
{ display: table; content: ""; }

.nav-tabs::after, .nav-pills::after { clear: both; }

.nav-tabs > li, .nav-pills > li { float: left; }

.nav-tabs > li > a, .nav-pills > li > a { padding-right: 12px; padding-left=
: 12px; margin-right: 2px; line-height: 14px; }

.nav-tabs { border-bottom: 1px solid rgb(221, 221, 221); }

.nav-tabs > li { margin-bottom: -1px; }

.nav-tabs > li > a { padding-top: 8px; padding-bottom: 8px; line-height: 1.=
25em; border: 1px solid transparent; border-radius: 4px 4px 0px 0px; }

.nav-tabs > li > a:hover { border-color: rgb(238, 238, 238) rgb(238, 238, 2=
38) rgb(221, 221, 221); }

.nav-tabs > .active > a, .nav-tabs > .active > a:hover { color: rgb(85, 85,=
 85); background-color: rgb(255, 255, 255); border-width: 1px; border-style=
: solid; border-color: rgb(221, 221, 221) rgb(221, 221, 221) transparent; b=
order-image: initial; cursor: default; }

.nav-pills > li > a { padding-top: 8px; padding-bottom: 8px; margin-top: 2p=
x; margin-bottom: 2px; border-radius: 5px; }

.nav-pills > .active > a, .nav-pills > .active > a:hover { color: rgb(255, =
255, 255); background-color: rgb(255, 153, 0); }

.nav-stacked > li { float: none; }

.nav-stacked > li > a { margin-right: 0px; }

.nav-tabs.nav-stacked { border-bottom: 0px; }

.nav-tabs.nav-stacked > li > a { border: 1px solid rgb(221, 221, 221); bord=
er-radius: 0px; }

.nav-tabs.nav-stacked > li:first-child > a { border-radius: 4px 4px 0px 0px=
; }

.nav-tabs.nav-stacked > li:last-child > a { border-radius: 0px 0px 4px 4px;=
 }

.nav-tabs.nav-stacked > li > a:hover { border-color: rgb(221, 221, 221); z-=
index: 2; }

.nav-pills.nav-stacked > li > a { margin-bottom: 3px; }

.nav-pills.nav-stacked > li:last-child > a { margin-bottom: 1px; }

.nav-tabs .dropdown-menu, .nav-pills .dropdown-menu { margin-top: 1px; bord=
er-width: 1px; }

.nav-pills .dropdown-menu { border-radius: 4px; }

.nav-tabs .dropdown-toggle .caret, .nav-pills .dropdown-toggle .caret { bor=
der-top-color: rgb(255, 153, 0); border-bottom-color: rgb(255, 153, 0); mar=
gin-top: 6px; }

.nav-tabs .dropdown-toggle:hover .caret, .nav-pills .dropdown-toggle:hover =
.caret { border-top-color: rgb(179, 107, 0); border-bottom-color: rgb(179, =
107, 0); }

.nav-tabs .active .dropdown-toggle .caret, .nav-pills .active .dropdown-tog=
gle .caret { border-top-color: rgb(115, 115, 115); border-bottom-color: rgb=
(115, 115, 115); }

.nav > .dropdown.active > a:hover { color: rgb(0, 0, 0); cursor: pointer; }

.nav-tabs .open .dropdown-toggle, .nav-pills .open .dropdown-toggle, .nav >=
 .open.active > a:hover { color: rgb(255, 255, 255); background-color: rgb(=
153, 153, 153); border-color: rgb(153, 153, 153); }

.nav .open .caret, .nav .open.active .caret, .nav .open a:hover .caret { bo=
rder-top-color: rgb(255, 255, 255); border-bottom-color: rgb(255, 255, 255)=
; opacity: 1; }

.tabs-stacked .open > a:hover { border-color: rgb(153, 153, 153); }

.tabbable { }

.tabbable::before, .tabbable::after { display: table; content: ""; }

.tabbable::after { clear: both; }

.tabbable::before, .tabbable::after { display: table; content: ""; }

.tabbable::after { clear: both; }

.tab-content { display: table; width: 100%; }

.tabs-below .nav-tabs, .tabs-right .nav-tabs, .tabs-left .nav-tabs { border=
-bottom: 0px; }

.tab-content > .tab-pane, .pill-content > .pill-pane { display: none; }

.tab-content > .active, .pill-content > .active { display: block; }

.tabs-below .nav-tabs { border-top: 1px solid rgb(221, 221, 221); }

.tabs-below .nav-tabs > li { margin-top: -1px; margin-bottom: 0px; }

.tabs-below .nav-tabs > li > a { border-radius: 0px 0px 4px 4px; }

.tabs-below .nav-tabs > li > a:hover { border-bottom-color: transparent; bo=
rder-top-color: rgb(221, 221, 221); }

.tabs-below .nav-tabs .active > a, .tabs-below .nav-tabs .active > a:hover =
{ border-color: transparent rgb(221, 221, 221) rgb(221, 221, 221); }

.tabs-left .nav-tabs > li, .tabs-right .nav-tabs > li { float: none; }

.tabs-left .nav-tabs > li > a, .tabs-right .nav-tabs > li > a { min-width: =
74px; margin-right: 0px; margin-bottom: 3px; }

.tabs-left .nav-tabs { float: left; margin-right: 19px; border-right: 1px s=
olid rgb(221, 221, 221); }

.tabs-left .nav-tabs > li > a { margin-right: -1px; border-radius: 4px 0px =
0px 4px; }

.tabs-left .nav-tabs > li > a:hover { border-color: rgb(238, 238, 238) rgb(=
221, 221, 221) rgb(238, 238, 238) rgb(238, 238, 238); }

.tabs-left .nav-tabs .active > a, .tabs-left .nav-tabs .active > a:hover { =
border-color: rgb(221, 221, 221) transparent rgb(221, 221, 221) rgb(221, 22=
1, 221); }

.tabs-right .nav-tabs { float: right; margin-left: 19px; border-left: 1px s=
olid rgb(221, 221, 221); }

.tabs-right .nav-tabs > li > a { margin-left: -1px; border-radius: 0px 4px =
4px 0px; }

.tabs-right .nav-tabs > li > a:hover { border-color: rgb(238, 238, 238) rgb=
(238, 238, 238) rgb(238, 238, 238) rgb(221, 221, 221); }

.tabs-right .nav-tabs .active > a, .tabs-right .nav-tabs .active > a:hover =
{ border-color: rgb(221, 221, 221) rgb(221, 221, 221) rgb(221, 221, 221) tr=
ansparent; }

.navbar { overflow: visible; margin-bottom: 1.25em; }

.navbar-inner { padding-left: 0px; padding-right: 0px; }

.navbar .container { width: auto; }

.btn-navbar { display: none; float: right; padding: 7px 10px; margin-left: =
5px; margin-right: 5px; background-color: rgb(233, 232, 232); background-im=
age: -webkit-linear-gradient(top, rgb(240, 240, 240), rgb(223, 221, 221)); =
background-repeat: repeat-x; border-color: rgba(0, 0, 0, 0.1) rgba(0, 0, 0,=
 0.1) rgba(0, 0, 0, 0.25); box-shadow: rgba(255, 255, 255, 0.6) 0px 1px 0px=
 inset, rgba(0, 0, 0, 0.075) 0px 1px 1px; }

.btn-navbar:hover, .btn-navbar:active, .btn-navbar.active, .btn-navbar.disa=
bled, .btn-navbar[disabled] { background-color: rgb(223, 221, 221); }

.btn-navbar:active, .btn-navbar.active { }

.btn-navbar:hover, .btn-navbar:active, .btn-navbar.active, .btn-navbar.disa=
bled, .btn-navbar[disabled] { background-color: rgb(223, 221, 221); }

.btn-navbar:active, .btn-navbar.active { }

.btn-navbar .icon-bar { display: block; width: 18px; height: 2px; backgroun=
d-color: rgb(171, 171, 171); border-radius: 1px; box-shadow: rgba(255, 255,=
 255, 0.55) 0px 1px 0px; }

.btn-navbar .icon-bar + .icon-bar { margin-top: 3px; }

.nav-collapse.collapse { height: auto; }

.navbar { color: rgb(115, 115, 115); }

.navbar .brand:hover { text-decoration: none; }

.navbar .brand { float: left; display: block; padding: 8px 20px 12px; margi=
n-left: -20px; font-size: 20px; font-weight: 200; line-height: 1; color: rg=
b(255, 255, 255); }

.navbar .navbar-text { margin-bottom: 0px; line-height: 40px; }

.navbar .btn, .navbar .btn-group { margin-top: 5px; margin-bottom: 5px; }

.navbar .btn-group .btn { margin-top: 0px; }

.navbar-form { margin-bottom: 0px; }

.navbar-form::before, .navbar-form::after { display: table; content: ""; }

.navbar-form::after { clear: both; }

.navbar-form::before, .navbar-form::after { display: table; content: ""; }

.navbar-form::after { clear: both; }

.navbar-form input, .navbar-form select, .navbar-form .radio, .navbar-form =
.checkbox { margin-top: 5px; }

.navbar-form input, .navbar-form select { display: inline-block; margin-bot=
tom: 0px; }

.navbar-form input[type=3D"image"], .navbar-form input[type=3D"checkbox"], =
.navbar-form input[type=3D"radio"] { margin-top: 3px; }

.navbar-form .input-append, .navbar-form .input-prepend { margin-top: 6px; =
white-space: nowrap; }

.navbar-form .input-append input, .navbar-form .input-prepend input { margi=
n-top: 0px; }

.navbar-search { position: relative; float: left; margin-top: 6px; margin-b=
ottom: 0px; }

.navbar-search .search-query { padding: 4px 9px; font-family: "Helvetica Ne=
ue", Helvetica, Arial, sans-serif; font-size: 13px; font-weight: normal; li=
ne-height: 1; color: rgb(255, 255, 255); background-color: rgb(255, 255, 25=
5); border: 1px solid rgb(179, 179, 179); box-shadow: rgba(0, 0, 0, 0.1) 0p=
x 1px 2px inset, rgba(255, 255, 255, 0.15) 0px 1px 0px; transition: none; }

.navbar-search .search-query::-webkit-input-placeholder { color: rgb(204, 2=
04, 204); }

.navbar-search .search-query:focus, .navbar-search .search-query.focused { =
padding: 5px 10px; color: rgb(115, 115, 115); text-shadow: rgb(255, 255, 25=
5) 0px 1px 0px; background-color: rgb(255, 255, 255); border: 0px; box-shad=
ow: rgba(0, 0, 0, 0.15) 0px 0px 3px; outline: 0px; }

.navbar-fixed-top, .navbar-fixed-bottom { position: fixed; right: 0px; left=
: 0px; z-index: 1030; margin-bottom: 0px; }

.navbar-fixed-top .navbar-inner, .navbar-fixed-bottom .navbar-inner { paddi=
ng-left: 0px; padding-right: 0px; border-radius: 0px; }

.navbar-fixed-top .container, .navbar-fixed-bottom .container { width: 940p=
x; }

.navbar-fixed-top { top: 0px; }

.navbar-fixed-bottom { bottom: 0px; }

.navbar .nav { position: relative; left: 0px; display: block; float: left; =
margin: 0px 10px 0px 0px; }

.navbar .nav.pull-right { float: right; }

.navbar .nav > li { display: block; float: left; }

.navbar .nav > li > a { float: none; padding: 10px 15px 11px; line-height: =
19px; color: rgb(115, 115, 115); text-decoration: none; }

.navbar .nav > li > a:hover { color: rgb(115, 115, 115); text-decoration: n=
one; }

.navbar .nav .active > a, .navbar .nav .active > a:hover { color: rgb(115, =
115, 115); text-decoration: none; background-color: rgb(255, 255, 255); }

.navbar .divider-vertical { height: 40px; width: 1px; margin: 0px 9px; over=
flow: hidden; background-color: rgb(255, 255, 255); border-right: 1px solid=
 rgb(255, 255, 255); }

.navbar .nav.pull-right { margin-left: 10px; margin-right: 0px; }

.navbar .dropdown-menu { margin-top: 1px; border-radius: 0px; }

.navbar .dropdown-menu::before { content: ""; display: inline-block; border=
-left: 7px solid transparent; border-right: 7px solid transparent; border-b=
ottom: 7px solid rgba(0, 0, 0, 0.2); position: absolute; top: -7px; left: 9=
px; }

.navbar .dropdown-menu::after { content: ""; display: inline-block; border-=
left: 6px solid transparent; border-right: 6px solid transparent; border-bo=
ttom: 6px solid rgb(255, 255, 255); position: absolute; top: -6px; left: 10=
px; }

.navbar-fixed-bottom .dropdown-menu::before { border-top: 7px solid rgba(0,=
 0, 0, 0.2); border-bottom: 0px; bottom: -7px; top: auto; }

.navbar-fixed-bottom .dropdown-menu::after { border-top: 6px solid rgb(255,=
 255, 255); border-bottom: 0px; bottom: -6px; top: auto; }

.navbar .nav .dropdown-toggle .caret, .navbar .nav .open.dropdown .caret { =
border-top-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); }

.navbar .nav .active .caret { opacity: 1; }

.navbar .nav .open > .dropdown-toggle, .navbar .nav .active > .dropdown-tog=
gle, .navbar .nav .open.active > .dropdown-toggle { background-color: rgb(2=
55, 255, 255); box-shadow: rgba(0, 0, 0, 0.1) 0px 1px 1px inset; border-bot=
tom: 1px solid rgb(255, 153, 0); color: rgb(144, 144, 144); }

.navbar .nav .active > .dropdown-toggle:hover { color: rgb(115, 115, 115); =
}

.navbar .nav.pull-right .dropdown-menu, .navbar .nav .dropdown-menu.pull-ri=
ght { left: auto; right: 0px; }

.navbar .nav.pull-right .dropdown-menu::before, .navbar .nav .dropdown-menu=
.pull-right::before { left: auto; right: 12px; }

.navbar .nav.pull-right .dropdown-menu::after, .navbar .nav .dropdown-menu.=
pull-right::after { left: auto; right: 13px; }

.breadcrumb { padding: 7px 14px; margin: 0px 0px 1.25em; list-style: none; =
background-color: rgb(251, 251, 251); background-image: -webkit-linear-grad=
ient(top, rgb(255, 255, 255), rgb(245, 245, 245)); background-repeat: repea=
t-x; border: 1px solid rgb(221, 221, 221); border-radius: 3px; box-shadow: =
rgb(255, 255, 255) 0px 1px 0px inset; }

.breadcrumb li { display: inline-block; text-shadow: rgb(255, 255, 255) 0px=
 1px 0px; }

.breadcrumb .divider { padding: 0px 5px; color: rgb(153, 153, 153); }

.breadcrumb .active a { color: rgb(115, 115, 115); }

.pagination { height: 2.5em; margin: 1.25em 0px; }

.pagination ul { display: inline-block; margin-left: 0px; margin-bottom: 0p=
x; border-radius: 3px; box-shadow: rgba(0, 0, 0, 0.05) 0px 1px 2px; }

.pagination li { display: inline; }

.pagination a { float: left; padding: 0px 14px; line-height: 0.5em; text-de=
coration: none; border-width: 1px 1px 1px 0px; border-style: solid; border-=
color: rgb(221, 221, 221); border-image: initial; }

.pagination a:hover, .pagination .active a { background-color: rgb(245, 245=
, 245); }

.pagination .active a { color: rgb(153, 153, 153); cursor: default; }

.pagination .disabled span, .pagination .disabled a, .pagination .disabled =
a:hover { color: rgb(153, 153, 153); background-color: transparent; cursor:=
 default; }

.pagination li:first-child a { border-left-width: 1px; border-radius: 3px 0=
px 0px 3px; }

.pagination li:last-child a { border-radius: 0px 3px 3px 0px; }

.pagination-centered { text-align: center; }

.pagination-right { text-align: right; }

.pager { margin-left: 0px; margin-bottom: 1.25em; list-style: none; text-al=
ign: center; }

.pager::before, .pager::after { display: table; content: ""; }

.pager::after { clear: both; }

.pager::before, .pager::after { display: table; content: ""; }

.pager::after { clear: both; }

.pager li { display: inline; }

.pager a { display: inline-block; padding: 5px 14px; background-color: rgb(=
255, 255, 255); border: 1px solid rgb(221, 221, 221); border-radius: 15px; =
}

.pager a:hover { text-decoration: none; background-color: rgb(245, 245, 245=
); }

.pager .next a { float: right; }

.pager .previous a { float: left; }

.pager .disabled a, .pager .disabled a:hover { color: rgb(153, 153, 153); b=
ackground-color: rgb(255, 255, 255); cursor: default; }

.modal-open .dropdown-menu { z-index: 2050; }

.modal-open .dropdown.open { }

.modal-open .popover { z-index: 2060; }

.modal-open .tooltip { z-index: 2070; }

.modal-backdrop { position: fixed; inset: 0px; z-index: 1040; background-co=
lor: rgb(0, 0, 0); }

.modal-backdrop.fade { opacity: 0; }

.modal-backdrop, .modal-backdrop.fade.in { opacity: 0.8; }

.modal { position: fixed; top: 50%; left: 50%; z-index: 1050; overflow: aut=
o; width: 560px; margin: -250px 0px 0px -280px; background-color: rgb(255, =
255, 255); border: 1px solid rgba(0, 0, 0, 0.3); border-radius: 6px; box-sh=
adow: rgba(0, 0, 0, 0.3) 0px 3px 7px; background-clip: padding-box; }

.modal.fade { transition: opacity 0.3s linear, top 0.3s ease-out; top: -25%=
; }

.modal.fade.in { top: 50%; }

.modal-header { padding: 9px 15px; border-bottom: 1px solid rgb(238, 238, 2=
38); }

.modal-header .close { margin-top: 2px; }

.modal-body { overflow-y: auto; max-height: 400px; padding: 15px; }

.modal-form { margin-bottom: 0px; }

.modal-footer { padding: 14px 15px 15px; margin-bottom: 0px; text-align: ri=
ght; background-color: rgb(245, 245, 245); border-top: 1px solid rgb(221, 2=
21, 221); border-radius: 0px 0px 6px 6px; box-shadow: rgb(255, 255, 255) 0p=
x 1px 0px inset; }

.modal-footer::before, .modal-footer::after { display: table; content: ""; =
}

.modal-footer::after { clear: both; }

.modal-footer::before, .modal-footer::after { display: table; content: ""; =
}

.modal-footer::after { clear: both; }

.modal-footer .btn + .btn { margin-left: 5px; margin-bottom: 0px; }

.modal-footer .btn-group .btn + .btn { margin-left: -1px; }

.tooltip { position: absolute; z-index: 1020; display: block; visibility: v=
isible; padding: 5px; font-size: 11px; opacity: 0; }

.tooltip.in { opacity: 0.8; }

.tooltip.top { margin-top: -2px; }

.tooltip.right { margin-left: 2px; }

.tooltip.bottom { margin-top: 2px; }

.tooltip.left { margin-left: -2px; }

.tooltip.top .tooltip-arrow { bottom: 0px; left: 50%; margin-left: -5px; bo=
rder-left: 5px solid transparent; border-right: 5px solid transparent; bord=
er-top: 5px solid rgb(0, 0, 0); }

.tooltip.left .tooltip-arrow { top: 50%; right: 0px; margin-top: -5px; bord=
er-top: 5px solid transparent; border-bottom: 5px solid transparent; border=
-left: 5px solid rgb(0, 0, 0); }

.tooltip.bottom .tooltip-arrow { top: 0px; left: 50%; margin-left: -5px; bo=
rder-left: 5px solid transparent; border-right: 5px solid transparent; bord=
er-bottom: 5px solid rgb(0, 0, 0); }

.tooltip.right .tooltip-arrow { top: 50%; left: 0px; margin-top: -5px; bord=
er-top: 5px solid transparent; border-bottom: 5px solid transparent; border=
-right: 5px solid rgb(0, 0, 0); }

.tooltip-inner { max-width: 200px; padding: 3px 8px; color: rgb(255, 255, 2=
55); text-align: center; text-decoration: none; background-color: rgb(0, 0,=
 0); border-radius: 4px; }

.tooltip-arrow { position: absolute; width: 0px; height: 0px; }

.popover { position: absolute; top: 0px; left: 0px; z-index: 1010; display:=
 none; padding: 5px; }

.popover.top { margin-top: -5px; }

.popover.right { margin-left: 5px; }

.popover.bottom { margin-top: 5px; }

.popover.left { margin-left: -5px; }

.popover.top .arrow { bottom: 0px; left: 50%; margin-left: -5px; border-lef=
t: 5px solid transparent; border-right: 5px solid transparent; border-top: =
5px solid rgb(0, 0, 0); }

.popover.right .arrow { top: 50%; left: 0px; margin-top: -5px; border-top: =
5px solid transparent; border-bottom: 5px solid transparent; border-right: =
5px solid rgb(0, 0, 0); }

.popover.bottom .arrow { top: 0px; left: 50%; margin-left: -5px; border-lef=
t: 5px solid transparent; border-right: 5px solid transparent; border-botto=
m: 5px solid rgb(0, 0, 0); }

.popover.left .arrow { top: 50%; right: 0px; margin-top: -5px; border-top: =
5px solid transparent; border-bottom: 5px solid transparent; border-left: 5=
px solid rgb(0, 0, 0); }

.popover .arrow { position: absolute; width: 0px; height: 0px; }

.popover-inner { padding: 3px; width: 280px; overflow: hidden; background: =
rgba(0, 0, 0, 0.8); border-radius: 6px; box-shadow: rgba(0, 0, 0, 0.3) 0px =
3px 7px; }

.popover-title { padding: 9px 15px; line-height: 1; background-color: rgb(2=
45, 245, 245); border-bottom: 1px solid rgb(238, 238, 238); border-radius: =
3px 3px 0px 0px; }

.popover-content { padding: 14px; background-color: rgb(255, 255, 255); bor=
der-radius: 0px 0px 3px 3px; background-clip: padding-box; }

.popover-content p, .popover-content ul, .popover-content ol { margin-botto=
m: 0px; }

.thumbnails { margin-left: -20px; list-style: none; }

.thumbnails::before, .thumbnails::after { display: table; content: ""; }

.thumbnails::after { clear: both; }

.thumbnails::before, .thumbnails::after { display: table; content: ""; }

.thumbnails::after { clear: both; }

.thumbnails > li { float: left; margin: 0px 0px 1.25em 20px; }

.thumbnail { display: block; padding: 4px; line-height: 1; border: 1px soli=
d rgb(221, 221, 221); border-radius: 4px; box-shadow: rgba(0, 0, 0, 0.075) =
0px 1px 1px; }

a.thumbnail:hover { border-color: rgb(255, 153, 0); box-shadow: rgba(0, 105=
, 214, 0.25) 0px 1px 4px; }

.thumbnail > img { display: block; max-width: 100%; margin-left: auto; marg=
in-right: auto; }

.thumbnail .caption { padding: 9px; }

.label { padding: 1px 4px 2px; font-size: 0.687375em; font-weight: bold; li=
ne-height: 13px; color: rgb(255, 255, 255); vertical-align: middle; white-s=
pace: nowrap; text-shadow: rgba(0, 0, 0, 0.25) 0px -1px 0px; background-col=
or: rgb(153, 153, 153); border-radius: 3px; }

.label:hover { color: rgb(255, 255, 255); text-decoration: none; }

.label-important { background-color: rgb(185, 74, 72); }

.label-important:hover { background-color: rgb(149, 59, 57); }

.label-warning { background-color: rgb(248, 148, 6); }

.label-warning:hover { background-color: rgb(198, 118, 5); }

.label-success { background-color: rgb(70, 136, 71); }

.label-success:hover { background-color: rgb(53, 102, 53); }

.label-info { background-color: rgb(58, 135, 173); }

.label-info:hover { background-color: rgb(45, 105, 135); }

.label-inverse { background-color: rgb(115, 115, 115); }

.label-inverse:hover { background-color: rgb(90, 90, 90); }

.badge { padding: 1px 9px 2px; font-size: 0.751563em; font-weight: bold; wh=
ite-space: nowrap; color: rgb(255, 255, 255); background-color: rgb(153, 15=
3, 153); border-radius: 9px; }

.badge:hover { color: rgb(255, 255, 255); text-decoration: none; cursor: po=
inter; }

.badge-error { background-color: rgb(185, 74, 72); }

.badge-error:hover { background-color: rgb(149, 59, 57); }

.badge-warning { background-color: rgb(248, 148, 6); }

.badge-warning:hover { background-color: rgb(198, 118, 5); }

.badge-success { background-color: rgb(70, 136, 71); }

.badge-success:hover { background-color: rgb(53, 102, 53); }

.badge-info { background-color: rgb(58, 135, 173); }

.badge-info:hover { background-color: rgb(45, 105, 135); }

.badge-inverse { background-color: rgb(115, 115, 115); }

.badge-inverse:hover { background-color: rgb(90, 90, 90); }

@-webkit-keyframes progress-bar-stripes {=20
  0% { background-position: 0px 0px; }
  100% { background-position: 40px 0px; }
}

@keyframes progress-bar-stripes {=20
  0% { background-position: 0px 0px; }
  100% { background-position: 40px 0px; }
}

.progress { overflow: hidden; height: 18px; margin-bottom: 18px; background=
-color: rgb(247, 247, 247); background-image: -webkit-linear-gradient(top, =
rgb(245, 245, 245), rgb(249, 249, 249)); background-repeat: repeat-x; box-s=
hadow: rgba(0, 0, 0, 0.1) 0px 1px 2px inset; border-radius: 4px; }

.progress .bar { width: 0%; height: 18px; color: rgb(255, 255, 255); font-s=
ize: 12px; text-align: center; text-shadow: rgba(0, 0, 0, 0.25) 0px -1px 0p=
x; background-color: rgb(14, 144, 210); background-image: -webkit-linear-gr=
adient(top, rgb(20, 155, 223), rgb(4, 128, 190)); background-repeat: repeat=
-x; box-shadow: rgba(0, 0, 0, 0.15) 0px -1px 0px inset; box-sizing: border-=
box; transition: width 0.6s; }

.progress-striped .bar { background-color: rgb(20, 155, 223); background-im=
age: linear-gradient(-45deg, rgba(255, 255, 255, 0.15) 25%, transparent 25%=
, transparent 50%, rgba(255, 255, 255, 0.15) 50%, rgba(255, 255, 255, 0.15)=
 75%, transparent 75%, transparent); background-size: 40px 40px; }

.progress.active .bar { animation: 2s linear 0s infinite normal none runnin=
g progress-bar-stripes; }

.progress-danger .bar { background-color: rgb(221, 81, 76); background-imag=
e: -webkit-linear-gradient(top, rgb(238, 95, 91), rgb(196, 60, 53)); backgr=
ound-repeat: repeat-x; }

.progress-danger.progress-striped .bar { background-color: rgb(238, 95, 91)=
; background-image: linear-gradient(-45deg, rgba(255, 255, 255, 0.15) 25%, =
transparent 25%, transparent 50%, rgba(255, 255, 255, 0.15) 50%, rgba(255, =
255, 255, 0.15) 75%, transparent 75%, transparent); }

.progress-success .bar { background-color: rgb(94, 185, 94); background-ima=
ge: -webkit-linear-gradient(top, rgb(98, 196, 98), rgb(87, 169, 87)); backg=
round-repeat: repeat-x; }

.progress-success.progress-striped .bar { background-color: rgb(98, 196, 98=
); background-image: linear-gradient(-45deg, rgba(255, 255, 255, 0.15) 25%,=
 transparent 25%, transparent 50%, rgba(255, 255, 255, 0.15) 50%, rgba(255,=
 255, 255, 0.15) 75%, transparent 75%, transparent); }

.progress-info .bar { background-color: rgb(75, 177, 207); background-image=
: -webkit-linear-gradient(top, rgb(91, 192, 222), rgb(51, 155, 185)); backg=
round-repeat: repeat-x; }

.progress-info.progress-striped .bar { background-color: rgb(91, 192, 222);=
 background-image: linear-gradient(-45deg, rgba(255, 255, 255, 0.15) 25%, t=
ransparent 25%, transparent 50%, rgba(255, 255, 255, 0.15) 50%, rgba(255, 2=
55, 255, 0.15) 75%, transparent 75%, transparent); }

.progress-warning .bar { background-color: rgb(250, 167, 50); background-im=
age: -webkit-linear-gradient(top, rgb(251, 180, 80), rgb(248, 148, 6)); bac=
kground-repeat: repeat-x; }

.progress-warning.progress-striped .bar { background-color: rgb(251, 180, 8=
0); background-image: linear-gradient(-45deg, rgba(255, 255, 255, 0.15) 25%=
, transparent 25%, transparent 50%, rgba(255, 255, 255, 0.15) 50%, rgba(255=
, 255, 255, 0.15) 75%, transparent 75%, transparent); }

.accordion { margin-bottom: 1.25em; }

.accordion-group { margin-bottom: 2px; border: 1px solid rgb(229, 229, 229)=
; border-radius: 4px; }

.accordion-heading { border-bottom: 0px; }

.accordion-heading .accordion-toggle { display: block; padding: 8px 15px; }

.accordion-inner { padding: 9px 15px; border-top: 1px solid rgb(229, 229, 2=
29); }

.carousel { position: relative; margin-bottom: 1.25em; line-height: 1; }

.carousel-inner { overflow: hidden; width: 100%; position: relative; }

.carousel .item { display: none; position: relative; transition: left 0.6s =
ease-in-out; }

.carousel .item > img { display: block; line-height: 1; }

.carousel .active, .carousel .next, .carousel .prev { display: block; }

.carousel .active { left: 0px; }

.carousel .next, .carousel .prev { position: absolute; top: 0px; width: 100=
%; }

.carousel .next { left: 100%; }

.carousel .prev { left: -100%; }

.carousel .next.left, .carousel .prev.right { left: 0px; }

.carousel .active.left { left: -100%; }

.carousel .active.right { left: 100%; }

.carousel-control { position: absolute; top: 40%; left: 15px; width: 40px; =
height: 40px; margin-top: -20px; font-size: 60px; font-weight: 100; line-he=
ight: 30px; color: rgb(255, 255, 255); text-align: center; background: rgb(=
34, 34, 34); border: 3px solid rgb(255, 255, 255); border-radius: 23px; opa=
city: 0.5; }

.carousel-control.right { left: auto; right: 15px; }

.carousel-control:hover { color: rgb(255, 255, 255); text-decoration: none;=
 opacity: 0.9; }

.carousel-caption { position: absolute; left: 0px; right: 0px; bottom: 0px;=
 padding: 10px 15px 5px; background: rgba(0, 0, 0, 0.75); }

.carousel-caption h4, .carousel-caption p { color: rgb(255, 255, 255); }

.hero-unit { padding: 60px; margin-bottom: 30px; background-color: rgb(238,=
 238, 238); border-radius: 6px; }

.hero-unit h1 { margin-bottom: 0px; font-size: 60px; line-height: 1; color:=
 inherit; letter-spacing: -1px; }

.hero-unit p { font-size: 18px; font-weight: 200; line-height: 1.875em; col=
or: inherit; }

.clearfix { }

.clearfix::before, .clearfix::after { display: table; content: ""; }

.clearfix::after { clear: both; }

.hide-text { overflow: hidden; text-indent: 100%; white-space: nowrap; }

.input-block-level { display: block; width: 100%; min-height: 28px; box-siz=
ing: border-box; }

.hidden { display: none; visibility: hidden; }

.visible-phone { display: none; }

.visible-tablet { display: none; }

.visible-desktop { display: block; }

.hidden-phone { display: block; }

.hidden-tablet { display: block; }

.hidden-desktop { display: none; }

@media (max-width: 767px) {
  .visible-phone { display: block; }
  .hidden-phone { display: none; }
  .hidden-desktop { display: block; }
  .visible-desktop { display: none; }
}

@media (min-width: 768px) and (max-width: 1024px) {
  .visible-tablet { display: block; }
  .hidden-tablet { display: none; }
  .hidden-desktop { display: block; }
  .visible-desktop { display: none; }
}

@media (max-width: 480px) {
  .nav-collapse { transform: translate3d(0px, 0px, 0px); }
  .page-header h1 small { display: block; line-height: 1.25em; }
  input[type=3D"checkbox"], input[type=3D"radio"] { border: 1px solid rgb(2=
04, 204, 204); }
  .form-horizontal .control-group > label { float: none; width: auto; paddi=
ng-top: 0px; text-align: left; }
  .form-horizontal .controls { margin-left: 0px; }
  .form-horizontal .control-list { padding-top: 0px; }
  .form-horizontal .form-actions { padding-left: 10px; padding-right: 10px;=
 }
  .modal { position: absolute; top: 10px; left: 10px; right: 10px; width: a=
uto; margin: 0px; }
  .modal.fade.in { top: auto; }
  .modal-header .close { padding: 10px; margin: -10px; }
  .carousel-caption { position: static; }
}

@media (max-width: 767px) {
  body { padding-left: 20px; padding-right: 20px; }
  .navbar-fixed-top { margin-left: -20px; margin-right: -20px; }
  .container { width: auto; }
  .row-fluid { width: 100%; }
  .folio_fix { }
  .row > [class*=3D"span"], .row-fluid > [class*=3D"span"] { float: none; d=
isplay: block; width: auto; }
  .thumbnails [class*=3D"span"] { width: auto; }
  .panel_2col.span6 { width: 335px; }
  .panel.span4 { width: 337px; }
  input[class*=3D"span"], select[class*=3D"span"], textarea[class*=3D"span"=
], .uneditable-input { display: block; width: 100%; min-height: 28px; box-s=
izing: border-box; }
  .input-prepend input[class*=3D"span"], .input-append input[class*=3D"span=
"] { width: auto; }
}

@media (min-width: 745px) and (max-width: 768px) {
  .span4.swipe { width: 227px; }
}

@media (min-width: 768px) and (max-width: 979px) {
  .row { margin-left: -20px; }
  .row::before, .row::after { display: table; content: ""; }
  .row::after { clear: both; }
  .row::before, .row::after { display: table; content: ""; }
  .row::after { clear: both; }
  [class*=3D"span"] { float: left; margin-left: 20px; }
  .container, .navbar-fixed-top .container, .navbar-fixed-bottom .container=
 { width: 724px; }
  .span12 { width: 724px; }
  .span11 { width: 662px; }
  .span10 { width: 600px; }
  .span9 { width: 538px; }
  .span8 { width: 476px; }
  .span7 { width: 414px; }
  .span6 { width: 352px; }
  .span5 { width: 290px; }
  .span4 { width: 228px; }
  .span3 { width: 200px; }
  .span2 { width: 104px; }
  .span1 { width: 42px; }
  .offset12 { margin-left: 764px; }
  .offset11 { margin-left: 702px; }
  .offset10 { margin-left: 640px; }
  .offset9 { margin-left: 578px; }
  .offset8 { margin-left: 516px; }
  .offset7 { margin-left: 454px; }
  .offset6 { margin-left: 392px; }
  .offset5 { margin-left: 330px; }
  .offset4 { margin-left: 268px; }
  .offset3 { margin-left: 206px; }
  .offset2 { margin-left: 144px; }
  .offset1 { margin-left: 82px; }
  .row { margin-left: -20px; }
  .row::before, .row::after { display: table; content: ""; }
  .row::after { clear: both; }
  .row::before, .row::after { display: table; content: ""; }
  .row::after { clear: both; }
  [class*=3D"span"] { float: left; margin-left: 20px; }
  .container, .navbar-fixed-top .container, .navbar-fixed-bottom .container=
 { width: 724px; }
  .span12 { width: 724px; }
  .span11 { width: 662px; }
  .span10 { width: 600px; }
  .span9 { width: 538px; }
  .span8 { width: 476px; }
  .span7 { width: 414px; }
  .span6 { width: 352px; }
  .span5 { width: 290px; }
  .span4 { width: 228px; }
  .span3 { width: 200px; }
  .span2 { width: 104px; }
  .span1 { width: 42px; }
  .offset12 { margin-left: 764px; }
  .offset11 { margin-left: 702px; }
  .offset10 { margin-left: 640px; }
  .offset9 { margin-left: 578px; }
  .offset8 { margin-left: 516px; }
  .offset7 { margin-left: 454px; }
  .offset6 { margin-left: 392px; }
  .offset5 { margin-left: 330px; }
  .offset4 { margin-left: 268px; }
  .offset3 { margin-left: 206px; }
  .offset2 { margin-left: 144px; }
  .offset1 { margin-left: 82px; }
  .row-fluid { width: 100%; }
  .row-fluid::before, .row-fluid::after { display: table; content: ""; }
  .row-fluid::after { clear: both; }
  .row-fluid::before, .row-fluid::after { display: table; content: ""; }
  .row-fluid::after { clear: both; }
  .row-fluid > [class*=3D"span"] { float: left; margin-left: 2.76243%; }
  .row-fluid > [class*=3D"span"]:first-child { margin-left: 0px; }
  .row-fluid > .span12 { width: 100%; }
  .row-fluid > .span11 { width: 91.4365%; }
  .row-fluid > .span10 { width: 82.8729%; }
  .row-fluid > .span9 { width: 74.3094%; }
  .row-fluid > .span8 { width: 65.7459%; }
  .row-fluid > .span7 { width: 57.1823%; }
  .row-fluid > .span6 { width: 48.6188%; }
  .row-fluid > .span5 { width: 40.0552%; }
  .row-fluid > .span4 { width: 31.4917%; }
  .row-fluid > .span3 { width: 22.9282%; }
  .row-fluid > .span2 { width: 14.3646%; }
  .row-fluid > .span1 { width: 5.8011%; }
  .row-fluid { width: 100%; }
  .row-fluid::before, .row-fluid::after { display: table; content: ""; }
  .row-fluid::after { clear: both; }
  .row-fluid::before, .row-fluid::after { display: table; content: ""; }
  .row-fluid::after { clear: both; }
  .row-fluid > [class*=3D"span"] { float: left; margin-left: 2.76243%; }
  .row-fluid > [class*=3D"span"]:first-child { margin-left: 0px; }
  .row-fluid > .span12 { width: 100%; }
  .row-fluid > .span11 { width: 91.4365%; }
  .row-fluid > .span10 { width: 82.8729%; }
  .row-fluid > .span9 { width: 74.3094%; }
  .row-fluid > .span8 { width: 65.7459%; }
  .row-fluid > .span7 { width: 57.1823%; }
  .row-fluid > .span6 { width: 48.6188%; }
  .row-fluid > .span5 { width: 40.0552%; }
  .row-fluid > .span4 { width: 31.4917%; }
  .row-fluid > .span3 { width: 22.9282%; }
  .row-fluid > .span2 { width: 14.3646%; }
  .row-fluid > .span1 { width: 5.8011%; }
  input, textarea, .uneditable-input { margin-left: 0px; }
  input.span12, textarea.span12, .uneditable-input.span12 { width: 714px; }
  input.span11, textarea.span11, .uneditable-input.span11 { width: 652px; }
  input.span10, textarea.span10, .uneditable-input.span10 { width: 590px; }
  input.span9, textarea.span9, .uneditable-input.span9 { width: 528px; }
  input.span8, textarea.span8, .uneditable-input.span8 { width: 466px; }
  input.span7, textarea.span7, .uneditable-input.span7 { width: 404px; }
  input.span6, textarea.span6, .uneditable-input.span6 { width: 342px; }
  input.span5, textarea.span5, .uneditable-input.span5 { width: 280px; }
  input.span4, textarea.span4, .uneditable-input.span4 { width: 218px; }
  input.span3, textarea.span3, .uneditable-input.span3 { width: 156px; }
  input.span2, textarea.span2, .uneditable-input.span2 { width: 94px; }
  input.span1, textarea.span1, .uneditable-input.span1 { width: 32px; }
  input, textarea, .uneditable-input { margin-left: 0px; }
  input.span12, textarea.span12, .uneditable-input.span12 { width: 714px; }
  input.span11, textarea.span11, .uneditable-input.span11 { width: 652px; }
  input.span10, textarea.span10, .uneditable-input.span10 { width: 590px; }
  input.span9, textarea.span9, .uneditable-input.span9 { width: 528px; }
  input.span8, textarea.span8, .uneditable-input.span8 { width: 466px; }
  input.span7, textarea.span7, .uneditable-input.span7 { width: 404px; }
  input.span6, textarea.span6, .uneditable-input.span6 { width: 342px; }
  input.span5, textarea.span5, .uneditable-input.span5 { width: 280px; }
  input.span4, textarea.span4, .uneditable-input.span4 { width: 218px; }
  input.span3, textarea.span3, .uneditable-input.span3 { width: 156px; }
  input.span2, textarea.span2, .uneditable-input.span2 { width: 94px; }
  input.span1, textarea.span1, .uneditable-input.span1 { width: 32px; }
}

@media (max-width: 979px) {
  body { padding-top: 0px; }
  .navbar-fixed-top { position: static; margin-bottom: 1.25em; }
  .navbar-fixed-top .navbar-inner { padding: 5px; }
  .navbar .container { width: auto; padding: 0px; }
  .navbar .brand { padding-left: 10px; padding-right: 10px; margin: 0px 0px=
 0px -5px; }
  .navbar .nav-collapse { clear: left; }
  .navbar .nav { float: none; margin: 0px 0px 0.625em; }
  .navbar .nav > li { float: none; }
  .navbar .nav > li > a { margin-bottom: 2px; }
  .navbar .nav > .divider-vertical { display: none; }
  .navbar .nav .nav-header { color: rgb(115, 115, 115); text-shadow: none; =
}
  .navbar .nav > li > a, .navbar .dropdown-menu a { padding: 6px 15px; colo=
r: rgb(115, 115, 115); }
  .navbar .dropdown-menu li + li a { margin-bottom: 2px; }
  .navbar .nav > li > a:hover, .navbar .dropdown-menu a:hover { background-=
color: rgb(255, 255, 255); }
  .navbar .dropdown-menu { position: static; top: auto; left: auto; float: =
none; display: none; max-width: none; margin: 0px 15px; padding: 0px; backg=
round-color: transparent; border: none; border-radius: 0px; box-shadow: non=
e; }
  .navbar .dropdown-menu::before, .navbar .dropdown-menu::after { display: =
none; }
  .navbar .dropdown-menu .divider { display: none; }
  .navbar-form, .navbar-search { float: none; padding: 0.625em 15px; margin=
: 0.625em 0px; border-top: 1px solid rgb(255, 255, 255); border-bottom: 1px=
 solid rgb(255, 255, 255); box-shadow: rgba(255, 255, 255, 0.1) 0px 1px 0px=
 inset, rgba(255, 255, 255, 0.1) 0px 1px 0px; }
  .navbar .nav.pull-right { float: none; margin-left: 0px; }
  .navbar-static .navbar-inner { padding-left: 10px; padding-right: 10px; }
  .btn-navbar { display: block; }
  .nav-collapse { overflow: hidden; height: 0px; }
}

@media (min-width: 980px) {
  .nav-collapse.collapse { height: auto !important; overflow: visible !impo=
rtant; }
}

.pull-right { float: right; }

.pull-left { float: left; }

.hide { display: none; }

.show { display: block; }

.invisible { visibility: hidden; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/styles.css

@charset "utf-8";

div.wpcf7 { margin: 0px; padding: 0px; }

div.wpcf7-response-output { margin: 2em 0.5em 1em; padding: 0.2em 1em; }

div.wpcf7-mail-sent-ok { border: 2px solid rgb(57, 143, 20); }

div.wpcf7-mail-sent-ng { border: 2px solid rgb(255, 0, 0); }

div.wpcf7-spam-blocked { border: 2px solid rgb(255, 165, 0); }

div.wpcf7-validation-errors { border: 2px solid rgb(247, 231, 0); }

span.wpcf7-form-control-wrap { position: relative; }

span.wpcf7-not-valid-tip { position: absolute; top: 20%; left: 20%; z-index=
: 100; background: rgb(255, 255, 255); border: 1px solid rgb(255, 0, 0); fo=
nt-size: 10pt; width: 280px; padding: 2px; }

span.wpcf7-not-valid-tip-no-ajax { color: rgb(255, 0, 0); font-size: 10pt; =
display: block; }

span.wpcf7-list-item { margin-left: 0.5em; }

.wpcf7-display-none { display: none; }

div.wpcf7 img.ajax-loader { border: none; vertical-align: middle; margin-le=
ft: 4px; }

div.wpcf7 .placeheld { color: rgb(136, 136, 136); }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/frontend.css

@charset "utf-8";

div.fp_sc_div { display: inline !important; margin: 0px !important; padding=
: 0px !important; }

h1, h2, h3, h4, h5, h6 { font-family: "Open Sans"; color: rgb(26, 65, 170) =
!important; }

.widget h4 { font-family: "Open Sans"; font-size: 15px !important; color: r=
gb(85, 85, 85) !important; }

.flex-caption-title, .stat, .flipicon { font-family: "Open Sans"; color: rg=
b(255, 255, 255) !important; }

.flex-caption-container h6 { font-family: "Open Sans"; font-size: 22px !imp=
ortant; }

a.portfolio_link { font-family: "Open Sans"; font-size: 22px !important; co=
lor: rgb(255, 255, 255) !important; }

#content h4 { font-family: "Open Sans"; font-size: 24px !important; color: =
rgb(26, 65, 170) !important; }

.folio desc h3 { font-family: "Open Sans"; color: rgb(255, 255, 255) !impor=
tant; }

.stats li em { font-family: "Open Sans"; color: rgb(26, 65, 170) !important=
; }

.navbar .nav > li { font-family: "Open Sans"; font-size: 25px !important; c=
olor: rgb(85, 85, 85) !important; }

.stats li a { font-family: "Open Sans"; font-size: 22px !important; color: =
rgb(51, 51, 51) !important; }

.img post a i { font-family: "Open Sans"; color: rgb(255, 255, 255) !import=
ant; }

.copy { font-family: "Open Sans"; font-size: 18px !important; line-height: =
20px !important; color: rgb(51, 51, 51) !important; }

#jqueryslidemenu ul li a { font-family: "Open Sans"; font-size: 14px !impor=
tant; color: rgb(116, 124, 120) !important; }

@font-face { font-family: "Bebas Neue Regular"; src: url("https://www.vikin=
gtherapeutics.com/wp-content/plugins/fontpress/fonts/Bebas_Neue_Regular/beb=
asneue-webfont.woff") format("woff"), url("https://www.vikingtherapeutics.c=
om/wp-content/plugins/fontpress/fonts/Bebas_Neue_Regular/bebasneue-webfont.=
ttf") format("truetype"); }

font.fp_ff_Bebas_Neue_Regular, font.fp_ff_Bebas_Neue_Regular * { font-famil=
y: "Bebas Neue Regular"; }

font.fp_wf_Open_Sans, font.fp_wf_Open_Sans * { font-family: "Open Sans"; }

#jqueryslidemenu ul li a:hover { color: rgb(221, 58, 46) !important; }

.flex-caption-title { text-transform: none; letter-spacing: -2px; font-weig=
ht: 400 !important; }

.flex-caption-title span { padding: 2px 0px; font-size: 2.9em !important; l=
ine-height: 1.1em !important; }

#jqueryslidemenu ul li a { font-weight: 400 !important; }

#content a, #contact_info a { color: rgb(26, 65, 170) !important; }

#content a:hover, #contact_info a:hover { text-decoration: none; color: rgb=
(51, 51, 51) !important; }

.widget h4 { text-transform: uppercase; font-weight: 400 !important; color:=
 rgb(119, 119, 119) !important; font-size: 14px !important; }

a.portfolio_link { text-transform: uppercase; }

.navbar .nav > li { text-transform: uppercase; }

#content h1 { font-weight: 300; font-size: 2.3em; line-height: 1.15em; marg=
in-bottom: 20px; color: rgb(85, 85, 85) !important; }

#content h2 { font-size: 1.8em; line-height: 1.45em; margin-top: 5px; margi=
n-bottom: 10px; font-weight: 300 !important; color: rgb(204, 0, 0) !importa=
nt; }

#content h3 { font-size: 1.8em; line-height: 1.2em; margin-top: 10px; margi=
n-bottom: 10px; font-weight: 300 !important; color: rgb(85, 85, 85) !import=
ant; }

#content h4 { font-size: 1.2em; line-height: 1.5em; margin-top: 20px; margi=
n-bottom: 10px; font-weight: 300 !important; }

.callout { color: rgb(26, 65, 170); font-size: 1em; line-height: 1.5em; fon=
t-weight: 300 !important; }

.subhead-focus { font-size: 1.2em; line-height: 1.5em; margin-top: 0px; mar=
gin-bottom: 10px; font-weight: 400 !important; }

#content h5 { font-size: 1.2em; line-height: 1.5em; margin-top: 0px; margin=
-bottom: 5px; font-weight: 400 !important; color: rgb(68, 68, 68) !importan=
t; }

p, .copy { font-family: "Open Sans" !important; font-weight: 300 !important=
; font-size: 16px !important; line-height: 26px !important; }

div.copy { margin-bottom: 30px; }

li { color: rgb(85, 85, 85); font-family: "Open Sans" !important; font-weig=
ht: 300 !important; }

strong { font-weight: 400 !important; }

.textwidget { font-size: 14px; line-height: 20px; color: rgb(0, 0, 0); font=
-family: "Open Sans" !important; font-weight: 300 !important; }

.footnote { font-size: 0.8em; }

.textwidget a, .textwidget a:visited { color: rgb(26, 65, 170) !important; =
font-weight: 300 !important; }

.textwidget a:hover { color: rgb(51, 51, 51) !important; text-decoration: n=
one !important; }

em { font-family: "Open Sans" !important; font-weight: 300 !important; font=
-style: italic !important; }

li.post { margin-bottom: 20px; font-size: 16px !important; line-height: 26p=
x !important; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://fonts.googleapis.com/css2?family=Open+Sans:wght@700&display=swap

@charset "utf-8";

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ta=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+460-52F, U+1C80-1C8=
A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ka=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+301, U+400-45F, U+4=
90-491, U+4B0-4B1, U+2116; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4sa=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+1F00-1FFF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ja=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+370-377, U+37A-37F,=
 U+384-38A, U+38C, U+38E-3A1, U+3A3-3FF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ia=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+307-308, U+590-5FF,=
 U+200C-2010, U+20AA, U+25CC, U+FB1D-FB4F; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x5ca=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+302-303, U+305, U+3=
07-308, U+310, U+312, U+315, U+31A, U+326-327, U+32C, U+32F-330, U+332-333,=
 U+338, U+33A, U+346, U+34D, U+391-3A1, U+3A3-3A9, U+3B1-3C9, U+3D1, U+3D5-=
3D6, U+3F0-3F1, U+3F4-3F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043=
, U+2047, U+2050, U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+=
20D0-20DC, U+20E1, U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+21=
23-214F, U+2190, U+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211=
, U+2213-2214, U+2216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+233=
6-237A, U+237C, U+2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25=
AF, U+25B3, U+25B7, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+=
27C0-27FF, U+2900-2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U=
+FF5D, U+1D400-1D7FF, U+1EE00-1EEFF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x5Oa=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+1-C, U+E-1F, U+7F-9=
F, U+20DD-20E0, U+20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21=
AF, U+21E6-21F0, U+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2=
440-244A, U+2460-24FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29B=
F, U+29EB, U+2B00-2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-10=
19C, U+101A0, U+101D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U=
+1D2E0-1D37F, U+1F000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U=
+1F315, U+1F31C, U+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382=
, U+1F393-1F39F, U+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F=
3CA-1F3CE, U+1F3D4-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U=
+1F415, U+1F41F, U+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U=
+1F44C-1F44E, U+1F453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9=
, U+1F4BB, U+1F4BF, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6=
, U+1F4EA-1F4ED, U+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F=
50B, U+1F50D, U+1F512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650=
-1F67F, U+1F687, U+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F=
6B9-1F6BA, U+1F6BC, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F=
6F3, U+1F6F7-1F6FC, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F=
859, U+1F860-1F887, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F=
90B, U+1F93B, U+1F946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1F=
A7C, U+1FA80-1FA89, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1F=
AF8, U+1FB00-1FBFF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4va=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+102-103, U+110-111,=
 U+128-129, U+168-169, U+1A0-1A1, U+1AF-1B0, U+300-301, U+303-304, U+308-30=
9, U+323, U+329, U+1EA0-1EF9, U+20AB; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ua=
VIUwaEQbjB_mQ.woff2") format("woff2"); unicode-range: U+100-2BA, U+2BD-2C5,=
 U+2C7-2CC, U+2CE-2D7, U+2DD-2FF, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-=
1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U=
+A720-A7FF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 700=
; font-stretch: 100%; font-display: swap; src: url("https://fonts.gstatic.c=
om/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1x4ga=
VIUwaEQbjA.woff2") format("woff2"); unicode-range: U+0-FF, U+131, U+152-153=
, U+2BB-2BC, U+2C6, U+2DA, U+2DC, U+304, U+308, U+329, U+2000-206F, U+20AC,=
 U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C400italic&ver=3.5.2

@charset "utf-8";

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWV0ewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+460-52F, U+1C80-1C8A, U+20B4, U+2DE0-=
2DFF, U+A640-A69F, U+FE2E-FE2F; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWVQewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+301, U+400-45F, U+490-491, U+4B0-4B1,=
 U+2116; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWVwewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+1F00-1FFF; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWVMewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+370-377, U+37A-37F, U+384-38A, U+38C,=
 U+38E-3A1, U+3A3-3FF; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWVIewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+307-308, U+590-5FF, U+200C-2010, U+20=
AA, U+25CC, U+FB1D-FB4F; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWSwewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+302-303, U+305, U+307-308, U+310, U+3=
12, U+315, U+31A, U+326-327, U+32C, U+32F-330, U+332-333, U+338, U+33A, U+3=
46, U+34D, U+391-3A1, U+3A3-3A9, U+3B1-3C9, U+3D1, U+3D5-3D6, U+3F0-3F1, U+=
3F4-3F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, =
U+2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1,=
 U+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U=
+2192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2=
216-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+=
2395, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7=
, U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-=
2AFF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7=
FF, U+1EE00-1EEFF; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWT4ewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+1-C, U+E-1F, U+7F-9F, U+20DD-20E0, U+=
20E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U=
+21F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-2=
4FF, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-=
2BFF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+10=
1D0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F=
000-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U=
+1F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U=
+1F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4=
-1F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U=
+1F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F=
453, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF=
, U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U=
+1F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F=
512-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U=
+1F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC=
, U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC=
, U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887=
, U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F=
946, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89=
, U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF=
; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWV8ewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+102-103, U+110-111, U+128-129, U+168-=
169, U+1A0-1A1, U+1AF-1B0, U+300-301, U+303-304, U+308-309, U+323, U+329, U=
+1EA0-1EF9, U+20AB; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWV4ewIMUdjFXmSU_.woff=
2") format("woff2"); unicode-range: U+100-2BA, U+2BD-2C5, U+2C7-2CC, U+2CE-=
2D7, U+2DD-2FF, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF,=
 U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF; }

@font-face { font-family: "Open Sans"; font-style: italic; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkWVAewIMUdjFXmQ.woff2"=
) format("woff2"); unicode-range: U+0-FF, U+131, U+152-153, U+2BB-2BC, U+2C=
6, U+2DA, U+2DC, U+304, U+308, U+329, U+2000-206F, U+20AC, U+2122, U+2191, =
U+2193, U+2212, U+2215, U+FEFF, U+FFFD; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4taVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+460-52F, U+1C80-1C8A, U+20B4, U+2DE0-2D=
FF, U+A640-A69F, U+FE2E-FE2F; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4kaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+301, U+400-45F, U+490-491, U+4B0-4B1, U=
+2116; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4saVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+1F00-1FFF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4jaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+370-377, U+37A-37F, U+384-38A, U+38C, U=
+38E-3A1, U+3A3-3FF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4iaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+307-308, U+590-5FF, U+200C-2010, U+20AA=
, U+25CC, U+FB1D-FB4F; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B5caVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+302-303, U+305, U+307-308, U+310, U+312=
, U+315, U+31A, U+326-327, U+32C, U+32F-330, U+332-333, U+338, U+33A, U+346=
, U+34D, U+391-3A1, U+3A3-3A9, U+3B1-3C9, U+3D1, U+3D5-3D6, U+3F0-3F1, U+3F=
4-3F5, U+2016-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+=
2057, U+205F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U=
+20E5-20EF, U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2=
192, U+2194-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+221=
6-22FF, U+2308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+23=
95, U+239B-23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, =
U+25BD, U+25C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2A=
FF, U+2B0E-2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF=
, U+1EE00-1EEFF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B5OaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+1-C, U+E-1F, U+7F-9F, U+20DD-20E0, U+20=
E2-20E4, U+2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+2=
1F3, U+2218-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24F=
F, U+25A0-27BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2B=
FF, U+4DC0-4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D=
0-101FD, U+102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F00=
0-1F0FF, U+1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1=
F31E, U+1F320-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1=
F3A7-1F3A8, U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1=
F3E0, U+1F3ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1=
F426, U+1F43F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F45=
3, U+1F46A, U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, =
U+1F4C8-1F4CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1=
F4F7, U+1F4F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F51=
2-1F513, U+1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1=
F68D, U+1F691, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, =
U+1F6C6-1F6CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, =
U+1F700-1F7FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, =
U+1F890-1F8AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F94=
6, U+1F984, U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, =
U+1FA8F-1FAC6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF; =
}

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4vaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+102-103, U+110-111, U+128-129, U+168-16=
9, U+1A0-1A1, U+1AF-1B0, U+300-301, U+303-304, U+308-309, U+323, U+329, U+1=
EA0-1EF9, U+20AB; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4uaVIUwaEQbjB_mQ.woff2"=
) format("woff2"); unicode-range: U+100-2BA, U+2BD-2C5, U+2C7-2CC, U+2CE-2D=
7, U+2DD-2FF, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U=
+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF; }

@font-face { font-family: "Open Sans"; font-style: normal; font-weight: 400=
; font-stretch: 100%; src: url("https://fonts.gstatic.com/s/opensans/v40/me=
mSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0B4gaVIUwaEQbjA.woff2") f=
ormat("woff2"); unicode-range: U+0-FF, U+131, U+152-153, U+2BB-2BC, U+2C6, =
U+2DA, U+2DC, U+304, U+308, U+329, U+2000-206F, U+20AC, U+2122, U+2191, U+2=
193, U+2212, U+2215, U+FEFF, U+FFFD; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/HttpCombiner.ashx

@charset "utf-8";

a.ccbn-inlay-trigger { background: url("http://media.corporate-ir.net/media=
_files/IROL/global_images/sprite-inlay-toggle.png") left 3px no-repeat scro=
ll transparent; color: rgb(0, 0, 0); font-weight: bold; padding-left: 20px;=
 text-decoration: none; }

a.ccbn-inlay-trigger-expand { background-position: left -16px; }

.ccbnPopover { position: absolute; visibility: hidden; overflow: auto; widt=
h: 200px; height: auto; background: rgb(255, 255, 255); text-align: left; b=
order: 1px solid rgb(0, 0, 0); top: 0px; left: 0px; }

.ccbn-loading-placeholder { height: 20px; background: url("http://media.cor=
porate-ir.net/media_files/IROL/global_images/ajax-loader.gif") 30px center =
no-repeat transparent; display: none; }

.ccbn-print-link-inactive { display: none; }

.ccbn-print-page { background: url("http://media.corporate-ir.net/media_fil=
es/IROL/global_images/toolkit_print_t.gif") 0px 2px no-repeat scroll transp=
arent; display: inline-block; padding-left: 16px; }

a.ccbn-social-link-google, a.ccbn-social-link-google:hover { background: ur=
l("http://media.corporate-ir.net/media_files/IROL/global_images/social-icon=
s/google.png") left center no-repeat transparent !important; }

a.ccbn-social-link-googleplus, a.ccbn-social-link-googleplus:hover { backgr=
ound: url("http://media.corporate-ir.net/media_files/IROL/global_images/soc=
ial-icons/googleplus.png") left center no-repeat transparent !important; }

a.ccbn-social-link-buzzup, a.ccbn-social-link-buzzup:hover { background: ur=
l("http://media.corporate-ir.net/media_files/IROL/global_images/social-icon=
s/buzzfeed.png") left center no-repeat transparent !important; }

a.ccbn-social-link-linkedin, a.ccbn-social-link-linkedin:hover { background=
: url("http://media.corporate-ir.net/media_files/IROL/global_images/social-=
icons/linkedin.png") left center no-repeat transparent !important; }

a.ccbn-social-link-delicious, a.ccbn-social-link-delicious:hover { backgrou=
nd: url("http://media.corporate-ir.net/media_files/IROL/global_images/socia=
l-icons/delicious.png") left center no-repeat transparent !important; }

a.ccbn-social-link-reddit, a.ccbn-social-link-reddit:hover { background: ur=
l("http://media.corporate-ir.net/media_files/IROL/global_images/social-icon=
s/reddit.png") left center no-repeat transparent !important; }

a.ccbn-social-link-digg, a.ccbn-social-link-digg:hover { background: url("h=
ttp://media.corporate-ir.net/media_files/IROL/global_images/social-icons/di=
gg.png") left center no-repeat transparent !important; }

a.ccbn-social-link-stumbleupon, a.ccbn-social-link-stumbleupon:hover { back=
ground: url("http://media.corporate-ir.net/media_files/IROL/global_images/s=
ocial-icons/stumbleupon.png") left center no-repeat transparent !important;=
 }

a.ccbn-social-link-facebook, a.ccbn-social-link-facebook:hover { background=
: url("http://media.corporate-ir.net/media_files/IROL/global_images/social-=
icons/facebook.png") left center no-repeat transparent !important; }

a.ccbn-social-link-twitter, a.ccbn-social-link-twitter:hover { background: =
url("http://media.corporate-ir.net/media_files/IROL/global_images/social-ic=
ons/twitter.png") left center no-repeat transparent !important; }

a.ccbn-social-link-email, a.ccbn-social-link-email:hover { background: url(=
"http://media.corporate-ir.net/media_files/IROL/global_images/social-icons/=
icon-email.png") left center no-repeat transparent !important; }

.ccbn-rss-link { background: url("http://media.corporate-ir.net/media_files=
/IROL/global_images/toolkit_rss_t.gif") left center no-repeat scroll transp=
arent; display: inline-block; padding-left: 18px; }

.ccbn-link-more { margin: 0px; padding: 0px; }

.ccbn-link-more-text { float: left; padding-right: 8px; }

.ccbn-arrow { width: 0px; height: 0px; line-height: 0; border-width: 1px; b=
order-style: solid; margin-top: 3px; float: left; margin-right: 12px; }

.ccbn-arrow { border-width: 4px 0px 4px 4px; border-top-style: dotted; bord=
er-top-color: transparent; border-bottom-style: dotted; border-bottom-color=
: transparent; border-left-style: solid; border-left-color: rgb(0, 0, 0); b=
order-right-style: initial; border-right-color: initial; }

.ccbn-arrow { }

.ccbn-doc a { background-color: transparent; background-repeat: no-repeat; =
background-image: url("/media_files/priv/ccbn/event_help/icons/other.gif");=
 background-position: 0px 0px; background-attachment: scroll; display: inli=
ne-block; min-height: 16px; padding-left: 24px; }

.ccbn-doc-multi-item, .ccbn-doc-multi-sec { display: none; }

.ccbn-doc-multi ul { display: none; }

.ccbn-doc-multi a { padding-left: 8px; }

.ccbn-doc-multi-expanded ul, .ccbn-doc-multi-expanded .ccbn-loading-placeho=
lder { display: block; }

.ccbn-doc-multi-expanded a { padding-left: 6px; }

.ccbn-doc-multi-expanded li a { padding-left: 24px; }

.ccbn-doc-multi-expanded .ccbn-arrow { margin-top: 5px; margin-right: 11px;=
 border-width: 4px 4px 0px; border-left-style: dotted; border-left-color: t=
ransparent; border-right-style: dotted; border-right-color: transparent; bo=
rder-top-style: solid; border-top-color: rgb(0, 0, 0); border-bottom-style:=
 initial; border-bottom-color: initial; }

.ccbn-doc-multi-expanded .ccbn-arrow { }

.ccbn-doc-pdf a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/md_pdf.gif"); background-position: 0px 0px; }

.ccbn-doc-doc a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/md_doc.gif"); background-position: 0px 0px; }

.ccbn-doc-xls a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/md_xls.gif"); background-position: 0px 0px; }

.ccbn-doc-ppt a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/md_ppt.gif"); background-position: 0px 0px; }

.ccbn-doc-html a { background-image: url("/media_files/priv/CCBN/event_help=
/icons/HTML_small.gif"); background-position: 0px 0px; }

.ccbn-doc-txt a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/PlainText_small.gif"); background-position: 0px 0px; }

.ccbn-doc-wks a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/Lotus_small.gif"); background-position: 0px 0px; }

.ccbn-doc-mob a { background-image: url("/media_files/priv/CCBN/event_help/=
icons/Mobular_small.gif"); background-position: 0px 0px; }

.ccbn-doc-xbrl a { background-image: url("/media_files/priv/ccbn/event_help=
/smalldownload/xbrl.gif"); background-position: 0px 0px; }

.ccbn-doc-other a { background-image: url("/media_files/priv/ccbn/event_hel=
p/icons/other.gif"); background-position: 0px 0px; }

.ccbn-doc-win a { background-image: url("/media_files/priv/ccbn/event_help/=
icons/md_win.gif"); background-position: 0px 0px; }

.ccbn-doc-mov a { background-image: url("/media_files/priv/ccbn/event_help/=
icons/md_quicktime.gif"); background-position: 0px 0px; }

.ccbn-doc-ram a { background-image: url("/media_files/priv/ccbn/event_help/=
icons/md_real.gif"); background-position: 0px 0px; }

.ccbn-doc-wav a { background-image: url("http://media.corporate-ir.net/medi=
a_files/priv/CCBN/event_help/icons/WAV_small.gif"); background-position: 0p=
x 0px; }

.ccbn-new-window a, a.ccbn-new-window { background: url("http://media.corpo=
rate-ir.net/media_files/IROL/global_images/icon-open-window.gif") right 0px=
 no-repeat scroll transparent; display: inline-block; min-height: 16px; pad=
ding-right: 24px; }

.ccbn-tools { border-bottom: 1px solid rgb(230, 230, 230); margin-bottom: 1=
0px; display: none; }

.ccbn-nav-toolbar { border-top: 1px solid rgb(230, 230, 230); list-style: n=
one; margin: 10px 0px 0px; padding: 0px; clear: both; }

.ccbn-nav-toolbar li { border-right: 1px solid rgb(238, 238, 238); float: l=
eft; padding: 0px; margin: 0px !important; }

.ccbn-nav-toolbar li.ccbn-last { border-right: 0px; }

.ccbn-nav-toolbar li a { float: left; padding: 5px 10px; text-decoration: n=
one; }

.ccbn-nav-toolbar li a:hover { background-color: rgb(250, 250, 250); color:=
 rgb(51, 51, 51); }

.ccbn-nav-toolbar li.ccbn-nav-toolbar-active a { background: rgb(224, 225, =
226); color: rgb(0, 0, 0); }

.ccbn-tools-content { background: url("http://media.corporate-ir.net/media_=
files/IROL/global_images/earnings-release/bg-toolbar-content-gradient.png")=
 0px 0px repeat-x scroll rgb(239, 239, 240); }

.ccbn-tools-content h3 { font-size: 12px; padding-left: 50px; margin: 0px; =
line-height: 16px; }

.ccbn-tools-content h4 { font-size: 11px; font-weight: bold; margin: 0px 0p=
x 10px; }

.ccbn-tools-content p { font-size: 11px; margin-bottom: 10px; }

.ccbn-tools-content-header { float: left; padding-bottom: 40px; width: 20%;=
 }

.ccbn-tools-content-instructions { float: right; width: 30%; }

.ccbn-tools-content-main { float: left; padding-left: 3%; width: 45%; }

.ccbn-tabs-nav { margin: 0px; padding: 5px 5px 0px; background: url("http:/=
/media.corporate-ir.net/media_files/IROL/global_images/earnings-release/bg-=
graygrad.png") center bottom repeat-x scroll rgb(228, 228, 229); clear: bot=
h; }

.ccbn-tabs-nav li { list-style: none; padding: 0px 5px 0px 0px; float: left=
; font-size: 12px; margin: 0px !important; }

.ccbn-tabs-nav li a { float: left; cursor: pointer; padding: 5px 10px; back=
ground: url("http://media.corporate-ir.net/media_files/IROL/global_images/e=
arnings-release/bg-lightgraygrad.png") center bottom repeat-x scroll rgb(25=
1, 251, 251); text-decoration: none; }

.ccbn-tabs-nav li.ccbn-tab-active a { color: rgb(0, 0, 0); font-weight: bol=
d; background: none 0px 0px repeat scroll rgb(255, 255, 255); border-bottom=
: 3px solid rgb(255, 255, 255); }

.ccbn-tab-content-area { padding: 10px 0px 10px 15px; }

.ccbn-tab-content-inactive, .ccbn-tab-inactive { display: none; }

.ccbn-content-secondary { float: right; padding: 10px 15px 10px 20px; width=
: 200px; font-size: 10px; }

.ccbn-content-secondary-container { margin-bottom: 20px; }

.ccbn-accordion { margin: 0px; padding: 0px; display: none; }

.ccbn-accordion-item { list-style: none; margin: 0px; padding: 0px; border-=
top: 1px solid rgb(230, 230, 230); }

.ccbn-accordion-item-link { padding: 5px 7px; width: 185px; display: inline=
-block; font-weight: bold; text-decoration: none; background: rgb(255, 255,=
 255); }

.ccbn-accordion-item-link:hover { background-color: rgb(250, 250, 250); col=
or: rgb(51, 51, 51); }

.ccbn-accordion-item-active a.ccbn-accordion-item-link, .ccbn-accordion-ite=
m-active a.ccbn-accordion-item-link:hover { background: rgb(224, 225, 226);=
 color: rgb(0, 0, 0); }

.ccbn-accordion-item-active a.ccbn-accordion-item-link .ccbn-arrow { margin=
-top: 5px; margin-right: 11px; border-width: 4px 4px 0px; border-left-style=
: dotted; border-left-color: transparent; border-right-style: dotted; borde=
r-right-color: transparent; border-top-style: solid; border-top-color: rgb(=
0, 0, 0); border-bottom-style: initial; border-bottom-color: initial; }

.ccbn-accordion-item-active a.ccbn-accordion-item-link .ccbn-arrow { }

.ccbn-accordion li.ccbn-last { border-bottom: 1px solid rgb(230, 230, 230);=
 }

.ccbn-accordion-item-active { background: rgb(224, 225, 226); }

.ccbn-accordion-content { display: none; background: url("http://media.corp=
orate-ir.net/media_files/IROL/global_images/earnings-release/bg-toolbar-con=
tent-gradient.png") 0px 0px repeat-x scroll rgb(239, 239, 240); padding: 0p=
x 10px 5px; }

.ccbn-accordion-content li.ccbn-last { border-bottom: 0px; }

.ccbn-tabs-nav::after, .ccbn-nav-toolbar::after, .ccbn-link-more::after, .c=
cbn-share::after, .ccbn-share-two-col::after, .ccbn-share-hoz::after, .ccbn=
-share-hoz-more::after, .ccbn-share-main ul::after, .ccbn-share-hoz-more ul=
::after, .ccbn-connect::after, .ccbn-connect li::after { clear: both; conte=
nt: "."; display: block; height: 0px; visibility: hidden; }

.ccbn-tabs-nav, .ccbn-nav-toolbar, .ccbn-link-more, .ccbn-share, .ccbn-shar=
e-two-col, .ccbn-share-hoz, .ccbn-share-hoz-more, .ccbn-share-main ul, .ccb=
n-share-hoz-more ul, .ccbn-connect { zoom: 1; }

.ccbn-toggle-heading, .ccbn-toggle-sub-heading { font-weight: bold; cursor:=
 pointer; }

.ccbn-toggle-content, .ccbn-toggle-sub-content { display: none; }

.ccbn-close-btn { border: 1px solid rgb(204, 204, 204); position: relative;=
 top: 1px; left: 107px; padding: 1px 5px; background: rgb(102, 102, 102); f=
ont-size: 11px; font-weight: bold; text-decoration: none; cursor: pointer; =
color: rgb(255, 255, 255) !important; font-family: Arial, Helvetica, sans-s=
erif !important; }

#ccbn-share-page .ccbn-tools-content-main a.ccbn-social-link-google, #ccbn-=
share-page .ccbn-tools-content-main a.ccbn-social-link-googleplus, #ccbn-sh=
are-page .ccbn-tools-content-main a.ccbn-social-link-linkedin, #ccbn-share-=
page .ccbn-tools-content-main a.ccbn-social-link-delicious, #ccbn-share-pag=
e .ccbn-tools-content-main a.ccbn-social-link-reddit, #ccbn-share-page .ccb=
n-tools-content-main a.ccbn-social-link-digg, #ccbn-share-page .ccbn-tools-=
content-main a.ccbn-social-link-stumbleupon, #ccbn-share-page .ccbn-tools-c=
ontent-main a.ccbn-social-link-facebook, #ccbn-share-page .ccbn-tools-conte=
nt-main a.ccbn-social-link-twitter, #ccbn-share-page .ccbn-tools-content-ma=
in a.ccbn-social-link-email { background-repeat: no-repeat; padding-left: 2=
0px; background-position: 0px -1px; }

.ccbn-share h4.ccbn-heading, .ccbn-share-two-col h4.ccbn-heading, .ccbn-sha=
re-hoz h4.ccbn-heading, .ccbn-share-hoz-more h4.ccbn-heading, .ccbn-share-t=
wocol-toolkit h4.ccbn-heading { background: url("http://media.corporate-ir.=
net/media_files/IROL/global_images/social-icons/icon-share.gif") left cente=
r no-repeat; font-weight: bold; padding-left: 20px; margin: 0px; cursor: po=
inter; }

.ccbn-share-main { background: rgb(255, 255, 255); border-width: 1px; borde=
r-style: solid; border-color: rgb(204, 204, 204) rgb(102, 102, 102) rgb(102=
, 102, 102) rgb(204, 204, 204); border-image: initial; margin: 1px 0px 0px;=
 padding: 3px 8px; position: absolute; z-index: 999; }

.ccbn-share .ccbn-share-main { width: 120px; }

a.ccbn-social-link, a.ccbn-social-link-email { background-repeat: no-repeat=
; padding-left: 20px; background-position: 0px -1px; text-decoration: none;=
 }

a.ccbn-social-link:hover { text-decoration: underline; }

.ccbn-share .ccbn-share-main ul, .ccbn-share-two-col .ccbn-share-main ul, .=
ccbn-share-twocol-toolkit .ccbn-share-main ul { margin: -20px 0px 0px; padd=
ing: 0px; }

.ccbn-share-main li { list-style-type: none; padding: 0px; margin: 0px; lin=
e-height: 20px; }

li.ccbn-share-header { margin: 5px 0px 0px; padding: 0px; font-weight: bold=
; }

li.ccbn-share-footer { border-top: 1px dotted rgb(204, 204, 204); margin: 5=
px 0px 0px; padding: 5px 0px; }

.ccbn-share-twocol-toolkit { position: relative; }

.ccbn-share-twocol-toolkit h4.ccbn-heading, .ccbn-toolkit-vert h4.ccbn-head=
ing { display: inline; font-weight: normal; }

.ccbn-share-two-col .ccbn-share-main, .ccbn-share-twocol-toolkit .ccbn-shar=
e-main { width: 200px; margin-top: 1px; display: none; }

.ccbn-share-twocol-toolkit .ccbn-share-main { left: 0px; top: 20px; text-al=
ign: left; }

.ccbn-share-two-col .ccbn-share-main li, .ccbn-share-twocol-toolkit .ccbn-s=
hare-main li { float: left; width: 48%; }

.ccbn-share-two-col .ccbn-share-main li.ccbn-share-header { width: 100%; }

.ccbn-share-two-col .ccbn-share-main .ccbn-share-header, .ccbn-share-two-co=
l .ccbn-share-main .ccbn-share-footer, .ccbn-share-twocol-toolkit .ccbn-sha=
re-main .ccbn-share-header, .ccbn-share-twocol-toolkit .ccbn-share-main .cc=
bn-share-footer { width: 100%; }

.ccbn-share-two-col .ccbn-close-btn, .ccbn-share-twocol-toolkit .ccbn-close=
-btn { left: 186px; }

.ccbn-share-hoz .ccbn-share-main { padding: 0px; margin: 0px 0px 10px; bord=
er: 0px; display: block; position: relative; background: transparent; }

.ccbn-share-hoz .ccbn-share-main ul { margin: 0px; padding: 0px; border: 0p=
x; }

.ccbn-share-hoz .ccbn-share-main li { float: left; border: 0px; margin: 0px=
 8px 0px 0px; padding: 0px; }

.ccbn-share-hoz .ccbn-toggle-sub-content { font-weight: normal; width: 200p=
x; background: rgb(255, 255, 255); border-width: 1px; border-style: solid; =
border-color: rgb(204, 204, 204) rgb(102, 102, 102) rgb(102, 102, 102) rgb(=
204, 204, 204); border-image: initial; margin: 1px 0px 0px; padding: 0px 5p=
x; position: absolute; z-index: 999; }

.ccbn-share-hoz .ccbn-close-btn { float: right; top: 1px; left: 4px; line-h=
eight: 15px; }

.ccbn-share-hoz-more { padding: 0px; margin: 0px 0px 10px; border: 0px; dis=
play: block; position: relative; background: transparent; }

.ccbn-share-hoz-more li, .ccbn-share-hoz-more li h4 { float: left; list-sty=
le-type: none; margin: 0px 8px 0px 0px; padding: 0px; }

.ccbn-share-main { margin-top: 15px; }

.ccbn-share-hoz-more .ccbn-toggle-content ul { margin: -15px 0px 0px; paddi=
ng: 0px; }

.ccbn-share-hoz-more .ccbn-toggle-content li { display: list-item; padding:=
 0px; margin: 0px; float: none !important; }

.ccbn-share-hoz-more .ccbn-close-btn { left: 87px; }

.ccbn-share-hoz-more .ccbn-toggle-content .ccbn-share-footer { border-top: =
1px dotted rgb(204, 204, 204); margin-top: 3px; padding: 5px 0px; width: 10=
0px; }

.ccbn-share-hoz-more .ccbn-share-main { clear: left; }

.ccbn-connect h4 { margin: 0px 0px 8px; }

.ccbn-connect ul { margin: 0px; padding: 0px; }

.ccbn-connect li { list-style-type: none; padding: 5px 6px 5px 0px; margin:=
 0px; }

.ccbn-connect img { float: left; margin-right: 5px; border: 0px; }

.ccbn-connect ul.ccbn-hoz li { display: inline; float: left; }

.ccbn-connect ul.ccbn-vert { display: block; margin: 2px 50px 0px 28px; }

.ccbn-connect ul.ccbn-vert li { display: block; float: none; }

.ccbn-event-option-addToCal { display: none; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/jquery.qtip.css

@charset "utf-8";

.qtip { position: absolute; left: -28000px; top: -28000px; display: none; m=
ax-width: 280px; min-width: 50px; font-size: 10.5px; line-height: 12px; dir=
ection: ltr; box-shadow: none; padding: 0px !important; }

.qtip-content { position: relative; padding: 0px; overflow: hidden; text-al=
ign: left; overflow-wrap: break-word; }

.qtip-titlebar { position: relative; padding: 5px 35px 5px 10px; overflow: =
hidden; border-width: 0px 0px 1px; font-weight: bold; }

.qtip-titlebar + .qtip-content { border-top-width: 0px !important; }

.qtip-close { position: absolute; right: -9px; top: -9px; cursor: pointer; =
outline: none medium; border-width: 1px; border-style: solid; border-color:=
 transparent; }

.qtip-titlebar .qtip-close { right: 4px; top: 50%; margin-top: -9px; }

* html .qtip-titlebar .qtip-close { top: 16px; }

.qtip-titlebar .ui-icon, .qtip-icon .ui-icon { display: block; text-indent:=
 -1000em; direction: ltr; }

.qtip-icon, .qtip-icon .ui-icon { border-radius: 3px; text-decoration: none=
; }

.qtip-icon .ui-icon { width: 18px; height: 14px; text-align: center; text-i=
ndent: 0px; font: bold 10px / 13px Tahoma, sans-serif; color: inherit; back=
ground: none -100em -100em no-repeat transparent; }

.qtip-focus { }

.qtip-hover { }

.qtip-default { border-width: 1px; border-style: solid; border-color: rgb(2=
41, 208, 49); background-color: rgb(255, 255, 163); color: rgb(85, 85, 85);=
 }

.qtip-default .qtip-titlebar { background-color: rgb(255, 239, 147); }

.qtip-default .qtip-icon { border-color: rgb(204, 204, 204); background: rg=
b(241, 241, 241); color: rgb(119, 119, 119); }

.qtip-default .qtip-titlebar .qtip-close { border-color: rgb(170, 170, 170)=
; color: rgb(17, 17, 17); }

.qtip-light { background-color: white; border-color: rgb(226, 226, 226); co=
lor: rgb(69, 69, 69); }

.qtip-light .qtip-titlebar { background-color: rgb(241, 241, 241); }

.qtip-dark { background-color: rgb(80, 80, 80); border-color: rgb(48, 48, 4=
8); color: rgb(243, 243, 243); }

.qtip-dark .qtip-titlebar { background-color: rgb(64, 64, 64); }

.qtip-dark .qtip-icon { border-color: rgb(68, 68, 68); }

.qtip-dark .qtip-titlebar .ui-state-hover { border-color: rgb(48, 48, 48); =
}

.qtip-cream { background-color: rgb(251, 247, 170); border-color: rgb(249, =
233, 142); color: rgb(162, 125, 53); }

.qtip-cream .qtip-titlebar { background-color: rgb(240, 222, 125); }

.qtip-cream .qtip-close .qtip-icon { background-position: -82px 0px; }

.qtip-red { background-color: rgb(247, 139, 131); border-color: rgb(217, 82=
, 82); color: rgb(145, 35, 35); }

.qtip-red .qtip-titlebar { background-color: rgb(240, 109, 101); }

.qtip-red .qtip-close .qtip-icon { background-position: -102px 0px; }

.qtip-red .qtip-icon { border-color: rgb(217, 82, 82); }

.qtip-red .qtip-titlebar .ui-state-hover { border-color: rgb(217, 82, 82); =
}

.qtip-green { background-color: rgb(202, 237, 158); border-color: rgb(144, =
217, 63); color: rgb(63, 98, 25); }

.qtip-green .qtip-titlebar { background-color: rgb(176, 222, 120); }

.qtip-green .qtip-close .qtip-icon { background-position: -42px 0px; }

.qtip-blue { background-color: rgb(229, 246, 254); border-color: rgb(173, 2=
17, 237); color: rgb(94, 153, 189); }

.qtip-blue .qtip-titlebar { background-color: rgb(208, 233, 245); }

.qtip-blue .qtip-close .qtip-icon { background-position: -2px 0px; }

.qtip-shadow { box-shadow: rgba(0, 0, 0, 0.15) 1px 1px 3px 1px; }

.qtip-rounded, .qtip-tipsy, .qtip-bootstrap { border-radius: 5px; }

.qtip-rounded .qtip-titlebar { border-radius: 4px 4px 0px 0px; }

.qtip-youtube { border-radius: 2px; box-shadow: rgb(51, 51, 51) 0px 0px 3px=
; color: white; border-width: 0px; background: -webkit-linear-gradient(top,=
 rgb(74, 74, 74) 0px, black 100%) rgb(74, 74, 74); }

.qtip-youtube .qtip-titlebar { background-color: rgba(0, 0, 0, 0); }

.qtip-youtube .qtip-content { padding: 0.75em; font: 12px arial, sans-serif=
; }

.qtip-youtube .qtip-icon { border-color: rgb(34, 34, 34); }

.qtip-youtube .qtip-titlebar .ui-state-hover { border-color: rgb(48, 48, 48=
); }

.qtip-jtools { background: -webkit-linear-gradient(top, rgb(113, 113, 113),=
 rgb(35, 35, 35)) rgba(0, 0, 0, 0.7); border: 2px solid rgb(241, 241, 241);=
 border-radius: 2px; box-shadow: rgb(51, 51, 51) 0px 0px 12px; }

.qtip-jtools .qtip-titlebar { background-color: transparent; }

.qtip-jtools .qtip-content { }

.qtip-jtools .qtip-titlebar, .qtip-jtools .qtip-content { background: trans=
parent; color: white; border: 0px dashed transparent; }

.qtip-jtools .qtip-icon { border-color: rgb(85, 85, 85); }

.qtip-jtools .qtip-titlebar .ui-state-hover { border-color: rgb(51, 51, 51)=
; }

.qtip-cluetip { box-shadow: rgba(0, 0, 0, 0.4) 4px 4px 5px; background-colo=
r: rgb(217, 217, 194); color: rgb(17, 17, 17); border: 0px dashed transpare=
nt; }

.qtip-cluetip .qtip-titlebar { background-color: rgb(135, 135, 106); color:=
 white; border: 0px dashed transparent; }

.qtip-cluetip .qtip-icon { border-color: rgb(128, 128, 100); }

.qtip-cluetip .qtip-titlebar .ui-state-hover { border-color: rgb(105, 105, =
82); color: rgb(105, 105, 82); }

.qtip-tipsy { background: rgba(0, 0, 0, 0.87); color: white; border: 0px so=
lid transparent; font-size: 11px; font-family: "Lucida Grande", sans-serif;=
 font-weight: bold; line-height: 16px; text-shadow: black 0px 1px; }

.qtip-tipsy .qtip-titlebar { padding: 6px 35px 0px 10px; background-color: =
transparent; }

.qtip-tipsy .qtip-content { padding: 6px 10px; }

.qtip-tipsy .qtip-icon { border-color: rgb(34, 34, 34); text-shadow: none; =
}

.qtip-tipsy .qtip-titlebar .ui-state-hover { border-color: rgb(48, 48, 48);=
 }

.qtip-tipped { border: 3px solid rgb(149, 159, 169); border-radius: 3px; ba=
ckground-color: rgb(249, 249, 249); color: rgb(69, 69, 69); font-weight: no=
rmal; font-family: serif; }

.qtip-tipped .qtip-titlebar { border-bottom-width: 0px; color: white; backg=
round: -webkit-linear-gradient(top, rgb(58, 121, 184), rgb(46, 98, 157)) rg=
b(58, 121, 184); }

.qtip-tipped .qtip-icon { border: 2px solid rgb(40, 85, 137); background: r=
gb(40, 85, 137); }

.qtip-tipped .qtip-icon .ui-icon { background-color: rgb(251, 251, 251); co=
lor: rgb(85, 85, 85); }

.qtip-bootstrap { font-size: 14px; line-height: 20px; color: rgb(51, 51, 51=
); padding: 1px; background-color: rgb(255, 255, 255); border: 1px solid rg=
ba(0, 0, 0, 0.2); border-radius: 6px; box-shadow: rgba(0, 0, 0, 0.2) 0px 5p=
x 10px; background-clip: padding-box; }

.qtip-bootstrap .qtip-titlebar { padding: 8px 14px; margin: 0px; font-size:=
 14px; font-weight: normal; line-height: 18px; background-color: rgb(247, 2=
47, 247); border-bottom: 1px solid rgb(235, 235, 235); border-radius: 5px 5=
px 0px 0px; }

.qtip-bootstrap .qtip-titlebar .qtip-close { right: 11px; top: 45%; border-=
style: none; }

.qtip-bootstrap .qtip-content { padding: 9px 14px; }

.qtip-bootstrap .qtip-icon { background: transparent; }

.qtip-bootstrap .qtip-icon .ui-icon { width: auto; height: auto; float: rig=
ht; font-size: 20px; font-weight: bold; line-height: 18px; color: rgb(0, 0,=
 0); text-shadow: rgb(255, 255, 255) 0px 1px 0px; opacity: 0.2; }

.qtip-bootstrap .qtip-icon .ui-icon:hover { color: rgb(0, 0, 0); text-decor=
ation: none; cursor: pointer; opacity: 0.4; }

.qtip:not(.ie9haxors) div.qtip-content, .qtip:not(.ie9haxors) div.qtip-titl=
ebar { filter: none; }

.qtip .qtip-tip { margin: 0px auto; overflow: hidden; z-index: 10; }

.qtip .qtip-tip, .qtip .qtip-tip .qtip-vml, .qtip .qtip-tip canvas { positi=
on: absolute; color: rgb(18, 52, 86); background: transparent; border: 0px =
dashed transparent; }

.qtip .qtip-tip canvas { top: 0px; left: 0px; }

.qtip .qtip-tip .qtip-vml { display: inline-block; visibility: visible; }

#qtip-overlay { position: fixed; left: -10000em; top: -10000em; }

#qtip-overlay.blurs { cursor: pointer; }

#qtip-overlay div { position: absolute; left: 0px; top: 0px; width: 100%; h=
eight: 100%; background-color: black; opacity: 0.7; }

.qtipmodal-ie6fix { position: absolute !important; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/wd_form.css

@charset "utf-8";

.wd_form_field { overflow: auto; margin: 5px; padding: 0px; border: none; }

.wd_form_field_label { padding: 0px; }

.wd_form_field_error { color: rgb(255, 0, 0); }

.wd_input_border { display: inline-block; border: 0px solid transparent; ma=
rgin: 0px; padding: 0px; }

.wd_form_footer { margin: 5px; }

@media (max-width: 768px) {
  .wd_form_field_label { text-align: left; }
  .wd_form_field_pos_left_inline .wd_form_field_input, .wd_form_field_pos_l=
eft_inline .wd_form_field_label, .wd_form_field_pos_right_inline .wd_form_f=
ield_input, .wd_form_field_pos_right_inline .wd_form_field_label { display:=
 inline; }
}

@media (min-width: 769px) {
  .wd_form_field_pos_right .wd_form_field_label, .wd_form_field_pos_right_i=
nline .wd_form_field_label, div.wd_form_footer div.wd_form_legend { float: =
left; width: 150px; text-align: right; }
  .wd_form_field_pos_left .wd_form_field_input, .wd_form_field_pos_left_inl=
ine .wd_form_field_input { float: left; min-width: 150px; text-align: right=
; }
  .wd_form_field_pos_left .wd_form_field_label, .wd_form_field_pos_left_inl=
ine .wd_form_field_label, .wd_form_field_pos_right .wd_form_field_input, .w=
d_form_field_pos_right_inline .wd_form_field_input, .wd_form_field_pos_abov=
e .wd_form_field_input, .wd_form_field_pos_above .wd_form_field_label, .wd_=
form_field_pos_below .wd_form_field_input, .wd_form_field_pos_below .wd_for=
m_field_label, div.wd_form_footer div.wd_form_buttons { margin-left: 155px;=
 overflow: auto; }
}

.wd_featureboxes-vertical .wd_form_field_input, .wd_featureboxes-vertical .=
wd_form_field_label, .wd_featureboxes-vertical div.wd_form_footer div.wd_fo=
rm_legend, .wd_featureboxes-vertical div.wd_form_footer div.wd_form_buttons=
 { display: inline; float: none; width: 100%; box-sizing: border-box; text-=
align: left; margin-left: 0px; overflow: auto; }

.wd_featureboxes-vertical .wd_form_field_input input { max-width: 100%; box=
-sizing: border-box; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/wd_wai_datepicker.css

@charset "utf-8";

.wd_wai_datepicker { position: inherit; display: inline; }

.wd_wai_dp_button { border: none; background: none; }

.wd_wai_datepicker button.icon { padding: 4px; margin: 0px; border: 2px sol=
id transparent; border-radius: 5px; text-align: left; background-color: whi=
te; position: relative; left: -4px; top: 3px; }

.wd_wai_datepicker button.icon:focus { outline: none; border-color: rgb(48,=
 122, 232); }

.wd_wai_datepicker span.arrow { margin: 0px; padding: 0px; display: none; b=
ackground: transparent; }

.wd_wai_datepicker input { margin: 0px; width: 20%; }

.wd_wai_datepicker .wd_wai_datepickerDialog { position: absolute; width: 45=
%; clear: both; display: none; border: 3px solid rgb(119, 119, 119); border=
-radius: 0px; padding: 0px; background-color: rgb(255, 255, 255); }

.wd_wai_datepicker .wd_wai_header { cursor: default; background-color: rgb(=
119, 119, 119); padding: 7px; font-weight: bold; color: white; display: fle=
x; justify-content: space-around; }

.wd_wai_datepicker .wd_wai_header div.wd_wai_monthYear { margin: 0px; paddi=
ng: 0px; display: inline-block; font-size: 1em; color: white; text-transfor=
m: none; font-weight: bold; }

.wd_wai_datepicker .wd_wai_header button { border-style: none; background: =
transparent; }

.wd_wai_datepicker .wd_wai_prevYear, .wd_wai_datepicker .wd_wai_prevMonth, =
.wd_wai_datepicker .wd_wai_nextMonth, .wd_wai_datepicker .wd_wai_nextYear {=
 padding: 0px 4px; width: 24px; height: 24px; color: white; }

.wd_wai_datepicker .wd_wai_prevYear:focus, .wd_wai_datepicker .wd_wai_prevM=
onth:focus, .wd_wai_datepicker .wd_wai_nextMonth:focus, .wd_wai_datepicker =
.wd_wai_nextYear:focus { padding: 0px; border: 2px solid white; border-radi=
us: 4px; outline: 0px; line-height: 20px; }

.wd_wai_datepicker .wd_wai_dialogButtonGroup { text-align: right; margin-to=
p: 1em; margin-bottom: 1em; margin-right: 1em; }

.wd_wai_datepicker .wd_wai_dialogButton { padding: 5px; margin-left: 1em; w=
idth: 5em; background-color: rgb(204, 204, 204); font-size: 0.85em; color: =
black; outline: none; border: 0px; border-radius: 5px; }

.wd_wai_datepicker .wd_wai_dialogButton:focus { padding: 4px; border: 2px s=
olid black; }

.wd_wai_datepicker .fa-calendar-alt { color: rgb(120, 171, 247); }

.wd_wai_datepicker .wd_wai_monthYear { display: inline-block; width: 12em; =
text-align: center; }

.wd_wai_datepicker table.wd_wai_dates { width: 100%; border-collapse: separ=
ate !important; }

.wd_wai_datepicker table.wd_wai_dates th, .wd_wai_datepicker table.wd_wai_d=
ates td { text-align: center; }

.wd_wai_datepicker .wd_wai_dateRow { border: 1px solid black; }

.wd_wai_datepicker .wd_wai_dateCell { outline: 0px; border: 0px; padding: 0=
px; margin: 0px; height: 40px; width: 40px; }

.wd_wai_datepicker .wd_wai_dateButton { padding: 0px; margin: 0px; line-hei=
ght: inherit; height: 100%; width: 100%; border: 1px solid rgb(238, 238, 23=
8); border-radius: 5px; font-size: 15px; background: rgb(238, 238, 238); }

.wd_wai_datepicker .wd_wai_dateButton:focus, .wd_wai_datepicker .wd_wai_dat=
eButton:hover { padding: 0px; background-color: rgb(218, 231, 251); }

.wd_wai_datepicker .wd_wai_dateButton:focus { border-width: 2px; border-col=
or: rgb(100, 100, 100); outline: 0px; }

.wd_wai_datepicker .wd_wai_dateButton[aria-selected] { border-color: rgb(10=
0, 100, 100); }

.wd_wai_datepicker .wd_wai_dateButton[tabindex=3D"0"] { background-color: r=
gb(204, 204, 204); }

.wd_wai_datepicker .disabled { color: rgb(175, 175, 175); }

.wd_wai_datepicker .disabled:hover { color: black; }

.wd_wai_datepicker .wd_wai_dateButton:disabled { color: rgb(119, 119, 119);=
 background-color: rgb(255, 255, 255); border: none; cursor: not-allowed; }

.wd_wai_datepicker .wd_wai_message { padding-top: 0.25em; padding-left: 1em=
; height: 1.75em; background: rgb(48, 122, 232); color: white; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://ir.vikingtherapeutics.com/css/wd_wcag.css

@charset "utf-8";

.wd_sr-only.wd_sr-only.wd_sr-only.wd_sr-only { position: absolute; width: 1=
px; height: 1px; padding: 0px; margin: -1px; overflow: hidden; clip: rect(0=
px, 0px, 0px, 0px); border: 0px; }

.wd_sr-only.wd_sr-only.wd_sr-only.wd_sr-only:active, .wd_sr-only.wd_sr-only=
.wd_sr-only.wd_sr-only:focus { position: static; width: auto; height: auto;=
 margin: 0px; overflow: visible; clip: auto; }

.wd_sr-only-focusable:active, .wd_sr-only-focusable:focus { position: stati=
c; width: auto; height: auto; margin: 0px; overflow: visible; clip: auto; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-c30bfeed-d10a-4edf-a078-b533e59f7e95@mhtml.blink

@charset "utf-8";

.mboxDefault { visibility: hidden; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-8884a772-68a2-472e-aac5-2d1331d759dd@mhtml.blink

@charset "utf-8";

.mboxDefault { visibility: hidden; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-9777b737-9473-4306-b5d5-50404d05a661@mhtml.blink

@charset "utf-8";

.wd_category_header { margin: 10px 0px; overflow: auto; }

.wd_thumbnail { float: left; margin: 0px 5px 5px 0px; }

.wd_item_list { margin: 10px 0px; overflow: auto; }

.wd_item { padding: 0px; margin: 0px 0px 10px; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-f3b80716-04d7-43c8-a8df-a6b3c39d51f1@mhtml.blink

@charset "utf-8";

ul.wd_layout-simple { padding: 0px; margin: 10px 0px; list-style: none; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-4daecc4a-4244-41c0-8cbf-990f7e160d94@mhtml.blink

@charset "utf-8";

.wd_item { overflow: auto; }

.wd_item .wd_thumbnail { float: left; margin: 0px 5px 5px 0px; }

.wd_item .wd_date { text-transform: uppercase; font-weight: bold; font-size=
: 1.167em; color: rgb(204, 204, 204); }

.wd_item .wd_title { font-weight: bold; font-size: 2em; }

.wd_item .wd_subtitle { font-weight: bold; }

.wd_item .wd_summary p { margin-bottom: 0px; }

.wd_asset_type_link_list { display: inline-block; margin: 10px 0px 0px; bor=
der: 1px solid rgb(204, 204, 204); padding: 2px; }

.wd_item_wrapper { margin-left: 149px; }

.wd_item_wrapper:first-child, .wd_layout-masonry .wd_item_wrapper, .wd_layo=
ut-grid .wd_item_wrapper { margin-left: 0px; }

.wd_layout-masonry .wd_item, .wd_layout-grid .wd_item { border: 1px solid r=
gb(225, 225, 225); padding: 5px; }

.wd_layout-masonry .wd_thumbnail, .wd_layout-grid .wd_thumbnail { float: no=
ne; text-align: center; margin: 0px 0px 5px; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-a6862650-9da1-4702-949a-80e43b63dddf@mhtml.blink

@charset "utf-8";

.wd_tooltip .qtip-content { margin: 0px; padding: 10px; background-color: r=
gb(254, 253, 225); }

.wd_tooltip-trigger { display: inline-block; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-49ddf4b3-3340-4f7e-b70c-3df76045a0ae@mhtml.blink

@charset "utf-8";

.wd_item_search_form_container .wd_search_form_basic { display: inline-bloc=
k; }

.wd_search_basic_fields { display: inline-block; background-color: rgb(241,=
 241, 241); border: 1px solid rgb(211, 211, 211); padding: 3px; vertical-al=
ign: middle; }

.wd_search_basic_fields > * { vertical-align: middle; }

.wd_item_search_form_container .wd_input_datepicker { margin-right: 2px; }

.wd_search_button { color: rgb(153, 153, 153); }

.wd_search_button.wd_highlight { color: rgb(0, 0, 0); }

.wd_search_advanced_link, .wd_search_titles_only, .wd_checkbox { white-spac=
e: nowrap; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-f5bdcc36-e2f6-4e67-a23a-ce93881fcc8c@mhtml.blink

@charset "utf-8";

div.wd_subscribe_link { text-align: right; margin: 10px 0px; padding: 0px; =
border: 0px; }

span.wd_subscribe_icon { margin-left: 1em; }

.wd_subscribe_link img { vertical-align: middle; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-90dded43-0c2e-4904-8c88-06532348acc1@mhtml.blink

@charset "utf-8";

.wd_search_form .wd_input_datepicker { margin-right: 2px; }

.wd_search_type_checkbox { margin-left: 20px; }
------MultipartBoundary--Xc7rm1InhmyzXF4xUkq0ykquh2NYntRnwNRGUYLa4h------
